"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Ben, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Year-End 2015 Financial Results and Business Update. [Operator Instructions] Thank you. I would lik",60,"Good morning. My name is Ben, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Year-End 2015 Financial Results and Business Update. [Operator Instructions] Thank you. I would like -- I would like to turn the call over to Mr. Butz, Senior Director of Investor Relations."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thank you, and welcome to Biogen's Fourth Quarter and Full-year 2015 Earnings Conference Call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and the related financial tables, including a reco",193,"Thank you, and welcome to Biogen's Fourth Quarter and Full-year 2015 Earnings Conference Call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and the related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. 
Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. 
We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Al Sandrock, our Chief Medical Officer; and our CFO, Paul Clancy.
Now I'll turn the call over to George."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt, and good morning, everyone, and thanks for joining us today. In 2015, Biogen generated revenues of $10.8 billion, an 11% increase over 2014 and non-GAAP EPS of $17.01, a 23% increase over 2014. Although the revenues were less than we had a",723,"Thanks, Matt, and good morning, everyone, and thanks for joining us today. 
In 2015, Biogen generated revenues of $10.8 billion, an 11% increase over 2014 and non-GAAP EPS of $17.01, a 23% increase over 2014. Although the revenues were less than we had anticipated at the beginning of last year, I'm pleased that we were able to take appropriate action in the second half of the year to maintain healthy earnings growth while we continue to advise the potentially transformative therapies in our pipeline. 
TECFIDERA's demand has been stable in the U.S., and combined with growth in Europe, we expect TECFIDERA to continue to try for global leadership in multiple sclerosis. TECFIDERA is now not only the most prescribed oral MS therapy worldwide, it is also the most prescribed of all MS therapies in Germany, France and the U.K. Overall, more than 170,000 patients have been treated with TECFIDERA. 
Our hemophilia products, ELOCTATE and ALPROLIX, generated over $0.5 billion of revenue in their first full year on the market in the U.S. In November, the European Commission approved ELOCTA for the treatment of hemophilia A in the EU, which we believe will help to contribute growth in hemophilia this year, as our collaboration partner, Sobi, commercializes ELOCTA in additional markets. 
We also made progress in business development. We acquired Convergence Pharmaceuticals and Raxatrigine compound. Raxatrigine is an oral small molecule 1.7 blocker with promising Phase II data that will move into Phase III this year. We licensed Amiselimod, or MT-1303, for Mitsubishi Pharma, a late-stage S1P1 inhibitor for ulcerative colitis and Crohn's disease. We entered into a collaboration agreement with EGTC to develop gene-based therapies for multiple ophthalmic diseases. And this month, BENEPALI was approved in the EU. BENEPALI, the first biosimilar approved in the EU, is the first of 3 potential anti-TNFs to advance under our Samsung Bioepis joint venture with Samsung Biologics. Under our agreements with Samsung Bioepis, we will manufacture and commercialize BENEPALI in the EU. 
Meanwhile, we continued investing in 2015. We purchased land in Switzerland, and this Friday, January 29, we'll break ground on an advanced next-generation biologics manufacturing facility there. And we purchased a drug product manufacturing facility and supporting infrastructure in Research Triangle North Carolina. We also took actions to return capital and change the capital structure of the business. We fully implemented our $5 billion share repurchase program, and a portion of that repurchase was funded through the $6 billion debt offering that we completed in September. 
In R&D, we moved forward several exciting mid- and late-stage assets in our pipeline. It may seem like a long time ago now, but it was Q1 2015 that we presented the aducanumab data showing a statistically significant removal of pack and slowing of cognitive decline in Alzheimer's patients. We presented data suggesting that our anti-LINGO antibody is biologically active in remyelination, and the Phase II data for [indiscernible], generated by our partner Ionis, looks increasingly encouraging as a potential therapy for spinal muscular atrophy. We also initiated Phase I trials in ALS and Parkinson's disease. 
Al will discuss the many advances we made our pipeline in more detail, but I think this progress is a testament to our commitment to patients and our world-class capabilities across the breadth of R&D. 
We also continued to threaten our early-stage clinical and research capabilities. We bolstered research talent in our neuroscience group and established collaborations with first-rate academic centers around the world. As a result, I believe we're now in a better position than ever to both discovery novel therapies and accelerate drug development while minimizing risk. 
Lastly, summarizing 2015 would not be complete without commenting on the restructuring we implemented in October. Although it was a difficult decision, we've already seen positive results from the steps that we took. With the majority of the restructuring now completed, there's a palpable, reinvigorated focus on our key commercial initiatives and high-potential pipeline candidates, and our operating expenses are trending at a rate that we believe can continue to provide healthy earnings leverage going forward. 
So all in all, it was a busy and eventful year, and we believe that the progress we made and actions that lead positioned us well for a potentially transformative 2016 and beyond. 
With that, I'll pass the call along to Al for an update on R&D."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, George. 2015 was a productive year for the R&D organization. We advanced the next wave of potential medicines through the pipeline, added important assets through business development and acquisitions and expanded our research leadership by hiring",1038,"Thanks, George. 2015 was a productive year for the R&D organization. We advanced the next wave of potential medicines through the pipeline, added important assets through business development and acquisitions and expanded our research leadership by hiring world-class scientists. I believe our pipeline and our organization are stronger than they have ever been. 
Starting with Alzheimer's disease. Last year, we presented compelling interim Phase I data for aducanumab, the first investigational drug for Alzheimer's disease to demonstrate both the statistically significant reduction of amyloid plaque as well as slowing of cognitive decline. In August, we began enrolling patients into 2 pivotal Phase III trials of aducanumab in early Alzheimer's disease. We are pleased with the progress of these studies but recognize the inherent challenges in recruiting patients with early Alzheimer's disease and the limited availability of PET scanners. Fortunately, owing to the strong results from our clinical trials to date, there has been substantial interest in the program, which we believe has helped with recruitment. that said, we continue to anticipate that the Phase III enrollment duration will be similar to other large clinical trials in Alzheimer's disease. Looking ahead, in the second half of 2016, we expect to share additional safety data from the ongoing titration arms of the Phase Ib prime study for aducanumab. 
Our other 2 mid-stage clinical candidates for AD that are partnered with [indiscernible] continued to advance. [indiscernible] had indicated that they anticipate releasing interim safety data this year for E2609, a small molecule-based one inhibitor. And we are also expecting to see top line efficacy and safety data for Ban 2401, a monoclonal antibody targeting beta-amyloid. 
Moving to anti-LINGO. You may recall that last year, we presented Phase II data in acute optic neuritis. To our knowledge, this was the first clinical trial to show evidence of remyelination following an acute inflammatory demyelinating injury in humans. And we believe that these results support our ongoing development efforts. Our Phase II synergy study in MS is a 418-patient, double-blind, multicenter study assessing 4 doses of anti-LINGO versus placebo when added to Interferon beta therapy. It utilizes a composite endpoint comprising outcome measures of disability, cognition and physical function. We believe that a separation from placebo on any of these measures could be clinically meaningful. We are also looking at imaging endpoints that reflect the integrity of myelinated nerve fibers. Any differences in treatment effect between preexisting and newly acquired lesions will also be of interest. We believe that the robust design of this clinical trial will enable a better understanding of the therapy's potential in MS. An if the results are positive, the trial should provide valuable insight into the design of our Phase III program. Results for synergy are anticipated in mid-2016. 
Now turning to nusinersen. Our partner, Ionis, recently completed target enrollment of the Phase III study in children with child onset SMA. And by the first half of this year, we hope to complete enrollment in [indiscernible], the Phase III study evaluating nusinersen in infants with infantile onset SMA. This progress sets the stage for data -- from both of these rails to be available in the first half of 2017. Whereas the data from the early-stage open-label clinical trials are encouraging when compared to data from natural history studies, the well-controlled Phase III studies are designed to definitively assess the safety and efficacy of nusinersen. 
We are meeting frequently with regulators from Europe, Japan and the United States with the goal of making the drug available to SMA patients as rapidly as possible. 
Moving on to our hemophilia therapies. Last month, at the 57th American Society of Hematology annual meeting, we presented new data demonstrating that ELOCTATE and ALPROLIX effectively managed bleeding into joints and maintained low annualized bleeding rates in people with severe hemophilia A and B, reaffirming the benefits of these 2 therapies. In addition, teams from the University of Pittsburgh, the Hemophilia Center of Western Pennsylvania and the University of Texas Southwestern Medical Center presented data showing that immune tolerance induction using ELOCTATE was successful in 3 children with inhibitors, including a child previously failing recombinant Factor 8 immune tolerance induction. The time to  achieving tolerance in the study was 4 to 12 weeks, which appears to be significantly shorter than with the standard of practice, which can take several months to several years. 
During the quarter, we, in collaboration with Ionis, also announced the initiation of a Phase I/II clinical study of an antisense drug against superoxide dismutase, or SOD1, in patients with [indiscernible] lateral sclerosis. I am pleased to announce that last week, we dosed our first patient in the trial. Mutations in the SOD1 gene result in the second most common form of familial ALS, affecting approximately 2% of all ALS patients. 
We also continue to make excellent progress toward initiating multiple late-stage clinical trials in 2016. Next month, we anticipate sharing additional Phase II study results for TYSABRI in acute ischemic stroke at the International Stroke Conference in Los Angeles. While single dose administered -- of natalizumab administered up to 9 hours after stroke onset did not reduce focal infarct volume, treatment was associated with meaningful improvements in clinical outcomes over the course of 90 days. 
The clinical profile and treatment window supports further investigation of natalizumab as a potential novel approach for treating acute ischemic stroke, and we intend to conduct a Phase IIb trial. 
Amiselimod, or MT-1303, an S1P1 inhibitor for inflammatory bowel disease, is anticipated to advance to Phase III trials this year. In the second half of the year, we plan to initiate Phase III studies for both ulcerative colitis and Crohn's disease. We currently have no plans for the asset in MS but expect to continue to evaluate other options for the molecule in collaboration with our partner, Mitsubishi Tanabe. 
Raxatrigine, a small molecule inhibitor of the Nav 1.7 sodium channel, is in development for several pain indications. In the second half of the year, we anticipate initiating a Phase III trial to confirm the efficacy of Raxatrigine in patients with trigeminal neuralgia. We also plan to initiate a Phase II trial in patients with sciatica later this year. 
I'll now pass the call over to Paul."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Al. Our GAAP diluted earnings per share were $3.77 in the fourth quarter and $15.34 for the full year. Our non-GAAP diluted earnings per share were $4.50 in the fourth quarter and $17.01 for the full year. Total revenue for Q4 grew 8% year-over-ye",1447,"Thanks, Al. Our GAAP diluted earnings per share were $3.77 in the fourth quarter and $15.34 for the full year. Our non-GAAP diluted earnings per share were $4.50 in the fourth quarter and $17.01 for the full year. Total revenue for Q4 grew 8% year-over-year to approximately $2.8 billion and grew 11% for the full year to $10.8 billion. 
Foreign exchange, offset by hedging, weakened fourth quarter revenue by approximately $35 million versus prior year and by approximately $227 million for the full year versus prior year. 
Global Q4 TECFIDERA revenue was $993 million. We recorded revenues of $785 million in the U.S. and $208 million outside the U.S. TECFIDERA U.S. revenue benefited from an increase in wholesale inventory by approximately $30 million versus prior quarter. At this point, we believe TECFIDERA's safety perceptions in physician intend to prescribe has largely stabilized in the U.S. We're seeing positive leading indicators for the recently launched marketing campaign for TECFIDERA, including increased visits to our website and higher call volume into our patient services organization. In Europe, TECFIDERA continued its trend of solid patient growth this quarter, especially in more recently launched markets such as the U.K., Italy and Spain. The European label for TECFIDERA was updated in December, and we're actively educating physicians on appropriate patient monitoring. For the full year, worldwide TECFIDERA revenues were $3.6 billion, consisting of $2.9 billion in the U.S. and $730 million in sales outside the U.S. 
Foreign exchange impact, offset by hedging, weakened full year TECFIDERA revenue by approximately $27 million versus prior year. 
Interferon revenues, including both Avonex and PLEGRIDY, were $740 million during the fourth quarter, which includes $506 million in the U.S. and $233 million in sales outside the U.S. For the full year, worldwide Interferon revenues were $3 billion, consisting of $2 billion in the U.S. and $951 million in sales outside the U.S. Foreign exchange impact, offset by hedging, weakened full year Interferon revenues by approximately $88 million versus prior year. 
TYSABRI continued to add patients this quarter, with worldwide revenues of $481 million. These results were comprised of $278 million in the U.S. and $203 million internationally. For the full year, worldwide TYSABRI revenues were approximately $1.9 billion. We recorded U.S. revenue of $1.1 billion and $783 million internationally. Foreign exchange impact, offset by hedging, weakened full year revenue for TYSABRI by approximately $90 million versus prior year. 
Physicians continue to choose TYSABRI for patients requiring high efficacy, and nearly 10 years after approval, we believe its well-understood safeties profile positions TYSABRI. 
Turning to hemophilia business. ELOCTATE revenue for the quarter was $101 million and $320 million for the full year. ALPROLIX revenue in Q4 was $71 million and $234 million for the full year. 
Turning to our anti-CD20 unconsolidated joint business, which includes our profit share for Rituxan and GAZYVA in the U.S. as well as our profit share and royalties on sales of rituximab outside the U.S. We recorded $334 million for Q4 and $1.3 billion for the full year. While there was a slight inventory drawdown for Rituxan in the fourth quarter, we ended the year with a higher inventory level than we had anticipated. We also benefited from a $6 million payment from Roche in exchange for access to data supporting the development of ocrelizumab. 
Corporate partner revenues were $69 million for the fourth quarter compared to $40 million in the prior year quarter. The increase was related to contract manufacturing for Samsung Bioepis and another strategic partner. For the full year, corporate partner revenues were $189 million. 
During the quarter, we booked a total GAAP charge of approximately $93 million related to the restructuring announced in October. 
Now turning to the non-GAAP expense lines on the P&L. Q4 cost of goods sold were $332 million or 12% of revenue. For the full year, COGS were $1.2 billion or 12% of revenue. Q4 non-GAAP R&D expense was $542 million or 19% of revenue, which includes a $60 million payment to Mitsubishi Tanabe. For the full year, non-GAAP R&D expense was $2 billion or 19% of revenue. Q4 non-GAAP SG&A expense was $583 million or 21% of revenue. For the full year, non-GAAP SG&A expense was $2.1 billion or 20% of revenue. Other net expense was approximately $82 million in the fourth quarter, which includes $67 million in interest expense, primarily related to our recent bond offering. Full year other net expense was $124 million, including approximately $96 million in interest expense. 
Our Q4 non-GAAP tax rate was approximately 23% for the fourth quarter, as we benefited from the reinstated R&D tax credit. Our full year tax rate was approximately 24%. 
During the year, we repurchased approximately 16.8 million shares of our common stock, completing our previously authorized $5 billion share repurchase program. Our weighted average diluted share count was approximately 221 million for Q4, 231 million for the full year. And we ended the year with approximately 219 million basic shares outstanding. This brings us to our non-GAAP diluted earnings per share toward $4.50 [ph] for the fourth quarter and $17.01 for the full year, representing a 23% increase for the full year. 
We ended the year with approximately $62.2 billion in cash and marketable securities, split approximately 40-60 between the U.S. and ex U.S. 
So overall, we had a strong quarter, benefiting from favorable inventory dynamics for TECFIDERA, stronger-than-anticipated contract manufacturing in RITUXAN revenue and the restatement of the R&D tax credit. 
Let me turn to our full year 2016 guidance. We expect revenues of approximately $11.1 billion to $11.3 billion. Starting with multiple sclerosis. Our plan assumes relatively stable demand for TECFIDERA in 2016 in the United States. While we're hopeful our recently launched marketing campaign can reaccelerate growth, we remain cautious as we believe we will not ascertain the impact until the second quarter of this year. In Europe, we anticipate constant pricing through the rest of the year and continued patient growth, particularly in recently launched markets. For TYSABRI, we believe the therapy will remain on a stable trajectory. We believe the number of patients using Avonex and PLEGRIDY, combined, will continue to decline as patients move toward orals, but we remain well positioned within this segment of the market. 
Our financial guidance assumes no U.S. price increases for Avonex, PLEGRIDY and TECFIDERA for the remainder of the year. 
With respect to foreign exchange, our plan is based on the current spot rates. Of note, we had an approximately $170 million in hedge gains in 2015. Given our hedges, our usually placed 12-month forward, we expect limited hedge gains in 2016, so the year-over-year comparison is less favorable. 
Moving to our hemophilia therapies. We anticipate continued growth with ELOCTATE, as we believe there remains a significant portion of the patient population that can benefit from long-acting therapies. We're assuming moderating patient adds for ALPROLIX, given the rapid uptake in penetration so far. 
In 2016, we're assuming our profit share for Rituxan and GAZYVA will decrease to 39% from 40% upon FDA approval of GAZYVA and RITUXAN refractory indolent non-Hodgkin's lymphoma. Our plan assumes ocrelizumab will launch in 2017. 
Moving to an expense perspective. We anticipate slight upward pressure on cost of goods sold rate, largely due to increases in contract manufacturing, biosimilars and increased hemophilia royalties. We anticipate R&D expense between 19% and 20% of sales, which includes approximately $100 million earmarked for business development activity. We plan to invest in a number of R&D programs across our late-stage pipeline, including aducanumab, nusinersen, Raxatrigine and [indiscernible] for inflammatory bowel disease. 
SG&A expense is expected to be approximately 17% to 18% of revenue. The headcount reduction in restructuring announced in October is expected to benefit operating expenses by approximately $250 million. We've also planned to reduce targeted fees and services expenses, which are largely reflected in SG&A. 
From a tax perspective, we anticipate upward pressure on our 2016 tax rate, as our profitability mix shifts toward the U.S. We anticipate non-GAAP earnings per share results between $18.30 and $18.60 and GAAP EPS to be between $16.85 and $17.15. Our plan assumes share stabilization, with a weighted average diluted share count of approximately 219 million. 
From a cost perspective, we expect to pay $1.2 billion in CVR payments to Fumapharm in 2016 related to the sales of TECFIDERA. And we anticipate capital expenditures of approximately $800 million to $850 million, an increase over 2015, primarily driven by the investment in the Swiss manufacturing plants. 
So the business plan is designed to provide investment to support TECFIDERA, surgically look to control spending and ensure we're heavily focused on investing in and progressing the pipeline. 
I'll turn the call over to George."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Okay, thank you, Paul. Clearly, the commercial trajectory of TECFIDERA was not where we thought it would be at the beginning of last year, and as a result, the revenues fell short of our initial projections. While obviously not happy with that, I'm very p",581,"Okay, thank you, Paul. Clearly, the commercial trajectory of TECFIDERA was not where we thought it would be at the beginning of last year, and as a result, the revenues fell short of our initial projections. While obviously not happy with that, I'm very pleased with the way the company responded. We put additional marketing muscle behind TECFIDERA. We reduced cost and focused the company, and we accelerated our stock repurchase program. As a result, we maintained healthy earnings growth at the same time as we continued our investments in aducanumab, LINGO and the other exciting programs in our pipeline. We also continued to invest in additions to our pipeline. We acquired Convergence and its lead compound, Raxatrigine. We licensed Amiselimod from Mitsubishi Tanabe. We completed the gene therapy relationship with AGTC, and we brought additional compounds into the clinic from our own and partner's research efforts. 
Our commercial portfolio continued to expand globally, as we expanded our position as the worldwide leader in multiple sclerosis and significantly grew our hemophilia business. In 2016, we plan to remain focused on commercial execution and advancing our pipeline, which we expect to be the primary source of value creation over the long term. We're looking forward to many updates over the next year, including insight into the potential impact of TECFIDERA's recently launched marketing campaign by the second quarter; Phase II top line results for anti-LINGO in MS in the middle of the year; Phase II data for BAN2401 and E2609; continued Phase II data for nusinersen from Ionis, followed by Phase III data next year; and Phase Ib titration data for aducanumab in the second half of the year. 
We expect to launch up to 3 compounds this year: BENEPALI in Europe following approval from the European Commission earlier this month; ZINBRYTA pending approval in the first half of the year; and potentially [indiscernible] biosimilar also in Europe. 
Thinking even further ahead, we believe that we're entering the early years of a potentially transformative era in neuro generation drug discovery and development. And we believe that our commitment to research has the potential to yield results that are truly meaningful for patients and shareholders. As I said at the recent JPMorgan conference, I believe that our pipeline and our approach, which has the risk inherent in all truly innovative and ground-breaking approaches, is measured and thoughtful. The combination of a much better understanding of disease biology; the focus on genetically validated targets; the use of biomarkers to learn early, whether or not our compounds are having the desired biological effects; and the adoption of multiple therapeutic modalities may meaningfully increase success rates and identify those projects likely to fail early in the process before large amounts of time and money are spent. Our strategy is evident in the design of the aducanumab Phase Ib trial to Phase II study of nusinersen, the Phase II studies of anti-LINGO and our recently initiated Phase I trial for SOD1 ALS. We have additional examples, some of which we'll talk about as the year goes on. 
In closing, and as always, I'd like to thank our employees who are dedicated to making a positive impact on patients' lives and also the patients and physicians who are involved in our clinical development programs. The achievements we've been together could not have been realized without their passion and commitment. 
So thank you all for joining us this morning. And operator, we'll now open up the call for questions."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Geoff Meacham from Barclays.",14,"[Operator Instructions] Your first question comes from the line of Geoff Meacham from Barclays."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Just have a couple of quick ones. One on the commercial side. I know it's early days, but are there any additional metrics on the [indiscernible] campaign when you look at things like new starts or returning patients? And then the second one is on the pip",87,"Just have a couple of quick ones. One on the commercial side. I know it's early days, but are there any additional metrics on the [indiscernible] campaign when you look at things like new starts or returning patients? And then the second one is on the pipeline. When you look at the ENGAGE and EMERGE studies, Al, are there lessons to be learned from Lily in terms of managing PET scan facilities? And what do you think identification of early-stage Alzheimer's patients mean to the market opportunity?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Geoff. Let me start with the tech TTC question. I guess, I'd reinforce what we said in our prepared remarks around that really to try to discern it, we're going to be looking kind of in the Q2 time period. I mean, clearly, Q2 is not a light switch",154,"Thanks, Geoff. Let me start with the tech TTC question. I guess, I'd reinforce what we said in our prepared remarks around that really to try to discern it, we're going to be looking kind of in the Q2 time period. I mean, clearly, Q2 is not a light switch to determine that. We're seeing early data with respect to, as I had mentioned, kind of hits to the website, conversations into our patient services organization, which lean us to think that it's positive. We haven't seen a discernible yet change with respect to specifically in your question. But our judgment is that this takes a little bit of time. It's really first week of October. Obviously, script data, as we come through the holiday time, as everybody knows, gets a little bit noisy in Thanksgiving in December. So we are going to look really hard probably 60, 70, 90 days out from now."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Geoff, this is Al. We have learned a lot from our predecessors, including Lily and others. And we are employing actually pretty innovative ways of finding where the patients are and where the sites are and -- which includes where the PET scans are because",213,"Geoff, this is Al. We have learned a lot from our predecessors, including Lily and others. And we are employing actually pretty innovative ways of finding where the patients are and where the sites are and -- which includes where the PET scans are because the scanners have to be pretty close to where the [indiscernible] are made. And of course, the patients have to get there. The other thing we're doing is to screen patients before they need PET scans by using a neuropsychological test battery to make sure that by the time to get to the PET scanners, there's a high likelihood that they'll actually have amyloid. And then in terms of early AD, what we mean by early AD are prodromal and the earlier stages of mild Alzheimer's. And in terms of what it means for the marketplace, I do believe that there's going to be a change ultimately in the way the patients are diagnosed early, perhaps, and certainly before their functional deficits, but when they have mild cognitive impairment, I believe the health care system will set up ways of identifying those patients who need treatment early. And we're working on many of those, too, along with many colleagues outside who are also thinking about the same thing."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen & Company.",13,"Your next question comes from the line of Eric Schmidt from Cowen & Company."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Another one for Al. It looks like you're going to be faced with a couple of go, no-go decisions on Phase III programs in 2016. I'm just thinking specifically for LINGO and for the base compound E2609. Just kind of wondering, what kind of hurdle you've set",93,"Another one for Al. It looks like you're going to be faced with a couple of go, no-go decisions on Phase III programs in 2016. I'm just thinking specifically for LINGO and for the base compound E2609. Just kind of wondering, what kind of hurdle you've set for yourselves in terms of going forward and maybe also further justify if the hurdle is not be kind the low and, although I sense that's what you're signaling to investors, why it makes sense to move forward to for the risky programs of low-ish hurdle?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","I wouldn't say that the hurdle is very low. I think what I'm try to stay with the LINGO, this is a Phase II trial, and it's pretty novel territory we're on, where not too many people have looked at repair strategies for any neurologic disease, including M",268,"I wouldn't say that the hurdle is very low. I think what I'm try to stay with the LINGO, this is a Phase II trial, and it's pretty novel territory we're on, where not too many people have looked at repair strategies for any neurologic disease, including MS. So I would say that we're going to look at the totality of the data. We're going to combine the clinical outcome measures, along with the imaging outcome measures, learn as much as we can and really decide, does the program deserves a continued investment. And if so, can we go to Phase III? Are we ready to go to Phase III? Because in Phase III, we're going to have to employ outcome measures that everybody agrees, including regulators, obviously. But also the MS community, everybody agrees, will provide answers on whether or not the treatment effect is clinically meaningful. And in the case of the BACE inhibitor, the main thing we're going to be looking at is safety. And I don't think it's uncommon. In fact, I think all of our competitors have gone from early-stage safety data right to large registrational trials. And I think there are good reasons for that. We are confident in the pharmacodynamic effect that we see in that when we look at a beta 42 levels in CSF, we get nice, very strong, dose-dependent decreases in beta 42. So we're not going, I mean, as George said, we won a match their risk by making sure that we have a desired biological effect. And we're pretty confident already that we have that."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Two quick ones on TYSABRI. Looks like you're seeing stabilization. Wondering if you could talk about the dynamics you are seeing there amongst patients since the SPMS data was reported. And then for Paul, just curious, you earmarked $100 million for BD ne",61,"Two quick ones on TYSABRI. Looks like you're seeing stabilization. Wondering if you could talk about the dynamics you are seeing there amongst patients since the SPMS data was reported. And then for Paul, just curious, you earmarked $100 million for BD next year. How the sector pulled back amongst the smaller biotechs might influence your capital allocation strategy this year?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, I'll try to take the TYSABRI one as well, but Al can chime in here. Thanks, Brian, for the question. Yes, we did not see a discernible change kind of coming out of the SPMS readout. It may be early, it may not. And I think that was, to some extent, o",221,"Yes, I'll try to take the TYSABRI one as well, but Al can chime in here. Thanks, Brian, for the question. Yes, we did not see a discernible change kind of coming out of the SPMS readout. It may be early, it may not. And I think that was, to some extent, our thesis as well. Patients doing very, very well and have individual experiments with TYSABRI that's generally quite positive. With respect to the earmarking for $100 million, it's -- we always debate this internally. Should it be more than that? Should it be less? Should we trade it off against R&D dollars? All that type of stuff. But we try to earmarks some level of money that obviously is expense money, which has been -- we've been a little bit biased that way with the earlier-stage biotechs over the last number of years have had opportunities right to the IPO window's been open. It's been very open for them to continue on the there is a potential that with the change in the biotech sector, that as we we've looked at corporate development to business development-type deals, clearly, one of the last hurdles to get through is financial valuation. There's a change that, that dynamic is changing in favor for us. And George, maybe add some comments as well."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","No, if you're in a smaller biotech company and with the commercial and you have to raise revenue, there are only a couple of ways to do that. And as it gets more difficult and less attractive to raise money from the financial markets, obviously, other alt",116,"No, if you're in a smaller biotech company and with the commercial and you have to raise revenue, there are only a couple of ways to do that. And as it gets more difficult and less attractive to raise money from the financial markets, obviously, other alternatives become more attractive. And we hope that, and we believe that we'll all move in the favor of companies like also are out to in license or acquire additional compounds. So we'll see. It takes a while for that to happen. We'll take a recurrent use of the market to hold for a while or deteriorate further. If that happens, and I believe there'll be interesting opportunities for us."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Your next question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Just two. Just a couple of questions since everyone's breaking the one-question rule.",13,"Just two. Just a couple of questions since everyone's breaking the one-question rule."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","I think you started that trend, Mark.",7,"I think you started that trend, Mark."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","On TECFIDERA, Paul, I remember last year, I know you're not providing particular guidance for '16, but I think last year, you gave some color on expectations I'd be curious to know if you're into that this year. What and specifically what are you expectin",131,"On TECFIDERA, Paul, I remember last year, I know you're not providing particular guidance for '16, but I think last year, you gave some color on expectations I'd be curious to know if you're into that this year. What and specifically what are you expecting for price volume and '16 in the U.S? Should we be modeling and your price, any volume? And then on LINGO, Al, this has come up in prior questions so just to push you a little bit. When you say separation, should we think of that as common sense separation of the clinical endpoints would be clinically relevant and that we don't necessarily need sadistically A P value under point 05 when you're analyzing the data in order to make a good decision into Phase III?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Mark, this is Paul. I -- the only additional -- I really don't want to provide anything additional no comments further, just like reinforce what I did say in the prepared remarks. On TECFIDERA, our plan assumes stable demand for tech in the United States,",89,"Mark, this is Paul. I -- the only additional -- I really don't want to provide anything additional no comments further, just like reinforce what I did say in the prepared remarks. On TECFIDERA, our plan assumes stable demand for tech in the United States, right? We're looking us very firmer, but that's what the plan assumes. And that's really what we have seen for a number of quarters. On the U.S. pricing side, our financial guidance assumes no U.S. prices for TECFIDERA for the remainder of the year."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","On LINGO, Mark, we have a trial with about 80 patients per arm. And so it's not -- it's a robust tryout. But yes, I think we're more on the common sense side, as you put it. We want to know -- and we can look at separation in several ways. I mean, we can",149,"On LINGO, Mark, we have a trial with about 80 patients per arm. And so it's not -- it's a robust tryout. But yes, I think we're more on the common sense side, as you put it. We want to know -- and we can look at separation in several ways. I mean, we can look at proportion of patients who are improving relative to placebo. We can look at patients who are slowing -- their progression has slowed so that -- so we can look at both ways. And that's sort of what I mean by separation. But I think it's more on the common sense side. And I tried to indicate that there's a lot of exploratory pieces to these trials because some of these endpoints have really never been employed in any significant way in large trials. So that's what I was trying to say, Mark."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","I think, Mark, this is George, the decision on the LINGO trial will be whether or not we will have a meaningful clinical impact on endpoints that the regulators would consider a provable endpoint in the Phase III trial, right? And there are many and was t",117,"I think, Mark, this is George, the decision on the LINGO trial will be whether or not we will have a meaningful clinical impact on endpoints that the regulators would consider a provable endpoint in the Phase III trial, right? And there are many and was that were going to be looking at in the trial, and there could be some combination of them. And we're not going to have a low bar, but it is a Phase II exploratory study. And as we look at those endpoints, we will make a decision. But when I characterize it as low bar, I characterize it right now is a little bit undefined bar until we see the data."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","And your next question comes from the line of Michael Yee from RBC Capital Markets.",15,"And your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","On SMN-Rx, and I refer to it as [indiscernible] I pronounce your new name. Can you just talk a little bit about some of the data you've seen so far and how your commentary has changed around that a little bit to the positive, which is fine. But I guess, i",136,"On SMN-Rx, and I refer to it as [indiscernible] I pronounce your new name. Can you just talk a little bit about some of the data you've seen so far and how your commentary has changed around that a little bit to the positive, which is fine. But I guess, it always don't go comparing historical literature and there is about different things out there. So Al, can you maybe just talk a little bit your confidence in the literature and the range of the median survival other and what you think is going on here? You previously talked about weight gain. [indiscernible] talk a little bit about that just decimated up a little bit about that in what you are seeing an I guess why versus historical literature I guess I'm a bit better."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. So the main data we are looking at is the Type 1 SMA or the infantile onset. And as you know, we're comparing it -- we and I, we're comparing it to natural history. And those things are always tricky because natural history -- the care of patients ch",249,"Yes. So the main data we are looking at is the Type 1 SMA or the infantile onset. And as you know, we're comparing it -- we and I, we're comparing it to natural history. And those things are always tricky because natural history -- the care of patients changed over time and stuff like that. And you have to sort of find matching patients, patients that are similar to the ones that you looked at in your open-label study. My confidence grows with every passing day because, as you know, these children are supposed to -- their median survival is 2 years. And so we're at the point where many of these babies are getting to that point or going beyond it. And so I think that if they are surviving, our confidence grows. And also we're also looking at whether or not they're gaining, whether they're making improvements. These children generally don't improve, and they're hitting milestones that are not commonly seen in the natural history. So we believe the data looking promising, but there are caveats to comparison to natural history studies. And we have to be cautious because everybody, including parents and the whole world, wants to see a cure for these babies. So our bias is certainly leaning toward wanting to see something, and we have to be cautious about that. So the Phase III trials are sham-controlled. They're blinded. And I think that's where we believe that the definitive data will come from."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matthew Harrison from Morgan Stanley.",13,"Your next question comes from the line of Matthew Harrison from Morgan Stanley."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","So I'm going to ask two. One on Alzheimer's. We've recently had a handful of physician feedback that there's a dearth of skilled readers for some of these endpoints and these studies. Can you just talk a little bit about what you are doing to make sure th",150,"So I'm going to ask two. One on Alzheimer's. We've recently had a handful of physician feedback that there's a dearth of skilled readers for some of these endpoints and these studies. Can you just talk a little bit about what you are doing to make sure that the readers are well-trained, especially given the small change in the endpoints is likely to demonstrate the benefit of the drug? And then just on LINGO, can you remind us what our expectation should be? I remember, in 2015, when you moved out the time lines, you said that a small interval group would be seeing some of the LINGO data ahead of sort of the full analyses, and they'd be planning for Phase III. Should we expect, if you decide to move ahead for Phase III, you'll be able to talk about that pretty quickly when we see the data?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, let me get the second question first. I want to be sure that the trial remains fully blinded. Nobody at Biogen has broken the blind and looked at the unblinded data. So that small team, there's no small team looking at any data. And in terms of the A",201,"Yes, let me get the second question first. I want to be sure that the trial remains fully blinded. Nobody at Biogen has broken the blind and looked at the unblinded data. So that small team, there's no small team looking at any data. And in terms of the AD, there are -- it is sort of an art to look to read PET scans. I don't know if that's what you're referring to. But the readers of these images have to be trained, and we actually employed a quality control step in a blinded way where we have somebody at Minnesota, an expert, reviewing every single scan. Moreover, the terms of the collective testing, the clinical outcome measures, we -- the main thing we want is consistency over time. And we have to -- and we're doing a lot of the things that we actually do in MS, where we have -- we do a lot of training, we have examining neurologists, and we separate them from an neurologists that actually treat the patients for side effects and things. So I think we've employed sort of the state-of-the-art methods for collecting these data and hopefully avoided many of the pitfalls."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","And your next question comes from the line of Chris Raymond from Raymond James.",14,"And your next question comes from the line of Chris Raymond from Raymond James."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Just a couple of quick commercial questions. Paul, on TECFIDERA, you guys called out the $30 million of inventory during the quarter. And I think Q3's $10 million to $15 million, if I recall correctly. So how should we think, I guess, about Q1? Are we tal",150,"Just a couple of quick commercial questions. Paul, on TECFIDERA, you guys called out the $30 million of inventory during the quarter. And I think Q3's $10 million to $15 million, if I recall correctly. So how should we think, I guess, about Q1? Are we talking about $40 million to $45 million that needs to burden off? Or is there some other dynamic there that we should be modeling? And then also on PLEGRIDY, just wondering if you could share insights on, as the launch has progressed, any change specifically in the source of patients, either from AVONEX or other beta interference? And if I have some discussions some of the checks indicate there's been a shift or PLEGRIDY is taking patients now from other beta interference versus more from AVONEX early on. I'm wondering if that's what you're seeing, too, or if there's something else going on there."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Chris, this is Paul. TECFIDERA, let me just kind of level set and just clarify because you're exactly on it. What we had noted in Q3 is that our estimate that the time was that there was about $10 million to $15 million of building in the SPP, in the spec",406,"Chris, this is Paul. TECFIDERA, let me just kind of level set and just clarify because you're exactly on it. What we had noted in Q3 is that our estimate that the time was that there was about $10 million to $15 million of building in the SPP, in the specialty pharmacy part of the combined channel. And that was mostly what we believe related to a government purchase, related to kind of their fiscal year timing. I think, our belief is that, that's largely burned through. On a quarter-to-quarter basis within specialty pharmacies, there is sometimes ebbs and flows on inventory levels, and we'll try to do our best to point that out. But we think it's at -- and I would think that we may have things like what we had in Q3. But I think that's largely burned through. What we know that in Q4 is actually related to the wholesaler portion of the channel and, on a quarter-over-quarter basis, that there was a little bit of build. So I think, as we move into Q1, we're really probably dealing with the $30 million to get to kind on a sequential quarter basis. We always -- just to complete the thought, we always deal with kind of a Q1 -- Q4 to Q1 dynamics that sometimes you don't have great visibility on the so-called shoebox effect, the change in Q1 with respect to patients on insurance and -- which is really that obviously to shoebox. So Q1 oftentimes and gross in that change so discounts allowances rates close-up in Q1 as well for us as well as the industry. So we're always mindful of that. On PLEGRIDY, it's very interesting. Your checks are probably are consistent with what we're seeing as well. We saw early on, and to some extent, it was our marketing strategy early on was a conversion of Avonex patients. And we hit some speed bumps along that early on in the launch in the first -- in the last quarter of 2014 and going into early into 2015. We're starting to see both from a -- we're trying to do on a marketing strategy, but we're also starting to see the benefits of PLEGRIDY being seen as sourcing volumes from the other interferons. Look, this is a great product vis--vis kind of capturing our penetrating and capturing share within that interferon segment of the marketplace. Great question. Thanks, Chris."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Your next question comes from the line of Terence Flynn from Goldman Sachs."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","This is Cameron filling in for Terence. Congrats on your Enbrel biosimilar in the EU. I was wondering, is there anything you can share regarding your pricing and commercialization strategies there?",31,"This is Cameron filling in for Terence. Congrats on your Enbrel biosimilar in the EU. I was wondering, is there anything you can share regarding your pricing and commercialization strategies there?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Cameron, obviously, we're in discussions country-by-country but really can't share anything. So no comments on that. We'll try to as we begin to post revenues to try to provide some commentary.",31,"Cameron, obviously, we're in discussions country-by-country but really can't share anything. So no comments on that. We'll try to as we begin to post revenues to try to provide some commentary."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matt Roden from UBS.",12,"Your next question comes from the line of Matt Roden from UBS."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","I think, as a sector, we needed some good news. So I had kind of a specific on the BACE inhibitor E2609. The Phase II study is in 700 patients, but my understanding the data that we'll get on this year's disclosures is just on safety from the initial coho",105,"I think, as a sector, we needed some good news. So I had kind of a specific on the BACE inhibitor E2609. The Phase II study is in 700 patients, but my understanding the data that we'll get on this year's disclosures is just on safety from the initial cohorts, not the whole 700 patients. So can you just clarify what we should expect to see from this disclosure this year and help us understand what exactly you'll be looking for and how this information would pertain to a go, no-go decision? And then lastly, just when we'll get initial efficacy findings from this program."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, you're right, Matt. We're going to look at the first cohort. The original plan was that the first cohort would then trigger a second cohort. I'm not -- the main thing we're going to look at is the safety data from the first cohort and also to confirm",74,"Yes, you're right, Matt. We're going to look at the first cohort. The original plan was that the first cohort would then trigger a second cohort. I'm not -- the main thing we're going to look at is the safety data from the first cohort and also to confirm the pharmacodynamic effect that we saw with our Phase I study. So it's really safety and repeat or confirmation of pharmacodynamic effect in the CSF."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Okay. And does that pertain to any go, no-go decision? And then when we should expect to see initial efficacy?",20,"Okay. And does that pertain to any go, no-go decision? And then when we should expect to see initial efficacy?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Well, with the number of patients in the first cohort, I have low expectations in terms of efficacy. And it will lead to a go, no-go decision to Phase III.",30,"Well, with the number of patients in the first cohort, I have low expectations in terms of efficacy. And it will lead to a go, no-go decision to Phase III."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang from the Bank of America Merrill Lynch.",17,"Your next question comes from the line of Ying Huang from the Bank of America Merrill Lynch."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Maybe for Al. You mentioned that you should expect the enrollment or full enrollment of aducanumab Phase III similar to the timeline of the other Phase II trials. Does that mean that we should probably expect 18 to 24 months or potentially even longer for",113,"Maybe for Al. You mentioned that you should expect the enrollment or full enrollment of aducanumab Phase III similar to the timeline of the other Phase II trials. Does that mean that we should probably expect 18 to 24 months or potentially even longer for the enrollment to be accrued? And then also secondly, I was curious, your thoughts on TYSABRI because ocrelizumab could be approved probably towards end of this year. We know that about 30% of JCB patients are on TYSABRI. I mean, 30% of TYSABRI patients are JCB-positive. And then there's also the level of level U.S. from PPMS and SPMS. So if you could provide some thought on that."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. So in terms of enrollment, I don't want to hazard a guess as to exactly how long it's going to take to enroll patients. I think we're pleased with what we're seeing so far, but it's early days. And right now, our timelines are assuming that the enrol",183,"Yes. So in terms of enrollment, I don't want to hazard a guess as to exactly how long it's going to take to enroll patients. I think we're pleased with what we're seeing so far, but it's early days. And right now, our timelines are assuming that the enrollment rate on a patients-per-site basis to what we've seen with other Phase III trials. And then in terms of ocrelizumab, it's great to have a new drug for patients, particularly for PPMS patients. I don't think that there were a lot of PPMS patients who are on TYSABRI, if that's what you're asking. There probably are some people who are have SPMS on TYSABRI because our label says relapsing forms of MS, and patients with SPMS have relapses in the early stages of SPMS. So it would be unlabeled to be on TYSABRI if you have relapsing SPMS. Now ocrelizumab, I don't think, will have a label for SPMS as far as I understand. I don't recall the data trial in SPMS. I don't see how that would affect the SPMS piece very much."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Cason morphed from JPMorgan.",13,"Your next question comes from the line of Cory Cason morphed from JPMorgan."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","I guess, first for Paul on capital allocation. Now that you've finished the $5 billion share repurchase program, do you have plans to start another one? I'm just curious how we should be thinking about share count in '16. And then also, Paul, on your comm",89,"I guess, first for Paul on capital allocation. Now that you've finished the $5 billion share repurchase program, do you have plans to start another one? I'm just curious how we should be thinking about share count in '16. And then also, Paul, on your comment with regard to price increases not being ashamed in your 2016 guidance. Can you just remind us how you've built that into past guidance and prior years? And is this a change that simply the result of the current pricing environment and controversy?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. With respect -- let's kind of start on capital allocation and share repurchases. And you're right. We've exhausted the $5 billion characterization that was authorized and approved by the Board back in the spring of 2015. George and I are in constant",200,"Yes. With respect -- let's kind of start on capital allocation and share repurchases. And you're right. We've exhausted the $5 billion characterization that was authorized and approved by the Board back in the spring of 2015. George and I are in constant contact, in constant dialogue, in constant discussion about best deployment of capital. I think our thinking right now is a bit focused on strategic deployment. And -- but I would continue to emphasize is that we always frame these as one or the other in, and it's -- over a longer the time, it's appropriately a mix. And I think the cash flow generation of the company remains quite robust such that we can deploy capital in a lot of different ways, all with the objective of increasing intrinsic value per share. So we'll look towards a lot of different things. I mean, I'm being a little bit vague and opaque but the thing that's just because a little bit where we are right now and thinking through all of the dynamics of that. No real comment on the pricing dynamics for the balance of the year. The financial guidance for this year does not assume it."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Wells Fargo.",10,"Your next question comes from the line of Wells Fargo."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","I'll sneak in Jim this morning. A couple of quick questions. In terms of the remyelination programs, you have the oral remyelination agent 61. Clearly, remyelination is a very complex process. Have you looked to combining that with anti-LINGO? Do you use",122,"I'll sneak in Jim this morning. A couple of quick questions. In terms of the remyelination programs, you have the oral remyelination agent 61. Clearly, remyelination is a very complex process. Have you looked to combining that with anti-LINGO? Do you use it remyelination as a single-drug opportunity? Or do you think it's going to be combination therapy in perhaps subsets of patients? And then for the Ionis SOD1 trial, for these kinds of trials where you're looking at these early rare-to-find mutations or question opportunities that do you see the pattern repeating that we saw in nusinersen and can you generate enough compelling data of Phase I trial in effected patients that you can jump into a potentially registration-enabling trial?"
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. Thanks those questions, Jim, on the remyelination. Right now, we're thinking of it that we would use one agent for remyelination based on our preclinical studies. Of course, the remyelinating drug would probably be combined with an anti-inflammatory",224,"Yes. Thanks those questions, Jim, on the remyelination. Right now, we're thinking of it that we would use one agent for remyelination based on our preclinical studies. Of course, the remyelinating drug would probably be combined with an anti-inflammatory or immunomodulatory drug, and that's exactly how we're conducting the SYNERGY study of anti-LINGO-1 in MS. We're adding it to Interferon. But right now, we don't have any plans to combine the 2 remyelinating drugs that we have in our pipeline. That may change over time, but that's our current plan. And then in terms of the Ionis SOD1 Phase I trial, yes, we've done a lot of work. We many Biogen also the ALS community on biomarkers and not only in human studies because you'll recall that there was a fire [indiscernible] study with a less potent [indiscernible] in SOD1 patients. And there's been some a lot of animal work. And we had CSF measures that we code template at we think will predict parenchymal spinal cord SOD1 levels. The whole point of what we're trying to do is to reduce levels of SOD1 because we believe that the mutated forms of SOD1 are toxic. So we have actually validated -- we believe very good measures and that we can use to take the program for the from the current trial to registrational study."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","And this is George. I think that's often the case in the advantage of working on genetically homogeneous diseases of the result of a single gene. So I want to thank everybody for your attention this morning and for your interest. We are going to go back t",63,"And this is George. I think that's often the case in the advantage of working on genetically homogeneous diseases of the result of a single gene. So I want to thank everybody for your attention this morning and for your interest. We are going to go back to work, and do our best to deliver a great 2016 for everyone. So thank you."
29726,320091841,921368,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Ben, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Year-End 2015 Financial Results and Business Update. [Operator Instructions] Thank you. I would lik",62,"Good morning. My name is Ben, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Year-End 2015 Financial Results and Business Update. [Operator Instructions] Thank you. I would like -- I would now like to turn the call over to Mr. Matt Calistri, Senior Director of Investor Relations."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thank you, and welcome to Biogen's fourth quarter and full-year 2015 earnings conference call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconcil",192,"Thank you, and welcome to Biogen's fourth quarter and full-year 2015 earnings conference call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. 
We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Al Sandrock, our Chief Medical Officer; and our CFO, Paul Clancy.
Now I'll turn the call over to George."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt, and good morning, everyone, and thanks for joining us today. In 2015, Biogen generated revenues of $10.8 billion, an 11% increase over 2014, and non-GAAP EPS of $17.01, a 23% increase over 2014. Although the revenues were less than we had",732,"Thanks, Matt, and good morning, everyone, and thanks for joining us today. 
In 2015, Biogen generated revenues of $10.8 billion, an 11% increase over 2014, and non-GAAP EPS of $17.01, a 23% increase over 2014. Although the revenues were less than we had anticipated at the beginning of last year, I'm pleased that we were able to take appropriate action in the second half of the year to maintain healthy earnings growth while we continued to advance the potentially transformative therapies in our pipeline. 
TECFIDERA's demand has been stable in the U.S., and combined with growth in Europe, we expect TECFIDERA to continue to drive our global leadership in multiple sclerosis. TECFIDERA is now not only the most prescribed oral MS therapy worldwide, it is also the most prescribed of all MS therapies in Germany, France and the U.K. Overall, more than 170,000 patients have been treated with TECFIDERA. 
Our hemophilia products, ELOCTATE and ALPROLIX, generated over $0.5 billion of revenue in their first full year on the market in the U.S. In November, the European Commission approved ELOCTA for the treatment of hemophilia A in the EU, which we believe will help to contribute growth in hemophilia this year as our collaboration partner, Sobi, commercializes ELOCTA in additional markets. 
We also made progress in business development. We acquired Convergence Pharmaceuticals and raxatrigine, their early compound. Raxatrigine is an oral, small molecule Nav 1.7 blocker with promising Phase II data that will move into Phase III this year. 
We licensed amiselimod, or MT-1303, for Mitsubishi Tanabe Pharma, a late-stage S1P1 inhibitor for ulcerative colitis and Crohn's disease. 
We entered into a collaboration agreement with AGTC to develop gene-based therapies for multiple ophthalmic diseases. 
And this month, BENEPALI was approved in the EU. BENEPALI, the first etanercept biosimilar approved in the EU, is the first of 3 potential anti-TNFs to advance under our Samsung Bioepis joint venture with Samsung Biologics. Under our agreements with Samsung Bioepis, we will manufacture and commercialize BENEPALI in the EU. 
Meanwhile, we continued investing in 2015. We purchased land in Solothurn, Switzerland, and this Friday, January 29, we'll break ground on an advanced next-generation biologics manufacturing facility there. And we purchased Eisai's drug product manufacturing facility and supporting infrastructure in Research Triangle Park, North Carolina. 
We also took actions to return capital and change the capital structure of the business. We fully implemented our $5 billion share repurchase program, and a portion of that repurchase was funded through the $6 billion debt offering that we completed in September. 
In R&D, we moved forward several exciting mid- and late-stage assets in our pipeline. It may seem like a long time ago now, but it was Q1 2015 that we presented the aducanumab data showing a statistically significant removal of plaque and slowing of cognitive decline in Alzheimer's patients. 
We presented data suggesting that our anti-LINGO antibody is biologically active in remyelination, and the Phase II data for nusinersen generated by our partner Ionis looks increasingly encouraging as a potential therapy for spinal muscular atrophy. 
We also initiated Phase I trials in ALS and Parkinson's disease. 
Al will discuss the many advances we made in our pipeline in more detail, but I think this progress is a testament to our commitment to patients and our world-class capabilities across the breadth of R&D. 
We also continued to strengthen our early-stage clinical and research capabilities. We bolstered research talent in our neuroscience group and established collaborations with first-rate academic centers around the world. As a result, I believe we're now in a better position than ever to both discover novel therapies and accelerate drug development while minimizing risk. 
Lastly, summarizing 2015 would not be complete without commenting on the restructuring we implemented in October. Although it was a difficult decision, we've already seen positive results from the steps that we took. With the majority of the restructuring now completed, there's a palpable, reinvigorated focus on our key commercial initiatives and high-potential pipeline candidates, and our operating expenses are trending at a rate that we believe can continue to provide healthy earnings leverage going forward. 
So all in all, it was a busy and eventful year, and we believe that the progress we made and the actions we took positioned us well for a potentially transformative 2016 and beyond. 
With that, I'll pass the call along to Al for an update on R&D."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, George. 2015 was a productive year for the R&D organization. We advanced the next wave of potential medicines through the pipeline, added important assets through business development and acquisitions and expanded our research leadership by hiring",1037,"Thanks, George. 2015 was a productive year for the R&D organization. We advanced the next wave of potential medicines through the pipeline, added important assets through business development and acquisitions and expanded our research leadership by hiring world-class scientists. I believe our pipeline and our organization are stronger than they have ever been. 
Starting with Alzheimer's disease. Last year, we presented compelling interim Phase Ib data for aducanumab, the first investigational drug for Alzheimer's disease, to demonstrate both the statistically significant reduction of amyloid plaque as well as slowing of cognitive decline. In August, we began enrolling patients into 2 pivotal Phase III trials of aducanumab in early Alzheimer's disease. 
We are pleased with the progress of these studies but recognize the inherent challenges in recruiting patients with early Alzheimer's disease and the limited availability of PET scanners. Fortunately, owing to the strong results from our clinical trials to date, there has been substantial interest in the program, which we believe has helped with recruitment. That said, we continue to anticipate that the Phase III enrollment duration will be similar to other large clinical trials in Alzheimer's disease. Looking ahead, in the second half of 2016, we expect to share additional safety data from the ongoing titration arms of the Phase Ib PRIME study for aducanumab. 
Our other 2 mid-stage clinical candidates for AD that are partnered with Eisai continued to advance. Eisai had indicated that they anticipate releasing interim safety data this year for E2609, a small molecule BACE1 inhibitor, and we are also expecting to see top line efficacy and safety data for BAN2401, a monoclonal antibody targeting beta-amyloid. 
Moving to anti-LINGO. You may recall that last year, we presented Phase II data in acute optic neuritis. To our knowledge, this was the first clinical trial to show evidence of remyelination following an acute inflammatory demyelinating injury in humans. And we believe that these results support our ongoing development efforts. 
Our Phase II SYNERGY study in MS is a 418-patient, double-blind, multicenter study assessing 4 doses of anti-LINGO versus placebo when added to interferon beta therapy. It utilizes a composite endpoint comprising outcome measures of disability, cognition and physical function. We believe that a separation from placebo on any of these measures could be clinically meaningful. We are also looking at imaging endpoints that reflect the integrity of myelinated nerve fibers. Any differences in treatment effect between pre-existing and newly acquired lesions will also be of interest. 
We believe that the robust design of this clinical trial will enable a better understanding of the therapy's potential in MS. And if the results are positive, the trial should provide valuable insight into the design of our Phase III program. Results for SYNERGY are anticipated in mid-2016. 
Now turning to nusinersen. Our partner, Ionis, recently completed target enrollment of the Phase III CHERISH study in children with childhood-onset SMA. And by the first half of this year, we hope to complete enrollment in ENDEAR, the Phase III study evaluating nusinersen in infants with infantile-onset SMA. This progress sets the stage for data from both of these trials to be available in the first half of 2017. 
Whereas the data from the early-stage, open-label clinical trials are encouraging when compared to data from natural history studies, the well-controlled Phase III studies are designed to definitively assess the safety and efficacy of nusinersen. We are meeting frequently with regulators from Europe, Japan and the United States with the goal of making the drug available to SMA patients as rapidly as possible. 
Moving on to our hemophilia therapies. Last month, at the 57th American Society of Hematology Annual Meeting, we presented new data demonstrating that ELOCTATE and ALPROLIX effectively managed bleeding into joints and maintained low annualized bleeding rates in people with severe hemophilia A and B, reaffirming the benefits of these 2 therapies. In addition, teams from the University of Pittsburgh, The Hemophilia Center of Western Pennsylvania and The University of Texas Southwestern Medical Center presented data showing that immune tolerance induction using ELOCTATE was successful in 3 children with inhibitors, including a child previously failing recombinant factor VIII immune tolerance induction The time to achieving tolerance in the study was 4 to 12 weeks, which appears to be significantly shorter than with the standard of practice, which can take several months to several years. 
During the quarter, we, in collaboration with Ionis, also announced the initiation of a Phase I/II clinical study of an antisense drug against superoxide dismutase, or SOD1, in patients with amyotrophic lateral sclerosis. I am pleased to announce that last week, we dosed our first patient in the trial. Mutations in the SOD1 gene result in the second most common form of familial ALS, affecting approximately 2% of all ALS patients. 
We also continue to make excellent progress toward initiating multiple late-stage clinical trials in 2016. Next month, we anticipate sharing additional Phase II study results for TYSABRI in acute ischemic stroke at the International Stroke Conference in Los Angeles. While a single dose of administered -- of natalizumab administered up to 9 hours after stroke onset did not reduce focal infarct volume, treatment was associated with meaningful improvements in clinical outcomes over the course of 90 days. The clinical profile and treatment window supports further investigation of natalizumab as a potential novel approach for treating acute ischemic stroke, and we intend to conduct a Phase IIb trial. 
Amiselimod, or MT-1303, an S1P1 inhibitor for inflammatory bowel disease, is anticipated to advance to Phase III trials this year. In the second half of the year, we plan to initiate Phase III studies for both ulcerative colitis and Crohn's disease. We currently have no plans for the asset in MS but expect to continue to evaluate other options for the molecule in collaboration with our partner, Mitsubishi Tanabe. 
Raxatrigine, a small molecule inhibitor of the Nav 1.7 sodium channel, is in development for several pain indications. In the second half of the year, we anticipate initiating a Phase III trial to confirm the efficacy of raxatrigine in patients with trigeminal neuralgia. We also plan to initiate a Phase II trial in patients with sciatica later this year. 
I'll now pass the call over to Paul."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Al. Our GAAP diluted earnings per share were $3.77 in the fourth quarter and $15.34 for the full year. Our non-GAAP diluted earnings per share were $4.50 in the fourth quarter and $17.01 for the full year. Total revenue for Q4 grew 8% year-over-",1447,"Thanks, Al. Our GAAP diluted earnings per share were $3.77 in the fourth quarter and $15.34 for the full year. Our non-GAAP diluted earnings per share were $4.50 in the fourth quarter and $17.01 for the full year. 
Total revenue for Q4 grew 8% year-over-year to approximately $2.8 billion and grew 11% for the full year to $10.8 billion. Foreign exchange, offset by hedging, weakened fourth quarter revenue by approximately $35 million versus prior year and by approximately $227 million for the full year versus prior year. 
Global Q4 TECFIDERA revenue was $993 million. We recorded revenues of $785 million in the U.S. and $208 million outside the U.S. TECFIDERA U.S. revenue benefited from an increase in wholesale inventory by approximately $30 million versus prior quarter. At this point, we believe TECFIDERA's safety perceptions and physician intent to prescribe have largely stabilized in the U.S. We're seeing positive leading indicators for the recently launched marketing campaign for TECFIDERA, including increased visits to our website and higher call volume into our Patient Services organization. 
In Europe, TECFIDERA continued its trend of solid patient growth this quarter, especially in more recently launched markets such as the U.K., Italy and Spain. The European label for TECFIDERA was updated in December, and we're actively educating physicians on appropriate patient monitoring. 
For the full year, worldwide TECFIDERA revenues were $3.6 billion consisting of $2.9 billion in the U.S. and $730 million in sales outside the U.S. Foreign exchange impact, offset by hedging, weakened full year TECFIDERA revenue by approximately $27 million versus prior year. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $740 million during the fourth quarter, which includes $506 million in the U.S. and $233 million in sales outside the U.S. 
For the full year, worldwide interferon revenues were $3 billion consisting of $2 billion in the U.S. and $951 million in sales outside the U.S. Foreign exchange impact, offset by hedging, weakened full year interferon revenues by approximately $88 million versus prior year. 
TYSABRI continued to add patients this quarter with worldwide revenues of $481 million. These results were comprised of $278 million in the U.S. and $203 million internationally. 
For the full year, worldwide TYSABRI revenues were approximately $1.9 billion. We recorded U.S. revenue of $1.1 billion and $783 million internationally. Foreign exchange impact, offset by hedging, weakened full year revenue for TYSABRI by approximately $90 million versus prior year. 
Physicians continued to choose TYSABRI for patients requiring high efficacy, and nearly 10 years after approval, we believe its well-understood safety profile positions TYSABRI well. 
Turning to hemophilia business. ELOCTATE revenue for the quarter was $101 million and $320 million for the full year. ALPROLIX revenue in Q4 was $71 million and $234 million for the full year. 
Turning to our anti-CD20 unconsolidated joint business, which includes our profit share for RITUXAN and GAZYVA in the U.S. as well as our profit share in royalties on sales of rituximab outside the U.S. We recorded $334 million for Q4 and $1.3 billion for the full year. While there was a slight inventory drawdown for RITUXAN in the fourth quarter, we ended the year with a higher inventory level than we had anticipated. We also benefited from a $6 million payment from Roche in exchange for access to data supporting the development of ocrelizumab. 
Corporate partner revenues were $69 million for the fourth quarter compared to $40 million in the prior quarter. The increase was related to contract manufacturing for Samsung Bioepis and another strategic partner. For the full year, corporate partner revenues were $189 million. 
During the quarter, we booked a total GAAP charge of approximately $93 million related to the restructuring announced in October. 
Now turning to the non-GAAP expense lines on the P&L. Q4 cost of goods sold were $332 million or 12% of revenue. For the full year, COGS were $1.2 billion or 12% of revenue. 
Q4 non-GAAP R&D expense was $542 million or 19% of revenue, which includes a $60 million payment to Mitsubishi Tanabe. For the full year, non-GAAP R&D expense was $2 billion or 19% of revenue. 
Q4 non-GAAP SG&A expense was $583 million or 21% of revenue. For the full year, non-GAAP SG&A expense was $2.1 billion or 20% of revenue. 
Other net expense was approximately $82 million in the fourth quarter, which includes $67 million in interest expense primarily related to our recent bond offering. Full year other net expense was $124 million, including approximately $96 million in interest expense. 
Our Q4 non-GAAP tax rate was approximately 23% for the fourth quarter as we benefited from the reinstated R&D tax credit. Our full year tax rate was approximately 24%. 
During the year, we repurchased approximately 16.8 million shares of our common stock, completing our previously authorized $5 billion share repurchase program. 
Our weighted average diluted share count was approximately 221 million for Q4, 231 million for the full year. And we ended the year with approximately 219 million basic shares outstanding. This brings us to our non-GAAP diluted earnings per share of $4.50 for the fourth quarter and $17.01 for the full year, representing a 23% increase for the full year. 
We ended the year with approximately $6.2 billion in cash and marketable securities, split approximately 40-60 between the U.S. and ex U.S. 
So overall, we had a strong quarter, benefiting from favorable inventory dynamics for TECFIDERA, stronger-than-anticipated contract manufacturing in RITUXAN revenue and the reinstatement of the R&D tax credit. 
Let me turn to our full year 2016 guidance. We expect revenues of approximately $11.1 billion to $11.3 billion. Starting with multiple sclerosis. Our plan assumes relatively stable demand for TECFIDERA in 2016 in the United States. While we're hopeful our recently launched marketing campaign can reaccelerate growth, we remain cautious as we believe we will not ascertain the impact until the second quarter of this year. In Europe, we anticipate constant pricing through the rest of the year and continued patient growth, particularly in recently launched markets. For TYSABRI, we believe the therapy will remain on a stable trajectory. We believe the number of patients using AVONEX and PLEGRIDY combined will continue to decline as patients move toward orals, but we remain well positioned within this segment of the market. 
Our financial guidance assumes no U.S. price increases for AVONEX, PLEGRIDY and TECFIDERA for the remainder of the year. 
With respect to foreign exchange, our plan is based on the current spot rates. Of note, we had an approximately $170 million in hedge gains in 2015. Given our hedges, our usually placed 12-month forward, we expect limited hedge gains in 2016, so the year-over-year comparison is less favorable. 
Moving to our hemophilia therapies. We anticipate continued growth with ELOCTATE as we believe there remains a significant portion of the patient population that can benefit from long-acting therapies. We're assuming moderating patient adds for ALPROLIX given the rapid uptake in penetration so far. 
In 2016, we are assuming our profit share for RITUXAN and GAZYVA will decrease to 39% from 40% upon FDA approval of GAZYVA in RITUXAN refractory indolent non-Hodgkin's lymphoma. Our plan assumes ocrelizumab will launch in 2017. 
Moving to an expense perspective. We anticipate slight upward pressure on cost of goods sold rate largely due to increases in contract manufacturing, biosimilars and increased hemophilia royalties. 
We anticipate R&D expense between 19% and 20% of sales, which includes approximately $100 million earmarked for business development activity. We plan to invest in a number of R&D programs across our late-stage pipeline, including aducanumab, nusinersen, raxatrigine and amiselimod for inflammatory bowel disease. 
SG&A expense is expected to be approximately 17% to 18% of revenue. The headcount reduction in restructuring announced in October is expected to benefit operating expenses by approximately $250 million. We've also planned to reduce targeted fees and services expenses, which are largely reflected in SG&A. 
From a tax perspective, we anticipate upward pressure on our 2016 tax rate as our profitability mix shifts toward the U.S. 
We anticipate non-GAAP earnings per share results between $18.30 and $18.60 and GAAP EPS to be between $16.85 and $17.15. 
Our plan assumes share stabilization with a weighted average diluted share count of approximately 219 million. 
From a cash perspective, we expect to pay $1.2 billion in CVR payments to Fumapharm in 2016 related to the sales of TECFIDERA. 
And we anticipate capital expenditures of approximately $800 million to $850 million, an increase over 2015 primarily driven by the investment in the Swiss manufacturing plant. 
So the business plan is designed to provide investment to support TECFIDERA, surgically look to control spending and ensure we're utterly focused on investing in and progressing the pipeline. 
I'll turn the call over to George."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Okay, thank you, Paul. Clearly, the commercial trajectory of TECFIDERA was not where we thought it would be at the beginning of last year. And as a result, the revenues fell short of our initial projections. While obviously not happy with that, I'm very p",582,"Okay, thank you, Paul. Clearly, the commercial trajectory of TECFIDERA was not where we thought it would be at the beginning of last year. And as a result, the revenues fell short of our initial projections. While obviously not happy with that, I'm very pleased with the way the company responded. We put additional marketing muscle behind TECFIDERA, we reduced costs and focused the company and we accelerated our stock repurchase program. As a result, we maintained healthy earnings growth at the same time as we continued our investments in aducanumab, LINGO and the other exciting programs in our pipeline. We also continued to invest in additions to our pipeline. We acquired Convergence and its lead compound, raxatrigine. We licensed amiselimod from Mitsubishi Tanabe. We completed the gene therapy relationship with AGTC. And we brought additional compounds into the clinic from our own and partners' research efforts. 
Our commercial portfolio continued to expand  globally as we extended our position as the worldwide leader in multiple sclerosis and significantly grew our hemophilia business. In 2016, we plan to remain focused on commercial execution and advancing our pipeline, which we expect to be the primary source of value creation over the long term. We're looking forward to many updates over the next year, including insight into the potential impact of TECFIDERA's recently launched marketing campaign by the second quarter; Phase II top line results for anti-LINGO in MS in the middle of the year; Phase II data for BAN2401 and E2609; continued Phase II data for nusinersen from Ionis, followed by Phase III data next year; and Phase Ib titration data for aducanumab in the second half of the year. 
We expect to launch up to 3 compounds this year: BENEPALI in Europe following approval from the European Commission earlier this month, ZINBRYTA pending approval in the first half of the year and potentially an infliximab biosimilar, also in Europe. 
Thinking even further ahead, we believe that we're entering the early years of a potentially transformative era in neuro generation drug discovery and development. And we believe that our commitment to research has the potential to yield results that are truly meaningful for patients and shareholders. 
As I said at the recent JPMorgan conference, I believe that our pipeline and our approach, which has the risk inherent in all truly innovative and ground-breaking approaches, is measured and thoughtful. The combination of a much better understanding of disease biology, the focus on genetically validated targets, the use of biomarkers to learn early whether or not our compounds are having the desired biological effects and the adoption of multiple therapeutic modalities may meaningfully increase success rates and identify those projects likely to fail early in the process before large amounts of time and money are spent. Our strategy is evident in the design of the aducanumab Phase Ib trial, the Phase II study of nusinersen, the Phase II studies of anti-LINGO and our recently initiated Phase I trial for SOD1 ALS. We have additional examples, some of which we'll talk about as the year goes on. 
In closing, and as always, I'd like to thank our employees who are dedicated to making a positive impact on patients' lives, and also the patients and physicians who are involved in our clinical development programs. The achievements we made together could not have been realized without their passion and commitment. 
So thank you all for joining us this morning. And operator, we'll now open up the call for questions."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Geoff  Meacham from Barclays.",14,"[Operator Instructions] Your first question comes from the line of Geoff  Meacham from Barclays."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Just have a couple of quick ones, and one on the commercial side. I know it's early days, but are there any initial metrics on the TEC TTC [ph] campaign when you look at things like new starts or returning patients? And then a second one is on the pipelin",90,"Just have a couple of quick ones, and one on the commercial side. I know it's early days, but are there any initial metrics on the TEC TTC [ph] campaign when you look at things like new starts or returning patients? And then a second one is on the pipeline. When you look at the ENGAGE and EMERGE studies, Al, are there lessons to be learned from Lilly in terms of managing PET scan facilities? And what do you think identification of early-stage Alzheimer's patients means to the market opportunity?"
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Geoff. Let me start with the TEC TTC [ph] question. I guess I'd reinforce what we said in our prepared remarks around that really, to try to discern it is going to be looking kind of in the Q2 time period. I mean, clearly, Q2 is not a light switch",154,"Thanks, Geoff. Let me start with the TEC TTC [ph] question. I guess I'd reinforce what we said in our prepared remarks around that really, to try to discern it is going to be looking kind of in the Q2 time period. I mean, clearly, Q2 is not a light switch to determine that. We're seeing early data with respect to, as I had mentioned, kind of hits to the website, conversations into our Patient Services organization, which lean us to think that it's positive. We haven't seen a discernible yet change with respect to specifically your question, but our judgment is that this takes a little bit of time. It's really first week of October. Obviously, script data as we come through the holiday time, as everybody knows, gets a little bit noisy in Thanksgiving in December. So we are going to look really hard probably 60, 70, 90 days out from now."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","This is Al. Well, we have learned a lot from our predecessors, including Lilly and others. And we are employing actually pretty innovative ways of finding where the patients are and where the sites are and -- which includes where the PET scans are because",216,"This is Al. Well, we have learned a lot from our predecessors, including Lilly and others. And we are employing actually pretty innovative ways of finding where the patients are and where the sites are and -- which includes where the PET scans are because the scans -- the scanners have to be pretty close to where the ligands are made. And of course, the patients have to get there. The other thing we're doing is to screen patients before they need PET scans by using a neuropsychological test battery to make sure that by the time they get to the PET scanner, there's a high likelihood they'll actually have amyloid. And then in terms of early AD, what we mean by early AD are prodromal and the earlier stages of mild Alzheimer's. And in terms of what it means for the marketplace, I do believe that there's going to be a change ultimately in the way the patients are diagnosed early. Perhaps -- and certainly before their functional deficits but when they have mild cognitive impairment, I believe the health care system will set up ways of identifying those patients who need treatment early. And we're working on many of those, too, along with many colleagues outside who are also thinking about the same thing."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Another one for Al. It looks like you're going to be faced with a couple of go, no-go decisions on Phase III programs in 2016. I'm just thinking specifically for LINGO and for the BACE compound E2609. I'm just kind of wondering what kind of hurdle you've",98,"Another one for Al. It looks like you're going to be faced with a couple of go, no-go decisions on Phase III programs in 2016. I'm just thinking specifically for LINGO and for the BACE compound E2609. I'm just kind of wondering what kind of hurdle you've set for yourselves in terms of going forward. And maybe you can also further justify if the hurdle is going to be kind the low-end hurdle. I sense that's what you've been signaling to investors, why it makes sense to move forward with -- to fairly risky programs of low-ish-end hurdle."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Well, I wouldn't say that the hurdle is very low. I think what I'm trying to say with LINGO is that this is a Phase II trial and it's pretty novel territory we're on, where not too many people have looked at repair strategies for any neurologic disease, i",269,"Well, I wouldn't say that the hurdle is very low. I think what I'm trying to say with LINGO is that this is a Phase II trial and it's pretty novel territory we're on, where not too many people have looked at repair strategies for any neurologic disease, including MS. So I would say that we're going to look at the totality of the data. We're going to combine the clinical outcome measures, along with the imaging outcome measures, learn as much as we can and really decide, does the program deserve a continued investment? And if so, can we go to Phase III? Are we ready to go to Phase III? Because in Phase III, we're going to have to employ outcome measures that everybody agrees, including regulators, obviously, but also the MS community, everybody agrees will provide answers on whether or not the treatment effect is clinically meaningful. And in the case of the BACE inhibitor, the main thing we're going to be looking at is safety, and I don't think it's uncommon. And in fact, I think all of our competitors have gone from early-stage safety data right to large registrational trials. And I think there are good reasons for that. We are confident in the pharmacodynamic effect that we see in that when we look at Abeta 42 levels in CSF, we get nice, very strong, dose-dependent decreases in Abeta 42. So we're not going -- I mean, as George said, we want to manage the risk by making sure we have the desired biological effect, and we're pretty confident already that we have that."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Two quick ones on TYSABRI. Looks like you're seeing stabilization. Wondering if you could talk a little bit about the dynamics you're seeing there amongst patients since the SPMS data was reported. And then for Paul, just curious, you earmarked about; $10",63,"Two quick ones on TYSABRI. Looks like you're seeing stabilization. Wondering if you could talk a little bit about the dynamics you're seeing there amongst patients since the SPMS data was reported. And then for Paul, just curious, you earmarked about; $100 million for BD next year. How the sector pullback amongst the smaller biotechs might influence your capital allocation strategy this year."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, why don't -- I'll try to take the TYSABRI one as well, but Al can chime in here. Thanks, Brian, for the question. Yes, we did not see a discernible change kind of coming out of the SPMS readout. It may be early, it may not. And I think that was, to s",230,"Yes, why don't -- I'll try to take the TYSABRI one as well, but Al can chime in here. Thanks, Brian, for the question. Yes, we did not see a discernible change kind of coming out of the SPMS readout. It may be early, it may not. And I think that was, to some extent, our thesis as well: patients doing -- that are doing very, very well and have an individual experience with TYSABRI that's generally quite positive. With respect to the earmarking for $100 million, it's -- we always debate this internally. Should it be more than that? Should it be less? Should we trade it off against R&D dollars? All that type of stuff. But we try to earmark some level of money that obviously is expense money which has been -- we've been a little bit biased that way with the earlier-stage biotechs over the last number of years have had opportunities right to the IPO window's been open. They've -- it's been very open for them to continue on. There's a potential that with the change in the biotech sector, that as we we've looked at corporate development, business development-type deals, clearly one of the last hurdles to get through is financial valuation. There's a change that, that dynamic is changing in favor for us. And George, I'll -- maybe add some comments as well."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. Look, if you're in a smaller biotech company and that's pre-commercial and you have to raise revenue, there are only a couple of ways to do that. And as it gets more difficult and less attractive to raise money from the financial markets, obviously o",118,"Yes. Look, if you're in a smaller biotech company and that's pre-commercial and you have to raise revenue, there are only a couple of ways to do that. And as it gets more difficult and less attractive to raise money from the financial markets, obviously other alternatives become more attractive. And we hope that and we believe that will all move in the favor of companies like us who are out to in-license or acquire additional compounds. So we'll see. It takes a while for that to happen. We'll take a -- the current views of the market to hold for a while or deteriorate further if that happens, and I believe there'll be interesting opportunities for us."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Your next question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Paul, Al, George, thanks for all the transparency after the guidance forum [ph] last year and on the call today. I really appreciate it. I think The Street does, too. Just a couple of questions since everyone's breaking the one-question rule.",41,"Paul, Al, George, thanks for all the transparency after the guidance forum [ph] last year and on the call today. I really appreciate it. I think The Street does, too. Just a couple of questions since everyone's breaking the one-question rule."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","I think you started that trend, Mark.",7,"I think you started that trend, Mark."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","No, I'm -- I'm like the fifth question. Everyone's asked you, so it's not me. I'm a good boy. On TECFIDERA, Paul, I remember last year you -- and I know you're not providing TECFIDERA guidance for '16, but I think last year, you gave some color on your ex",157,"No, I'm -- I'm like the fifth question. Everyone's asked you, so it's not me. I'm a good boy. On TECFIDERA, Paul, I remember last year you -- and I know you're not providing TECFIDERA guidance for '16, but I think last year, you gave some color on your expectations. I'd be curious to know if you're willing to do that this year. What -- and specifically, what are you expecting for price and volume in '16 in the U.S.? Should we be modeling any price, any volume? And then on LINGO, Al, this has come up in prior questions, so just to push you a little bit, when you say separation, should we think of that as commonsense separation on the clinical endpoints would be clinically relevant? Or in that we don't necessarily need statistically a p value of under 0.05 when you're analyzing the data in order to make a go decision into Phase III?"
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Mark, this is Paul. I -- the only additional -- I really don't want to provide anything additional. No comments further, just, like -- but reinforce what I did say in the prepared remarks. On TECFIDERA, our plan assumes stable demand for TEC in the United",91,"Mark, this is Paul. I -- the only additional -- I really don't want to provide anything additional. No comments further, just, like -- but reinforce what I did say in the prepared remarks. On TECFIDERA, our plan assumes stable demand for TEC in the United States, right? We're looking -- aspiring for more, but that's what the plan assumes. And that's really what we've seen for a number of quarters. On the U.S. pricing side, our financial guidance assumes no U.S. prices for TECFIDERA for the remainder of the year."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","On LINGO, Mark, we have a trial with about 80 patients per arm. And so it's not -- it's a robust trial. But yes, I think we're more on the commonsense side, as you put it. We want to know -- and we can look at separation in several ways. I mean, we can lo",152,"On LINGO, Mark, we have a trial with about 80 patients per arm. And so it's not -- it's a robust trial. But yes, I think we're more on the commonsense side, as you put it. We want to know -- and we can look at separation in several ways. I mean, we can look for a proportion of patients who are improving relative to placebo. We can look at patients who are slowing -- their progression has slowed so that -- so we can look at both ways. And that's sort of what I mean by separation. But I think it's more on the commonsense side. And as I -- and I tried to indicate that there's a lot of exploratory pieces to this trial because some of these endpoints have really never been employed in any significant way in large trials. So that's what I was trying to say, Mark."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","I think, Mark, this is George, the decision on the LINGO trial will be whether or not we have a meaningful clinical impact on endpoints that the regulators would consider provable endpoints in a Phase III trial, right? And there are many endpoints that we",118,"I think, Mark, this is George, the decision on the LINGO trial will be whether or not we have a meaningful clinical impact on endpoints that the regulators would consider provable endpoints in a Phase III trial, right? And there are many endpoints that we're going to be looking at in the trial and there could be some combination of them. So we're not going to have a low bar, but we -- it is a Phase II exploratory study. And as we look at those endpoints, we'll make our decisions. But I wouldn't characterize it as a low bar. I'd characterize it right now as a little bit of an undefined bar until we see the data."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","And your next question comes from the line of Michael Yee from RBC Capital Markets.",15,"And your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","On SMN-Rx, and I refer to it  as [indiscernible], I pronounce your new name, can you just talk for a little bit about some of the data you've seen so far and how some of your commentary has changed around that? A little bit to the positive, which is fine,",143,"On SMN-Rx, and I refer to it  as [indiscernible], I pronounce your new name, can you just talk for a little bit about some of the data you've seen so far and how some of your commentary has changed around that? A little bit to the positive, which is fine, but I guess it always comes down to comparing the historical literature and there's a lot of different things out there. So Al, can you maybe just talk a little bit about your confidence in the literature and the range of median survival there and what you think is going on here? You previously talked about weight gain. Everybody talked -- heard about that.  So I guess maybe talk a little bit about that and what you're seeing? And I guess why versus historical literature you feel, I guess, a bit better?"
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, so the main data we're looking at is the Type 1 SMA or the infantile-onset. And we're -- and as you know, we're comparing it -- we and I, we're comparing it to natural history. And those things are always tricky because natural -- the care of patient",252,"Yes, so the main data we're looking at is the Type 1 SMA or the infantile-onset. And we're -- and as you know, we're comparing it -- we and I, we're comparing it to natural history. And those things are always tricky because natural -- the care of patients change over time and stuff like that, and you have to sort of find matching patients, patients that are similar to the ones that you looked at in your open-label study. My confidence grows with every passing day because as you know, these children are supposed to -- their median survival is 2 years. And so we're at the point where many of these babies are getting to that point or going beyond it. And so I think that if they are surviving, our confidence grows. And also, we're also looking at whether or not they're gaining, whether -- if they're making improvements. These children generally don't improve, and they're hitting motor milestones that are not commonly seen in the natural history. So we believe the data looking promising, but there are caveats to comparison to natural history studies. And we have to be cautious because everybody, including parents and the whole world, wants to see a cure for these babies. So our bias is certainly leaning toward wanting to see something, and we have to be cautious about that. So the Phase III trials are sham controlled, they're blinded. And I think that's where we believe a definitive data will come from."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matthew Harrison from Morgan Stanley.",13,"Your next question comes from the line of Matthew Harrison from Morgan Stanley."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","So I'm going to ask 2. One on Alzheimer's. We've recently had a handful of physician feedback that there's a dearth of skilled readers for some of these endpoints in these studies. Can you talk a little bit about what you are doing to make sure the reader",150,"So I'm going to ask 2. One on Alzheimer's. We've recently had a handful of physician feedback that there's a dearth of skilled readers for some of these endpoints in these studies. Can you talk a little bit about what you are doing to make sure the readers are well trained, especially given that a small change in the endpoints is likely to demonstrate the benefit of the drug? And then just on LINGO, can you remind us what our expectation should be? I remember in 2015 when you moved out the time lines, you said that a small internal group would be seeing some of the LINGO data ahead of sort of the full analysis, and they'd be planning for Phase III. Should we expect, if you decide to move ahead for Phase III, you'll be able to talk about that pretty quickly when we see the data?"
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, let me get the second question first. I want to be sure that the trial remains fully blinded. Nobody at Biogen has broken the blind and looked at the unblinded data. So that small team -- there is no small team looking at any data. And in terms of th",206,"Yes, let me get the second question first. I want to be sure that the trial remains fully blinded. Nobody at Biogen has broken the blind and looked at the unblinded data. So that small team -- there is no small team looking at any data. And in terms of the AD, there are -- it is sort of an art to look -- to read PET scans. I don't know if that's what you're referring to, but the readers of these images have to be trained, and we actually employed a quality control step in a blinded way where we had somebody at Minnesota, an expert, reviewing every single scan. Moreover, the -- in terms of the cognitive testing, the clinical outcome measures, we -- the main thing we want is consistency over time. And we have to -- and we're doing a lot of the things that we actually do in MS where we have -- where we do a lot of training, we have examining neurologists and we separate them from the neurologists that actually treat the patients for side effects and things. So I think we've employed sort of state-of-the-art methods for collecting these data and, hopefully, avoided many of the pitfalls."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","And your next question comes from the line of Chris Raymond from Raymond James.",14,"And your next question comes from the line of Chris Raymond from Raymond James."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Just a couple of quick commercial questions. Paul, on TECFIDERA, you guys called out the $30 million of inventory during the quarter and, I think, Q3's $10 million to $15 million, if I recall correctly. So how should we think, I guess, about Q1? Are we ta",156,"Just a couple of quick commercial questions. Paul, on TECFIDERA, you guys called out the $30 million of inventory during the quarter and, I think, Q3's $10 million to $15 million, if I recall correctly. So how should we think, I guess, about Q1? Are we talking about $40 million to $45 million that needs to burden off? Or is there some other dynamic there that we should be modeling? And then also on PLEGRIDY, just wondering if you could share any insights on, as the launch has progressed, any change specifically in the source of patients, either from AVONEX or other beta interferons? And if I ask this question, because some of our checks seem to indicate there's been a shift where PLEGRIDY is taking patients now from other beta interferons versus more from AVONEX early on. I'm just kind of wondering if that's what you're seeing, too, if there's something else going on there."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Chris, great. questions. This is Paul. TECFIDERA, let me just kind of level set and just clarify because you're exactly on it. What we had noted in Q3 is that our estimate at the time was that there was about $10 million to $15 million of build in the SPP",413,"Chris, great. questions. This is Paul. TECFIDERA, let me just kind of level set and just clarify because you're exactly on it. What we had noted in Q3 is that our estimate at the time was that there was about $10 million to $15 million of build in the SPP, in the specialty pharmacy, part of the combined channel. And that was mostly what we believe related to a government purchase, related to kind of their fiscal year timing. I think our belief is that, that's largely burned through. On a quarter-to-quarter basis within Specialty Pharmacies, there is sometimes ebbs and flows on inventory levels, and we'll try to do our best to point that out. But we think it's at -- and I would think that we may have things like what we had in Q3, but I think that's largely burned through. What we noted in Q4 is actually related to the wholesaler portion of the channel and, on a quarter-over-quarter basis, that there was a little bit of build. So I think what -- as we move into Q1, we're really probably dealing with the $30 million to get to kind of on a sequential quarter basis. We always -- just to complete the thought, we always deal with kind of a Q1 -- Q4 to Q1 dynamics that sometimes we don't have great visibility on the so-called shoebox effect, the change in Q1 with respect to patients on insurance and -- which is related, obviously, to shoebox. So Q1 oftentimes -- and gross-to-net-change, and so discounts and allowances rate, goes up in Q1 as well for us as well as the industry. So we're always -- be mindful of that. On PLEGRIDY, it's very interesting. Your checks probably are consistent with what we're seeing as well. We saw early on -- and to some extent, it was our marketing strategy early on was a conversion of AVONEX patients, and we hit some speed bumps along that early on in the launch in the first -- in the last quarter of 2014 and going into -- early into 2015. We're starting to see both from what we're trying to do on our marketing strategy, but we're also starting to see the benefits of PLEGRIDY being seen as sourcing volumes from the other interferons. Look, this is a great product vis--vis kind of capturing our -- penetrating and capturing share within that interferon segment of the marketplace. Great question. Thanks, Chris."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Your next question comes from the line of Terence Flynn from Goldman Sachs."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","This is Cameron filling in for Terence. Congrats on your approval of you Enbrel biosimilar in the EU. I was wondering, is there anything you can share regarding your pricing and commercialization strategy there?",34,"This is Cameron filling in for Terence. Congrats on your approval of you Enbrel biosimilar in the EU. I was wondering, is there anything you can share regarding your pricing and commercialization strategy there?"
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Cameron, obviously, we're in discussions country-by-country but really can't share anything. So no comments on that. I -- we'll try to as we begin to post revenues to try to provide some commentary.",33,"Cameron, obviously, we're in discussions country-by-country but really can't share anything. So no comments on that. I -- we'll try to as we begin to post revenues to try to provide some commentary."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matt Roden from UBS.",12,"Your next question comes from the line of Matt Roden from UBS."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Thanks for delivering a nice quarter on guidance here. I think as a sector, we needed some good news. So I had kind of a specific on the BACE inhibitor, E2609. The Phase II study is in 700 patients, but my understanding is that the data that we'll get on",116,"Thanks for delivering a nice quarter on guidance here. I think as a sector, we needed some good news. So I had kind of a specific on the BACE inhibitor, E2609. The Phase II study is in 700 patients, but my understanding is that the data that we'll get on this year's disclosures is just on safety from the initial cohorts, not the whole 700 patients. So can you just clarify what we should expect to see from this disclosure this year? And help us understand what exactly you'll be looking for and how this information would pertain to a go, no-go decision. And then lastly, just when we'll get initial efficacy findings from this program."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, you're right, Matt, we're going to look at the first cohort. And the original plan was that the first cohort would then trigger a second cohort. I'm not -- the main thing we're going to look at is the safety data from the first cohort and also to con",75,"Yes, you're right, Matt, we're going to look at the first cohort. And the original plan was that the first cohort would then trigger a second cohort. I'm not -- the main thing we're going to look at is the safety data from the first cohort and also to confirm the pharmacodynamic effect that we saw with our Phase I study. So it's really safety and repeat or confirmation of pharmacodynamic effect in the CSF."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Okay. And then does that pertain to any go, no-go decision? And then when we should expect to see initial efficacy?",21,"Okay. And then does that pertain to any go, no-go decision? And then when we should expect to see initial efficacy?"
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. Well, with the number of patients in the first cohort, I have low expectations in terms of efficacy. And it will lead to a go, no-go decision to Phase III.",31,"Yes. Well, with the number of patients in the first cohort, I have low expectations in terms of efficacy. And it will lead to a go, no-go decision to Phase III."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang from the Bank of America Merrill Lynch.",17,"Your next question comes from the line of Ying Huang from the Bank of America Merrill Lynch."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Maybe for Al. You mentioned that you should expect the enrollment or full enrollment of aducanumab Phase III similar to the time line of the other Phase II trials. Does that mean we should probably expect 18 to 24 months or potentially even longer for the",115,"Maybe for Al. You mentioned that you should expect the enrollment or full enrollment of aducanumab Phase III similar to the time line of the other Phase II trials. Does that mean we should probably expect 18 to 24 months or potentially even longer for the enrollment to be accrued? And then also secondly, I was curious, your thought on TYSABRI because ocrelizumab could be approved probably towards end of this year. We know that about 30% of JCV-positive patients are on TYSABRI. I mean, sorry, 30% of TYSABRI patients are JCV-positive. And then there's also a certain level of off-label use from PPMS and SPMS. So if you could provide some thought on that."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. So in terms of enrollment, I don't want to hazard a guess as to exactly how long it's going to take to enroll patients. I think we're pleased with what we're seeing so far, but it's early days. And right now, our time lines are assuming the enrollmen",190,"Yes. So in terms of enrollment, I don't want to hazard a guess as to exactly how long it's going to take to enroll patients. I think we're pleased with what we're seeing so far, but it's early days. And right now, our time lines are assuming the enrollment rate on a per -- patients-per-site basis to what we've seen with other Phase III trials. And then in terms of ocrelizumab, it's great to have a new drug for patients, particularly for PPMS patients. I don't think there were a lot of PPMS patients who are on TYSABRI, if that's what you're asking. There are -- there probably are some people who are -- who have SPMS on TYSABRI because our label says relapsing forms of MS, and patients with SPMS have relapses in their early stages of SPMS. So it would be unlabeled to be on TYSABRI if you have relapsing SPMS. Now ocrelizumab, I don't think, will have a label for SPMS as far as I understand. I don't recall the data trial on SPMS. So I don't see how that would affect the SPMS piece very much."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","I guess, first, for Paul on capital allocation. Now that you've finished the $5 billion share repurchase program, do you have plans to start another one? I'm just curious how we should be thinking about share count in '16. And then also, Paul, on your com",89,"I guess, first, for Paul on capital allocation. Now that you've finished the $5 billion share repurchase program, do you have plans to start another one? I'm just curious how we should be thinking about share count in '16. And then also, Paul, on your comment with regard to price increases not being assumed in your 2016 guidance, can you just remind us how you've built that into past guidance in prior years? And is this a change that's simply the result of the current pricing environment and controversy?"
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, with respect to -- let's kind of start on capital allocation and share repurchases. And you're right, we've exhausted the $5 billion share characterization that was authorized and approved by the board back in the spring of 2015. George and I are in",205,"Yes, with respect to -- let's kind of start on capital allocation and share repurchases. And you're right, we've exhausted the $5 billion share characterization that was authorized and approved by the board back in the spring of 2015. George and I are in constant contact, in constant dialogue, in constant discussion about best deployment of capital. I think that our thinking right now is a bit focused on strategic deployment, and -- but I would continue to emphasize that we always frame this as one or the other, and it's -- over a longer the time, it's appropriately a mix. And I think the cash flow generation of the company is -- remains quite robust such that we can deploy capital in a lot of different ways, all with the objective of increasing intrinsic value per share. So we'll look towards a lot of different means. I mean, I know  I'm being a little bit vague and opaque, but I think it's just because that's a little bit where we are right now in thinking through all the dynamics of that. No real comment on the pricing dynamics for the balance of the year. The financial guidance for this year does not assume it."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Jim Birchenough from Wells Fargo.",13,"Your next question comes from the line of Jim Birchenough from Wells Fargo."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","I sneak in, Jim, this morning. A couple of quick questions. In terms of the remyelination programs, you have the oral remyelination agent, $BIIB061. Clearly, remyelination is a very complex process. Have you looked to combining that with anti-LINGO? Do yo",123,"I sneak in, Jim, this morning. A couple of quick questions. In terms of the remyelination programs, you have the oral remyelination agent, $BIIB061. Clearly, remyelination is a very complex process. Have you looked to combining that with anti-LINGO? Do you see remyelination as a single-drug opportunity? Or do you think it's going to need combination therapy in perhaps some subsets of patients? And then for the Ionis SOD1 trial, for these kinds of trials where you're looking at these very rare-to-find sort of mutations or correction opportunities, do you see the pattern repeating that we saw in nusinersen that can you generate enough compelling data in a Phase I trial in affected patients that you can jump into a potentially registration-enabling trial?"
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, thanks those questions, Jim. On the remyelination, right now, we're thinking of it that we would use one agent for remyelination based on our preclinical studies. Of course, the remyelinating drug would probably be combined with an anti-inflammatory",228,"Yes, thanks those questions, Jim. On the remyelination, right now, we're thinking of it that we would use one agent for remyelination based on our preclinical studies. Of course, the remyelinating drug would probably be combined with an anti-inflammatory or immunomodulatory drug, and that's exactly how we're conducting the SYNERGY study of anti-LINGO-1 in MS. We're adding it to interferon. But I -- right now, we don't have any plans to combine the 2 remyelinating drugs that we have in our pipeline. That may change over time, but that's our current plan. And then in terms of the Ionis SOD1 Phase I trial, yes, we've done a lot of work, we meaning Biogen, also the ALS community, on biomarkers and not only in human studies because you'll recall that there was a prior antisense study with a less potent antisense in SOD1 patients, and there's been some -- a lot of animal work. And we have CSF measures that we could employ that we think will predict parenchymal spinal cord SOD1 levels. The whole point of what we're trying to do is to reduce levels of SOD1 because we believe that the mutated forms of SOD1 are toxic. So we have actually validated, I -- we believe, very good measures that we can use to take the program for the -- from the current trial to registrational study."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","And this is George. I think that's often the case and the advantage of working on genetically homogeneous disease as a result of a single gene. So look, I want to thank everybody for your attention this morning and for your interest. We are going to go",64,"And this is George. I think that's often the case and the advantage of working on genetically homogeneous disease as a result of a single gene. 
So look, I want to thank everybody for your attention this morning and for your interest. We are going to go back to work and do our best to deliver a great 2016 for everyone. So thank you."
29726,320091841,921605,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Year-End 2015 Financial Results and Business Update. [Operator Instructions] Thank you. I would lik",62,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Year-End 2015 Financial Results and Business Update. [Operator Instructions] Thank you. I would like -- I would now like to turn the call over to Mr. Matt Calistri, Senior Director of Investor Relations."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thank you, and welcome to Biogen's fourth quarter and full-year 2015 earnings conference call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconcil",192,"Thank you, and welcome to Biogen's fourth quarter and full-year 2015 earnings conference call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. 
We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Al Sandrock, our Chief Medical Officer; and our CFO, Paul Clancy.
Now I'll turn the call over to George."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt, and good morning, everyone, and thanks for joining us today. In 2015, Biogen generated revenues of $10.8 billion, an 11% increase over 2014, and non-GAAP EPS of $17.01, a 23% increase over 2014. Although the revenues were less than we had",732,"Thanks, Matt, and good morning, everyone, and thanks for joining us today. 
In 2015, Biogen generated revenues of $10.8 billion, an 11% increase over 2014, and non-GAAP EPS of $17.01, a 23% increase over 2014. Although the revenues were less than we had anticipated at the beginning of last year, I'm pleased that we were able to take appropriate action in the second half of the year to maintain healthy earnings growth while we continued to advance the potentially transformative therapies in our pipeline. 
TECFIDERA's demand has been stable in the U.S., and combined with growth in Europe, we expect TECFIDERA to continue to drive our global leadership in multiple sclerosis. TECFIDERA is now not only the most prescribed oral MS therapy worldwide, it is also the most prescribed of all MS therapies in Germany, France and the U.K. Overall, more than 170,000 patients have been treated with TECFIDERA. 
Our hemophilia products, ELOCTATE and ALPROLIX, generated over $0.5 billion of revenue in their first full year on the market in the U.S. In November, the European Commission approved ELOCTA for the treatment of hemophilia A in the EU, which we believe will help to contribute growth in hemophilia this year as our collaboration partner, Sobi, commercializes ELOCTA in additional markets. 
We also made progress in business development. We acquired Convergence Pharmaceuticals and raxatrigine, their early compound. Raxatrigine is an oral, small molecule Nav 1.7 blocker with promising Phase II data that will move into Phase III this year. 
We licensed amiselimod, or MT-1303, for Mitsubishi Tanabe Pharma, a late-stage S1P1 inhibitor for ulcerative colitis and Crohn's disease. 
We entered into a collaboration agreement with AGTC to develop gene-based therapies for multiple ophthalmic diseases. 
And this month, BENEPALI was approved in the EU. BENEPALI, the first etanercept biosimilar approved in the EU, is the first of 3 potential anti-TNFs to advance under our Samsung Bioepis joint venture with Samsung Biologics. Under our agreements with Samsung Bioepis, we will manufacture and commercialize BENEPALI in the EU. 
Meanwhile, we continued investing in 2015. We purchased land in Solothurn, Switzerland, and this Friday, January 29, we'll break ground on an advanced next-generation biologics manufacturing facility there. And we purchased Eisai's drug product manufacturing facility and supporting infrastructure in Research Triangle Park, North Carolina. 
We also took actions to return capital and change the capital structure of the business. We fully implemented our $5 billion share repurchase program, and a portion of that repurchase was funded through the $6 billion debt offering that we completed in September. 
In R&D, we moved forward several exciting mid- and late-stage assets in our pipeline. It may seem like a long time ago now, but it was Q1 2015 that we presented the aducanumab data showing a statistically significant removal of plaque and slowing of cognitive decline in Alzheimer's patients. 
We presented data suggesting that our anti-LINGO antibody is biologically active in remyelination, and the Phase II data for nusinersen generated by our partner Ionis looks increasingly encouraging as a potential therapy for spinal muscular atrophy. 
We also initiated Phase I trials in ALS and Parkinson's disease. 
Al will discuss the many advances we made in our pipeline in more detail, but I think this progress is a testament to our commitment to patients and our world-class capabilities across the breadth of R&D. 
We also continued to strengthen our early-stage clinical and research capabilities. We bolstered research talent in our neuroscience group and established collaborations with first-rate academic centers around the world. As a result, I believe we're now in a better position than ever to both discover novel therapies and accelerate drug development while minimizing risk. 
Lastly, summarizing 2015 would not be complete without commenting on the restructuring we implemented in October. Although it was a difficult decision, we've already seen positive results from the steps that we took. With the majority of the restructuring now completed, there's a palpable, reinvigorated focus on our key commercial initiatives and high-potential pipeline candidates, and our operating expenses are trending at a rate that we believe can continue to provide healthy earnings leverage going forward. 
So all in all, it was a busy and eventful year, and we believe that the progress we made and the actions we took positioned us well for a potentially transformative 2016 and beyond. 
With that, I'll pass the call along to Al for an update on R&D."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, George. 2015 was a productive year for the R&D organization. We advanced the next wave of potential medicines through the pipeline, added important assets through business development and acquisitions and expanded our research leadership by hiring",1037,"Thanks, George. 2015 was a productive year for the R&D organization. We advanced the next wave of potential medicines through the pipeline, added important assets through business development and acquisitions and expanded our research leadership by hiring world-class scientists. I believe our pipeline and our organization are stronger than they have ever been. 
Starting with Alzheimer's disease. Last year, we presented compelling interim Phase Ib data for aducanumab, the first investigational drug for Alzheimer's disease, to demonstrate both the statistically significant reduction of amyloid plaque as well as slowing of cognitive decline. In August, we began enrolling patients into 2 pivotal Phase III trials of aducanumab in early Alzheimer's disease. 
We are pleased with the progress of these studies, but recognize the inherent challenges in recruiting patients with early Alzheimer's disease and the limited availability of PET scanners. Fortunately, owing to the strong results from our clinical trials to date, there has been substantial interest in the program, which we believe has helped with recruitment. That said, we continue to anticipate that the Phase III enrollment duration will be similar to other large clinical trials in Alzheimer's disease. Looking ahead, in the second half of 2016, we expect to share additional safety data from the ongoing titration arms of the Phase Ib PRIME study for aducanumab. 
Our other 2 mid-stage clinical candidates for AD that are partnered with Eisai continued to advance. Eisai had indicated that they anticipate releasing interim safety data this year for E2609, a small molecule BACE1 inhibitor, and we are also expecting to see top line efficacy and safety data for BAN2401, a monoclonal antibody targeting beta-amyloid. 
Moving to anti-LINGO. You may recall that last year, we presented Phase II data in acute optic neuritis. To our knowledge, this was the first clinical trial to show evidence of remyelination following an acute inflammatory demyelinating injury in humans. And we believe that these results support our ongoing development efforts. 
Our Phase II SYNERGY study in MS is a 418-patient, double-blind, multicenter study assessing 4 doses of anti-LINGO versus placebo when added to interferon beta therapy. It utilizes a composite endpoint comprising outcome measures of disability, cognition and physical function. We believe that a separation from placebo on any of these measures could be clinically meaningful. We are also looking at imaging endpoints that reflect the integrity of myelinated nerve fibers. Any differences in treatment effect between pre-existing and newly acquired lesions will also be of interest. 
We believe that the robust design of this clinical trial will enable a better understanding of the therapy's potential in MS. And if the results are positive, the trial should provide valuable insight into the design of our Phase III program. Results for SYNERGY are anticipated in mid-2016. 
Now turning to nusinersen. Our partner, Ionis, recently completed target enrollment of the Phase III CHERISH study in children with childhood-onset SMA. And by the first half of this year, we hope to complete enrollment in ENDEAR, the Phase III study evaluating nusinersen in infants with infantile-onset SMA. This progress sets the stage for data from both of these trials to be available in the first half of 2017. 
Whereas the data from the early-stage, open-label clinical trials are encouraging when compared to data from natural history studies, the well-controlled Phase III studies are designed to definitively assess the safety and efficacy of nusinersen. We are meeting frequently with regulators from Europe, Japan and the United States with the goal of making the drug available to SMA patients as rapidly as possible. 
Moving on to our hemophilia therapies. Last month, at the 57th American Society of Hematology Annual Meeting, we presented new data demonstrating that ELOCTATE and ALPROLIX effectively managed bleeding into joints and maintained low annualized bleeding rates in people with severe hemophilia A and B, reaffirming the benefits of these 2 therapies. In addition, teams from the University of Pittsburgh, The Hemophilia Center of Western Pennsylvania and The University of Texas Southwestern Medical Center presented data showing that immune tolerance induction using ELOCTATE was successful in 3 children with inhibitors, including a child previously failing recombinant factor VIII immune tolerance induction The time to achieving tolerance in the study was 4 to 12 weeks, which appears to be significantly shorter than with the standard of practice, which can take several months to several years. 
During the quarter, we, in collaboration with Ionis, also announced the initiation of a Phase I/II clinical study of an antisense drug against superoxide dismutase, or SOD1, in patients with amyotrophic lateral sclerosis. I am pleased to announce that last week, we dosed our first patient in the trial. Mutations in the SOD1 gene result in the second most common form of familial ALS, affecting approximately 2% of all ALS patients. 
We also continue to make excellent progress toward initiating multiple late-stage clinical trials in 2016. Next month, we anticipate sharing additional Phase II study results for TYSABRI in acute ischemic stroke at the International Stroke Conference in Los Angeles. While a single dose of administered -- of natalizumab administered up to 9 hours after stroke onset did not reduce focal infarct volume, treatment was associated with meaningful improvements in clinical outcomes over the course of 90 days. The clinical profile and treatment window supports further investigation of natalizumab as a potential novel approach for treating acute ischemic stroke, and we intend to conduct a Phase IIb trial. 
Amiselimod, or MT-1303, an S1P1 inhibitor for inflammatory bowel disease, is anticipated to advance to Phase III trials this year. In the second half of the year, we plan to initiate Phase III studies for both ulcerative colitis and Crohn's disease. We currently have no plans for the asset in MS but expect to continue to evaluate other options for the molecule in collaboration with our partner, Mitsubishi Tanabe. 
Raxatrigine, a small molecule inhibitor of the Nav 1.7 sodium channel, is in development for several pain indications. In the second half of the year, we anticipate initiating a Phase III trial to confirm the efficacy of raxatrigine in patients with trigeminal neuralgia. We also plan to initiate a Phase II trial in patients with sciatica later this year. 
I'll now pass the call over to Paul."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Al. Our GAAP diluted earnings per share were $3.77 in the fourth quarter and $15.34 for the full year. Our non-GAAP diluted earnings per share were $4.50 in the fourth quarter and $17.01 for the full year. Total revenue for Q4 grew 8% year-over-",1447,"Thanks, Al. Our GAAP diluted earnings per share were $3.77 in the fourth quarter and $15.34 for the full year. Our non-GAAP diluted earnings per share were $4.50 in the fourth quarter and $17.01 for the full year. 
Total revenue for Q4 grew 8% year-over-year to approximately $2.8 billion and grew 11% for the full year to $10.8 billion. Foreign exchange, offset by hedging, weakened fourth quarter revenue by approximately $35 million versus prior year and by approximately $227 million for the full year versus prior year. 
Global Q4 TECFIDERA revenue was $993 million. We recorded revenues of $785 million in the U.S. and $208 million outside the U.S. TECFIDERA U.S. revenue benefited from an increase in wholesale inventory by approximately $30 million versus prior quarter. At this point, we believe TECFIDERA's safety perceptions and physician intent to prescribe have largely stabilized in the U.S. We're seeing positive leading indicators for the recently launched marketing campaign for TECFIDERA, including increased visits to our website and higher call volume into our Patient Services organization. 
In Europe, TECFIDERA continued its trend of solid patient growth this quarter, especially in more recently launched markets such as the U.K., Italy and Spain. The European label for TECFIDERA was updated in December, and we're actively educating physicians on appropriate patient monitoring. 
For the full year, worldwide TECFIDERA revenues were $3.6 billion consisting of $2.9 billion in the U.S. and $730 million in sales outside the U.S. Foreign exchange impact, offset by hedging, weakened full year TECFIDERA revenue by approximately $27 million versus prior year. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $740 million during the fourth quarter, which includes $506 million in the U.S. and $233 million in sales outside the U.S. 
For the full year, worldwide interferon revenues were $3 billion consisting of $2 billion in the U.S. and $951 million in sales outside the U.S. Foreign exchange impact, offset by hedging, weakened full year interferon revenues by approximately $88 million versus prior year. 
TYSABRI continued to add patients this quarter with worldwide revenues of $481 million. These results were comprised of $278 million in the U.S. and $203 million internationally. 
For the full year, worldwide TYSABRI revenues were approximately $1.9 billion. We recorded U.S. revenue of $1.1 billion and $783 million internationally. Foreign exchange impact, offset by hedging, weakened full year revenue for TYSABRI by approximately $90 million versus prior year. 
Physicians continued to choose TYSABRI for patients requiring high efficacy, and nearly 10 years after approval, we believe its well-understood safety profile positions TYSABRI well. 
Turning to hemophilia business. ELOCTATE revenue for the quarter was $101 million and $320 million for the full year. ALPROLIX revenue in Q4 was $71 million and $234 million for the full year. 
Turning to our anti-CD20 unconsolidated joint business, which includes our profit share for RITUXAN and GAZYVA in the U.S. as well as our profit share in royalties on sales of rituximab outside the U.S. We recorded $334 million for Q4 and $1.3 billion for the full year. While there was a slight inventory drawdown for RITUXAN in the fourth quarter, we ended the year with a higher inventory level than we had anticipated. We also benefited from a $6 million payment from Roche in exchange for access to data supporting the development of ocrelizumab. 
Corporate partner revenues were $69 million for the fourth quarter compared to $40 million in the prior quarter. The increase was related to contract manufacturing for Samsung Bioepis and another strategic partner. For the full year, corporate partner revenues were $189 million. 
During the quarter, we booked a total GAAP charge of approximately $93 million related to the restructuring announced in October. 
Now turning to the non-GAAP expense lines on the P&L. Q4 cost of goods sold were $332 million or 12% of revenue. For the full year, COGS were $1.2 billion or 12% of revenue. 
Q4 non-GAAP R&D expense was $542 million or 19% of revenue, which includes a $60 million payment to Mitsubishi Tanabe. For the full year, non-GAAP R&D expense was $2 billion or 19% of revenue. 
Q4 non-GAAP SG&A expense was $583 million or 21% of revenue. For the full year, non-GAAP SG&A expense was $2.1 billion or 20% of revenue. 
Other net expense was approximately $82 million in the fourth quarter, which includes $67 million in interest expense primarily related to our recent bond offering. Full year other net expense was $124 million, including approximately $96 million in interest expense. 
Our Q4 non-GAAP tax rate was approximately 23% for the fourth quarter as we benefited from the reinstated R&D tax credit. Our full year tax rate was approximately 24%. 
During the year, we repurchased approximately 16.8 million shares of our common stock, completing our previously authorized $5 billion share repurchase program. 
Our weighted average diluted share count was approximately 221 million for Q4, 231 million for the full year. And we ended the year with approximately 219 million basic shares outstanding. This brings us to our non-GAAP diluted earnings per share of $4.50 for the fourth quarter and $17.01 for the full year, representing a 23% increase for the full year. 
We ended the year with approximately $6.2 billion in cash and marketable securities, split approximately 40-60 between the U.S. and ex U.S. 
So overall, we had a strong quarter, benefiting from favorable inventory dynamics for TECFIDERA, stronger-than-anticipated contract manufacturing in RITUXAN revenue and the reinstatement of the R&D tax credit. 
Let me turn to our full year 2016 guidance. We expect revenues of approximately $11.1 billion to $11.3 billion. Starting with multiple sclerosis. Our plan assumes relatively stable demand for TECFIDERA in 2016 in the United States. While we're hopeful our recently launched marketing campaign can reaccelerate growth, we remain cautious as we believe we will not ascertain the impact until the second quarter of this year. In Europe, we anticipate constant pricing through the rest of the year and continued patient growth, particularly in recently launched markets. For TYSABRI, we believe the therapy will remain on a stable trajectory. We believe the number of patients using AVONEX and PLEGRIDY combined will continue to decline as patients move toward orals, but we remain well positioned within this segment of the market. 
Our financial guidance assumes no U.S. price increases for AVONEX, PLEGRIDY and TECFIDERA for the remainder of the year. 
With respect to foreign exchange, our plan is based on the current spot rates. Of note, we had an approximately $170 million in hedge gains in 2015. Given our hedges are usually placed 12-month forward, we expect limited hedge gains in 2016, so the year-over-year comparison is less favorable. 
Moving to our hemophilia therapies. We anticipate continued growth with ELOCTATE as we believe there remains a significant portion of the patient population that can benefit from long-acting therapies. We're assuming moderating patient adds for ALPROLIX, given the rapid uptake in penetration so far. 
In 2016, we are assuming our profit share for RITUXAN and GAZYVA will decrease to 39% from 40% upon FDA approval of GAZYVA in RITUXAN refractory indolent non-Hodgkin's lymphoma. Our plan assumes ocrelizumab will launch in 2017. 
Moving to an expense perspective. We anticipate slight upward pressure on cost of goods sold rate largely due to increases in contract manufacturing, biosimilars and increased hemophilia royalties. 
We anticipate R&D expense between 19% and 20% of sales, which includes approximately $100 million earmarked for business development activity. We plan to invest in a number of R&D programs across our late-stage pipeline, including aducanumab, nusinersen, raxatrigine and amiselimod for inflammatory bowel disease. 
SG&A expense is expected to be approximately 17% to 18% of revenue. The headcount reduction and restructuring announced in October is expected to benefit operating expenses by approximately $250 million. We've also planned to reduce targeted fees and services expenses, which are largely reflected in SG&A. 
From a tax perspective, we anticipate upward pressure on our 2016 tax rate as our profitability mix shifts toward the U.S. 
We anticipate non-GAAP earnings per share results between $18.30 and $18.60 and GAAP EPS to be between $16.85 and $17.15. 
Our plan assumes share stabilization with a weighted average diluted share count of approximately 219 million. 
From a cash perspective, we expect to pay $1.2 billion in CVR payments to Fumapharm in 2016 related to the sales of TECFIDERA. 
And we anticipate capital expenditures of approximately $800 million to $850 million, an increase over 2015 primarily driven by the investment in the Swiss manufacturing plant. 
So the business plan is designed to provide investment to support TECFIDERA, surgically look to control spending and ensure we're utterly focused on investing in and progressing the pipeline. 
I'll turn the call over to George."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Okay, thank you, Paul. Clearly, the commercial trajectory of TECFIDERA was not where we thought it would be at the beginning of last year. And as a result, the revenues fell short of our initial projections. While obviously not happy with that, I'm very p",582,"Okay, thank you, Paul. Clearly, the commercial trajectory of TECFIDERA was not where we thought it would be at the beginning of last year. And as a result, the revenues fell short of our initial projections. While obviously not happy with that, I'm very pleased with the way the company responded. We put additional marketing muscle behind TECFIDERA, we reduced costs and focused the company and we accelerated our stock repurchase program. As a result, we maintained healthy earnings growth at the same time as we continued our investments in aducanumab, LINGO and the other exciting programs in our pipeline. We also continued to invest in additions to our pipeline. We acquired Convergence and its lead compound, raxatrigine. We licensed amiselimod from Mitsubishi Tanabe. We completed the gene therapy relationship with AGTC. And we brought additional compounds into the clinic from our own and partners' research efforts. 
Our commercial portfolio continued to expand  globally as we extended our position as the worldwide leader in multiple sclerosis and significantly grew our hemophilia business. In 2016, we plan to remain focused on commercial execution and advancing our pipeline, which we expect to be the primary source of value creation over the long term. We're looking forward to many updates over the next year, including insight into the potential impact of TECFIDERA's recently launched marketing campaign by the second quarter; Phase II top line results for anti-LINGO in MS in the middle of the year; Phase II data for BAN2401 and E2609; continued Phase II data for nusinersen from Ionis, followed by Phase III data next year; and Phase Ib titration data for aducanumab in the second half of the year. 
We expect to launch up to 3 compounds this year: BENEPALI in Europe following approval from the European Commission earlier this month, ZINBRYTA pending approval in the first half of the year and potentially an infliximab biosimilar, also in Europe. 
Thinking even further ahead, we believe that we're entering the early years of a potentially transformative era in neuro generation drug discovery and development. And we believe that our commitment to research has the potential to yield results that are truly meaningful for patients and shareholders. 
As I said at the recent JPMorgan conference, I believe that our pipeline and our approach, which has the risk inherent in all truly innovative and ground-breaking approaches, is measured and thoughtful. The combination of a much better understanding of disease biology, the focus on genetically validated targets, the use of biomarkers to learn early whether or not our compounds are having the desired biological effects and the adoption of multiple therapeutic modalities may meaningfully increase success rates and identify those projects likely to fail early in the process before large amounts of time and money are spent. Our strategy is evident in the design of the aducanumab Phase Ib trial, the Phase II study of nusinersen, the Phase II studies of anti-LINGO and our recently initiated Phase I trial for SOD1 ALS. We have additional examples, some of which we'll talk about as the year goes on. 
In closing, and as always, I'd like to thank our employees who are dedicated to making a positive impact on patients' lives, and also the patients and physicians who are involved in our clinical development programs. The achievements we made together could not have been realized without their passion and commitment. 
So thank you all for joining us this morning. And operator, we'll now open up the call for questions."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Geoff Meacham from Barclays.",14,"[Operator Instructions] Your first question comes from the line of Geoff Meacham from Barclays."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Just have a couple of quick ones, and one on the commercial side. I know it's early days, but are there any initial metrics on the TEC TTC [ph] campaign when you look at things like new starts or returning patients? And then a second one is on the pipelin",90,"Just have a couple of quick ones, and one on the commercial side. I know it's early days, but are there any initial metrics on the TEC TTC [ph] campaign when you look at things like new starts or returning patients? And then a second one is on the pipeline. When you look at the ENGAGE and EMERGE studies, Al, are there lessons to be learned from Lilly in terms of managing PET scan facilities? And what do you think identification of early-stage Alzheimer's patients means to the market opportunity?"
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Thanks, Geoff. Let me start with the TEC TTC [ph] question. I guess I'd reinforce what we said in our prepared remarks around that really, to try to discern if it's going to be looking kind of in the Q2 time period. I mean, clearly, Q2 is not a light swit",154,"Thanks, Geoff. Let me start with the TEC TTC [ph] question. I guess I'd reinforce what we said in our prepared remarks around that really, to try to discern if it's going to be looking kind of in the Q2 time period. I mean, clearly, Q2 is not a light switch to determine that. We're seeing early data with respect to, as I had mentioned, kind of hits to the website, conversations into our Patient Services organization, which lean us to think that it's positive. We haven't seen a discernible yet change with respect to specifically your question, but our judgment is that this takes a little bit of time. It's really first week of October. Obviously, script data as we come through the holiday time, as everybody knows, gets a little bit noisy in Thanksgiving, in December. So we are going to look really hard probably 60, 70, 90 days out from now."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Geoff, this is Al. Well, we have learned a lot from our predecessors, including Lilly and others. And we are employing actually pretty innovative ways of finding where the patients are and where the sites are and -- which includes where the PET scans are",218,"Geoff, this is Al. Well, we have learned a lot from our predecessors, including Lilly and others. And we are employing actually pretty innovative ways of finding where the patients are and where the sites are and -- which includes where the PET scans are because the scans -- the scanners have to be pretty close to where the ligands are made. And of course, the patients have to get there. The other thing we're doing is to screen patients before they need PET scans by using a neuropsychological test battery to make sure that by the time they get to the PET scanner, there's a high likelihood they'll actually have amyloid. And then in terms of early AD, what we mean by early AD are prodromal and the earlier stages of mild Alzheimer's. And in terms of what it means for the marketplace, I do believe that there's going to be a change ultimately in the way the patients are diagnosed early. Perhaps -- and certainly before they are functional deficits but when they have mild cognitive impairment, I believe the health care system will set up ways of identifying those patients who need treatment early. And we're working on many of those, too, along with many colleagues outside who are also thinking about the same thing."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Another one for Al. It looks like you're going to be faced with a couple of go, no-go decisions on Phase III programs in 2016. I'm just thinking specifically for LINGO and for the BACE compound E2609. I'm just kind of wondering what kind of hurdle you've",97,"Another one for Al. It looks like you're going to be faced with a couple of go, no-go decisions on Phase III programs in 2016. I'm just thinking specifically for LINGO and for the BACE compound E2609. I'm just kind of wondering what kind of hurdle you've set for yourselves in terms of going forward. And maybe you can also further justify if the hurdle is going to be kind the low-end hurdle. I sense that's what you've been signaling to investors, why it makes sense to move forward with 2 fairly risky programs of low-ish-end hurdle."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Well, I wouldn't say that the hurdle is very low. I think what I'm trying to say with LINGO is that this is a Phase II trial and it's pretty novel territory we're on, where not too many people have looked at repair strategies for any neurologic disease, i",267,"Well, I wouldn't say that the hurdle is very low. I think what I'm trying to say with LINGO is that this is a Phase II trial and it's pretty novel territory we're on, where not too many people have looked at repair strategies for any neurologic disease, including MS. So I would say that we're going to look at the totality of the data. We're going to combine the clinical outcome measures, along with the imaging outcome measures, learn as much as we can and really decide, does the program deserve a continued investment? And if so, can we go to Phase III? Are we ready to go to Phase III? Because in Phase III, we're going to have to employ outcome measures that everybody agrees, including regulators, obviously, but also the MS community, everybody agrees will provide answers on whether or not the treatment effect is clinically meaningful. And in the case of the BACE inhibitor, the main thing we're going to be looking at is safety, and I don't think it's uncommon. And in fact, I think all of our competitors have gone from early-stage safety data right to large registrational trials. And I think there are good reasons for that. We are confident in the pharmacodynamic effect that we see in that when we look at Abeta42 levels in CSF, we get nice, very strong, dose-dependent decreases in Abeta42. So we're not going -- I mean, as George said, we want to manage the risk by making sure we have the desired biological effect, and we're pretty confident already that we have that."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Two quick ones on TYSABRI. Looks like you're seeing stabilization. Wondering if you could talk a little bit about the dynamics you're seeing there amongst patients since the SPMS data was reported. And then for Paul, just curious, you earmarked about; $10",63,"Two quick ones on TYSABRI. Looks like you're seeing stabilization. Wondering if you could talk a little bit about the dynamics you're seeing there amongst patients since the SPMS data was reported. And then for Paul, just curious, you earmarked about; $100 million for BD next year. How the sector pullback amongst the smaller biotechs might influence your capital allocation strategy this year."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, why don't -- I'll try to take the TYSABRI one as well, but Al can chime in here. Thanks, Brian, for the question. Yes, we did not see a discernible change kind of coming out of the SPMS readout. It may be early, it may not. And I think that was, to s",230,"Yes, why don't -- I'll try to take the TYSABRI one as well, but Al can chime in here. Thanks, Brian, for the question. Yes, we did not see a discernible change kind of coming out of the SPMS readout. It may be early, it may not. And I think that was, to some extent, our thesis as well: patients doing -- that are doing very, very well and have an individual experience with TYSABRI that's generally quite positive. With respect to the earmarking for $100 million, it's -- we always debate this internally. Should it be more than that? Should it be less? Should we trade it off against R&D dollars? All that type of stuff. But we try to earmark some level of money that obviously is expense money which has been -- we've been a little bit biased that way with the earlier-stage biotechs over the last number of years have had opportunities right to the IPO window's been open. They've -- it's been very open for them to continue on. There's a potential that with the change in the biotech sector, that as we we've looked at corporate development, business development-type deals, clearly one of the last hurdles to get through is financial valuation. There's a change that, that dynamic is changing in favor for us. And George, I'll -- maybe add some comments as well."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. Look, if you're in a smaller biotech company and that's pre-commercial and you have to raise revenue, there are only a couple of ways to do that. And as it gets more difficult and less attractive to raise money from the financial markets, obviously o",118,"Yes. Look, if you're in a smaller biotech company and that's pre-commercial and you have to raise revenue, there are only a couple of ways to do that. And as it gets more difficult and less attractive to raise money from the financial markets, obviously other alternatives become more attractive. And we hope that and we believe that will all move in the favor of companies like us who are out to in-license or acquire additional compounds. So we'll see. It takes a while for that to happen. We'll take a -- the current views of the market to hold for a while or deteriorate further if that happens, and I believe there'll be interesting opportunities for us."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Your next question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Paul, Al, George, thanks for all the transparency after the guidance forum last year and on the call today. I really appreciate it. I think The Street does, too. Just a couple of questions, since everyone's breaking the one-question rule.",40,"Paul, Al, George, thanks for all the transparency after the guidance forum last year and on the call today. I really appreciate it. I think The Street does, too. Just a couple of questions, since everyone's breaking the one-question rule."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","I think you started that trend, Mark.",7,"I think you started that trend, Mark."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","No, I'm -- I'm like the fifth question. Everyone's asked you, so it's not me. I'm a good boy. On TECFIDERA, Paul, I remember last year you -- and I know you're not providing TECFIDERA guidance for '16, but I think last year, you gave some color on your ex",157,"No, I'm -- I'm like the fifth question. Everyone's asked you, so it's not me. I'm a good boy. On TECFIDERA, Paul, I remember last year you -- and I know you're not providing TECFIDERA guidance for '16, but I think last year, you gave some color on your expectations. I'd be curious to know if you're willing to do that this year. What -- and specifically, what are you expecting for price and volume in '16 in the U.S.? Should we be modeling any price, any volume? And then on LINGO, Al, this has come up in prior questions, so just to push you a little bit. When you say separation, should we think of that as commonsense separation on the clinical endpoints would be clinically relevant? Or in that we don't necessarily need statistically a p value of under 0.05 when you're analyzing the data in order to make a go decision into Phase III?"
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Mark, this is Paul. I -- the only additional -- I really don't want to provide anything additional. No comments further, just, like -- but reinforce what I did say in the prepared remarks. On TECFIDERA, our plan assumes stable demand for TEC in the United",91,"Mark, this is Paul. I -- the only additional -- I really don't want to provide anything additional. No comments further, just, like -- but reinforce what I did say in the prepared remarks. On TECFIDERA, our plan assumes stable demand for TEC in the United States, right? We're looking and aspiring for more, but that's what the plan assumes. And that's really what we've seen for a number of quarters. On the U.S. pricing side, our financial guidance assumes no U.S. prices for TECFIDERA for the remainder of the year."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","On LINGO, Mark, we have a trial with about 80 patients per arm. And so it's not -- it's a robust trial. But yes, I think we're more on the commonsense side, as you put it. We want to know -- and we can look at separation in several ways. I mean, we can lo",152,"On LINGO, Mark, we have a trial with about 80 patients per arm. And so it's not -- it's a robust trial. But yes, I think we're more on the commonsense side, as you put it. We want to know -- and we can look at separation in several ways. I mean, we can look for a proportion of patients who are improving relative to placebo. We can look at patients who are slowing -- their progression has slowed so that -- so we can look at both ways. And that's sort of what I mean by separation. But I think it's more on the commonsense side. And as I -- and I tried to indicate that there's a lot of exploratory pieces to this trial because some of these endpoints have really never been employed in any significant way in large trials. So that's what I was trying to say, Mark."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","I think, Mark, this is George, the decision on the LINGO trial will be whether or not we have a meaningful clinical impact on endpoints that the regulators would consider approvable endpoints in a Phase III trial, right? And there are many endpoints that",118,"I think, Mark, this is George, the decision on the LINGO trial will be whether or not we have a meaningful clinical impact on endpoints that the regulators would consider approvable endpoints in a Phase III trial, right? And there are many endpoints that we're going to be looking at in the trial and there could be some combination of them. So we're not going to have a low bar, but we -- it is a Phase II exploratory study. And as we look at those endpoints, we'll make our decisions. But I wouldn't characterize it as a low bar. I'd characterize it right now as a little bit of an undefined bar until we see the data."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","And your next question comes from the line of Michael Yee from RBC Capital Markets.",15,"And your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","On SMN-Rx, and I refer to it as that because I pronounce your new name, can you just talk for a little bit about some of the data you've seen so far and how some of your commentary has changed around that? A little bit to the positive, which is fine, but",144,"On SMN-Rx, and I refer to it as that because I pronounce your new name, can you just talk for a little bit about some of the data you've seen so far and how some of your commentary has changed around that? A little bit to the positive, which is fine, but I guess it always comes down to comparing the historical literature and there's a lot of different things out there. So Al, can you maybe just talk a little bit about your confidence in the literature and the range of median survival there and what you think is going on here? You previously talked about weight gain. Everybody talked -- heard about that.  So I guess maybe talk a little bit about that and what you're seeing? And I guess why versus historical literature you feel, I guess, a bit better?"
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, so the main data we're looking at is the Type 1 SMA or the infantile-onset. And we're -- and as you know, we're comparing it -- we and I, we're comparing it to natural history. And those things are always tricky because natural -- the care of patient",253,"Yes, so the main data we're looking at is the Type 1 SMA or the infantile-onset. And we're -- and as you know, we're comparing it -- we and I, we're comparing it to natural history. And those things are always tricky because natural -- the care of patients change over time and stuff like that, and you have to sort of find matching patients, the patients that are similar to the ones that you looked at in your open-label study. My confidence grows with every passing day because as you know, these children are supposed to -- their median survival is 2 years. And so we're at the point where many of these babies are getting to that point or going beyond it. And so I think that if they are surviving, our confidence grows. And also, we're also looking at whether or not they're gaining, whether -- if they're making improvements. These children generally don't improve, and they're hitting motor milestones that are not commonly seen in the natural history. So we believe the data are looking promising, but there are caveats to comparison to natural history studies. And we have to be cautious because everybody, including parents and the whole world, wants to see a cure for these babies. So our bias is certainly leaning toward wanting to see something, and we have to be cautious about that. So the Phase III trials are sham-controlled, they're blinded. And I think that's where we believe a definitive data will come from."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matthew Harrison from Morgan Stanley.",13,"Your next question comes from the line of Matthew Harrison from Morgan Stanley."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","So I'm going to ask 2. One on Alzheimer's. We've recently had a handful of physician feedback that there's a dearth of skilled readers for some of these endpoints in these studies. Can you talk a little bit about what you are doing to make sure the reader",150,"So I'm going to ask 2. One on Alzheimer's. We've recently had a handful of physician feedback that there's a dearth of skilled readers for some of these endpoints in these studies. Can you talk a little bit about what you are doing to make sure the readers are well trained, especially given that a small change in the endpoints is likely to demonstrate the benefit of the drug? And then just on LINGO, can you remind us what our expectation should be? I remember in 2015 when you moved out the time lines, you said that a small internal group would be seeing some of the LINGO data ahead of sort of the full analysis, and they'd be planning for Phase III. Should we expect, if you decide to move ahead for Phase III, you'll be able to talk about that pretty quickly when we see the data?"
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, let me get the second question first. I want to be sure that the trial remains fully blinded. Nobody at Biogen has broken the blind and looked at the unblinded data. So that small team -- there is no small team looking at any data. And in terms of th",206,"Yes, let me get the second question first. I want to be sure that the trial remains fully blinded. Nobody at Biogen has broken the blind and looked at the unblinded data. So that small team -- there is no small team looking at any data. And in terms of the AD, there are -- it is sort of an art to look -- to read PET scans. I don't know if that's what you're referring to, but the readers of these images have to be trained, and we actually employed a quality control step in a blinded way where we had somebody at Minnesota, an expert, reviewing every single scan. Moreover, the -- in terms of the cognitive testing, the clinical outcome measures, we -- the main thing we want is consistency over time. And we have to -- and we're doing a lot of the things that we actually do in MS where we have -- where we do a lot of training, we have examining neurologists and we separate them from the neurologists that actually treat the patients for side effects and things. So I think we've employed sort of state-of-the-art methods for collecting these data and, hopefully, avoided many of the pitfalls."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","And your next question comes from the line of Chris Raymond from Raymond James.",14,"And your next question comes from the line of Chris Raymond from Raymond James."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Just a couple of quick commercial questions. Paul, on TECFIDERA, you guys called out the $30 million of inventory during the quarter and, I think, Q3's $10 million to $15 million, if I recall correctly. So how should we think, I guess, about Q1? Are we ta",157,"Just a couple of quick commercial questions. Paul, on TECFIDERA, you guys called out the $30 million of inventory during the quarter and, I think, Q3's $10 million to $15 million, if I recall correctly. So how should we think, I guess, about Q1? Are we talking about $40 million to $45 million that needs to be burned off? Or is there some other dynamic there that we should be modeling? And then also on PLEGRIDY, just wondering if you could share any insights on, as the launch has progressed, any change specifically in the source of patients, either from AVONEX or other beta interferons? And if I ask this question, because some of our checks seem to indicate there's been a shift where PLEGRIDY is taking patients now from other beta interferons versus more from AVONEX early on. I'm just kind of wondering if that's what you're seeing, too, if there's something else going on there."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Chris, great. questions. This is Paul. TECFIDERA, let me just kind of level set and just clarify because you're exactly on it. What we had noted in Q3 is that our estimate at the time was that there was about $10 million to $15 million of build in the SPP",415,"Chris, great. questions. This is Paul. TECFIDERA, let me just kind of level set and just clarify because you're exactly on it. What we had noted in Q3 is that our estimate at the time was that there was about $10 million to $15 million of build in the SPP, in the specialty pharmacy, part of the combined channel. And that was mostly what we believe were related to a government purchase, related to kind of their fiscal year timing. I think our belief is that, that's largely burned through. On a quarter-to-quarter basis within Specialty Pharmacies, there is sometimes ebbs and flows on inventory levels, and we'll try to do our best to point that out. But we think it's at -- and I would think that we may have things like what we had in Q3, but I think that's largely burned through. What we noted in Q4 is actually related to the wholesaler portion of the channel and, on a quarter-over-quarter basis, that there was a little bit of build. So I think what -- as we move into Q1, we're really probably dealing with the $30 million to get to kind of on a sequential quarter basis. We always -- just to complete the thought, we always deal with kind of a Q1 -- Q4 to Q1 dynamics that sometimes we don't have great visibility on the so-called shoebox effect, the change in Q1 with respect to patients on insurance and -- which is related, obviously, to shoebox. So Q1 oftentimes -- and gross-to-net-change, and so discounts and allowances rate, goes up in Q1 as well for us as well as the industry. So we're always -- be mindful of that. On PLEGRIDY, it's very interesting. Your checks probably are consistent with what we're seeing as well. We saw early on -- and to some extent, it was our marketing strategy early on was a conversion of AVONEX patients, and we hit some speed bumps along that early on in the launch in the first -- in the last quarter of 2014 and going into -- early into 2015. We're starting to see both from what we're trying to do on our marketing strategy, but we're also starting to see the benefits of PLEGRIDY being seen as sourcing volumes from the other interferons. Look, this is a great product vis--vis kind of capturing our -- and penetrating and capturing share within that interferon segment of the marketplace. Great question. Thanks, Chris."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Your next question comes from the line of Terence Flynn from Goldman Sachs."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","This is Cameron [ph] filling in for Terence. Congrats on your approval of you Enbrel biosimilar in the EU. I was wondering, is there anything you can share regarding your pricing and commercialization strategy there?",35,"This is Cameron [ph] filling in for Terence. Congrats on your approval of you Enbrel biosimilar in the EU. I was wondering, is there anything you can share regarding your pricing and commercialization strategy there?"
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Cameron [ph], obviously, we're in discussions country-by-country but really can't share anything. So no comments on that. I -- we'll try to as we begin to post revenues to try to provide some commentary.",34,"Cameron [ph], obviously, we're in discussions country-by-country but really can't share anything. So no comments on that. I -- we'll try to as we begin to post revenues to try to provide some commentary."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matt Roden from UBS.",12,"Your next question comes from the line of Matt Roden from UBS."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Thanks for delivering a nice quarter on guidance here. I think as a sector, we needed some good news. So I had kind of a specific on the BACE inhibitor, E2609. The Phase II study is in 700 patients, but my understanding is that the data that we'll get on",116,"Thanks for delivering a nice quarter on guidance here. I think as a sector, we needed some good news. So I had kind of a specific on the BACE inhibitor, E2609. The Phase II study is in 700 patients, but my understanding is that the data that we'll get on this year's disclosures is just on safety from the initial cohorts, not the whole 700 patients. So can you just clarify what we should expect to see from this disclosure this year? And help us understand what exactly you'll be looking for and how this information would pertain to a go, no-go decision. And then lastly, just when we'll get initial efficacy findings from this program."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, you're right, Matt, we're going to look at the first cohort. And the original plan was that the first cohort would then trigger a second cohort. I'm not -- the main thing we're going to look at is the safety data from the first cohort and also to con",75,"Yes, you're right, Matt, we're going to look at the first cohort. And the original plan was that the first cohort would then trigger a second cohort. I'm not -- the main thing we're going to look at is the safety data from the first cohort and also to confirm the pharmacodynamic effect that we saw with our Phase I study. So it's really safety and repeat or confirmation of pharmacodynamic effect in the CSF."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Okay. And then does that pertain to any go, no-go decision? And then when we should expect to see initial efficacy?",21,"Okay. And then does that pertain to any go, no-go decision? And then when we should expect to see initial efficacy?"
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. Well, with the number of patients in the first cohort, I have low expectations in terms of efficacy. And it will lead to a go, no-go decision to Phase III.",31,"Yes. Well, with the number of patients in the first cohort, I have low expectations in terms of efficacy. And it will lead to a go, no-go decision to Phase III."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang from the Bank of America Merrill Lynch.",17,"Your next question comes from the line of Ying Huang from the Bank of America Merrill Lynch."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","Maybe for Al. You mentioned that you should expect the enrollment or full enrollment of aducanumab Phase III similar to the time line of the other Phase III trials. Does that mean we should probably expect 18 to 24 months or potentially even longer for th",115,"Maybe for Al. You mentioned that you should expect the enrollment or full enrollment of aducanumab Phase III similar to the time line of the other Phase III trials. Does that mean we should probably expect 18 to 24 months or potentially even longer for the enrollment to be accrued? And then also secondly, I was curious, your thought on TYSABRI because ocrelizumab could be approved probably towards end of this year. We know that about 30% of JCV-positive patients are on TYSABRI. I mean, sorry, 30% of TYSABRI patients are JCV-positive. And then there's also a certain level of off-label use from PPMS and SPMS. So if you could provide some thought on that."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes. So in terms of enrollment, I don't want to hazard a guess as to exactly how long it's going to take to enroll patients. I think we're pleased with what we're seeing so far, but it's early days. And right now, our time lines are assuming the enrollmen",190,"Yes. So in terms of enrollment, I don't want to hazard a guess as to exactly how long it's going to take to enroll patients. I think we're pleased with what we're seeing so far, but it's early days. And right now, our time lines are assuming the enrollment rate on a per -- patients-per-site basis to what we've seen with other Phase III trials. And then in terms of ocrelizumab, it's great to have a new drug for patients, particularly for PPMS patients. I don't think there were a lot of PPMS patients who are on TYSABRI, if that's what you're asking. There are -- there probably are some people who are -- who have SPMS on TYSABRI because our label says relapsing forms of MS, and patients with SPMS have relapses in their early stages of SPMS. So it would be unlabeled to be on TYSABRI if you have relapsing SPMS. Now ocrelizumab, I don't think, will have a label for SPMS as far as I understand. I don't recall the data trial on SPMS. So I don't see how that would affect the SPMS piece very much."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","I guess, first, for Paul on capital allocation. Now that you've finished the $5 billion share repurchase program, do you have plans to start another one? I'm just curious how we should be thinking about share count in '16. And then also, Paul, on your com",89,"I guess, first, for Paul on capital allocation. Now that you've finished the $5 billion share repurchase program, do you have plans to start another one? I'm just curious how we should be thinking about share count in '16. And then also, Paul, on your comment with regard to price increases not being assumed in your 2016 guidance, can you just remind us how you've built that into past guidance in prior years? And is this a change that's simply the result of the current pricing environment and controversy?"
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, with respect to -- let's kind of start on capital allocation and share repurchases. And you're right, we've exhausted the $5 billion share characterization that was authorized and approved by the board back in the spring of 2015. George and I are in",205,"Yes, with respect to -- let's kind of start on capital allocation and share repurchases. And you're right, we've exhausted the $5 billion share characterization that was authorized and approved by the board back in the spring of 2015. George and I are in constant contact, in constant dialogue, in constant discussion about best deployment of capital. I think that our thinking right now is a bit focused on strategic deployment, and -- but I would continue to emphasize that we always frame this as one or the other, and it's -- over a longer the time, it's appropriately a mix. And I think the cash flow generation of the company is -- remains quite robust such that we can deploy capital in a lot of different ways, all with the objective of increasing intrinsic value per share. So we'll look towards a lot of different means. I mean, I know  I'm being a little bit vague and opaque, but I think it's just because that's a little bit where we are right now in thinking through all the dynamics of that. No real comment on the pricing dynamics for the balance of the year. The financial guidance for this year does not assume it."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Jim Birchenough from Wells Fargo.",13,"Your next question comes from the line of Jim Birchenough from Wells Fargo."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Analysts","I sneak in, Jim, this morning. A couple of quick questions. In terms of the remyelination programs, you have the oral remyelination agent, BIIB061. Clearly, remyelination is a very complex process. Have you looked at combining that with anti-LINGO? Do you",123,"I sneak in, Jim, this morning. A couple of quick questions. In terms of the remyelination programs, you have the oral remyelination agent, BIIB061. Clearly, remyelination is a very complex process. Have you looked at combining that with anti-LINGO? Do you see remyelination as a single-drug opportunity? Or do you think it's going to need combination therapy in perhaps some subsets of patients? And then for the Ionis SOD1 trial, for these kinds of trials where you're looking at these very rare-to-find sort of mutations or correction opportunities, do you see the pattern repeating that we saw in nusinersen that can you generate enough compelling data in a Phase I trial in affected patients that you can jump into a potentially registration-enabling trial?"
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","Yes, thanks those questions, Jim. On the remyelination, right now, we're thinking of it that we would use one agent for remyelination based on our preclinical studies. Of course, the remyelinating drug would probably be combined with an anti-inflammatory",229,"Yes, thanks those questions, Jim. On the remyelination, right now, we're thinking of it that we would use one agent for remyelination based on our preclinical studies. Of course, the remyelinating drug would probably be combined with an anti-inflammatory or immunomodulatory drug, and that's exactly how we're conducting the SYNERGY study of anti-LINGO-1 in MS. We're adding it to interferon. But I -- right now, we don't have any plans to combine the 2 remyelinating drugs that we have in our pipeline. That may change over time, but that's our current plan. And then in terms of the Ionis SOD1 Phase I trial, yes, we've done a lot of work, we meaning Biogen, also the ALS community, on biomarkers and not only in human studies because you'll recall that there was a prior antisense study with a less potent antisense in SOD1 patients, and there's been some -- a lot of animal work. And we have CSF measures that we could employ that we think will predict parenchymal spinal cord SOD1 levels. The whole point of what we're trying to do is to reduce levels of SOD1, because we believe that the mutated forms of SOD1 are toxic. So we have actually validated, I -- we believe, very good measures that we can use to take the program for the -- from the current trial to a registrational study."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Executives","And this is George. I think that's often the case and the advantage of working on genetically homogeneous disease as a result of a single gene. So look, I want to thank everybody for your attention this morning and for your interest. We are going to go",64,"And this is George. I think that's often the case and the advantage of working on genetically homogeneous disease as a result of a single gene. 
So look, I want to thank everybody for your attention this morning and for your interest. We are going to go back to work and do our best to deliver a great 2016 for everyone. So thank you."
29726,320091841,921687,"Biogen Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2016 Financial Results and Business Update Conference Call. [Operator Instructions] Thank you. I would n",60,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2016 Financial Results and Business Update Conference Call. [Operator Instructions] Thank you. I would now like to turn the conference over to Mr. Matt Calistri, Senior Director of Investor Relations for Biogen."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, and welcome to Biogen's First Quarter 2016 Earnings Conference Call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the G",202,"Thank you, and welcome to Biogen's First Quarter 2016 Earnings Conference Call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today.
Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally.
We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Al Sandrock, our Chief Medical Officer; our CFO, Paul Clancy; and our new Chief Commercial Officer, Michel Vounatsos, is with us here today. Now I'll turn the call over to George."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay, thanks, Matt. And good morning, everyone, and thanks for joining us this morning. For the first quarter of 2016, Biogen generated $2.7 billion in total revenues, 7% increase from the same period a year ago. And our non-GAAP EPS was $4.79, 25% increa",494,"Okay, thanks, Matt. And good morning, everyone, and thanks for joining us this morning. For the first quarter of 2016, Biogen generated $2.7 billion in total revenues, 7% increase from the same period a year ago. And our non-GAAP EPS was $4.79, 25% increase from the same period a year ago. 
As you've heard from us since the beginning of the year, our cornerstone to our strategy for sustainable growth is our healthy commercial business and a strong focus on managing expenses and I think these results should reinforce that message. 
TECFIDERA continues to gain share globally, now with more than 190,000 patients having been treated. And at AAN this week, we presented compelling data that showcase its strong and sustained efficacy in newly diagnosed MS patients, emphasizing that earlier treatment with TECFIDERA improves long-term clinical outcomes. We also presented compelling data about TECFIDERA's real-world efficacy. 
Last month, we announced that our new Executive Vice President, Chief Commercial Officer, Michel Vounatsos have joined us. Michel brings a wealth of experience from 20 successful years of increasing responsibility at Merck, most recently as President of primary care and customer centricity. Michel officially started on Monday and we're excited to be working with him. He'll be instrumental in driving our near-term growth, while helping to prepare the organization to support our exciting pipeline.
In the first quarter we launched BENEPALI, our biosimilar version of Enbrel, in 6 European countries, the U.K., Germany, Denmark, Norway, Sweden and the Netherlands. And FLIXABI, our biosimilar version of Remicade, receive a positive opinion from the CHMP and we're awaiting approval from the European Commission shortly.
And, of course, an important part of our strategy for sustainable growth is our pipeline of potential future therapies. Notably, aducanumab is enrolling patients into a Phase III trials; opicinumab, which is anti-LINGO, results are expected midyear; and nusinersen, in collaboration with Ionis, is close to completing enrollment of the Phase III trial called [indiscernible]. Al will provide more color on the pipeline during his comments.
Finally, I'd like to make a few comments to address some questions that I know will come. First, we're in the final stages of hiring an R&D head and expect to make an announcement shortly. Second, like you, we've read the media reports about our hemophilia business and the subsequent analyst reports. As a matter of policy, we do not comment on speculation and will not do so in this instance. We're in an exciting stage in the evolution of Biogen. We're encouraged by the trajectory of our commercial portfolio and will continue to focus on cost containment to maximize our earnings. We're eagerly awaiting the data from opicinumab and nusinersen, and we're pleased with the early enthusiasm for our biosimilars in Europe. We recently brought several new compounds into development, and we continue to look for opportunities outside of Biogen. 
And with that, I'll turn the call over to Al, who'll update you on our progress in R&D."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, George, and good morning, everyone. This quarter, we continue to execute on our pipeline candidates and generate new data to support our commercialized products. Starting with opicinumab or anti-LINGO, we are looking forward to seeing the Phase II",700,"Thanks, George, and good morning, everyone. This quarter, we continue to execute on our pipeline candidates and generate new data to support our commercialized products. Starting with opicinumab or anti-LINGO, we are looking forward to seeing the Phase II data, which is still scheduled for the middle of this year. I should note that no one has seen this data. But after more than a decade of work on LINGO, beginning with discovering the gene and elucidating its biology, most of which was conducted at Biogen, we're excited to learn about opicinumab's potential as a reparative therapy for MS.
In Alzheimer's disease, we are working diligently to enroll our aducanumab Phase III trials and are pleased with progress, thus far. Looking ahead, we anticipate safety data from the titration arm of the Phase 1b PRIME study in the second half of this year.
Amiselimod or MT-1303, our S1P1 inhibitor for IBD, is currently being tested in the Phase II trial in Crohn's disease and we're working toward the start of Phase III studies in ulcerative colitis and Crohn's disease in the second half of this year.
Raxatrigine, a small molecule inhibitor of the Nav 1.7 sodium channel, is anticipated to begin a Phase III trial to confirm its efficacy in patients with trigeminal neuralgia. And we are also planning to initiate a Phase II trial in patients with painful, lumbosacral later this year. 
Turning to our hemophilia products, we find the data that was presented at the December ASH meeting on immune tolerance induction with ELOCTATE quite encouraging. We believe that the SC portion of this fusion proteins utilized in both ELOCTATE and ALPROLIX may offer additional benefits beyond half-life extension. Although these preliminary findings will require comp confirmation from additional studies. 
At this week's American Academy of Neurology meeting, we presented important new data demonstrating the breadth and diversity of our marketed and pipeline multiple sclerosis therapies, including TECFIDERA, TYSABRI, ZINBRYTA and PLEGRIDY. Let me provide some of the highlights of our presentation.
TECFIDERA was shown to provide sustained and strong efficacy in newly diagnosed MS patients, reinforcing that earlier treatment with TECFIDERA is important in improving long-term clinical outcomes. We also presented the results of another study that retrospectively examine the health insurance claims database of more than 5,000 patients in routine clinical practice. 
Annualized relapse rates 1 year after starting disease-modifying therapy were compared to the year before therapy initiation. These real-world data support the efficacy of TECFIDERA treatment seen in the controlled clinical trials and this combined with the safety profile and oral convenience make it a very compelling therapeutic option for MS patients.
Data presented at AAN reinforce the nearly 10 years of clinical experience with TYSABRI confirming its high efficacy, reversible immune effects and well-characterized safety profile. ZINBRYTA with its targeted and reversible mechanism of action, was shown to be positive on key MS cognitive outcomes. PLEGRIDY was shown to reduce the conversion of newly acquired MS lesions into T1 black holes, which have been associated with external loss.
Also at AAN, our collaboration partner, Ionis, presented an update on the ongoing open-label Phase II trial of nusinersen in infants with spinal muscular atrophy. An analysis as of January 2016 showed no new events as defined by progression to permanent ventilation or death in the study since December of 2014, continued increases in muscle function scores and achievement of new motor milestones when compared to natural history studies. We believe these data look increasingly encouraging and nusinersen could represent an important new therapy for spinal muscular atrophy.
With respect to our earlier stage efforts, at our R&D day last November, we talked about using human genetics to identify cause of biological pathways as we strive to discover and develop new treatment for difficult diseases. In February, we joined the Centre for Therapeutic Target Validation, the pioneering public-private collaboration that fosters interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting validated novel targets in drug development. This collaboration expands on our strategy of using genetically validated targets, biomarkers and multiple therapeutic approaches to decrease the risk of drug development. 
With that, I'll now pass the call to Paul."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Al. Our GAAP diluted earnings per share were $4.43 in the first quarter, while our non-GAAP diluted earnings per share were $4.79. Total revenue for Q1 grew 7% year-over-year to approximately $2.7 billion.Our revenue growth was driven by the sta",1000,"Thanks, Al. Our GAAP diluted earnings per share were $4.43 in the first quarter, while our non-GAAP diluted earnings per share were $4.79. Total revenue for Q1 grew 7% year-over-year to approximately $2.7 billion.
Our revenue growth was driven by the stable patient trends we now see for TECFIDERA and TYSABRI in the U.S. and continued growth in ELOCTATE and ALPROLIX. 
Although PLEGRIDY showed meaningful growth, our overall interferon business decline compared to the first quarter of last year as the market continues to migrate to orals. Overall, we're pleased that the breadth and strength of our product portfolio enabled us to absorb such fluctuations, expand our top line and maintain our global MS market share of approximately 38%.
As a reminder, we had $173 million in foreign exchange hedge gains in the 2015, which has begun to impact our year-over-year comparisons. Compared to the first quarter of last year, we had $26 million less in hedge gains this quarter. Combined with the $24 million headwind from natural foreign exchange rates, overall revenue was weakened by approximately $50 million year-over-year. I'll highlight the FX impact for each of the therapies.
Global first quarter TECFIDERA revenue was $946 million. We recorded revenues of $744 million in the U.S. and $202 million outside the U.S. In the U.S., we believe there was drawdown of TECFIDERA inventory in the wholesale channel representing approximately $20 million versus prior quarter. Despite an expected choppy start to the quarter as we work through the typical seasonality issues, we believe underlying U.S. TECFIDERA patient demand is largely stable. U.S. of gross to net percentage was comparable to Q4 and largely consistent with our average expected rate for the balance of the year.
Outside the U.S., foreign exchange impact including the reduction in hedge gains, weakened full year TECFIDERA revenue by approximately $14 million year-over-year. Last October, we bolstered our marketing efforts in the U.S. by launching a television campaign aimed at increasing patient awareness about MS and TECFIDERA. We believe we did increase awareness. Our current TV campaign will expire in the middle of this year. For various reasons, we plan to sunset this lever and don't currently plan to purchase additional TV spots beyond the middle of the year.
We do, nevertheless, plan to continue our marketing efforts across other print and digital channels. Interferon revenues, including both AVONEX and PLEGRIDY, were $670 million during the first quarter, which includes $467 million in the U.S. and $203 million in sales outside the U.S.
In the U.S., the results were weaker than anticipated due to a combination of lower underlying demand as patients continued to move toward orals, seasonality issues and a drawdown of AVONEX wholesale inventory of approximately $20 million. Outside the U.S., foreign exchange impact inclusive of a reduction in hedge gains, weakened Q1 interferon revenues by approximately $20 million year-over-year.
Now moving to TYSABRI. With nearly 10 years of postmarketing experience, TYSABRI continued to add patients this quarter with worldwide revenues of $477 million. These results were comprised of $288 million in the U.S. and $189 million internationally. We believe TYSABRI's well-understood safety profile and robust efficacy position it well. Foreign exchange impacts, including a reduction in hedge gains, weakened Q1 TYSABRI revenue by approximately $14 million year-over-year.
Turning to our hemophilia business. ELOCTATE revenue for the quarter was $108 million and ALPROLIX revenue in Q1 was $75 million. We recorded $329 million for Q1 in our anti-CD20 collaboration, which includes our profit share from RITUXAN and GAZYVA in the U.S. as well as our profit share in royalties on sales of rituximab outside the U.S. As expected, our share of pretax profits in the U.S. on sales of Rituxan decreased from 40% to 39% at the end of February, following approval of GAZYVA in RITUXAN refractory indolent non-Hodgkin's lymphoma. Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing were $88 million. We continue to benefit this quarter from contract manufacturing revenue related to a strategic partner.
Now turning to the expense lines on the P&L. Q1 cost of goods sold were $313 million or 11% of revenue as we experience lower-than-typical write-ups of manufacturing runs in inventory. Q1 R&D expense was $437 million or 16% of revenue. Of note, in Q1, we did not have any meaningful business development expense. Recall in the fourth quarter, we made a $60 million payment to Mitsubishi Tanabe related to the in-licensing of MT-1303. Additionally, the lower-than-expected R&D run rate seen in Q1 was also favorably impacted by the timing of clinical manufacturing campaigns in other R&D activities.
Q1 SG&A expense was $497 million or 18% of revenue. We remain focused on achieving savings in nonlabor expenses with the objective of reducing lower priority fees and services for the balance of 2016. Other net expense was $53 million in Q1, which includes the interest expense related to our 2015 bond offering.
In Q1, our non-GAAP tax rate was approximately 26%. This rate was negatively impacted by approximately 150 basis points related to discrete items.
Our weighted average diluted share count was approximately 219 million for Q1. And we ended the quarter with approximately $6.8 billion in cash and marketable securities with approximately 45% of this in the U.S.
This brings us to our non-GAAP diluted earnings per share, which were $4.79 for the quarter, representing a strong 25% increase year-over-year. Over the last few years, we've gone to an unprecedented number of product launches and thought it was the right strategy to not be penny wise and pound foolish. 
Starting in 2015, we pivoted to initiate a number of measures to curve operating expense growth. And late in 2015, we announced a restructuring, and we believe the benefits materialize this quarter.
For the balance of the year, we're focused on commercial execution and diligent efforts to further reduce spending where appropriate, while ensuring we simultaneously support the advancement of the pipeline. 
I'll turn the call over to George for his closing remarks comments."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay, thanks, Paul. Look, I'm pleased with the start of the year, and especially with the 25% increase in earnings versus Q1 of 2015. For the remainder of the year, we're focused on 3 areas: careful control of our costs, maximizing our revenues and rapidl",610,"Okay, thanks, Paul. Look, I'm pleased with the start of the year, and especially with the 25% increase in earnings versus Q1 of 2015. For the remainder of the year, we're focused on 3 areas: careful control of our costs, maximizing our revenues and rapidly advancing the pipeline. The cost reduction actions that we took last year resulted in a meaningful increase in earnings this quarter and as we move through the year we'll continue to focus on cost control to do all that we can to concentrate our resources in the activities that do we believe will have the greatest value.
On the revenue side, we're pleased to have Michel Vounatsos join us. I'm very confident in Michel and look forward to all that he and his did will do to maximize the value of our commercial portfolio as we move through this year and into next. We have great drugs that are benefiting a lot of patients, and we want to maximize the benefits to both patients and our shareholders.
Additionally, we hope to launch 2 additional compounds this year, ZINBRYTA and in the EU, FLIXABI. Since we think of revenue on a multiyear basis, we also will continue our focus on pursuing opportunities outside of Biogen. We continue to attract companies and compounds that are potentially interesting for us, and we are in constant discussions with multiple parties from the types of tuck-in acquisitions that we've done historically to later-stage assets closer to commercialization. And as we said in previous calls, we want to be active in this area, while remaining financially discipline.
This is a very important year for the advancement of our internal pipeline. It is important to make sure that the enrollment in the 2 Phase III trials of aducanumab continues to go well. We're pleased with how we're tracking so far but it's still early and we want to make sure that we stay on or ideally ahead of schedule for patient enrollment.
We aim to get the Phase III trials for raxatrigine and amiselimod starting on schedule. And we need to make sure that our early pipeline progresses quickly and that we make fact-based, go, no-go decisions. And, of course, once we have the Phase II data for opicinumab in the middle of the year, we'll quickly decide on the appropriate path forward for opicinumab itself and for the other remyelinating programs in our pipeline. 
As Al mentioned, the open-label data for nusinersen continue to look encouraging, and we need to do everything that we can to minimize the time to see data from the Phase III trials and if positive, to get the drug to patients as soon as possible
Although not so visible from outside the company, we'll continue to invest in R&D. We believe that our strategy of building world-class research and development will not only help us identify important new therapies ourselves but will also help us to make thoughtful, sophisticated decisions about what to bring in from outside the company.
So we have a lot to do. This is a year for us to keep our heads down and focus on execution and all of the areas that I just outlined. We have a great team and a dedicated group of employees. And as always, I'd like to thank our employees for making a positive impact on patients' lives and to thank the patients and physicians involved in our clinical development programs. The achievements that we've made together could not have been realized without their passion and commitment. 
So thank you, all for joining us this morning. And operator, we'll now open up the call for questions."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Matthew Harrison from Morgan Stanley.",15,"[Operator Instructions] Your first question comes from the line of Matthew Harrison from Morgan Stanley."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So I'm going to ask a two-part question, which you'll probably give me a hard time for. So on TECFIDERA, can you just talk a little bit about what's going on outside the U.S. If you back out the FX movements that you were talking, you only fall sequential",102,"So I'm going to ask a two-part question, which you'll probably give me a hard time for. So on TECFIDERA, can you just talk a little bit about what's going on outside the U.S. If you back out the FX movements that you were talking, you only fall sequential $9 million increase in revenues. Is volume substantially slowing outside the U.S.? and then maybe just related to that, you had some contracting changes across the portfolio specifically with CVS last year. Any big impacts progress to gross to net or some of the trends that may have affected the interferon franchise?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Great question. This is Paul. I'll try to take it. Outside the States, we're actually pretty pleased outside the United States. I'd say, Germany is a place  where we'd like to see performance a little bit better. It probably looks a lot like the United St",333,"Great question. This is Paul. I'll try to take it. Outside the States, we're actually pretty pleased outside the United States. I'd say, Germany is a place  where we'd like to see performance a little bit better. It probably looks a lot like the United States performance so TECFIDERA kind of getting too darned close to [indiscernible] this year and not being -- not punching through over the course of 2015. That's an important market outside the United States as you all know. When I go across other parts that really the big contributors outside the United States, it's kind of obviously France, U.K., Southern Europe countries of Italy and Spain. And we're very pleased with the performance in Southern Europe. Those our early days in terms of the launch curves for TECFIDERA specifically. We're very, very pleased with that. The performance has exceeded our expectations and certainly as we pointed out in the past, our U.K. performance is exceptionally strong. We've got what we feel is a remarkable team is there. They've kind of really -- really kind of broken down the marketplace and affected quite vigorously across the suite of Biogen MS therapies. So I think very pleased I'd say with the performance outside the United States with a little bit of homework to do in Germany, which, I think, we're actually showing some early signs, very early signs late in the quarter, positive signs. With respect to contracting, it is as people know, specific to AVONEX and PLEGRIDY, specific to newly diagnosed patients. I think that you combine that with typical seasonality issues in Q1, and we still feel we made the right choices there in terms of as we moved into 2016. So I think that's kind of -- we don't think there's been a meaningful impact. Certainly, we've kind of working through prior authorizations and things like that for some of the patients has become a more active part of what we do in our patient services organization."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Your next question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Paul, congrats again on great P&L management. We all appreciate, your investors appreciate it. On the -- So many questions asked. May be Al, just because this is the one I get the most. Just going back to the Eisai collaboration and the antibody that may",165,"Paul, congrats again on great P&L management. We all appreciate, your investors appreciate it. On the -- So many questions asked. May be Al, just because this is the one I get the most. Just going back to the Eisai collaboration and the antibody that may or may have not have data shortly. The question that I've been getting -- I just love to hear your thoughts are, you'd emphasized a lot to been looking at antibody really understanding what the imaging data show post therapy that is during from the brain. And if the answer to that is no, then the clinical outcome is perhaps less important. Doesn't do what you're aim at, so to speak. But there is some question specifically very Eisai antibody binds type of fibrils and whether or not given its binding -- specific binding affinities whether or not you would expect necessarily to see changes on PET scan? So I just wondered if you could talk us through that."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Mark. The BAN2401 to my understanding binds the fibrils as well as the oligomers, and I would expect it to reduce amyloid plaque burden. The question for me is, does it do that, first of all, and second, to what degree? The thing that was remarkable",173,"Yes, Mark. The BAN2401 to my understanding binds the fibrils as well as the oligomers, and I would expect it to reduce amyloid plaque burden. The question for me is, does it do that, first of all, and second, to what degree? The thing that was remarkable about aducanumab is that we had a very substantial reduction in the course of 1 year. Arguably, 85% or so. Compared to antibodies have not been that and I don't know were 2401 will land but that's an important piece. And then we can then start to understand the relationship between reduction and plaque burden and cognitive outcome. In our hands, in the aducanumab program, only the patients who reduced plaque burden by greater than 1 standard deviation change relative to what the placebo patient did, in other words, beyond the noise. Those are the people who got cognitive benefit. The people who did not do that did not have any benefit that we could detect. So we think that's an important piece to look at."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Alethia Young from Crdit Suisse.",13,"Your next question comes from the line of Alethia Young from Crdit Suisse."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","I guess from the DDC campaign that you had with TECFIDERA like what were some of the learnings that you took away for that campaign around the television from and why you chose to keep the press? And just kind of similar along that lines, like have you --",68,"I guess from the DDC campaign that you had with TECFIDERA like what were some of the learnings that you took away for that campaign around the television from and why you chose to keep the press? And just kind of similar along that lines, like have you -- do you have any color on what the average duration for TECFIDERA is right now in the United States?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","I'll take the first part of that question. The main purpose of the ad campaign, television campaign was to increase awareness of TECFIDERA. We were surprised, actually, the beginning by the low awareness among patients of TECFIDERA. And we had data sugges",181,"I'll take the first part of that question. The main purpose of the ad campaign, television campaign was to increase awareness of TECFIDERA. We were surprised, actually, the beginning by the low awareness among patients of TECFIDERA. And we had data suggesting that when patients did learn about TECFIDERA and went to their physician to discuss it, they often had it prescribed. So we wanted to get to the awareness up. The ad did succeed in getting awareness up. We would -- other than this is once awareness is up and they have those discussions, they will go to their physicians and we'll see an increase in prescriptions. We said we would see that if we do in Q2. We're in Q2 and so I think that we'll a final verdict on the success of that TV campaign when we talk to you next quarter. And so those ads don't run forever. So we're taking a pause. We'll continue our other types of activities and we will see what we learn and make decisions about any potential future television ads."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","This is Paul, I'll try to take the second part of your question. [indiscernible] in a slightly different way that is a little bit more customary to the way we look at the data and probably more indicative. We try to triangulate on what we call discontinua",160,"This is Paul, I'll try to take the second part of your question. [indiscernible] in a slightly different way that is a little bit more customary to the way we look at the data and probably more indicative. We try to triangulate on what we call discontinuation rates, percentage of patients that leave a therapy call it over the course of a 52-week period. And all the disease-modifying therapies have discontinuation rates. And we think that TECFIDERA experienced higher discontinuation rates than normal as we move through 2015, largely due to lymphocyte monitoring and kind that label change. We're actually importantly, think that we're kind of on hopefully on the backside of that. That the medical education is largely been completed. It never -- obviously, it never stops but we're hopeful that actually you that can provide a little bit of a tailwind as we move through 2016 and as it begins to get back to a more normal level."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink Partners."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Paul, just could you give us some color on how the rest of the year is looking now? You obviously have gotten a tailwind here with the significantly lower R&D expenses. You've tighten your belt on SG&A. But you did have what looks like $45 million of sequ",104,"Paul, just could you give us some color on how the rest of the year is looking now? You obviously have gotten a tailwind here with the significantly lower R&D expenses. You've tighten your belt on SG&A. But you did have what looks like $45 million of sequential currency headwind or loss of hedging from Q4. So how should we think about of those drivers for the rest of the year? Can you keep this sort of level on R&D and SG&A? And should we anticipate this kind the magnitude of currency effects through the balance of the year because of your hedge positions?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, let me kind of -- great questions, Geoff, because it's kind of a dynamic that loss of hedging, not a surprise to us. So that was actually part of our business plan as we swung into 2016. And fundamentally, we're not -- we don't make productions about",264,"Yes, let me kind of -- great questions, Geoff, because it's kind of a dynamic that loss of hedging, not a surprise to us. So that was actually part of our business plan as we swung into 2016. And fundamentally, we're not -- we don't make productions about where the currency is going to go. But we fully anticipate anticipated the fact that we had hatched gains throughout the P&L in 2015 that really come about from the hedges that we put on in 2014. So it's essentially a wrap around effects of the currency changes, mostly in the EU as we kind of ended, ended if you remember the changes were a very end of December 2014 and January of 2015. So that was fully expected. And so we believe that, that will just continue to be a bit of a headwind, which we have talked about. The R&D, I think, I'd point out 1 key dynamic is it's always a little bit choppy R&D as a percentage of sales based on business development activity. And we certainly want to and would welcome really good business development activity that's always a positive investment, a positive expense if done correctly. With all that said, no doubt about it that, as I said, we have made cost control and feel like we're reaping the benefits of what we did late in 2015 as we came into this year. And I think it will continue to be a meaningful effort for me, from the whole organization to make sure we focus on efficiencies throughout the year."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Yes, maybe on that R&D investment, either for Paul or George. We all appreciate the focus on the bottom line and cost and appreciate also there are some puts and takes in Q1. But you're 16% of revenue in the first quarter, I think, that's an all-time low",69,"Yes, maybe on that R&D investment, either for Paul or George. We all appreciate the focus on the bottom line and cost and appreciate also there are some puts and takes in Q1. But you're 16% of revenue in the first quarter, I think, that's an all-time low for Biogen. Is that an appropriate rate for this company kind of long-term, 3 to 5 years in terms of investment?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, let me take that question. Our R&D is choppy and I don't want anybody to interpret that number as a deliberate effort to cut back on R&D and deemphasis on R&D. It is quite the opposite, actually. We are continuing to build a world-class research grou",206,"Yes, let me take that question. Our R&D is choppy and I don't want anybody to interpret that number as a deliberate effort to cut back on R&D and deemphasis on R&D. It is quite the opposite, actually. We are continuing to build a world-class research group. We will continue to invest in research. We believe that is a fundamental part of our strategy to build value. I think we've done a really good job so far. We'll continue that focus. Clinical development, we will spend whatever is necessary to move our pipeline forward. Those pipeline compounds as our high potential, high-value, we've talked about those. We continued to invest in those. Practically, the expenses that are we would expect up to go up over time as we move more compounds into Phase III. So I think that the trend is largely in that direction. And part of this quarter was also, as Paul said, the lack of BD and not going to be a lack of BD forever. So it's the lack in 1 quarter. So I think it's -- I don't want anybody to interpret the 1 quarter number as a change in our strategy or deemphasis of R&D. It's quite the opposite, actually."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","I know you're not commenting on other outside on hemophilia, but I wanted to ask bigger picture. There's been changes in the market. The incumbent being acquired. There's a gene therapy dated yesterday. May be you can talk a little about for this business",82,"I know you're not commenting on other outside on hemophilia, but I wanted to ask bigger picture. There's been changes in the market. The incumbent being acquired. There's a gene therapy dated yesterday. May be you can talk a little about for this business and is this business the business you've been thinking about? And maybe talk a little bit about how this fits in overall in the growth that you see here given all the changes going on in hemophilia?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Sure. Happy to take that. ELOCTATE and ALPROLIX are doing well. They're gaining market share and we're pleased with their performance. So they are continuing to gain share so we feel good about them here. We have not yet seen any impact on their trajector",404,"Sure. Happy to take that. ELOCTATE and ALPROLIX are doing well. They're gaining market share and we're pleased with their performance. So they are continuing to gain share so we feel good about them here. We have not yet seen any impact on their trajectories from the introduction of other long-acting factors. So we take that as a positive sign. So I think the prospects for the business look quite healthy. In the longer term, there are a number of products as there are in every therapeutic area coming forward and we're keeping a close eye on them. There is certainly we saw data, which are interesting but early. I mean, I haven't seen anything that you haven't seen. I saw good [indiscernible] levels that persisted for some period of time, and we saw some liver enzyme ambitious that needed to be treated with corticosteroids specs, and we will see how that plays out over time. Those are early. I would say interesting data but early. A similar, I think, lower immune tolerance induction the that, that we have with ELOCTATE. And if you -- we haven't talked about this a lot but a fair number of hemophilia develop hematuria antibodies when they are treated and that results in the necessity for immune tolerance induction, which means high levels of factory that are given over a 12 to 18 months before immune intolerance emerges. There have been a very limited number of patients, 3, so I don't want to overstate this. Again, these are very early data and I don't want to be here overstating the case. But again, these are early data but also in encouraging. So of the 3 patients that have been treated with ELOCTATE from the intolerance induction, they all became tolerant within about 3 to 4 months. So a much shorter period of time. If those data are confirmed in further studies, we believe that, that could be important opportunities for ELOCTATE. So I think there are lots of early data emerging. They all need to be confirmed with larger studies. And we feel good about the business and where we are. We have our own longer-acting factors coming. We talked about some of them, there are earlier once that are in our research group now. So I think that we feel good about the current products, and we feel good about the future of the business as well."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch.",16,"Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","First 1 is many investors think you guys have lost flexibility on balance sheet because you guys don't have much net debt. I'm just probing the question for Paul. What's the willingness here to do another significant share buyback given your balance sheet",92,"First 1 is many investors think you guys have lost flexibility on balance sheet because you guys don't have much net debt. I'm just probing the question for Paul. What's the willingness here to do another significant share buyback given your balance sheet strength? And then secondly, I want to ask about the TECFIDERA inventory situation here. So in fourth quarter, you had a $30 million inventory build in the U.S. and then there's a destocking of $20 million this quarter. Should we expect another $10 million to go next quarter?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay, why don't I try to clean up the clarity on the second part of your question. So the $30 million that I talked about last quarter was our best estimate at that time. In retrospect now, it probably is closer to the $20 million. In reality, it's probab",296,"Okay, why don't I try to clean up the clarity on the second part of your question. So the $30 million that I talked about last quarter was our best estimate at that time. In retrospect now, it probably is closer to the $20 million. In reality, it's probably in between. So I think that we've gone through the destocking of what we talked about last quarter and just wanted to kind of clarify with the prepared remarks. With respect to the balance sheet, I think it gets to the broader question of capital allocation. Currently, we're actually sitting on a pretty high cash balance. As I pointed out, like many others, we have the peculiar situation of ex-U.S. cash a little bit more than half of that. But outside from that, that largely arises out 2 things, the great strong cash flow generation of the company, coupled with the debt financing that we did in the fall of 2015. Look, I think that we're going to look to strategically deploy it. And if we come up that there are not options to strategically deploy it, we will look towards returning capital to shareholders. We don't measure that on as we've talked about before in the 90 day basis just because that's not the kind of clock speed of things. In both situations, it depends on price and value. So it continues to -- it depends. And in both situations, the financial objective is to maximize intrinsic value per share. So we look towards investing in and deployment of capital that really drive great internal rate of return. I think, I'd also point out, look, over a longer period of time, I think these companies with the great cash flow generation has flexibly to do both."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just a question on strategy a little bit and thinking about the company longer term. So you've got stable but it's faced some compression from new therapies and you have hemophilia is a growing business and pipeline. I'm just wondering how are you thinkin",131,"Just a question on strategy a little bit and thinking about the company longer term. So you've got stable but it's faced some compression from new therapies and you have hemophilia is a growing business and pipeline. I'm just wondering how are you thinking about how important it is to diversify the business further? Do you have any concerns or know how are you thinking about could there be something that both pricing pressure on the MS market and what could trigger it? And how are you thinking about maybe derisking in the company funds or should notify us think of the best near-term but it's something that could happen over the long term? And then just help us think about the longer-term strategy the company and your thoughts on price?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","This is George. I'll start with that and other people can chime. Look, we are, I think, we're feeling good about the MS business as it exists today. We're going right but, I think, if you look at our pipeline, you will see that many of the things we're wo",220,"This is George. I'll start with that and other people can chime. Look, we are, I think, we're feeling good about the MS business as it exists today. We're going right but, I think, if you look at our pipeline, you will see that many of the things we're working on aren't not in MS. I think LINGO actually could be a transformative event even in that treatment of MS and we are not working beyond [indiscernible] novel ZINBRYTA in novel additional trials that would down regulate the immune system. I think there are enough of those in the market. There are more coming. For many MS patients, those don't stop the progression, they the progression but they don't stop the progression. And so we believe like LINGO actually are the types of compounds that could actually transform that market and give additional vibrancy as we move out through the 20s. That being said, if you look at what we're emphasizing and now and what we have in Phase III, it's nusinersen for SMA, it's aducanumab for Alzheimer's disease, it's raxatrigine for neuropathic pain, it's amiselimod for IBD and Crohn's disease. So we have deliberately brought in a series of compounds and are conducting late-stage trials and things that are outside of MS, partially for the reason you just outlined."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","[indiscernible] Anything that would trigger pricing compression in the marketplace?",10,"[indiscernible] Anything that would trigger pricing compression in the marketplace?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","We don't see anything in the near-term. No, as you move out of the 20s, certainly could be but don't see anything near-term.",24,"We don't see anything in the near-term. No, as you move out of the 20s, certainly could be but don't see anything near-term."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","A couple of commercial ones. In the context of your DTC campaign, I was curious if you guys have any data on retreatment of patients who went on TECFIDERA right at the launch? And then just would respect to related question with respect to first quarter t",64,"A couple of commercial ones. In the context of your DTC campaign, I was curious if you guys have any data on retreatment of patients who went on TECFIDERA right at the launch? And then just would respect to related question with respect to first quarter trends, or even fourth quarter, any impact thus far from generic Copaxone on the interferon market, vis--vis, share?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, I'll try to address that. Not a lot of data on retreatment so we have plenty of data about can't top of my head can think of anything as it relates to that. With respect to generic Cop, the data would suggest it's a pretty small percentage at this po",86,"Yes, I'll try to address that. Not a lot of data on retreatment so we have plenty of data about can't top of my head can think of anything as it relates to that. With respect to generic Cop, the data would suggest it's a pretty small percentage at this point in time and the data would suggest that it very much is just impacting Copaxone. So that's how we see it anecdotally as well as how the data market share and the patient trends suggests."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","A question for Michel, if I may, first of all, congratulations on the new position. I know it's very early days but I'm curious if you could may be talk about your objectives coming into Biogen, in, areas where you see the potential have the most impact o",82,"A question for Michel, if I may, first of all, congratulations on the new position. I know it's very early days but I'm curious if you could may be talk about your objectives coming into Biogen, in, areas where you see the potential have the most impact on commercial business under your leadership and perhaps more specifically how you're thinking about potentially accelerating growth in MS and positioning for potential ocrelizumab entry, while still balancing the company's focus on achieving cost savings?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Brian, this is Paul. We had we Michel prepared for a wholesale or inventory question. Michel?",16,"Brian, this is Paul. We had we Michel prepared for a wholesale or inventory question. Michel?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","so thanks for the question. Good morning, everybody. This is Michel Vounatsos. Week 1 at Biogen, so as you can imagine, I am on the learning and listening mode and it's not too early for me to assess this strategy. I will be focusing a lot of time on the",115,"so thanks for the question. Good morning, everybody. This is Michel Vounatsos. Week 1 at Biogen, so as you can imagine, I am on the learning and listening mode and it's not too early for me to assess this strategy. I will be focusing a lot of time on the obviously and the key customers to best understand and key franchises. So I hope that in the near future, I'll be in a better position to assess the next steps. What I can tell you is that I'm extremely encouraged and honor to be part of this team and looking forward and engaging with all of you in the near future. Thanks for your understanding."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of James Birchenough from Wells Fargo Securities.",14,"Your next question comes from the line of James Birchenough from Wells Fargo Securities."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","May be a question on the pipeline and some help in assessing the risk adjusted value of nusinersen. And on the risk side of it, when you look at the data we saw [indiscernible] we've seen over the last few years, how do you get comfortable with the compar",81,"May be a question on the pipeline and some help in assessing the risk adjusted value of nusinersen. And on the risk side of it, when you look at the data we saw [indiscernible] we've seen over the last few years, how do you get comfortable with the comparison with historical controls. And then on the opportunity perhaps you could speak to how you view that opportunity and in SMA between the type 1 and then the type 2, 3 patients?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Well the compare to historical control is always a little bit dangerous to do because you have to  choose cohorts and try to match them they are patients but the standard of practice changes over time. So these patients might be getting better over time j",198,"Well the compare to historical control is always a little bit dangerous to do because you have to  choose cohorts and try to match them they are patients but the standard of practice changes over time. So these patients might be getting better over time just by the clinical practice improving. On the other hand, when you start to see lack of events of the type that was shown at the AAN since December of 2014, no new events, that's pretty striking difference and these are hard endpoints like time to tracheostomy or ventilation and time to death. It's hard for me to see how that kind of thing could be happening due to simply improving our medical care. So I think we're getting more and more encouraged but I would note that we have these 2 well-controlled trials, 1 in infant onset SMA and 1 in childhood SMA and that to me is a definitive data set that we're going to be looking at. And in terms of the opportunities in infant and childhood, I mean, I think that they are both big opportunities and I look forward to being able to help patients in both categories."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Actually, I wanted to follow-up on nusinersen. George, in your script or comments, when you talk about doing whatever you can to minimize the time to Phase III data for the product, is there anything specific that can actually be done to shorten that time",70,"Actually, I wanted to follow-up on nusinersen. George, in your script or comments, when you talk about doing whatever you can to minimize the time to Phase III data for the product, is there anything specific that can actually be done to shorten that time line given that enrollment is complete for 1 of the trials and close to it to the other? Is there anything else you referring to?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Look, at this time, let me just say that we are cognizant of the need to get this drug to patients as soon as we can come if it works. So the first part of that is being confident that it works. And as Al said, we're going to need to see data from the con",169,"Look, at this time, let me just say that we are cognizant of the need to get this drug to patients as soon as we can come if it works. So the first part of that is being confident that it works. And as Al said, we're going to need to see data from the controlled trials in order to make that case to the agencies certainly and for us to be absolutely certain as well. So we want to get there as quickly as we can. And once we have those data, we absolutely want to minimize the time until these kids have access to it, again, if it works. And these are the especially type 1 kids who don't have a lot of time. And so there are a lot of kids out there today who could desperately need something and so that's what we're trying to shorten that time frame. But I don't want to go into any of the specifics of how we're doing that."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Your next question comes from the line of Terence Flynn from Goldman Sachs."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just on the LINGO MS data come in midyear, I know you guys are looking at a range of endpoints here, including disability and cognition. I think disability is pretty easy for us to benchmark because there's a lot of data there. But on the coalition side,",78,"Just on the LINGO MS data come in midyear, I know you guys are looking at a range of endpoints here, including disability and cognition. I think disability is pretty easy for us to benchmark because there's a lot of data there. But on the coalition side, I know you're using this [indiscernible] 3 scale. Anything you can do there just to help them for us in terms of what would be a meaningful outcome on that measurement?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, we've had a lot of experience with [indiscernible] We've been using it MS trials for about 20 years now. One of the things that we know is that there's a practice effect and so I expect to see some improvement on the score even in untreated patients",161,"Yes, we've had a lot of experience with [indiscernible] We've been using it MS trials for about 20 years now. One of the things that we know is that there's a practice effect and so I expect to see some improvement on the score even in untreated patients just because of the practic effect. What I am hoping to see with anti-LINGO and I don't know whether we will or not is that there would be an even better learning effect in the anti-LINGO treated patients and that will be great to see if those response that would make it even more compelling if we saw that. In terms of what is considered clinically meaningful, that hasn't been established in the world of MS yet. We have no established precedents on that. I will say that some compounds have shown some efficacy on this by virtue of preventing new MS lesions, but certainly not in this new era of reparative therapies."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of from BMO Capital Markets.",12,"Your next question comes from the line of from BMO Capital Markets."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just a question for Al. On aducanumab, I was hoping to get your thoughts on targeting of a beta specifically I think you've implied and if there's plenty of data out there suggesting that beta amyloid levels or amyloid beta levels might have actually plat",105,"Just a question for Al. On aducanumab, I was hoping to get your thoughts on targeting of a beta specifically I think you've implied and if there's plenty of data out there suggesting that beta amyloid levels or amyloid beta levels might have actually plateaued by the time a patient shows any signs of mild cognitive impairment. I'm just curious to get your thoughts sort of the appropriateness of targeting A beta in patients who are plaque level and what potential could be driving the disease in these patients in terms of their progression? And whether there's another target that would be make more sense?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, so it's true that when you look at plaque burden, it does tend to plateau in the -- already in the Pro phase, certainly by [indiscernible] it's pretty flat. And so what drives the progression beyond that? We believe is probably all. TAL comes on late",186,"Yes, so it's true that when you look at plaque burden, it does tend to plateau in the -- already in the Pro phase, certainly by [indiscernible] it's pretty flat. And so what drives the progression beyond that? We believe is probably all. TAL comes on later. If you look at the imaging studies, tall comes on later and there's a lot of data, preclinical data that shows that the data triggers TAL pathology. So we're learning a lot about TAL now. We know in normal aging there is some aggravated TAL in the medial temporal lobe but in patients with Alzheimer's disease, it spreads beyond the medial temporal lobe and that spread is probably triggered by A beta. And so that's the reason why we have some programs in TAL. We've just -- we have some preclinical as well as early clinical programs of both antibodies as well as antisense. And so in the later stages, we might need to treat for TAL, perhaps, in combination with the A beta therapies because I don't think you want to reaccumulate  A beta once we remove it."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","And your last question comes from the line of Chris Raymond from Raymond James.",14,"And your last question comes from the line of Chris Raymond from Raymond James."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So just a question on anti-LINGO. So at AAN, there was some interesting data on [ph] the agent seems to have at least some sort of similarity in terms of mechanism to LINGO in terms of impacting oligodendrocyte differentiation at least. Wondering, Al, if",68,"So just a question on anti-LINGO. So at AAN, there was some interesting data on [ph] the agent seems to have at least some sort of similarity in terms of mechanism to LINGO in terms of impacting oligodendrocyte differentiation at least. Wondering, Al, if you have any thoughts, is there any kind of readthrough we should be thinking about with respect to that agent and results there?"
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, so we -- the came from this micro pillar assay that was developed in San Francisco, where they have oligodendrocytes essentially around tubes. And what they found was that there were a number of compound that work as an stupidness as well as Ramstein",248,"Yes, so we -- the came from this micro pillar assay that was developed in San Francisco, where they have oligodendrocytes essentially around tubes. And what they found was that there were a number of compound that work as an stupidness as well as Ramstein. We've actually tested lambskin in our oligodendrocyte differentiation assay here and then in our hands it's less potent than our [ph] 61, our oral compound that we have in early clinical trials and it's also less effective overall in a side-by-side comparison in our hands. Nevertheless, I did look at the data, crossover designs like the 1 that they did are not, probably not the best approach for looking up disease-modifying therapies because when you switch from to placebo, I don't expect that if it is causing myelination, how would the placebo patients look? They would continue to get the benefit from the that they had received in the period prior. So, nevertheless, they did show a modest effect on latency of the conduction between the retina and the brain. And we're keeping a close eye on that. I think that these are all early day experiments in reparative therapies and I believe we have established one of the best ways of looking at this in our anti-LINGO program, both in the acute optic neuritis as well as the MS program. Okay, if there are no further questions, let me thank you, all, for your time this morning and we'll sign off. Thanks."
29726,328802932,960509,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2016 Financial Results and Business Update Conference Call. [Operator Instructions] Thank you. I would n",60,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2016 Financial Results and Business Update Conference Call. [Operator Instructions] Thank you. I would now like to turn the conference over to Mr. Matt Calistri, Senior Director of Investor Relations for Biogen."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, and welcome to Biogen's First Quarter 2016 Earnings Conference Call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the G",202,"Thank you, and welcome to Biogen's First Quarter 2016 Earnings Conference Call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today.
Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally.
We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Al Sandrock, our Chief Medical Officer; our CFO, Paul Clancy; and our new Chief Commercial Officer, Michel Vounatsos, is with us here today. Now I'll turn the call over to George."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt. Good morning, everyone, and thanks for joining us this morning. For the first quarter of 2016, Biogen generated $2.7 billion in total revenues, 7% increase from the same period a year ago. And our non-GAAP EPS was $4.79, 25% increase from th",493,"Thanks, Matt. Good morning, everyone, and thanks for joining us this morning. For the first quarter of 2016, Biogen generated $2.7 billion in total revenues, 7% increase from the same period a year ago. And our non-GAAP EPS was $4.79, 25% increase from the same period a year ago. 
As you've heard from us since the beginning of the year, our cornerstone to our strategy for sustainable growth is our healthy commercial business and a strong focus on properly managing expenses. And I think these results should reinforce that message. 
TECFIDERA continues to gain share globally, now with more than 190,000 patients having been treated. And at AAN this week, we presented compelling data that showcased its strong and sustained efficacy in newly diagnosed MS patients, emphasizing that earlier treatment with TECFIDERA improves long-term clinical outcomes. We also presented compelling data about TECFIDERA's real-world efficacy. 
Last month, we announced that our new Executive Vice President, Chief Commercial Officer, Michel Vounatsos have joined us. Michel brings a wealth of experience from 20 successful years of increasing responsibility at Merck, most recently as President of Primary Care and Customer Centricity. Michel officially started on Monday, and we're excited to be working with him. He'll be instrumental in driving our near-term growth, while helping to prepare the organization to support our exciting pipeline.
In the first quarter, we launched BENEPALI, our biosimilar version of Enbrel, in 6 European countries: the U.K., Germany, Denmark, Norway, Sweden and the Netherlands. And FLIXABI, our biosimilar version of Remicade, received a positive opinion from the CHMP, and we're awaiting approval from the European Commission shortly.
And of course, an important part of our strategy for sustainable growth is our pipeline of potential future therapies. Notably, aducanumab is enrolling patients in 2 Phase III trials; opicinumab, which is anti-LINGO, results are expected midyear; and nusinersen, in collaboration with Ionis, is close to completing enrollment of the Phase III trial called ENDEAR. Al will provide more color on the pipeline during his comments.
Finally, I'd like to make a few comments to address some questions that I know will come. First, we're in the final stages of hiring an R&D head and expect to make an announcement shortly. Second, like you, we've read the media reports about our hemophilia business and the subsequent analyst reports. As a matter of policy, we do not comment on speculation and will not do so in this instance. We're in an exciting stage in the evolution of Biogen. We're encouraged by the trajectory of our commercial portfolio, and will continue to focus on cost containment to maximize our earnings. We're eagerly awaiting the data from opicinumab and nusinersen, and we're pleased with the early enthusiasm for our biosimilars in Europe. We've recently brought several new compounds into development, and we continue to look for opportunities outside of Biogen. 
And with that, I'll turn the call over to Al, who'll update you on our progress in R&D."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, George, and good morning, everyone. This quarter, we continue to execute on our pipeline candidates and generate new data to support our commercialized products. Starting with opicinumab or anti-LINGO, we are looking forward to seeing the Phase II",704,"Thanks, George, and good morning, everyone. This quarter, we continue to execute on our pipeline candidates and generate new data to support our commercialized products. Starting with opicinumab or anti-LINGO, we are looking forward to seeing the Phase II data, which is still scheduled for the middle of this year. I should note that no one has seen this data yet, but after more than a decade of work on LINGO, beginning with discovering the gene and in elucidating its biology, most of which was conducted at Biogen, we're excited to learn about opicinumab's potential as a reparative therapy for MS.
In Alzheimer's disease, we are working diligently to enroll our aducanumab Phase III trials, and are pleased with progress thus far. Looking ahead, we anticipate safety data from the titration arm of the Phase 1b PRIME study in the second half of this year.
Amiselimod or MT-1303, our S1P1 inhibitor for IBD, is currently being tested in the Phase II trial in Crohn's disease, and we are working toward the start of Phase III studies in ulcerative colitis and Crohn's disease in the second half of this year.
Raxatrigine, a small molecule inhibitor of the Nav 1.7 sodium channel, is anticipated to begin a Phase III trial to confirm its efficacy in patients with trigeminal neuralgia. And we are also planning to initiate a Phase II trial in patients with painful, lumbosacral radiculopathy later this year. 
Turning to our hemophilia products, we find the data that was presented at the December ASH meeting on immune tolerance induction with ELOCTATE quite encouraging. We believe that the SC portion of these fusion proteins utilized in both ELOCTATE and ALPROLIX may offer additional benefits beyond half-life extension, although these preliminary findings will require confirmation from additional studies. 
At this week's American Academy of Neurology meeting, we presented important new data demonstrating the breadth and diversity of our marketed and pipeline multiple sclerosis therapies, including TECFIDERA, TYSABRI, ZINBRYTA and PLEGRIDY. Let me provide some of the highlights of our presentation.
TECFIDERA was shown to provide sustained and strong efficacy in newly diagnosed MS patients, reinforcing that earlier treatment with TECFIDERA is important in improving long-term clinical outcomes. We also presented the results of another study that retrospectively examined the health insurance claims database of more than 5,000 patients in routine clinical practice. 
Annualized relapse rates 1 year after starting disease-modifying therapy were compared to the year before therapy initiation. These real-world data support the efficacy of TECFIDERA treatment seen in the controlled clinical trials and this, combined with its safety profile and oral convenience, make it a very compelling therapeutic option for MS patients.
Data presented at AAN reinforced the nearly 10 years of clinical experience with TYSABRI, confirming its high efficacy, reversible immune effects and well-characterized safety profile. 
ZINBRYTA, with its targeted and reversible mechanism of action, was shown to be positive on key MS cognitive outcomes. 
PLEGRIDY was shown to reduce the conversion of newly acquired MS lesions into T1 black holes, which have been associated with axonal loss.
Also at AAN, our collaboration partner, Ionis, presented an update on the ongoing open-label Phase II trial of nusinersen in infants with spinal muscular atrophy. An analysis as of January 2016 showed no new events as defined by progression to permanent ventilation or death in the study since December of 2014, continued increases in muscle function scores and achievement of new motor milestones when compared to natural history studies. We believe these data look increasingly encouraging, and that nusinersen could represent an important new therapy for spinal muscular atrophy.
With respect to our earlier stage efforts, at our R&D day last November, we talked about using human genetics to identify causal biological pathways as we strive to discover and develop new treatment for difficult diseases. In February, we joined the Centre for Therapeutic Target Validation, the pioneering public-private collaboration that fosters interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development. This collaboration expands on our strategy of using genetically validated targets, biomarkers and multiple therapeutic approaches to decrease the risk of drug development. 
With that, I'll now pass the call to Paul."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Al. Our GAAP diluted earnings per share were $4.43 in the first quarter, while our non-GAAP diluted earnings per share were $4.79. Total revenue for Q1 grew 7% year-over-year to approximately $2.7 billion.Our revenue growth was driven by the sta",997,"Thanks, Al. Our GAAP diluted earnings per share were $4.43 in the first quarter, while our non-GAAP diluted earnings per share were $4.79. Total revenue for Q1 grew 7% year-over-year to approximately $2.7 billion.
Our revenue growth was driven by the stable patient trends we now see for TECFIDERA and TYSABRI in the U.S. and continued growth in ELOCTATE and ALPROLIX. 
Although PLEGRIDY showed meaningful growth, our overall interferon business declined compared to the first quarter of last year as the market continues to migrate to orals. Overall, we're pleased that the breadth and strength of our product portfolio enabled us to absorb such fluctuations, expand our top line and maintain our global MS market share of approximately 38%.
As a reminder, we had $173 million in foreign exchange hedge gains in the 2015, which has begun to impact our year-over-year comparisons. Compared to the first quarter of last year, we had $26 million less in hedge gains this quarter. Combined with the $24 million headwind from natural foreign exchange rates, overall revenue was weakened by approximately $50 million year-over-year. I'll highlight the FX impact for each of the therapies.
Global first quarter TECFIDERA revenue was $946 million. We recorded revenues of $744 million in the U.S. and $202 million outside the U.S. In the U.S., we believe there was a drawdown of TECFIDERA inventory in the wholesale channel, representing approximately $20 million versus prior quarter. Despite an expected choppy start to the quarter as we work through the typical seasonality issues, we believe underlying U.S. TECFIDERA patient demand is largely stable. U.S. gross-to-net percentage was comparable to Q4 and largely consistent with our average expected rate for the balance of the year.
Outside the U.S., foreign exchange impact, including the reduction in hedge gains, weakened full year TECFIDERA revenue by approximately $14 million year-over-year. Last October, we bolstered our marketing efforts in the U.S. by launching a television campaign aimed at increasing patient awareness about MS and TECFIDERA. We believe we did increase awareness. Our current TV campaign will expire in the middle of this year. For various reasons, we plan to sunset this lever, and don't currently plan to purchase additional TV spots beyond the middle of the year.
We do, nevertheless, plan to continue our marketing efforts across other print and digital channels. Interferon revenues, including both AVONEX and PLEGRIDY, were $670 million during the first quarter, which includes $467 million in the U.S. and $203 million in sales outside the U.S.
In the U.S., the results were weaker than anticipated due to a combination of lower underlying demand as patients continued to move toward orals, seasonality issues and a drawdown of AVONEX wholesale inventory of approximately $20 million. Outside the U.S., foreign exchange impact, inclusive of a reduction in hedge gains, weakened Q1 interferon revenues by approximately $20 million year-over-year.
Now moving to TYSABRI. With nearly 10 years of postmarketing experience, TYSABRI continued to add patients this quarter with worldwide revenues of $477 million. These results were comprised of $288 million in the U.S. and $189 million internationally. We believe TYSABRI's well-understood safety profile and robust efficacy position it well. Foreign exchange impacts, including a reduction in hedge gains, weakened Q1 TYSABRI revenue by approximately $14 million year-over-year.
Turning to our hemophilia business. ELOCTATE revenue for the quarter was $108 million and ALPROLIX revenue in Q1 was $75 million. We recorded $329 million for Q1 in our anti-CD20 collaboration, which includes our profit share from RITUXAN and GAZYVA in the U.S. as well as our profit share in royalties on sales of rituximab outside the U.S. As expected, our share of pretax profits in the U.S. on sales of RITUXAN decreased from 40% to 39% at the end of February, following approval of GAZYVA in RITUXAN refractory indolent non-Hodgkin's lymphoma. 
Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing were $88 million. We continue to benefit this quarter from contract manufacturing revenue related to a strategic partner.
Now turning to the expense lines on the P&L. Q1 cost of goods sold were $313 million or 11% of revenue as we experienced lower-than-typical write-offs of manufacturing runs in inventory. Q1 R&D expense was $437 million or 16% of revenue. Of note, in Q1, we did not have any meaningful business development expense. Recall, in the fourth quarter, we made a $60 million payment to Mitsubishi Tanabe related to the in-licensing of MT-1303. Additionally, the lower-than-expected R&D run rate seen in Q1 was also favorably impacted by the timing of clinical manufacturing campaigns in other R&D activities.
Q1 SG&A expense was $497 million or 18% of revenue. We remain focused on achieving savings in nonlabor expenses with the objective of reducing lower priority fees and services for the balance of 2016. Other net expense was $53 million in Q1, which includes the interest expense related to our 2015 bond offering.
In Q1, our non-GAAP tax rate was approximately 26%. This rate was negatively impacted by approximately 150 basis points related to discrete items.
Our weighted average diluted share count was approximately 219 million for Q1. And we ended the quarter with approximately $6.8 billion in cash and marketable securities, with approximately 45% of this in the U.S.
This brings us to our non-GAAP diluted earnings per share, which were $4.79 for the quarter, representing a strong 25% increase year-over-year. Over the last few years, we've gone to an unprecedented number of product launches and thought it was the right strategy to not be penny wise and pound foolish. 
Starting in 2015, we pivoted to initiate a number of measures to curb operating expense growth. And late in 2015, we announced a restructuring, and we believe the benefits materialize this quarter.
For the balance of the year, we're focused on commercial execution and diligent efforts to further reduce spending where appropriate, while ensuring we simultaneously support the advancement of the pipeline. 
I'll turn the call over to George for his closing comments."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thanks, Paul. Look, I'm pleased with the start of the year, and especially with the 25% increase in earnings versus Q1 of 2015. For the remainder of the year, we're focused on 3 areas: careful control of our costs, maximizing our revenues and rapidl",609,"Okay. Thanks, Paul. Look, I'm pleased with the start of the year, and especially with the 25% increase in earnings versus Q1 of 2015. For the remainder of the year, we're focused on 3 areas: careful control of our costs, maximizing our revenues and rapidly advancing the pipeline. The cost reduction actions that we took last year resulted in a meaningful increase in earnings this quarter. And as we move through the year, we'll continue to focus on cost control to do all that we can to concentrate our resources on the activities that we believe will add the greatest value.
On the revenue side, we're pleased to have Michel Vounatsos join us. I'm very confident in Michel and look forward to all that he and his team will do to maximize the value of our commercial portfolio as we move through this year and into next. We have great drugs that are benefiting a lot of patients, and we want to maximize the benefits to both patients and our shareholders.
Additionally, we hope to launch 2 additional compounds this year, ZINBRYTA; and in the EU, FLIXABI. Since we think of revenue on a multiyear basis, we also will continue our focus on pursuing opportunities outside of Biogen. We continue to attract companies and compounds that are potentially interesting for us, and we are in constant discussions with multiple parties from the types of tuck-in acquisitions that we've done historically to later-stage assets closer to commercialization. And as we said in previous calls, we want to be active in this area, while remaining financially disciplined.
This is a very important year for the advancement of our internal pipeline, and it's important to make sure that the enrollment in the 2 Phase III trials of aducanumab continues to go well. We're pleased with how we're tracking so far, but it's still early and we want to make sure that we stay on or ideally ahead of schedule for patient enrollment.
We aim to get the Phase III trials for raxatrigine and amiselimod started on schedule. And we need to make sure that our early pipeline progresses quickly and that we make fact-based go, no-go decisions. And of course, once we have the Phase II data for opicinumab in the middle of the year, we'll quickly decide on the appropriate path forward for opicinumab itself and for the other remyelinating programs in our pipeline. 
As Al mentioned, the open-label data for nusinersen continue to look encouraging, and we need to do everything that we can to minimize the time to see data from the Phase III trials and, if positive, to get the drug to patients as soon as possible.
Although not so visible from outside the company, we'll continue to invest in R&D. We believe that our strategy of building world-class research and development will not only help us identify important new therapies ourselves but will also help us to make thoughtful, sophisticated decisions about what to bring in from outside the company.
So we have a lot to do. This is a year for us to keep our heads down and focus on execution in all of the areas that I just outlined. We have a great team and a dedicated group of employees. And as always, I'd like to thank our employees for making a positive impact on patients' lives and to thank the patients and physicians involved in our clinical development programs. The achievements that we've made together could not have been realized without their passion and commitment. 
So thank you all for joining us this morning. And operator, we'll now open up the call for questions."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Matthew Harrison from Morgan Stanley.",15,"[Operator Instructions] Your first question comes from the line of Matthew Harrison from Morgan Stanley."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So I'm going to ask a two-part question, which you'll probably give me a hard time for. But -- so on TECFIDERA, can you just talk a little bit about what's going on outside the U.S.? If you back out the FX movements that you were talking, you only saw a s",104,"So I'm going to ask a two-part question, which you'll probably give me a hard time for. But -- so on TECFIDERA, can you just talk a little bit about what's going on outside the U.S.? If you back out the FX movements that you were talking, you only saw a sequential $9 million increase in revenues. Is volume substantially slowing outside the U.S.? And then maybe just related to that, you had some contracting changes across the portfolio, specifically with CVS last year. Any big impacts to gross to net or some of the trends that may have affected the interferon franchise?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt. Great question. This is Paul. I'll try to take it. Outside the United States -- we're actually pretty pleased outside the United States. I'd say, Germany is a place where we'd like to see performance a little bit better. It probably looks a",340,"Thanks, Matt. Great question. This is Paul. I'll try to take it. Outside the United States -- we're actually pretty pleased outside the United States. I'd say, Germany is a place where we'd like to see performance a little bit better. It probably looks a lot like the United States performance of TECFIDERA kind of getting to -- darn close to a 20 share [ph] and not being -- not punching through over the course of 2015. That's an important market outside the United States, as you all know. When I go across other parts that really are the big contributors outside the United States, it's kind of, obviously, France, U.K., Southern Europe countries of Italy and Spain. And we're very pleased with the performance in Southern Europe. Those are early days in terms of the launch curves for TECFIDERA specifically. We're very, very pleased with that. The performance has exceeded our expectations. And certainly, as we pointed out in the past, our U.K. performance is exceptionally strong. We've got what we feel is a remarkable team there. They've kind of really -- really kind of broken down the marketplace and attacked it quite vigorously across the suite of Biogen MS therapies. So I think very pleased, I'd say, with the performance outside the United States, with a little bit of homework to do in Germany which, I think, we're actually showing some early signs, very early signs late in the quarter, positive signs. With respect to contracting, it is as people know, specific to AVONEX and PLEGRIDY, specific to newly diagnosed patients. I think that you combine that with typical seasonality issues in Q1, and we still feel we made the right choices there in terms of as we moved into 2016. And so I think that's kind of -- we don't think there's been a meaningful impact. Certainly, kind of working through prior authorizations and things like that for some of the patients has become a more active part of what we do in our Patient Services organization."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Your next question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Paul, congrats again on a great P&L management. We all appreciate it, your investors appreciate it. On the -- so many questions asked, maybe Al, just because this is the one I get the most, just going back to the Eisai collaboration and the Abeta antibody",183,"Paul, congrats again on a great P&L management. We all appreciate it, your investors appreciate it. On the -- so many questions asked, maybe Al, just because this is the one I get the most, just going back to the Eisai collaboration and the Abeta antibody that may or may not have data shortly. The question that I've been getting -- I just love to hear your thoughts are, you emphasized a lot when looking at these competing Abeta antibody is really understanding if -- what the imaging data show post therapy, that is, is it draining plaque from the brain? And if the answer to that is no, then the clinical outcome is perhaps less important because it doesn't do what your amaB does, so to speak. And -- but there's been some questions about, specifically, where the Eisai BAN antibody binds, which types of fibrils and whether or not, given its binding -- its specific binding affinities, whether or not you would expect necessarily to see changes on PET scan? So I just wondered if you could talk us through that."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Mark. The BAN2401, to my understanding, binds the protofibrils as well as oligomers, and I would expect it to reduce amyloid plaque burden. The question for me is, does it do that, first of all; and second, to what degree? The thing that was remarkab",171,"Yes, Mark. The BAN2401, to my understanding, binds the protofibrils as well as oligomers, and I would expect it to reduce amyloid plaque burden. The question for me is, does it do that, first of all; and second, to what degree? The thing that was remarkable about aducanumab was that we had a very substantial reduction in the course of 1 year. Arguably, 85% or so. Competitor antibodies have not done that, and I don't know where 2401 will land but that's an important piece. And then we can then start to understand the relationship between reduction and plaque burden and cognitive outcome. In our hands, in the aducanumab program, only the patients who reduced plaque burden by greater than 1 standard deviation changed relative to what the placebo patient did, in other words, beyond the noise. Those are the people who got cognitive benefit. The people who did not do that did not have any benefit that we could detect. So we think that's an important piece to look at."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Alethia Young from Crdit Suisse.",13,"Your next question comes from the line of Alethia Young from Crdit Suisse."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Congrats on the expense management as well. I guess, from the DTC campaign that you had with TECFIDERA, like, what were some of the learnings that you took away for that campaign around the television form and why you chose to keep the press? And just kin",75,"Congrats on the expense management as well. I guess, from the DTC campaign that you had with TECFIDERA, like, what were some of the learnings that you took away for that campaign around the television form and why you chose to keep the press? And just kind of similar, along that line, like have you -- do you have any color on what the average duration for TECFIDERA is right now in the United States?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","I'll take the first part of that question. Look, we -- the main purpose of the ad campaign, television campaign was to increase awareness of TECFIDERA. We were surprised actually, at the beginning, by the low awareness among patients of TECFIDERA. And we",183,"I'll take the first part of that question. Look, we -- the main purpose of the ad campaign, television campaign was to increase awareness of TECFIDERA. We were surprised actually, at the beginning, by the low awareness among patients of TECFIDERA. And we had data suggesting that when patients did learn about TECFIDERA and went to their physician to discuss it, they often had it prescribed. So we wanted to get the awareness up. The ad did succeed in getting awareness up. We would -- and then the thesis is, once awareness is up and they have those discussions, they'll go to their physicians and we'll see an increase in prescriptions. We said we would see that, if we do, in Q2. We're in Q2 and so I think we'll have a final verdict on the success of that TV campaign when we talk to you next quarter. And so those ads don't run forever. So we're taking a pause. We'll continue our other types of activities and we'll see what we learn and make decisions about any potential future television ads."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Alethia, this is Paul, I'll try to take the second part of your question. And let me kind of answer it in a slightly different way that is a little bit more customary to the way we look at the data and probably more indicative. We try to triangulate on wh",169,"Alethia, this is Paul, I'll try to take the second part of your question. And let me kind of answer it in a slightly different way that is a little bit more customary to the way we look at the data and probably more indicative. We try to triangulate on what we call discontinuation rates, percentage of patients that leave a therapy, call it, over the course of a 52-week period. And all the disease-modifying therapies have discontinuation rates. And we think that TECFIDERA experienced higher discontinuation rates than normal as we move through 2015, largely due to lymphocyte monitoring and kind of a label change. We actually, importantly, think that we're kind of on -- and hopefully, on the backside of that; that the medical education has largely been completed. It never -- it obviously never stops, but we're hopeful that, actually, that can provide a little bit of a tailwind as we move through 2016 and as it begins to get back to a more normal level."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink Partners."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Paul, just could you give us some color on how the rest of the year is looking now? You obviously have got a tailwind here with the significantly lower R&D expenses. You've tightened your belt on SG&A, but you did have what looks like $45 million of seque",103,"Paul, just could you give us some color on how the rest of the year is looking now? You obviously have got a tailwind here with the significantly lower R&D expenses. You've tightened your belt on SG&A, but you did have what looks like $45 million of sequential currency headwind or loss of hedging from Q4. So how should we think about those drivers for the rest of the year? Can you keep at this sort of level on R&D and SG&A? And should we anticipate this kind magnitude of currency effect through the balance of the year because of your hedge positions?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, let me kind of -- great questions, Geoff, because it's kind of a dynamic that loss of hedging, not a surprise to us. So that was actually part of our business plan as we swung into 2016. And fundamentally, we're not -- we don't make predictions about",263,"Yes, let me kind of -- great questions, Geoff, because it's kind of a dynamic that loss of hedging, not a surprise to us. So that was actually part of our business plan as we swung into 2016. And fundamentally, we're not -- we don't make predictions about where the currencies are going to go. But we fully anticipated the fact that we had hedge gains throughout the P&L in 2015 that really come about from the hedges that we put on in 2014. So it's essentially a wraparound effect of the currency changes, mostly in the EU as we kind of ended, very end -- if you remember the changes were very end of December 2014 and January of 2015. So that was fully expected. And so we believe that, that will just continue to be a bit of a headwind, which we had thought about. The R&D, I think, I'd point out 1 key dynamic is it's always a little bit choppy, R&D as a percentage of sales, based on business development activity. And we certainly want to and would welcome really good business development activity that's always a positive investment, a positive expense if done correctly. With all that said, no doubt about it that, as I said, we have made cost control and feel like we're reaping the benefits of what we did late in 2015 as we came into this year. And I think it will continue to be a meaningful effort for me, from the whole organization to make sure we focus on efficiencies throughout the year."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Yes, maybe on that R&D investment, either for Paul or George. We all appreciate the focus on the bottom line and cost and appreciate also there are some puts and takes in Q1, but you're down 16% of revenue in the first quarter. That's, I think, an all-tim",71,"Yes, maybe on that R&D investment, either for Paul or George. We all appreciate the focus on the bottom line and cost and appreciate also there are some puts and takes in Q1, but you're down 16% of revenue in the first quarter. That's, I think, an all-time low for Biogen. Is that an appropriate rate for this company kind of long term, 3 to 5 years, in terms of investment?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, thanks, Eric. Let me take that question. Our R&D is choppy and I don't want anybody to interpret that number as a deliberate effort to cut back on R&D and a deemphasis on R&D. It is quite the opposite, actually. We are continuing to build a world-cla",209,"Yes, thanks, Eric. Let me take that question. Our R&D is choppy and I don't want anybody to interpret that number as a deliberate effort to cut back on R&D and a deemphasis on R&D. It is quite the opposite, actually. We are continuing to build a world-class research group. We will continue to invest in research. We believe that is a fundamental part of our strategy to build value. I think we've done a really good job so far. We'll continue that focus. Clinical development, we will spend whatever is necessary to move our pipeline forward, those pipeline compounds that are high potential, high value, we've talked about those. We'll continue to invest in those. Frankly, the expenses there, we would expect to go up over time as we move more compounds into Phase III. So I think the trend is largely in that direction. And part of this quarter was also, as Paul said, the lack of BD. And there's not going to be a lack of BD forever. So it's a lack in 1 quarter. So I think it's -- I don't want anybody to interpret the 1 quarter number as a change in our strategy or a deemphasis of R&D. It's quite the opposite, actually."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","I know you're not commenting on other outside reports on hemophilia, but I wanted to ask, bigger picture, there's been changes in the market. The incumbents being acquired. There's gene therapy data yesterday. Maybe you could talk a little about the push-",83,"I know you're not commenting on other outside reports on hemophilia, but I wanted to ask, bigger picture, there's been changes in the market. The incumbents being acquired. There's gene therapy data yesterday. Maybe you could talk a little about the push-pulls for this business and is this business the business you've been thinking about. And maybe talk a little bit about how this fits in overall in the growth that you see here, given all the changes going on in hemophilia."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Sure. Happy to take that. Look, ELOCTATE and ALPROLIX are doing well. They're gaining market share and we're pleased with their performance. So -- and they're continuing to gain share. So we're feeling good about them here. We have not yet seen any impact",409,"Sure. Happy to take that. Look, ELOCTATE and ALPROLIX are doing well. They're gaining market share and we're pleased with their performance. So -- and they're continuing to gain share. So we're feeling good about them here. We have not yet seen any impact on their trajectories from the introduction of other long-acting factors. So we take that as a positive sign. So I think the prospects for the business look quite healthy. In the longer term, there are a number of products, as there are in every therapeutic area, coming forward; and we're keeping a close eye on them. There is certainly -- we saw BioMarin's data, which are interesting but early. I mean, I haven't seen anything that you haven't seen. I saw good factor VIII levels that persisted for some period of time, and we saw some liver enzyme issues that needed to be treated with corticosteroids. So we'll see how that plays out over time. Those are early. I would say interesting data, but early. It's similar, I think, to our immune tolerance induction data that we have with ELOCTATE. And if you -- we haven't talked about this a lot, but a fair number of hemophiliacs [ph] develop inhibitory antibodies when they're treated, and that results in the necessity for immune tolerance induction, which means high levels of factor that are given over 12 to 18 months before immune tolerance emerges. There have been a very limited number of patients, 3, so I don't want to overstate this. Again, these are very early data, so -- and I don't want to be here overstating the case. But again, these are early data but also encouraging. So of the 3 patients that have been treated with ELOCTATE from the immune tolerance induction, they all became tolerant within about 3 to 4 months. So a much shorter period of time. If those data are confirmed in further studies, we believe that, that could be an important upward lift for ELOCTATE. So I think there are lots of early data emerging. They all need to be confirmed with larger studies. And we feel good about the business and where we are. We have our own longer-acting factors coming. We talked about some of them, there are earlier ones that are in our research group now. So I think we feel good about the current products, and we feel good about the future of the business as well."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch.",16,"Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","First one is many investors think you guys have lost flexibility on balance sheet because you guys really don't have much net debt. I'm just probing -- maybe the question is for Paul, what's the willingness here to do another significant share buyback giv",96,"First one is many investors think you guys have lost flexibility on balance sheet because you guys really don't have much net debt. I'm just probing -- maybe the question is for Paul, what's the willingness here to do another significant share buyback given your balance sheet strength? And then secondly, I want to ask about the TECFIDERA inventory situation here. So in fourth quarter, you had a $30 million inventory build in the U.S. and then there's a destocking of $20 million this quarter. Should we expect another $10 million to go next quarter?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay, why don't I try to clean up the clarity on the second part of your question. So the $30 million that I talked about last quarter was our best estimate at that time. In retrospect now, it probably is closer to the $20 million. In reality, it's probab",304,"Okay, why don't I try to clean up the clarity on the second part of your question. So the $30 million that I talked about last quarter was our best estimate at that time. In retrospect now, it probably is closer to the $20 million. In reality, it's probably in between. So I think that we've gone through the destocking of what we talked about last quarter and just wanted to kind of clarify it with the prepared remarks. With respect to the balance sheet, I think it gets to the broader question of capital allocation. Currently, we're actually sitting on a pretty high cash balance. As I pointed out, like many others, we have the peculiar situation of ex U.S. cash as a little bit more than half of that. But aside from that, that largely arises out of 2 things, the great strong cash flow generation of the company, coupled with the debt financing that we did in the fall of 2015. Look, I think we're going to -- we will look to strategically deploy it. And if we come up that there are not options to strategically deploy it, we will look towards returning capital to shareholders. We don't measure that on a -- as we've talked about before, on a 90-day basis just because that's not the kind of clock speed of things. In both situations, it depends on price and value. So it continues to -- it depends. And in both situations, the financial objective is to maximize intrinsic value per share. So we look towards investing in deployments of capital that really drive great internal rates of return. I think I'd also point out, look, over a longer period of time, I think this company, with the great cash flow generation it has, has flexibly to do both."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So just a question on strategy a little bit and thinking about the company longer term. So you've got the MS business now stable but it's faced some compression from new therapies. I mean, you have hemophilia as a growing business and pipeline. I'm just w",144,"So just a question on strategy a little bit and thinking about the company longer term. So you've got the MS business now stable but it's faced some compression from new therapies. I mean, you have hemophilia as a growing business and pipeline. I'm just wondering how are you thinking about how important it is to diversify the business further? Do you have any concerns or know -- or how are you thinking about could there be something that puts pricing pressure on the MS market and what could trigger it? And how are you thinking about maybe derisking the company from such an event? None of us think of it as a near-term event, but it's something that could happen over the long term. And maybe just help us think about like the longer-term strategy of the company and your thoughts on price?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Robyn. This is George. I'll start with that and other people can chime in. Look, we are -- I think we're feeling good about the MS business as it exists today. We're going right. But if you look at our pipeline, you'll see that many of the things",224,"Thanks, Robyn. This is George. I'll start with that and other people can chime in. Look, we are -- I think we're feeling good about the MS business as it exists today. We're going right. But if you look at our pipeline, you'll see that many of the things we're working on are not in MS. We think LINGO, actually, could be a transformative event in the treatment of MS so -- and we are not working beyond ZINBRYTA on novel, let's say, additional drugs that would down regulate the immune system. I think there are enough of those in the market. There are more coming. For many MS patients, those don't stop the progression. They slow the progression but they don't stop the progression. And so we believe things like LINGO actually are the types of compounds that could actually transform that market and give it additional vibrancy as we move out through the 20s. That being said, if you look at what we're emphasizing now and what we have in Phase III, it's nusinersen for SMA, it's aducanumab for Alzheimer's disease, it's raxatrigine for neuropathic pain, it's amiselimod for IBD and Crohn's disease. So we have deliberately brought in a series of compounds and are conducting late-stage trials and things that are outside of MS, partially for the reason you just outlined."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","[indiscernible] and your thoughts on price, anything that could trigger a pricing compression in the marketplace?",16,"[indiscernible] and your thoughts on price, anything that could trigger a pricing compression in the marketplace?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","We don't see anything in the near term. No, as you move out into the 20s, there certainly could be. But don't see anything near term.",27,"We don't see anything in the near term. No, as you move out into the 20s, there certainly could be. But don't see anything near term."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","A couple of commercial ones. In the context of your DTC campaign, I was curious if you guys have any data on retreatment of patients who went on TECFIDERA right at the launch. And then just with respect to a related question with respect to first quarter",65,"A couple of commercial ones. In the context of your DTC campaign, I was curious if you guys have any data on retreatment of patients who went on TECFIDERA right at the launch. And then just with respect to a related question with respect to first quarter trends, or even fourth quarter, any impact thus far from generic Copaxone on the interferon market vis--vis share?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Geoff. I'll try to address that. Not a lot of data on kind of retreatment. So we have plenty of data but I can't, off the top of my head, think of anything as it relates to that. With respect to generic Cop, the data would suggest that it's a pretty",93,"Yes, Geoff. I'll try to address that. Not a lot of data on kind of retreatment. So we have plenty of data but I can't, off the top of my head, think of anything as it relates to that. With respect to generic Cop, the data would suggest that it's a pretty small percentage at this point in time and the data would suggest that it very much is just impacting Copaxone. So that's how we see it anecdotally as well as how the data from market share and the patient trends suggests."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","A question for Michel, if I may, first of all, congratulations on the new position. I know it's very early days but I'm curious if you could maybe talk broadly about your objectives coming into Biogen, areas where you see the potential to have the most im",84,"A question for Michel, if I may, first of all, congratulations on the new position. I know it's very early days but I'm curious if you could maybe talk broadly about your objectives coming into Biogen, areas where you see the potential to have the most impact on the commercial business under your leadership; and perhaps, more specifically, how you're thinking about potentially reaccelerating growth in MS and positioning for a potential ocrelizumab entry, while still balancing the company's focus on achieving cost savings?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Brian. Brian, this is Paul. We had Michel prepared for a wholesale or inventory question. Michel?",17,"Thanks, Brian. Brian, this is Paul. We had Michel prepared for a wholesale or inventory question. Michel?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","So thanks for the question. Good morning, everybody. This is Michel Vounatsos. Week 1 at Biogen. So as you can imagine, I am more on the learning and listening mode and it's far too early for me to assess the strategy. I will be focusing a lot of time on",119,"So thanks for the question. Good morning, everybody. This is Michel Vounatsos. Week 1 at Biogen. So as you can imagine, I am more on the learning and listening mode and it's far too early for me to assess the strategy. I will be focusing a lot of time on the key geographies, obviously, and the key customers to best understand -- and the key franchises. So I hope that in the near future, I'll be in a better position to assess the next steps. What I can tell you is that I'm extremely encouraged and honored to be part of this team, and looking forward engaging with all of you in the near future. Thanks for your understanding."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Jim Birchenough from Wells Fargo Securities.",14,"Your next question comes from the line of Jim Birchenough from Wells Fargo Securities."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Maybe a question on the pipeline and some help in assessing the risk-adjusted value of nusinersen. And on the risk side of it, when you look at the data we saw at AAN and that we've seen over the last few years, how do you get comfortable with the compari",82,"Maybe a question on the pipeline and some help in assessing the risk-adjusted value of nusinersen. And on the risk side of it, when you look at the data we saw at AAN and that we've seen over the last few years, how do you get comfortable with the comparison with historical controls? And then on the opportunity, perhaps, you could speak to how you view that opportunity in SMA between the Type 1 and then the Type 2, 3 patients?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Well the comparison with historical controls is always a little bit dangerous to do because you have to choose cohorts and you try to match them to your patients. But the standard of practice changes over time. So these patients might be getting better ov",197,"Well the comparison with historical controls is always a little bit dangerous to do because you have to choose cohorts and you try to match them to your patients. But the standard of practice changes over time. So these patients might be getting better over time just by the clinical practice improving. On the other hand, when you start to see lack of events of the type that was shown at the AAN since December of 2014, no new events, that's pretty striking difference. And these are hard endpoints, like time to tracheostomy or ventilation and time to death. It's hard for me to see how that kind of thing could be happening due to simply improving medical care. So I think we're getting more and more encouraged, but I would note that we have these 2 well-controlled trials, 1 in infant onset SMA and 1 in childhood onset SMA. And that, to me, is the definitive data set that we're going to be looking at. And in terms of the opportunities in infant and childhood, I mean, I think they're both big opportunities and I look forward to being able to help patients in both categories."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","I actually wanted to follow up on nusinersen. George, in your scripted comments, when you talked about doing whatever you can to minimize the time to Phase III data for the product, is there anything specific that can actually be done to shorten that time",71,"I actually wanted to follow up on nusinersen. George, in your scripted comments, when you talked about doing whatever you can to minimize the time to Phase III data for the product, is there anything specific that can actually be done to shorten that time line, given that enrollment is complete for 1 of the trials and close to it for the other? Is there anything else you were referring to?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Look, at this time, let me just say that we are cognizant of the need to get this drug to patients as soon as we can, if it works. So the first part of that is being confident that it works. And as Al said, we're going to need to see data from the control",172,"Look, at this time, let me just say that we are cognizant of the need to get this drug to patients as soon as we can, if it works. So the first part of that is being confident that it works. And as Al said, we're going to need to see data from the controlled trials in order to make that case to the agencies, certainly, and then for us to be absolutely certain as well. So we want to get there as quickly as we can. And once we have those data, we absolutely want to minimize the time until these kids have access to it, again, if it works. And these are the -- especially the Type 1 kids who don't have a lot of time. And so there are a lot of kids out there today who could -- desperately need something, and so that's -- we're trying to shorten that time frame. But I don't want to get into any of the specifics of how we're doing that."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Your next question comes from the line of Terence Flynn from Goldman Sachs."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just on the LINGO MS data coming in midyear, I know you guys are looking at a range of endpoints here, including disability and cognition. I think disability is pretty easy for all of us to benchmark as there's a lot of data there. But on the cognition si",79,"Just on the LINGO MS data coming in midyear, I know you guys are looking at a range of endpoints here, including disability and cognition. I think disability is pretty easy for all of us to benchmark as there's a lot of data there. But on the cognition side, I know you're using this PASAT-3 scale. Anything you can do there just to help frame for us in terms of what would be a meaningful outcome on that measurement?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, we've had a lot of experience with PASAT. We've been using it in MS trials for about 20 years now. One of the things we know is that there's a practice effect, and so I expect to see some improvement on the score even in untreated patients just becau",162,"Yes, we've had a lot of experience with PASAT. We've been using it in MS trials for about 20 years now. One of the things we know is that there's a practice effect, and so I expect to see some improvement on the score even in untreated patients just because of the practice effect. What I am hoping to see with anti-LINGO, and I don't know whether we will or not, is that there would be an even better learning effect in the anti-LINGO treated patients and that it would be great to see a dose response that would make it even more compelling if we saw that. In terms of what is considered clinically meaningful, that hasn't been established in the world of MS yet. We have no established precedents on that. I will say that some compounds have shown some efficacy on this by virtue of preventing new MS lesions, but certainly not in this new era of reparative therapies."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ian Somaiya from BMO Capital Markets.",14,"Your next question comes from the line of Ian Somaiya from BMO Capital Markets."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just a question for Al. On aducanumab, I was just hoping to get your thoughts on targeting of Abeta, specifically, I think you've implied and I think there's plenty of data out there suggesting that the beta-amyloid levels or amyloid beta levels might hav",112,"Just a question for Al. On aducanumab, I was just hoping to get your thoughts on targeting of Abeta, specifically, I think you've implied and I think there's plenty of data out there suggesting that the beta-amyloid levels or amyloid beta levels might have actually plateaued by the time a patient shows any signs of mild cognitive impairment. I'm just curious to get your thoughts sort of the appropriateness of targeting Abeta in patients where plaque sort of already reached sort of a level, and what potential could be driving the disease in these patients in terms of their progression? And whether there's another target that would be -- make more sense?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, so it's true that when you look at plaque burden, it does tend to plateau in the -- already in the prodromal phase, and certainly by mild disease [ph], it's pretty flat. And so what drives the progression beyond that, we believe, is probably tau. Tau",187,"Yes, so it's true that when you look at plaque burden, it does tend to plateau in the -- already in the prodromal phase, and certainly by mild disease [ph], it's pretty flat. And so what drives the progression beyond that, we believe, is probably tau. Tau comes on later. If you look at the imaging studies, tau comes on later and there's a lot of data, preclinical data, that shows that Abeta pathology triggers tau pathology. So we're learning a lot about tau now. We know that in normal aging, there is some aggregated tau in the medial temporal lobe; but in patients with Alzheimer's disease, it spreads beyond the medial temporal lobe. And that spread is probably triggered by Abeta. And so that's the reason why we have some programs in tau. We've just -- we have some preclinical as well as early clinical programs of both antibodies as well as antisense. And so in the later stages, we might need to treat for tau, perhaps, in combination with the Abeta therapies because I don't think you want to reaccumulate Abeta once you've removed it."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","And your last question comes from the line of Chris Raymond from Raymond James.",14,"And your last question comes from the line of Chris Raymond from Raymond James."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So just a question on anti-LINGO. So at AAN, there was some interesting data on clemastine. That agent seems to have at least some sort of similarity in terms of mechanism to LINGO in terms of impacting oligodendrocyte differentiation at least. Wondering,",70,"So just a question on anti-LINGO. So at AAN, there was some interesting data on clemastine. That agent seems to have at least some sort of similarity in terms of mechanism to LINGO in terms of impacting oligodendrocyte differentiation at least. Wondering, Al, if you had any thoughts -- is there any kind of readthrough we should be thinking about with respect to that agent and the results there?"
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, so we -- the clemastine came from this micropillar assay that was developed in San Francisco, where they have oligodendrocytes wrapping myelin essentially around tubes. And what they found was that there were a number of antimuscarinic compounds that",226,"Yes, so we -- the clemastine came from this micropillar assay that was developed in San Francisco, where they have oligodendrocytes wrapping myelin essentially around tubes. And what they found was that there were a number of antimuscarinic compounds that work, benztropine as well as clemastine. We've actually tested clemastine in our oligodendrocyte differentiation assay here and in our hands, it's less potent than BIIB061, our oral compound that we have in early clinical trials and it's also less effective overall in a side-by-side comparison in our hands. Nevertheless, I did look at the data, crossover designs like the one that they did are not -- probably not the best approach for looking at disease-modifying therapies because when you switch from clemastine to placebo, I don't expect that if it is causing myelination, how would the placebo patients look? They would continue to get the benefit from the clemastine that they had received in the period prior. So nevertheless, they did show a modest effect on latency of the conductions between the retina and the brain. And we're keeping a close eye on that. I think that these are all early day experiments in reparative therapies, and I believe we have established one of the best ways of looking at this in our anti-LINGO program, both in acute optic neuritis as well as the MS program."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay. If there are no further questions, let me thank you all for your time this morning, and we'll sign off. Thanks.",22,"Okay. If there are no further questions, let me thank you all for your time this morning, and we'll sign off. Thanks."
29726,328802932,960797,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2016 Financial Results and Business Update Conference Call. [Operator Instructions] Thank you. I would n",60,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2016 Financial Results and Business Update Conference Call. [Operator Instructions] Thank you. I would now like to turn the conference over to Mr. Matt Calistri, Senior Director of Investor Relations for Biogen."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, and welcome to Biogen's First Quarter 2016 Earnings Conference Call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the G",202,"Thank you, and welcome to Biogen's First Quarter 2016 Earnings Conference Call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today.
Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally.
We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Al Sandrock, our Chief Medical Officer; our CFO, Paul Clancy; and our new Chief Commercial Officer, Michel Vounatsos, is with us here today. Now I'll turn the call over to George."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt. Good morning, everyone, and thanks for joining us this morning. For the first quarter of 2016, Biogen generated $2.7 billion in total revenues, 7% increase from the same period a year ago. And our non-GAAP EPS was $4.79, 25% increase from th",493,"Thanks, Matt. Good morning, everyone, and thanks for joining us this morning. For the first quarter of 2016, Biogen generated $2.7 billion in total revenues, 7% increase from the same period a year ago. And our non-GAAP EPS was $4.79, 25% increase from the same period a year ago. 
As you've heard from us since the beginning of the year, a cornerstone to our strategy for sustainable growth is our healthy commercial business and a strong focus on properly managing expenses. And I think these results should reinforce that message. 
TECFIDERA continues to gain share globally, now with more than 190,000 patients having been treated. And at AAN this week, we presented compelling data that showcased its strong and sustained efficacy in newly diagnosed MS patients, emphasizing that earlier treatment with TECFIDERA improves long-term clinical outcomes. We also presented compelling data about TECFIDERA's real-world efficacy. 
Last month, we announced that our new Executive Vice President, Chief Commercial Officer, Michel Vounatsos had joined us. Michel brings a wealth of experience from 20 successful years of increasing responsibility at Merck, most recently as President of Primary Care and Customer Centricity. Michel officially started on Monday, and we're excited to be working with him. He'll be instrumental in driving our near-term growth, while helping to prepare the organization to support our exciting pipeline.
In the first quarter, we launched BENEPALI, our biosimilar version of Enbrel, in 6 European countries: the U.K., Germany, Denmark, Norway, Sweden and the Netherlands. And FLIXABI, our biosimilar version of Remicade, received a positive opinion from the CHMP, and we're awaiting approval from the European Commission shortly.
And of course, an important part of our strategy for sustainable growth is our pipeline of potential future therapies. Notably, aducanumab is enrolling patients in 2 Phase III trials; opicinumab, which is anti-LINGO, results are expected midyear; and nusinersen, in collaboration with Ionis, is close to completing enrollment of the Phase III trial called ENDEAR. Al will provide more color on the pipeline during his comments.
Finally, I'd like to make a few comments to address some questions that I know will come. First, we're in the final stages of hiring an R&D head and expect to make an announcement shortly. Second, like you, we've read the media reports about our hemophilia business and the subsequent analyst reports. As a matter of policy, we do not comment on speculation and will not do so in this instance. We're in an exciting stage in the evolution of Biogen. We're encouraged by the trajectory of our commercial portfolio, and we'll continue to focus on cost containment to maximize our earnings. We're eagerly awaiting the data from opicinumab and nusinersen, and we're pleased with the early enthusiasm for our biosimilars in Europe. We've recently brought several new compounds into development, and we continue to look for opportunities outside of Biogen. 
And with that, I'll turn the call over to Al, who'll update you on our progress in R&D."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, George, and good morning, everyone. This quarter, we continued to execute on our pipeline candidates and generate new data to support our commercialized products. Starting with opicinumab, or anti-LINGO, we are looking forward to seeing the Phase",703,"Thanks, George, and good morning, everyone. This quarter, we continued to execute on our pipeline candidates and generate new data to support our commercialized products. Starting with opicinumab, or anti-LINGO, we are looking forward to seeing the Phase II data, which is still scheduled for the middle of this year. I should note that no one has seen these data yet, but after more than a decade of work on LINGO, beginning with discovering the gene and then elucidating its biology, most of which was conducted at Biogen, we're excited to learn about opicinumab's potential as a reparative therapy for MS.
In Alzheimer's disease, we are working diligently to enroll our aducanumab Phase III trials, and are pleased with progress thus far. Looking ahead, we anticipate safety data from the titration arm of the Phase 1b PRIME study in the second half of this year.
Amiselimod, or MT-1303, our S1P1 inhibitor for IBD, is currently being tested in a Phase II trial in Crohn's disease, and we are working toward the start of Phase III studies in ulcerative colitis and Crohn's disease in the second half of this year.
Raxatrigine, a small molecule inhibitor of the Nav 1.7 sodium channel, is anticipated to begin a Phase III trial to confirm its efficacy in patients with trigeminal neuralgia. And we are also planning to initiate a Phase II trial in patients with painful lumbosacral radiculopathy later this year. 
Turning to our hemophilia products, we find the data that was presented at the December ASH meeting on immune tolerance induction with ELOCTATE quite encouraging. We believe that the SC portion of these fusion proteins utilized in both ELOCTATE and ALPROLIX may offer additional benefits beyond half-life extension, although these preliminary findings will require confirmation from additional studies. 
At this week's American Academy of Neurology meeting, we presented important new data demonstrating the breadth and diversity of our marketed and pipeline multiple sclerosis therapies, including TECFIDERA, TYSABRI, ZINBRYTA and PLEGRIDY. Let me provide some of the highlights of our presentation.
TECFIDERA was shown to provide sustained and strong efficacy in newly diagnosed MS patients, reinforcing that earlier treatment with TECFIDERA is important in improving long-term clinical outcomes. We also presented the results of another study that retrospectively examined the health insurance claims database of more than 5,000 patients in routine clinical practice. 
Annualized relapse rates 1 year after starting disease-modifying therapy were compared to the year before therapy initiation. These real-world data support the efficacy of TECFIDERA treatment seen in the controlled clinical trials, and this, combined with its safety profile and oral convenience, make it a very compelling therapeutic option for MS patients.
Data presented at AAN reinforced the nearly 10 years of clinical experience with TYSABRI, confirming its high efficacy, reversible immune effects and well-characterized safety profile. 
ZINBRYTA, with its targeted and reversible mechanism of action, was shown to be positive on key MS cognitive outcomes. 
PLEGRIDY was shown to reduce the conversion of newly acquired MS lesions into T1 black holes, which have been associated with axonal loss.
Also at AAN, our collaboration partner, Ionis, presented an update on the ongoing open-label Phase II trial of nusinersen in infants with spinal muscular atrophy. An analysis as of January 2016 showed no new events as defined by progression to permanent ventilation or death in the study since December of 2014, continued increases in muscle function scores and achievement of new motor milestones when compared to natural history studies. We believe these data look increasingly encouraging, and that nusinersen could represent an important new therapy for spinal muscular atrophy.
With respect to our earlier stage efforts, at our R&D day last November, we talked about using human genetics to identify causal biological pathways as we strive to discover and develop new treatment for difficult diseases. In February, we joined the Centre for Therapeutic Target Validation, the pioneering public-private collaboration that fosters interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting unvalidated novel targets in drug development. This collaboration expands on our strategy of using genetically validated targets, biomarkers and multiple therapeutic approaches to decrease the risk of drug development. 
With that, I'll now pass the call to Paul."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Al. Our GAAP diluted earnings per share were $4.43 in the first quarter, while our non-GAAP diluted earnings per share were $4.79. Total revenue for Q1 grew 7% year-over-year to approximately $2.7 billion.Our revenue growth was driven by the sta",996,"Thanks, Al. Our GAAP diluted earnings per share were $4.43 in the first quarter, while our non-GAAP diluted earnings per share were $4.79. Total revenue for Q1 grew 7% year-over-year to approximately $2.7 billion.
Our revenue growth was driven by the stable patient trends we now see for TECFIDERA and TYSABRI in the U.S. and continued growth in ELOCTATE and ALPROLIX. 
Although PLEGRIDY showed meaningful growth, our overall interferon business declined compared to the first quarter of last year as the market continues to migrate to orals. Overall, we're pleased that the breadth and strength of our product portfolio enabled us to absorb such fluctuations, expand our top line and maintain our global MS market share of approximately 38%.
As a reminder, we had $173 million in foreign exchange hedge gains in 2015, which has begun to impact our year-over-year comparisons. Compared to the first quarter of last year, we had $26 million less in hedge gains this quarter. Combined with a $24 million headwind from natural foreign exchange rates, overall revenue was weakened by approximately $50 million year-over-year. I'll highlight the FX impact for each of the therapies.
Global first quarter TECFIDERA revenue was $946 million. We recorded revenues of $744 million in the U.S. and $202 million outside the U.S. In the U.S., we believe there was a drawdown of TECFIDERA inventory in the wholesale channel, representing approximately $20 million versus prior quarter. Despite an expected choppy start to the quarter as we work through the typical seasonality issues, we believe underlying U.S. TECFIDERA patient demand is largely stable. U.S. gross-to-net percentage was comparable to Q4 and largely consistent with our average expected rate for the balance of the year.
Outside the U.S., foreign exchange impact, including the reduction in hedge gains, weakened full year TECFIDERA revenue by approximately $14 million year-over-year. Last October, we bolstered our marketing efforts in the U.S. by launching a television campaign aimed at increasing patient awareness about MS and TECFIDERA. We believe we did increase awareness. Our current TV campaign will expire in the middle of this year. For various reasons, we plan to sunset this lever, and don't currently plan to purchase additional TV spots beyond the middle of the year.
We do, nevertheless, plan to continue our marketing efforts across other print and digital channels. Interferon revenues, including both AVONEX and PLEGRIDY, were $670 million during the first quarter, which includes $467 million in the U.S. and $203 million in sales outside the U.S.
In the U.S., the results were weaker than anticipated due to a combination of lower underlying demand as patients continued to move toward orals, seasonality issues and a drawdown of AVONEX wholesale inventory of approximately $20 million. Outside the U.S., foreign exchange impact, inclusive of a reduction in hedge gains, weakened Q1 interferon revenues by approximately $20 million year-over-year.
Now moving to TYSABRI. With nearly 10 years of postmarketing experience, TYSABRI continued to add patients this quarter, with worldwide revenues of $477 million. These results were comprised of $288 million in the U.S. and $189 million internationally. We believe TYSABRI's well-understood safety profile and robust efficacy position it well. Foreign exchange impact, including a reduction in hedge gains, weakened Q1 TYSABRI revenue by approximately $14 million year-over-year.
Turning to our hemophilia business. ELOCTATE revenue for the quarter was $108 million and ALPROLIX revenue in Q1 was $75 million. We recorded $329 million for Q1 in our anti-CD20 collaboration, which includes our profit share from RITUXAN and GAZYVA in the U.S. as well as our profit share in royalties on sales of rituximab outside the U.S. As expected, our share of pretax profits in the U.S. on sales of RITUXAN decreased from 40% to 39% at the end of February, following approval of GAZYVA in RITUXAN refractory indolent non-Hodgkin's lymphoma. 
Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing were $88 million. We continued to benefit this quarter from contract manufacturing revenue related to a strategic partner.
Now turning to the expense lines on the P&L. Q1 cost of goods sold were $313 million or 11% of revenue as we experienced lower-than-typical write-offs of manufacturing runs in inventory. Q1 R&D expense was $437 million or 16% of revenue. Of note, in Q1, we did not have any meaningful business development expense. Recall, in the fourth quarter, we made a $60 million payment to Mitsubishi Tanabe related to the in-licensing of MT-1303. Additionally, the lower-than-expected R&D run rate seen in Q1 was also favorably impacted by the timing of clinical manufacturing campaigns and other R&D activities.
Q1 SG&A expense was $497 million or 18% of revenue. We remain focused on achieving savings in nonlabor expenses with the objective of reducing lower priority fees and services for the balance of 2016. Other net expense was $53 million in Q1, which includes the interest expense related to our 2015 bond offering.
In Q1, our non-GAAP tax rate was approximately 26%. This rate was negatively impacted by approximately 150 basis points related to discrete items.
Our weighted average diluted share count was approximately 219 million for Q1. And we ended the quarter with approximately $6.8 billion in cash and marketable securities, with approximately 45% of this in the U.S.
This brings us to our non-GAAP diluted earnings per share, which were $4.79 for the quarter, representing a strong 25% increase year-over-year. Over the last few years, we've gone through an unprecedented number of product launches and thought it was the right strategy to not be penny wise and pound foolish. 
Starting in 2015, we pivoted to initiate a number of measures to curb operating expense growth. And late in 2015, we announced a restructuring, and we believe the benefits materialized this quarter.
For the balance of the year, we're focused on commercial execution and diligent efforts to further reduce spending where appropriate, while ensuring we simultaneously support the advancement of the pipeline. 
I'll turn the call over to George for his closing comments."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thanks, Paul. Look, I'm pleased with the start of the year, and especially with the 25% increase in earnings versus Q1 of 2015. For the remainder of the year, we're focused on 3 areas: careful control of our costs, maximizing our revenues and rapidl",599,"Okay. Thanks, Paul. Look, I'm pleased with the start of the year, and especially with the 25% increase in earnings versus Q1 of 2015. For the remainder of the year, we're focused on 3 areas: careful control of our costs, maximizing our revenues and rapidly advancing the pipeline. The cost reduction actions that we took last year resulted in a meaningful increase in earnings this quarter. And as we move through the year, we'll continue to focus on cost control to do all that we can to concentrate our resources on the activities that we believe will add the greatest value.
On the revenue side, we're pleased to have Michel Vounatsos join us. I'm very confident in Michel and look forward to all that he and his team will do to maximize the value of our commercial portfolio as we move through this year and into next. We have great drugs that are benefiting a lot of patients, and we want to maximize the benefits to both patients and our shareholders.
Additionally, we hope to launch 2 additional compounds this year, ZINBRYTA; and in the EU, FLIXABI. Since we think of revenue on a multiyear basis, we also will continue our focus on pursuing opportunities outside of Biogen. We continue to attract companies and compounds that are potentially interesting for us, and we are in constant discussions with multiple parties from the types of tuck-in acquisitions that we've done historically to later-stage assets closer to commercialization. And as we said in previous calls, we want to be active in this area, while remaining financially disciplined.
This is a very important year for the advancement of our internal pipeline, and it's important to make sure that the enrollment in the 2 Phase III trials of aducanumab continues to go well. We're pleased with how we're tracking so far, but it's still early and we want to make sure that we stay on or ideally ahead of schedule for patient enrollment.
We aim to get the Phase III trials for raxatrigine and amiselimod started on schedule. And we need to make sure that our early pipeline progresses quickly and that we make fact-based go, no-go decisions. And of course, once we have the Phase II data for opicinumab in the middle of the year, we'll quickly decide on the appropriate path forward for opicinumab itself and for the other remyelinating programs in our pipeline. 
As Al mentioned, the open-label data for nusinersen continue to look encouraging, and we need to do everything that we can to minimize the time to see data from the Phase III trials and, if positive, to get the drug to patients as soon as possible.
Although not so visible from outside the company, we'll continue to invest in R&D. We believe that our strategy of building world-class research and development will not only help us identify important new therapies ourselves but will also help us to make thoughtful, sophisticated decisions about what to bring in from outside the company.
So we have a lot to do. This is a year for us to keep our heads down and focus on execution in all of the areas that I just outlined. We have a great team and a dedicated group of employees. And as always, I'd like to thank our employees for making a positive impact on patients' lives and to thank the patients and physicians involved in our clinical development programs. The achievements that we've made together could not have been realized without their passion and commitment. 
So thank you all for joining us this morning."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Matthew Harrison from Morgan Stanley.",15,"[Operator Instructions] Your first question comes from the line of Matthew Harrison from Morgan Stanley."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So I'm going to ask a two-part question, which you'll probably give me a hard time for. But -- so on TECFIDERA, can you just talk a little bit about what's going on outside the U.S.? If you back out the FX movements that you were talking about, you only s",105,"So I'm going to ask a two-part question, which you'll probably give me a hard time for. But -- so on TECFIDERA, can you just talk a little bit about what's going on outside the U.S.? If you back out the FX movements that you were talking about, you only saw a sequential $9 million increase in revenues. Is volume substantially slowing outside the U.S.? And then maybe just related to that, you had some contracting changes across the portfolio, specifically with, CVS last year. Any big impacts to gross to net or some of the trends that may have affected the interferon franchise?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt. Great question. This is Paul. I'll try to take it. Outside the United States -- we're actually pretty pleased outside the United States. I'd say Germany is a place where we'd like to see performance a little bit better. It probably looks a l",339,"Thanks, Matt. Great question. This is Paul. I'll try to take it. Outside the United States -- we're actually pretty pleased outside the United States. I'd say Germany is a place where we'd like to see performance a little bit better. It probably looks a lot like the United States performance of TECFIDERA kind of getting to -- darn close to a 20 share and not being -- not punching through over the course of 2015. That's an important market outside the United States, as you all know. When I go across other parts that really are the big contributors outside the United States, it's kind of, obviously, France, U.K., Southern Europe countries of Italy and Spain. And we're very pleased with the performance in Southern Europe. Those are early days in terms of the launch curves for TECFIDERA specifically. We're very, very pleased with that. The performance has exceeded our expectations. And certainly, as we've pointed out in the past, our U.K. performance is exceptionally strong. We've got what we feel is a remarkable team there. They've kind of really -- really kind of broken down the marketplace and attacked it quite vigorously across the suite of Biogen MS therapies. So I think very pleased, I'd say, with the performance outside the United States, with a little bit of homework to do in Germany, which, I think, we're actually showing some early signs, very early signs late in the quarter, positive signs. With respect to contracting, it is as people know, specific to AVONEX and PLEGRIDY, specific to newly diagnosed patients. I think that you combine that with typical seasonality issues in Q1, and we still feel we made the right choices there in terms of as we moved into 2016. And so I think that's kind of -- we don't think there's been a meaningful impact. Certainly, kind of working through prior authorizations and things like that for some of the patients has become a more active part of what we do in our Patient Services organization."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Your next question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Paul, congrats again on great P&L management. We all appreciate it, and your investors appreciate it. On the -- I have so many questions to ask, maybe Al, just because this is the one I get the most, just going back to the Eisai collaboration and the Abet",186,"Paul, congrats again on great P&L management. We all appreciate it, and your investors appreciate it. On the -- I have so many questions to ask, maybe Al, just because this is the one I get the most, just going back to the Eisai collaboration and the Abeta antibody that may or may not have data shortly. The question that I've been getting -- I'd just love to hear your thoughts are, you emphasized a lot when looking at these competing Abeta antibodies really understanding if -- what the imaging data show post therapy, that is, is it draining plaque from the brain? And if the answer to that is no, then the clinical outcome is perhaps less important because it doesn't do what your amaB does, so to speak. And -- but there's been some questions about, specifically, where the Eisai BAN antibody binds, which types of fibrils and whether or not, given its binding -- its specific binding affinities, whether or not you would expect necessarily to see changes on PET scan? So I was just wondering if you could talk us through that."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Mark. The BAN2401, to my understanding, binds the protofibrils as well as oligomers, and I would expect it to reduce amyloid plaque burden. The question for me is, does it do that, first of all; and second, to what degree? The thing that was remarkab",171,"Yes, Mark. The BAN2401, to my understanding, binds the protofibrils as well as oligomers, and I would expect it to reduce amyloid plaque burden. The question for me is, does it do that, first of all; and second, to what degree? The thing that was remarkable about aducanumab was that we had a very substantial reduction in the course of 1 year. Arguably 85% or so. Competitor antibodies have not done that, and I don't know where 2401 will land but that's an important piece. And then we can then start to understand the relationship between reduction in plaque burden and cognitive outcome. In our hands, in the aducanumab program, only the patients who reduced plaque burden by greater than 1 standard deviation change relative to what the placebo patients did, in other words, beyond the noise, those are the people who got cognitive benefit. The people who did not do that did not have any benefit that we could detect. So we think that's an important piece to look at."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Alethia Young from Crdit Suisse.",13,"Your next question comes from the line of Alethia Young from Crdit Suisse."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Congrats on the expense management as well. I guess, from the DTC campaign that you had with TECFIDERA, like, what were some of the learnings that you took away for that campaign around the television form and why you chose to keep the print? And just kin",75,"Congrats on the expense management as well. I guess, from the DTC campaign that you had with TECFIDERA, like, what were some of the learnings that you took away for that campaign around the television form and why you chose to keep the print? And just kind of similar, along that line, like have you -- do you have any color on what the average duration for TECFIDERA is right now in the United States?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","I'll take the first part of that question. Look, we -- the main purpose of the ad campaign, the television campaign was to increase awareness of TECFIDERA. We were surprised actually, at the beginning, by the low awareness among patients of TECFIDERA. And",184,"I'll take the first part of that question. Look, we -- the main purpose of the ad campaign, the television campaign was to increase awareness of TECFIDERA. We were surprised actually, at the beginning, by the low awareness among patients of TECFIDERA. And we had data suggesting that when patients did learn about TECFIDERA and went to their physician to discuss it, they often had it prescribed. So we wanted to get the awareness up. The ad did succeed in getting awareness up. We would -- and then the thesis is, once awareness is up and they have those discussions, they'll go to their physicians and we'll see an increase in prescriptions. We've said we would see that, if we do, in Q2. We're in Q2 and so I think we'll have a final verdict on the success of that TV campaign when we talk to you next quarter. And so those ads don't run forever. So we're taking a pause. We'll continue our other types of activities and we'll see what we learn and make decisions about any potential future television ads."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Alethia, and this is Paul, I'll try to take the second part of your question. And let me kind of answer it in a slightly different way that is a little bit more customary to the way we look at the data and probably more indicative. We try to triangulate o",171,"Alethia, and this is Paul, I'll try to take the second part of your question. And let me kind of answer it in a slightly different way that is a little bit more customary to the way we look at the data and probably more indicative. We try to triangulate on what we call discontinuation rates, the percentage of patients that leave a therapy, call it, over the course of a 52-week period. And all the disease-modifying therapies have discontinuation rates. And we think that TECFIDERA experienced higher discontinuation rates than normal as we moved through 2015, largely due to lymphocyte monitoring and kind of a label change. We actually, importantly, think that we're kind of on -- hopefully, on the back side of that; that the medical education has largely been completed. It never -- it obviously never stops, but we're hopeful that, actually, that can provide a little bit of a tailwind as we move through 2016 and as it begins to get back to a more normal level."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink Partners."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Paul, just could you give us some color on how the rest of the year is looking now? You obviously have got a tailwind here with the significantly lower R&D expenses. You've tightened your belt on SG&A, but you did have what looks like $45 million of seque",104,"Paul, just could you give us some color on how the rest of the year is looking now? You obviously have got a tailwind here with the significantly lower R&D expenses. You've tightened your belt on SG&A, but you did have what looks like $45 million of sequential currency headwind, or loss of hedging from Q4. So how should we think about those drivers for the rest of the year? Can you keep at this sort of level on R&D and SG&A? And should we anticipate this kind of magnitude of currency effect through the balance of the year because of your hedge positions?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, let me kind of -- great questions, Geoff, because it's kind of a dynamic that the loss of hedging, not a surprise to us. So that was actually part of our business plan as we swung into 2016. And fundamentally, we're not -- we don't make predictions a",265,"Yes, let me kind of -- great questions, Geoff, because it's kind of a dynamic that the loss of hedging, not a surprise to us. So that was actually part of our business plan as we swung into 2016. And fundamentally, we're not -- we don't make predictions about where currencies are going to go. But we fully anticipated the fact that we had hedge gains throughout the P&L in 2015 that really come about from the hedges that we put on in 2014. So it's essentially a wraparound effect of the currency changes, mostly in the EU, as we kind of ended, very end -- if you remember the changes were very end of December of 2014 and January of 2015. So that was fully expected. And so we believe that, that will just continue to be a bit of a headwind, which we had thought about. The R&D, I think I'd point out one key dynamic is it's always a little bit choppy, R&D as a percentage of sales, it's based on business development activity. And we certainly want to and would welcome really good business development activity, that's always a positive investment, a positive expense if done correctly. With all that said, no doubt about it that, as I said, we have made cost control and feel like we're reaping the benefits of what we did late in 2015 as we came into this year. And I think it will continue to be a meaningful effort from me, from the whole organization, to make sure we focus on efficiencies throughout the year."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Yes, maybe on that R&D investment, either for Paul or George. We all appreciate the focus on the bottom line and costs and appreciate also there are some puts and takes in Q1, but you're down 16% of revenue in the first quarter. That's, I think, an all-ti",71,"Yes, maybe on that R&D investment, either for Paul or George. We all appreciate the focus on the bottom line and costs and appreciate also there are some puts and takes in Q1, but you're down 16% of revenue in the first quarter. That's, I think, an all-time low for Biogen. Is that an appropriate rate for this company kind of long term, 3 to 5 years, in terms of investment?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, thanks, Eric. Let me take that question. Look, our R&D is choppy, and I don't want anybody to interpret that number as a deliberate effort to cut back on R&D and a deemphasis on R&D. It is quite the opposite, actually. We are continuing to build a wo",213,"Yes, thanks, Eric. Let me take that question. Look, our R&D is choppy, and I don't want anybody to interpret that number as a deliberate effort to cut back on R&D and a deemphasis on R&D. It is quite the opposite, actually. We are continuing to build a world-class research group. We will continue to invest in research. We believe that is a fundamental part of our strategy to build value. I think it's -- we've done a really good job so far. We'll continue that focus. Clinical development, we will spend whatever is necessary to move our pipeline forward, those pipeline compounds that are high potential, high value, we've talked about those. We'll continue to invest in those. Frankly, the expenses there we would expect to go up over time as we move more compounds into Phase III. So I think the trend is largely in that direction. And part of this quarter was also, as Paul said, the lack of BD. And there's not going to be a lack of BD forever. So it was the lack in one quarter. So I think it's -- I don't want anybody to interpret the one quarter number as a change in our strategy or a deemphasis of R&D. It's quite the opposite, actually."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","I know you're not commenting on other outside reports on hemophilia, but I wanted to ask, bigger picture, there's been changes in the market. The incumbent's being acquired. There's gene therapy data yesterday. Maybe you could talk a little about the push",83,"I know you're not commenting on other outside reports on hemophilia, but I wanted to ask, bigger picture, there's been changes in the market. The incumbent's being acquired. There's gene therapy data yesterday. Maybe you could talk a little about the push-pulls for this business and is this business the business you've been thinking about. And maybe talk a little bit about how this fits in overall in the growth that you see here, given all the changes going on in hemophilia."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Sure. Happy to take that. Look, ELOCTATE and ALPROLIX are doing well. They're gaining market share and we're pleased with their performance. So -- and they're continuing to gain share. So we're feeling good about there. We have not yet seen any impact on",406,"Sure. Happy to take that. Look, ELOCTATE and ALPROLIX are doing well. They're gaining market share and we're pleased with their performance. So -- and they're continuing to gain share. So we're feeling good about there. We have not yet seen any impact on their trajectories from the introduction of other long-acting factors. So we take that as a positive sign. So I think the prospects for the business look quite healthy. In the longer term, there are a number of products, as there are in every therapeutic area, coming forward, and we're keeping a close eye on them. There is certainly -- we saw BioMarin's data, which are interesting but early. I mean, I haven't seen anything that you haven't seen. I saw good factor VIII levels that persisted for some period of time, and we saw some liver enzyme issues that needed to be treated with corticosteroids. So we'll see how that plays out over time. Those are early. I would say interesting data, but early. It's similar, I think, to our immune tolerance induction data that we have with ELOCTATE. And if you -- we haven't talked about this a lot, but a fair number of hemophiliacs develop inhibitory antibodies when they're treated, and that results in the necessity for immune tolerance induction, which means high levels of factor that are given over 12 to 18 months before immune tolerance emerges. There have been a very limited number of patients, 3, so I don't want to overstate this. Again, these are very early data, so -- and I don't want to be here overstating the case. But again, these are early data but also encouraging. So of the 3 patients that have been treated with ELOCTATE from the intolerance induction, they all became tolerant within about 3 to 4 months. So a much shorter period of time. If those data are confirmed in further studies, we believe that, that could be an important upward lift for ELOCTATE. So I think there are lots of early data emerging. They all need to be confirmed with larger studies. And we feel good about the business and where we are. We have our own longer-acting factors coming. We've talked about some of them, there are earlier ones that are in our research group now. So I think we feel good about the current products, and we feel good about the future of the business as well."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch.",16,"Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","First one is many investors think you guys have lost flexibility on balance sheet because you guys really don't have much net debt. I'm just probing -- maybe the question is for Paul, what's the willingness here to do another significant share buyback, gi",96,"First one is many investors think you guys have lost flexibility on balance sheet because you guys really don't have much net debt. I'm just probing -- maybe the question is for Paul, what's the willingness here to do another significant share buyback, given your balance sheet strength? And then secondly, I want to ask about the TECFIDERA inventory situation here. So in fourth quarter, you had a $30 million inventory build in the U.S. and then there's a destocking of $20 million this quarter. Should we expect another $10 million to go next quarter?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay, why don't I try to clean up the clarity on the second part of your question. So the $30 million that I talked about last quarter was our best estimate at that time. In retrospect now, it probably is closer to the $20 million. In reality, it's probab",304,"Okay, why don't I try to clean up the clarity on the second part of your question. So the $30 million that I talked about last quarter was our best estimate at that time. In retrospect now, it probably is closer to the $20 million. In reality, it's probably in between. So I think that we've gone through the destocking of what we talked about last quarter and just wanted to kind of clarify it with the prepared remarks. With respect to the balance sheet, I think it gets to the broader question of capital allocation. Currently, we're actually sitting on a pretty high cash balance. As I pointed out, like many others, we have the peculiar situation of ex U.S. cash as a little bit more than half of that. But aside from that, that largely arises out of 2 things, the great strong cash flow generation of the company coupled with the debt financing that we did in the fall of 2015. Look, I think we're going to -- we will look to strategically deploy it. And if we come up that there are not options to strategically deploy it, we will look towards returning capital to shareholders. We don't measure that on a -- as we've talked about before, on a 90-day basis just because that's not the kind of clock speed of things. In both situations, it depends on price and value. So it continues to -- it depends. And in both situations, the financial objective is to maximize intrinsic value per share. So we look towards investing in deployments of capital that really drive great internal rates of return. I think I'd also point out, look, over a longer period of time, I think this company, with the great cash flow generation it has, has flexibly to do both."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So just a question on strategy a little bit, in thinking about the company longer term. So you've got the MS business now stable but it's faced some compression from new therapies. I mean, you have hemophilia as a growing business and pipeline. I'm just w",144,"So just a question on strategy a little bit, in thinking about the company longer term. So you've got the MS business now stable but it's faced some compression from new therapies. I mean, you have hemophilia as a growing business and pipeline. I'm just wondering how are you thinking about how important it is to diversify the business further? Do you have any concerns or know -- or how are you thinking about could there be something that puts pricing pressure on the MS market and what could trigger it? And how are you thinking about maybe derisking the company from such an event? None of us think of it as a near-term event, but it's something that could happen over the long term. So maybe just help us think about like the longer-term strategy of the company and your thoughts on price."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Robyn. This is George. I'll start with that, and other people can chime in. Look, we are -- I think we're feeling good about the MS business as it exists today. We're going right. But if you look at our pipeline, you'll see that many of the things",224,"Thanks, Robyn. This is George. I'll start with that, and other people can chime in. Look, we are -- I think we're feeling good about the MS business as it exists today. We're going right. But if you look at our pipeline, you'll see that many of the things we're working on are not in MS. We think LINGO, actually, could be a transformative event in the treatment of MS, so -- and we are not working beyond ZINBRYTA on novel, let's say, additional drugs that would down regulate the immune system. I think there are enough of those on the market. There are more coming. For many MS patients, those don't stop the progression. They slow the progression but they don't stop the progression. And so we believe things like LINGO actually are the types of compounds that could actually transform that market and give it additional vibrancy as we move out through the 20s. That being said, if you look at what we're emphasizing now and what we have in Phase III, it's nusinersen for SMA, it's aducanumab for Alzheimer's disease, it's raxatrigine for neuropathic pain, it's amiselimod for IBD and Crohn's disease. So we have deliberately brought in a series of compounds and are conducting late-stage trials in things that are outside of MS, partially for the reason you just outlined."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","And your thoughts on price, anything that could trigger a pricing compression in the marketplace?",15,"And your thoughts on price, anything that could trigger a pricing compression in the marketplace?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","We don't see anything in the near term. No, as you move out into the 20s, there certainly could be. But don't see anything near term.",27,"We don't see anything in the near term. No, as you move out into the 20s, there certainly could be. But don't see anything near term."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","A couple of commercial ones. In the context of your DTC campaign, I was curious if you guys have any data on retreatment of patients who went on TECFIDERA right at the launch. And then just with respect to a related question with respect to first quarter",65,"A couple of commercial ones. In the context of your DTC campaign, I was curious if you guys have any data on retreatment of patients who went on TECFIDERA right at the launch. And then just with respect to a related question with respect to first quarter trends, or even fourth quarter, any impact thus far from generic Copaxone on the interferon market vis--vis share?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Geoff. I'll try to address that. Not a lot of data on kind of retreatment. So we have plenty of data but I can't, off the top of my head, think of anything as it relates to that. With respect to generic Cop, the data would suggest it's a pretty small",93,"Yes, Geoff. I'll try to address that. Not a lot of data on kind of retreatment. So we have plenty of data but I can't, off the top of my head, think of anything as it relates to that. With respect to generic Cop, the data would suggest it's a pretty small percentage at this point in time, and the data would suggest that it very much is just impacting Copaxone. So that's how we see it anecdotally as well as how the data from the market share and the patient trends suggests."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","A question for Michel, if I may -- first of all, congratulations on the new position. I know it's very early days, but I'm curious if you could maybe talk broadly about your objectives coming into Biogen, areas where you see the potential to have the most",85,"A question for Michel, if I may -- first of all, congratulations on the new position. I know it's very early days, but I'm curious if you could maybe talk broadly about your objectives coming into Biogen, areas where you see the potential to have the most impact on the commercial business under your leadership and perhaps, more specifically, how you're thinking about potentially reaccelerating growth in MS and positioning for a potential ocrelizumab entry, while still balancing the company's focus on achieving cost savings?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Brian. Brian, this is Paul. We had Michel prepared for a wholesale or inventory question. Michel?",17,"Thanks, Brian. Brian, this is Paul. We had Michel prepared for a wholesale or inventory question. Michel?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","So thanks for the question. Good morning, everybody. This is Michel Vounatsos. Week one at Biogen. So as you can imagine, I am more on the learning and listening mode and it's far too early for me to assess the strategy. I will be focusing a lot of time o",120,"So thanks for the question. Good morning, everybody. This is Michel Vounatsos. Week one at Biogen. So as you can imagine, I am more on the learning and listening mode and it's far too early for me to assess the strategy. I will be focusing a lot of time on the key geographies, obviously, and the key customers, to best understand -- and the key franchises. So I hope that in the near future, I'll be in a better position to assess the next steps. What I can tell you is that I'm extremely encouraged and honored to be part of this team, and looking forward to engaging with all of you in the near future. Thanks for your understanding."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Jim Birchenough from Wells Fargo Securities.",14,"Your next question comes from the line of Jim Birchenough from Wells Fargo Securities."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Maybe a question on the pipeline and some help in assessing the risk-adjusted value of nusinersen. And on the risk side of it, when you look at the data we saw at AAN and that we've seen over the last few years, how do you get comfortable with the compari",82,"Maybe a question on the pipeline and some help in assessing the risk-adjusted value of nusinersen. And on the risk side of it, when you look at the data we saw at AAN and that we've seen over the last few years, how do you get comfortable with the comparison with historical controls? And then on the opportunity, perhaps you could speak to how you view that opportunity in SMA between the Type 1 and then the Type 2, 3 patient?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Well the comparison with historical controls is always a little bit dangerous to do because you have to choose cohorts and you try to match them to your patients. But the standard of practice changes over time. So these patients might be getting better ov",197,"Well the comparison with historical controls is always a little bit dangerous to do because you have to choose cohorts and you try to match them to your patients. But the standard of practice changes over time. So these patients might be getting better over time just by the clinical practice improving. On the other hand, when you start to see lack of events of the type that was shown at AAN, since December of 2014, no new events, that's a pretty striking difference. And these are hard endpoints, like time to tracheostomy or ventilation and time to death. It's hard for me to see how that kind of thing could be happening due to simply improving medical care. So I think we're getting more and more encouraged, but I would note that we have these 2 well-controlled trials, one in infant onset SMA and one in childhood onset SMA. And that, to me, is the definitive data set that we're going to be looking at. And in terms of the opportunities in infant and childhood, I mean, I think they're both big opportunities, and I look forward to being able to help patients in both categories."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","I actually wanted to follow up on nusinersen. George, in your scripted comments, when you talked about doing whatever you can to minimize the time to Phase III data for the product, is there anything specific that can actually be done to shorten that time",70,"I actually wanted to follow up on nusinersen. George, in your scripted comments, when you talked about doing whatever you can to minimize the time to Phase III data for the product, is there anything specific that can actually be done to shorten that time line, given that enrollment is complete for one of the trials and close to it for the other? Is there anything else you're referring to?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Look, at this time, let me just say that we are cognizant of the need to get this drug to patients as soon as we can, if it works. So the first part of that is being confident that it works. And as Al said, we're going to need to see data from the control",172,"Look, at this time, let me just say that we are cognizant of the need to get this drug to patients as soon as we can, if it works. So the first part of that is being confident that it works. And as Al said, we're going to need to see data from the controlled trials in order to make that case to the agencies, certainly, and then for us to be absolutely certain as well. So we want to get there as quickly as we can. And once we have those data, we absolutely want to minimize the time until these kids have access to it, again, if it works. And these are the -- especially the Type 1 kids who don't have a lot of time. And so there are a lot of kids out there today who could -- desperately need something, and so that's -- we're trying to shorten that time frame. But I don't want to get into any of the specifics of how we're doing that."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Your next question comes from the line of Terence Flynn from Goldman Sachs."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just on the LINGO MS data coming in midyear, I know you guys are looking at a range of endpoints here, including disability and cognition. I think disability is pretty easy for all of us to benchmark as there's a lot of data there. But on the cognition si",79,"Just on the LINGO MS data coming in midyear, I know you guys are looking at a range of endpoints here, including disability and cognition. I think disability is pretty easy for all of us to benchmark as there's a lot of data there. But on the cognition side, I know you're using this PASAT-3 scale. Anything you can do there just to help frame for us in terms of what would be a meaningful outcome on that measurement?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, it's -- we've had a lot of experience with PASAT. We've been using it in MS trials for about 20 years now. One of the things we know is that there's a practice effect, and so I expect to see some improvement on the score even in untreated patients ju",164,"Yes, it's -- we've had a lot of experience with PASAT. We've been using it in MS trials for about 20 years now. One of the things we know is that there's a practice effect, and so I expect to see some improvement on the score even in untreated patients just because of the practice effect. What I am hoping to see with anti-LINGO, and I don't know whether we will or not, is that there would be an even better learning effect in the anti-LINGO treated patients and that it would be great to see a dose response, that would make it even more compelling if we saw that. In terms of what is considered clinically meaningful, that hasn't been established in the world of MS yet. We have no established precedents on that. I will say that some compounds have shown some efficacy on this by virtue of preventing new MS lesions, but certainly not in this new era of reparative therapies."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ian Somaiya from BMO Capital Markets.",14,"Your next question comes from the line of Ian Somaiya from BMO Capital Markets."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just a question for Al. On aducanumab, I was just hoping to get your thoughts on targeting of Abeta. Specifically, I think you've implied and I think there's plenty of data out there suggesting that beta-amyloid levels or amyloid beta levels might have ac",111,"Just a question for Al. On aducanumab, I was just hoping to get your thoughts on targeting of Abeta. Specifically, I think you've implied and I think there's plenty of data out there suggesting that beta-amyloid levels or amyloid beta levels might have actually plateaued by the time a patient shows any signs of mild cognitive impairment. I'm just curious to get your thoughts sort of the appropriateness of targeting Abeta in patients where plaque sort of already reached sort of a level, and what potentially could be driving the disease in these patients in terms of their progression? And whether there's another target that would be -- make more sense?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, so it's true that when you look at plaque burden, it does tend to plateau in the -- already in the prodromal phase, and certainly by the mild stage, it's pretty flat. And so what drives the progression beyond that, we believe, is probably tau. Tau co",187,"Yes, so it's true that when you look at plaque burden, it does tend to plateau in the -- already in the prodromal phase, and certainly by the mild stage, it's pretty flat. And so what drives the progression beyond that, we believe, is probably tau. Tau comes on later. If you look at the imaging studies, tau comes on later, and there's a lot of data, preclinical data, that shows that Abeta pathology triggers tau pathology. So we're learning a lot about tau now. We know that in normal aging, there is some aggregated tau in the medial temporal lobe; but in patients with Alzheimer's disease, it spreads beyond the medial temporal lobe. And that spread is probably triggered by Abeta. And so that's the reason why we have some programs in tau. We've just -- we have some preclinical as well as early clinical programs of both antibodies as well as antisense. And so in the later stages, we might need to treat for tau, perhaps in combination with the Abeta therapies because I don't think you want to reaccumulate Abeta once you've removed it."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","And your last question comes from the line of Chris Raymond from Raymond James.",14,"And your last question comes from the line of Chris Raymond from Raymond James."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So just a question on anti-LINGO. So at AAN, there was some interesting data on clemastine. That agent seems to have at least some sort of similarity in terms of mechanism to LINGO in terms of impacting oligodendrocyte differentiation, at least. Wondering",70,"So just a question on anti-LINGO. So at AAN, there was some interesting data on clemastine. That agent seems to have at least some sort of similarity in terms of mechanism to LINGO in terms of impacting oligodendrocyte differentiation, at least. Wondering, Al, if you had any thoughts -- is there any kind of readthrough we should be thinking about with respect to that agent and the results there?"
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, so we've -- the clemastine came from this micropillar assay that was developed in San Francisco, where they have oligodendrocytes wrapping myelin essentially around tubes. And what they found was that there were a number of antimuscarinic compounds t",228,"Yes, so we've -- the clemastine came from this micropillar assay that was developed in San Francisco, where they have oligodendrocytes wrapping myelin essentially around tubes. And what they found was that there were a number of antimuscarinic compounds that work, benztropine as well as clemastine. We've actually tested clemastine in our oligodendrocyte differentiation assay here, and in our hands, it's less potent than BIIB061, our oral compound that we have in early clinical trials, and it's also less effective overall in a side-by-side comparison in our hands. Nevertheless, I did look at the data, it's -- crossover designs like the one that they did are not -- probably not the best approach for looking at disease-modifying therapies because when you switch from clemastine to placebo, I don't expect that if it is causing myelination, how would the placebo patients look? They would continue to get the benefit from the clemastine that they had received in the period prior. So nevertheless, they did show a modest effect on latency of the conductions between the retina and the brain. And we're keeping a close eye on that. I think that these are all early day experiments in reparative therapies, and I believe we have established one of the best ways of looking at this in our anti-LINGO program, both in acute optic neuritis as well as the MS program."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay. If there are no further questions, let me thank you all for your time this morning, and we'll sign off. Thanks.",22,"Okay. If there are no further questions, let me thank you all for your time this morning, and we'll sign off. Thanks."
29726,328802932,961212,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2016 Financial Results and Business Update Conference Call. [Operator Instructions] Thank you. I would n",60,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2016 Financial Results and Business Update Conference Call. [Operator Instructions] Thank you. I would now like to turn the conference over to Mr. Matt Calistri, Senior Director of Investor Relations for Biogen."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, and welcome to Biogen's First Quarter 2016 Earnings Conference Call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the G",202,"Thank you, and welcome to Biogen's First Quarter 2016 Earnings Conference Call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today.
Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally.
We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Al Sandrock, our Chief Medical Officer; our CFO, Paul Clancy; and our new Chief Commercial Officer, Michel Vounatsos, is with us here today. Now I'll turn the call over to George."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt. Good morning, everyone, and thanks for joining us this morning. For the first quarter of 2016, Biogen generated $2.7 billion in total revenues, 7% increase from the same period a year ago. And our non-GAAP EPS was $4.79, 25% increase from th",493,"Thanks, Matt. Good morning, everyone, and thanks for joining us this morning. For the first quarter of 2016, Biogen generated $2.7 billion in total revenues, 7% increase from the same period a year ago. And our non-GAAP EPS was $4.79, 25% increase from the same period a year ago. 
As you've heard from us since the beginning of the year, a cornerstone to our strategy for sustainable growth is our healthy commercial business and a strong focus on properly managing expenses. And I think these results should reinforce that message. 
TECFIDERA continues to gain share globally, now with more than 190,000 patients having been treated. And at AAN this week, we presented compelling data that showcased its strong and sustained efficacy in newly diagnosed MS patients, emphasizing that earlier treatment with TECFIDERA improves long-term clinical outcomes. We also presented compelling data about TECFIDERA's real-world efficacy. 
Last month, we announced that our new Executive Vice President, Chief Commercial Officer, Michel Vounatsos had joined us. Michel brings a wealth of experience from 20 successful years of increasing responsibility at Merck, most recently as President of Primary Care and Customer Centricity. Michel officially started on Monday, and we're excited to be working with him. He'll be instrumental in driving our near-term growth, while helping to prepare the organization to support our exciting pipeline.
In the first quarter, we launched BENEPALI, our biosimilar version of Enbrel, in 6 European countries: the U.K., Germany, Denmark, Norway, Sweden and the Netherlands. And FLIXABI, our biosimilar version of Remicade, received a positive opinion from the CHMP, and we're awaiting approval from the European Commission shortly.
And of course, an important part of our strategy for sustainable growth is our pipeline of potential future therapies. Notably, aducanumab is enrolling patients in 2 Phase III trials; opicinumab, which is anti-LINGO, results are expected midyear; and nusinersen, in collaboration with Ionis, is close to completing enrollment of the Phase III trial called ENDEAR. Al will provide more color on the pipeline during his comments.
Finally, I'd like to make a few comments to address some questions that I know will come. First, we're in the final stages of hiring an R&D head and expect to make an announcement shortly. Second, like you, we've read the media reports about our hemophilia business and the subsequent analyst reports. As a matter of policy, we do not comment on speculation and will not do so in this instance. We're in an exciting stage in the evolution of Biogen. We're encouraged by the trajectory of our commercial portfolio, and we'll continue to focus on cost containment to maximize our earnings. We're eagerly awaiting the data from opicinumab and nusinersen, and we're pleased with the early enthusiasm for our biosimilars in Europe. We've recently brought several new compounds into development, and we continue to look for opportunities outside of Biogen. 
And with that, I'll turn the call over to Al, who'll update you on our progress in R&D."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, George, and good morning, everyone. This quarter, we continued to execute on our pipeline candidates and generate new data to support our commercialized products. Starting with opicinumab, or anti-LINGO, we are looking forward to seeing the Phase",703,"Thanks, George, and good morning, everyone. This quarter, we continued to execute on our pipeline candidates and generate new data to support our commercialized products. Starting with opicinumab, or anti-LINGO, we are looking forward to seeing the Phase II data, which is still scheduled for the middle of this year. I should note that no one has seen these data yet, but after more than a decade of work on LINGO, beginning with discovering the gene and then elucidating its biology, most of which was conducted at Biogen, we're excited to learn about opicinumab's potential as a reparative therapy for MS.
In Alzheimer's disease, we are working diligently to enroll our aducanumab Phase III trials, and are pleased with progress thus far. Looking ahead, we anticipate safety data from the titration arm of the Phase 1b PRIME study in the second half of this year.
Amiselimod, or MT-1303, our S1P1 inhibitor for IBD, is currently being tested in a Phase II trial in Crohn's disease, and we are working toward the start of Phase III studies in ulcerative colitis and Crohn's disease in the second half of this year.
Raxatrigine, a small molecule inhibitor of the Nav 1.7 sodium channel, is anticipated to begin a Phase III trial to confirm its efficacy in patients with trigeminal neuralgia. And we are also planning to initiate a Phase II trial in patients with painful lumbosacral radiculopathy later this year. 
Turning to our hemophilia products, we find the data that was presented at the December ASH meeting on immune tolerance induction with ELOCTATE quite encouraging. We believe that the SC portion of these fusion proteins utilized in both ELOCTATE and ALPROLIX may offer additional benefits beyond half-life extension, although these preliminary findings will require confirmation from additional studies. 
At this week's American Academy of Neurology meeting, we presented important new data demonstrating the breadth and diversity of our marketed and pipeline multiple sclerosis therapies, including TECFIDERA, TYSABRI, ZINBRYTA and PLEGRIDY. Let me provide some of the highlights of our presentation.
TECFIDERA was shown to provide sustained and strong efficacy in newly diagnosed MS patients, reinforcing that earlier treatment with TECFIDERA is important in improving long-term clinical outcomes. We also presented the results of another study that retrospectively examined the health insurance claims database of more than 5,000 patients in routine clinical practice. 
Annualized relapse rates 1 year after starting disease-modifying therapy were compared to the year before therapy initiation. These real-world data support the efficacy of TECFIDERA treatment seen in the controlled clinical trials, and this, combined with its safety profile and oral convenience, make it a very compelling therapeutic option for MS patients.
Data presented at AAN reinforced the nearly 10 years of clinical experience with TYSABRI, confirming its high efficacy, reversible immune effects and well-characterized safety profile. 
ZINBRYTA, with its targeted and reversible mechanism of action, was shown to be positive on key MS cognitive outcomes. 
PLEGRIDY was shown to reduce the conversion of newly acquired MS lesions into T1 black holes, which have been associated with axonal loss.
Also at AAN, our collaboration partner, Ionis, presented an update on the ongoing open-label Phase II trial of nusinersen in infants with spinal muscular atrophy. An analysis as of January 2016 showed no new events as defined by progression to permanent ventilation or death in the study since December of 2014, continued increases in muscle function scores and achievement of new motor milestones when compared to natural history studies. We believe these data look increasingly encouraging, and that nusinersen could represent an important new therapy for spinal muscular atrophy.
With respect to our earlier stage efforts, at our R&D day last November, we talked about using human genetics to identify causal biological pathways as we strive to discover and develop new treatment for difficult diseases. In February, we joined the Centre for Therapeutic Target Validation, the pioneering public-private collaboration that fosters interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting unvalidated novel targets in drug development. This collaboration expands on our strategy of using genetically validated targets, biomarkers and multiple therapeutic approaches to decrease the risk of drug development. 
With that, I'll now pass the call to Paul."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Al. Our GAAP diluted earnings per share were $4.43 in the first quarter, while our non-GAAP diluted earnings per share were $4.79. Total revenue for Q1 grew 7% year-over-year to approximately $2.7 billion.Our revenue growth was driven by the sta",996,"Thanks, Al. Our GAAP diluted earnings per share were $4.43 in the first quarter, while our non-GAAP diluted earnings per share were $4.79. Total revenue for Q1 grew 7% year-over-year to approximately $2.7 billion.
Our revenue growth was driven by the stable patient trends we now see for TECFIDERA and TYSABRI in the U.S. and continued growth in ELOCTATE and ALPROLIX. 
Although PLEGRIDY showed meaningful growth, our overall interferon business declined compared to the first quarter of last year as the market continues to migrate to orals. Overall, we're pleased that the breadth and strength of our product portfolio enabled us to absorb such fluctuations, expand our top line and maintain our global MS market share of approximately 38%.
As a reminder, we had $173 million in foreign exchange hedge gains in 2015, which has begun to impact our year-over-year comparisons. Compared to the first quarter of last year, we had $26 million less in hedge gains this quarter. Combined with a $24 million headwind from natural foreign exchange rates, overall revenue was weakened by approximately $50 million year-over-year. I'll highlight the FX impact for each of the therapies.
Global first quarter TECFIDERA revenue was $946 million. We recorded revenues of $744 million in the U.S. and $202 million outside the U.S. In the U.S., we believe there was a drawdown of TECFIDERA inventory in the wholesale channel, representing approximately $20 million versus prior quarter. Despite an expected choppy start to the quarter as we work through the typical seasonality issues, we believe underlying U.S. TECFIDERA patient demand is largely stable. U.S. gross-to-net percentage was comparable to Q4 and largely consistent with our average expected rate for the balance of the year.
Outside the U.S., foreign exchange impact, including the reduction in hedge gains, weakened full year TECFIDERA revenue by approximately $14 million year-over-year. Last October, we bolstered our marketing efforts in the U.S. by launching a television campaign aimed at increasing patient awareness about MS and TECFIDERA. We believe we did increase awareness. Our current TV campaign will expire in the middle of this year. For various reasons, we plan to sunset this lever, and don't currently plan to purchase additional TV spots beyond the middle of the year.
We do, nevertheless, plan to continue our marketing efforts across other print and digital channels. Interferon revenues, including both AVONEX and PLEGRIDY, were $670 million during the first quarter, which includes $467 million in the U.S. and $203 million in sales outside the U.S.
In the U.S., the results were weaker than anticipated due to a combination of lower underlying demand as patients continued to move toward orals, seasonality issues and a drawdown of AVONEX wholesale inventory of approximately $20 million. Outside the U.S., foreign exchange impact, inclusive of a reduction in hedge gains, weakened Q1 interferon revenues by approximately $20 million year-over-year.
Now moving to TYSABRI. With nearly 10 years of postmarketing experience, TYSABRI continued to add patients this quarter, with worldwide revenues of $477 million. These results were comprised of $288 million in the U.S. and $189 million internationally. We believe TYSABRI's well-understood safety profile and robust efficacy position it well. Foreign exchange impact, including a reduction in hedge gains, weakened Q1 TYSABRI revenue by approximately $14 million year-over-year.
Turning to our hemophilia business. ELOCTATE revenue for the quarter was $108 million and ALPROLIX revenue in Q1 was $75 million. We recorded $329 million for Q1 in our anti-CD20 collaboration, which includes our profit share from RITUXAN and GAZYVA in the U.S. as well as our profit share in royalties on sales of rituximab outside the U.S. As expected, our share of pretax profits in the U.S. on sales of RITUXAN decreased from 40% to 39% at the end of February, following approval of GAZYVA in RITUXAN refractory indolent non-Hodgkin's lymphoma. 
Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing were $88 million. We continued to benefit this quarter from contract manufacturing revenue related to a strategic partner.
Now turning to the expense lines on the P&L. Q1 cost of goods sold were $313 million or 11% of revenue as we experienced lower-than-typical write-offs of manufacturing runs in inventory. Q1 R&D expense was $437 million or 16% of revenue. Of note, in Q1, we did not have any meaningful business development expense. Recall, in the fourth quarter, we made a $60 million payment to Mitsubishi Tanabe related to the in-licensing of MT-1303. Additionally, the lower-than-expected R&D run rate seen in Q1 was also favorably impacted by the timing of clinical manufacturing campaigns and other R&D activities.
Q1 SG&A expense was $497 million or 18% of revenue. We remain focused on achieving savings in nonlabor expenses with the objective of reducing lower priority fees and services for the balance of 2016. Other net expense was $53 million in Q1, which includes the interest expense related to our 2015 bond offering.
In Q1, our non-GAAP tax rate was approximately 26%. This rate was negatively impacted by approximately 150 basis points related to discrete items.
Our weighted average diluted share count was approximately 219 million for Q1. And we ended the quarter with approximately $6.8 billion in cash and marketable securities, with approximately 45% of this in the U.S.
This brings us to our non-GAAP diluted earnings per share, which were $4.79 for the quarter, representing a strong 25% increase year-over-year. Over the last few years, we've gone through an unprecedented number of product launches and thought it was the right strategy to not be penny wise and pound foolish. 
Starting in 2015, we pivoted to initiate a number of measures to curb operating expense growth. And late in 2015, we announced a restructuring, and we believe the benefits materialized this quarter.
For the balance of the year, we're focused on commercial execution and diligent efforts to further reduce spending where appropriate, while ensuring we simultaneously support the advancement of the pipeline. 
I'll turn the call over to George for his closing comments."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thanks, Paul. Look, I'm pleased with the start of the year, and especially with the 25% increase in earnings versus Q1 of 2015. For the remainder of the year, we're focused on 3 areas: careful control of our costs, maximizing our revenues and rapidl",609,"Okay. Thanks, Paul. Look, I'm pleased with the start of the year, and especially with the 25% increase in earnings versus Q1 of 2015. For the remainder of the year, we're focused on 3 areas: careful control of our costs, maximizing our revenues and rapidly advancing the pipeline. The cost reduction actions that we took last year resulted in a meaningful increase in earnings this quarter. And as we move through the year, we'll continue to focus on cost control to do all that we can to concentrate our resources on the activities that we believe will add the greatest value.
On the revenue side, we're pleased to have Michel Vounatsos join us. I'm very confident in Michel and look forward to all that he and his team will do to maximize the value of our commercial portfolio as we move through this year and into next. We have great drugs that are benefiting a lot of patients, and we want to maximize the benefits to both patients and our shareholders.
Additionally, we hope to launch 2 additional compounds this year, ZINBRYTA; and in the EU, FLIXABI. Since we think of revenue on a multiyear basis, we also will continue our focus on pursuing opportunities outside of Biogen. We continue to attract companies and compounds that are potentially interesting for us, and we are in constant discussions with multiple parties from the types of tuck-in acquisitions that we've done historically to later-stage assets closer to commercialization. And as we said in previous calls, we want to be active in this area, while remaining financially disciplined.
This is a very important year for the advancement of our internal pipeline, and it's important to make sure that the enrollment in the 2 Phase III trials of aducanumab continues to go well. We're pleased with how we're tracking so far, but it's still early and we want to make sure that we stay on or ideally ahead of schedule for patient enrollment.
We aim to get the Phase III trials for raxatrigine and amiselimod started on schedule. And we need to make sure that our early pipeline progresses quickly and that we make fact-based go, no-go decisions. And of course, once we have the Phase II data for opicinumab in the middle of the year, we'll quickly decide on the appropriate path forward for opicinumab itself and for the other remyelinating programs in our pipeline. 
As Al mentioned, the open-label data for nusinersen continue to look encouraging, and we need to do everything that we can to minimize the time to see data from the Phase III trials and, if positive, to get the drug to patients as soon as possible.
Although not so visible from outside the company, we'll continue to invest in R&D. We believe that our strategy of building world-class research and development will not only help us identify important new therapies ourselves but will also help us to make thoughtful, sophisticated decisions about what to bring in from outside the company.
So we have a lot to do. This is a year for us to keep our heads down and focus on execution in all of the areas that I just outlined. We have a great team and a dedicated group of employees. And as always, I'd like to thank our employees for making a positive impact on patients' lives and to thank the patients and physicians involved in our clinical development programs. The achievements that we've made together could not have been realized without their passion and commitment. 
So thank you all for joining us this morning. And operator, we'll now open up the call for questions."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Matthew Harrison from Morgan Stanley.",15,"[Operator Instructions] Your first question comes from the line of Matthew Harrison from Morgan Stanley."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So I'm going to ask a two-part question, which you'll probably give me a hard time for. But -- so on TECFIDERA, can you just talk a little bit about what's going on outside the U.S.? If you back out the FX movements that you were talking about, you only s",105,"So I'm going to ask a two-part question, which you'll probably give me a hard time for. But -- so on TECFIDERA, can you just talk a little bit about what's going on outside the U.S.? If you back out the FX movements that you were talking about, you only saw a sequential $9 million increase in revenues. Is volume substantially slowing outside the U.S.? And then maybe just related to that, you had some contracting changes across the portfolio, specifically with, CVS last year. Any big impacts to gross to net or some of the trends that may have affected the interferon franchise?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Matt. Great question. This is Paul. I'll try to take it. Outside the United States -- we're actually pretty pleased outside the United States. I'd say Germany is a place where we'd like to see performance a little bit better. It probably looks a l",339,"Thanks, Matt. Great question. This is Paul. I'll try to take it. Outside the United States -- we're actually pretty pleased outside the United States. I'd say Germany is a place where we'd like to see performance a little bit better. It probably looks a lot like the United States performance of TECFIDERA kind of getting to -- darn close to a 20 share and not being -- not punching through over the course of 2015. That's an important market outside the United States, as you all know. When I go across other parts that really are the big contributors outside the United States, it's kind of, obviously, France, U.K., Southern Europe countries of Italy and Spain. And we're very pleased with the performance in Southern Europe. Those are early days in terms of the launch curves for TECFIDERA specifically. We're very, very pleased with that. The performance has exceeded our expectations. And certainly, as we've pointed out in the past, our U.K. performance is exceptionally strong. We've got what we feel is a remarkable team there. They've kind of really -- really kind of broken down the marketplace and attacked it quite vigorously across the suite of Biogen MS therapies. So I think very pleased, I'd say, with the performance outside the United States, with a little bit of homework to do in Germany, which, I think, we're actually showing some early signs, very early signs late in the quarter, positive signs. With respect to contracting, it is as people know, specific to AVONEX and PLEGRIDY, specific to newly diagnosed patients. I think that you combine that with typical seasonality issues in Q1, and we still feel we made the right choices there in terms of as we moved into 2016. And so I think that's kind of -- we don't think there's been a meaningful impact. Certainly, kind of working through prior authorizations and things like that for some of the patients has become a more active part of what we do in our Patient Services organization."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Mark Schoenebaum from Evercore ISI.",13,"Your next question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Paul, congrats again on great P&L management. We all appreciate it, and your investors appreciate it. On the -- I have so many questions to ask, maybe Al, just because this is the one I get the most, just going back to the Eisai collaboration and the Abet",186,"Paul, congrats again on great P&L management. We all appreciate it, and your investors appreciate it. On the -- I have so many questions to ask, maybe Al, just because this is the one I get the most, just going back to the Eisai collaboration and the Abeta antibody that may or may not have data shortly. The question that I've been getting -- I'd just love to hear your thoughts are, you emphasized a lot when looking at these competing Abeta antibodies really understanding if -- what the imaging data show post therapy, that is, is it draining plaque from the brain? And if the answer to that is no, then the clinical outcome is perhaps less important because it doesn't do what your amaB does, so to speak. And -- but there's been some questions about, specifically, where the Eisai BAN antibody binds, which types of fibrils and whether or not, given its binding -- its specific binding affinities, whether or not you would expect necessarily to see changes on PET scan? So I was just wondering if you could talk us through that."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Mark. The BAN2401, to my understanding, binds the protofibrils as well as oligomers, and I would expect it to reduce amyloid plaque burden. The question for me is, does it do that, first of all; and second, to what degree? The thing that was remarkab",171,"Yes, Mark. The BAN2401, to my understanding, binds the protofibrils as well as oligomers, and I would expect it to reduce amyloid plaque burden. The question for me is, does it do that, first of all; and second, to what degree? The thing that was remarkable about aducanumab was that we had a very substantial reduction in the course of 1 year. Arguably 85% or so. Competitor antibodies have not done that, and I don't know where 2401 will land but that's an important piece. And then we can then start to understand the relationship between reduction in plaque burden and cognitive outcome. In our hands, in the aducanumab program, only the patients who reduced plaque burden by greater than 1 standard deviation change relative to what the placebo patients did, in other words, beyond the noise, those are the people who got cognitive benefit. The people who did not do that did not have any benefit that we could detect. So we think that's an important piece to look at."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Alethia Young from Crdit Suisse.",13,"Your next question comes from the line of Alethia Young from Crdit Suisse."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Congrats on the expense management as well. I guess, from the DTC campaign that you had with TECFIDERA, like, what were some of the learnings that you took away for that campaign around the television form and why you chose to keep the print? And just kin",75,"Congrats on the expense management as well. I guess, from the DTC campaign that you had with TECFIDERA, like, what were some of the learnings that you took away for that campaign around the television form and why you chose to keep the print? And just kind of similar, along that line, like have you -- do you have any color on what the average duration for TECFIDERA is right now in the United States?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","I'll take the first part of that question. Look, we -- the main purpose of the ad campaign, the television campaign was to increase awareness of TECFIDERA. We were surprised actually, at the beginning, by the low awareness among patients of TECFIDERA. And",184,"I'll take the first part of that question. Look, we -- the main purpose of the ad campaign, the television campaign was to increase awareness of TECFIDERA. We were surprised actually, at the beginning, by the low awareness among patients of TECFIDERA. And we had data suggesting that when patients did learn about TECFIDERA and went to their physician to discuss it, they often had it prescribed. So we wanted to get the awareness up. The ad did succeed in getting awareness up. We would -- and then the thesis is, once awareness is up and they have those discussions, they'll go to their physicians and we'll see an increase in prescriptions. We've said we would see that, if we do, in Q2. We're in Q2 and so I think we'll have a final verdict on the success of that TV campaign when we talk to you next quarter. And so those ads don't run forever. So we're taking a pause. We'll continue our other types of activities and we'll see what we learn and make decisions about any potential future television ads."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Alethia, and this is Paul, I'll try to take the second part of your question. And let me kind of answer it in a slightly different way that is a little bit more customary to the way we look at the data and probably more indicative. We try to triangulate o",171,"Alethia, and this is Paul, I'll try to take the second part of your question. And let me kind of answer it in a slightly different way that is a little bit more customary to the way we look at the data and probably more indicative. We try to triangulate on what we call discontinuation rates, the percentage of patients that leave a therapy, call it, over the course of a 52-week period. And all the disease-modifying therapies have discontinuation rates. And we think that TECFIDERA experienced higher discontinuation rates than normal as we moved through 2015, largely due to lymphocyte monitoring and kind of a label change. We actually, importantly, think that we're kind of on -- hopefully, on the back side of that; that the medical education has largely been completed. It never -- it obviously never stops, but we're hopeful that, actually, that can provide a little bit of a tailwind as we move through 2016 and as it begins to get back to a more normal level."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink Partners."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Paul, just could you give us some color on how the rest of the year is looking now? You obviously have got a tailwind here with the significantly lower R&D expenses. You've tightened your belt on SG&A, but you did have what looks like $45 million of seque",104,"Paul, just could you give us some color on how the rest of the year is looking now? You obviously have got a tailwind here with the significantly lower R&D expenses. You've tightened your belt on SG&A, but you did have what looks like $45 million of sequential currency headwind, or loss of hedging from Q4. So how should we think about those drivers for the rest of the year? Can you keep at this sort of level on R&D and SG&A? And should we anticipate this kind of magnitude of currency effect through the balance of the year because of your hedge positions?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, let me kind of -- great questions, Geoff, because it's kind of a dynamic that the loss of hedging, not a surprise to us. So that was actually part of our business plan as we swung into 2016. And fundamentally, we're not -- we don't make predictions a",265,"Yes, let me kind of -- great questions, Geoff, because it's kind of a dynamic that the loss of hedging, not a surprise to us. So that was actually part of our business plan as we swung into 2016. And fundamentally, we're not -- we don't make predictions about where currencies are going to go. But we fully anticipated the fact that we had hedge gains throughout the P&L in 2015 that really come about from the hedges that we put on in 2014. So it's essentially a wraparound effect of the currency changes, mostly in the EU, as we kind of ended, very end -- if you remember the changes were very end of December of 2014 and January of 2015. So that was fully expected. And so we believe that, that will just continue to be a bit of a headwind, which we had thought about. The R&D, I think I'd point out one key dynamic is it's always a little bit choppy, R&D as a percentage of sales, it's based on business development activity. And we certainly want to and would welcome really good business development activity, that's always a positive investment, a positive expense if done correctly. With all that said, no doubt about it that, as I said, we have made cost control and feel like we're reaping the benefits of what we did late in 2015 as we came into this year. And I think it will continue to be a meaningful effort from me, from the whole organization, to make sure we focus on efficiencies throughout the year."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Yes, maybe on that R&D investment, either for Paul or George. We all appreciate the focus on the bottom line and costs and appreciate also there are some puts and takes in Q1, but you're down 16% of revenue in the first quarter. That's, I think, an all-ti",71,"Yes, maybe on that R&D investment, either for Paul or George. We all appreciate the focus on the bottom line and costs and appreciate also there are some puts and takes in Q1, but you're down 16% of revenue in the first quarter. That's, I think, an all-time low for Biogen. Is that an appropriate rate for this company kind of long term, 3 to 5 years, in terms of investment?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, thanks, Eric. Let me take that question. Look, our R&D is choppy, and I don't want anybody to interpret that number as a deliberate effort to cut back on R&D and a deemphasis on R&D. It is quite the opposite, actually. We are continuing to build a wo",213,"Yes, thanks, Eric. Let me take that question. Look, our R&D is choppy, and I don't want anybody to interpret that number as a deliberate effort to cut back on R&D and a deemphasis on R&D. It is quite the opposite, actually. We are continuing to build a world-class research group. We will continue to invest in research. We believe that is a fundamental part of our strategy to build value. I think it's -- we've done a really good job so far. We'll continue that focus. Clinical development, we will spend whatever is necessary to move our pipeline forward, those pipeline compounds that are high potential, high value, we've talked about those. We'll continue to invest in those. Frankly, the expenses there we would expect to go up over time as we move more compounds into Phase III. So I think the trend is largely in that direction. And part of this quarter was also, as Paul said, the lack of BD. And there's not going to be a lack of BD forever. So it was the lack in one quarter. So I think it's -- I don't want anybody to interpret the one quarter number as a change in our strategy or a deemphasis of R&D. It's quite the opposite, actually."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","I know you're not commenting on other outside reports on hemophilia, but I wanted to ask, bigger picture, there's been changes in the market. The incumbent's being acquired. There's gene therapy data yesterday. Maybe you could talk a little about the push",83,"I know you're not commenting on other outside reports on hemophilia, but I wanted to ask, bigger picture, there's been changes in the market. The incumbent's being acquired. There's gene therapy data yesterday. Maybe you could talk a little about the push-pulls for this business and is this business the business you've been thinking about. And maybe talk a little bit about how this fits in overall in the growth that you see here, given all the changes going on in hemophilia."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Sure. Happy to take that. Look, ELOCTATE and ALPROLIX are doing well. They're gaining market share and we're pleased with their performance. So -- and they're continuing to gain share. So we're feeling good about there. We have not yet seen any impact on",406,"Sure. Happy to take that. Look, ELOCTATE and ALPROLIX are doing well. They're gaining market share and we're pleased with their performance. So -- and they're continuing to gain share. So we're feeling good about there. We have not yet seen any impact on their trajectories from the introduction of other long-acting factors. So we take that as a positive sign. So I think the prospects for the business look quite healthy. In the longer term, there are a number of products, as there are in every therapeutic area, coming forward, and we're keeping a close eye on them. There is certainly -- we saw BioMarin's data, which are interesting but early. I mean, I haven't seen anything that you haven't seen. I saw good factor VIII levels that persisted for some period of time, and we saw some liver enzyme issues that needed to be treated with corticosteroids. So we'll see how that plays out over time. Those are early. I would say interesting data, but early. It's similar, I think, to our immune tolerance induction data that we have with ELOCTATE. And if you -- we haven't talked about this a lot, but a fair number of hemophiliacs develop inhibitory antibodies when they're treated, and that results in the necessity for immune tolerance induction, which means high levels of factor that are given over 12 to 18 months before immune tolerance emerges. There have been a very limited number of patients, 3, so I don't want to overstate this. Again, these are very early data, so -- and I don't want to be here overstating the case. But again, these are early data but also encouraging. So of the 3 patients that have been treated with ELOCTATE from the intolerance induction, they all became tolerant within about 3 to 4 months. So a much shorter period of time. If those data are confirmed in further studies, we believe that, that could be an important upward lift for ELOCTATE. So I think there are lots of early data emerging. They all need to be confirmed with larger studies. And we feel good about the business and where we are. We have our own longer-acting factors coming. We've talked about some of them, there are earlier ones that are in our research group now. So I think we feel good about the current products, and we feel good about the future of the business as well."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch.",16,"Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","First one is many investors think you guys have lost flexibility on balance sheet because you guys really don't have much net debt. I'm just probing -- maybe the question is for Paul, what's the willingness here to do another significant share buyback, gi",96,"First one is many investors think you guys have lost flexibility on balance sheet because you guys really don't have much net debt. I'm just probing -- maybe the question is for Paul, what's the willingness here to do another significant share buyback, given your balance sheet strength? And then secondly, I want to ask about the TECFIDERA inventory situation here. So in fourth quarter, you had a $30 million inventory build in the U.S. and then there's a destocking of $20 million this quarter. Should we expect another $10 million to go next quarter?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay, why don't I try to clean up the clarity on the second part of your question. So the $30 million that I talked about last quarter was our best estimate at that time. In retrospect now, it probably is closer to the $20 million. In reality, it's probab",304,"Okay, why don't I try to clean up the clarity on the second part of your question. So the $30 million that I talked about last quarter was our best estimate at that time. In retrospect now, it probably is closer to the $20 million. In reality, it's probably in between. So I think that we've gone through the destocking of what we talked about last quarter and just wanted to kind of clarify it with the prepared remarks. With respect to the balance sheet, I think it gets to the broader question of capital allocation. Currently, we're actually sitting on a pretty high cash balance. As I pointed out, like many others, we have the peculiar situation of ex U.S. cash as a little bit more than half of that. But aside from that, that largely arises out of 2 things, the great strong cash flow generation of the company coupled with the debt financing that we did in the fall of 2015. Look, I think we're going to -- we will look to strategically deploy it. And if we come up that there are not options to strategically deploy it, we will look towards returning capital to shareholders. We don't measure that on a -- as we've talked about before, on a 90-day basis just because that's not the kind of clock speed of things. In both situations, it depends on price and value. So it continues to -- it depends. And in both situations, the financial objective is to maximize intrinsic value per share. So we look towards investing in deployments of capital that really drive great internal rates of return. I think I'd also point out, look, over a longer period of time, I think this company, with the great cash flow generation it has, has flexibly to do both."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So just a question on strategy a little bit, in thinking about the company longer term. So you've got the MS business now stable but it's faced some compression from new therapies. I mean, you have hemophilia as a growing business and pipeline. I'm just w",144,"So just a question on strategy a little bit, in thinking about the company longer term. So you've got the MS business now stable but it's faced some compression from new therapies. I mean, you have hemophilia as a growing business and pipeline. I'm just wondering how are you thinking about how important it is to diversify the business further? Do you have any concerns or know -- or how are you thinking about could there be something that puts pricing pressure on the MS market and what could trigger it? And how are you thinking about maybe derisking the company from such an event? None of us think of it as a near-term event, but it's something that could happen over the long term. So maybe just help us think about like the longer-term strategy of the company and your thoughts on price."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Robyn. This is George. I'll start with that, and other people can chime in. Look, we are -- I think we're feeling good about the MS business as it exists today. We're going right. But if you look at our pipeline, you'll see that many of the things",224,"Thanks, Robyn. This is George. I'll start with that, and other people can chime in. Look, we are -- I think we're feeling good about the MS business as it exists today. We're going right. But if you look at our pipeline, you'll see that many of the things we're working on are not in MS. We think LINGO, actually, could be a transformative event in the treatment of MS, so -- and we are not working beyond ZINBRYTA on novel, let's say, additional drugs that would down regulate the immune system. I think there are enough of those on the market. There are more coming. For many MS patients, those don't stop the progression. They slow the progression but they don't stop the progression. And so we believe things like LINGO actually are the types of compounds that could actually transform that market and give it additional vibrancy as we move out through the 20s. That being said, if you look at what we're emphasizing now and what we have in Phase III, it's nusinersen for SMA, it's aducanumab for Alzheimer's disease, it's raxatrigine for neuropathic pain, it's amiselimod for IBD and Crohn's disease. So we have deliberately brought in a series of compounds and are conducting late-stage trials in things that are outside of MS, partially for the reason you just outlined."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","And your thoughts on price, anything that could trigger a pricing compression in the marketplace?",15,"And your thoughts on price, anything that could trigger a pricing compression in the marketplace?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","We don't see anything in the near term. No, as you move out into the 20s, there certainly could be. But don't see anything near term.",27,"We don't see anything in the near term. No, as you move out into the 20s, there certainly could be. But don't see anything near term."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","A couple of commercial ones. In the context of your DTC campaign, I was curious if you guys have any data on retreatment of patients who went on TECFIDERA right at the launch. And then just with respect to a related question with respect to first quarter",65,"A couple of commercial ones. In the context of your DTC campaign, I was curious if you guys have any data on retreatment of patients who went on TECFIDERA right at the launch. And then just with respect to a related question with respect to first quarter trends, or even fourth quarter, any impact thus far from generic Copaxone on the interferon market vis--vis share?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Geoff. I'll try to address that. Not a lot of data on kind of retreatment. So we have plenty of data but I can't, off the top of my head, think of anything as it relates to that. With respect to generic Cop, the data would suggest it's a pretty small",93,"Yes, Geoff. I'll try to address that. Not a lot of data on kind of retreatment. So we have plenty of data but I can't, off the top of my head, think of anything as it relates to that. With respect to generic Cop, the data would suggest it's a pretty small percentage at this point in time, and the data would suggest that it very much is just impacting Copaxone. So that's how we see it anecdotally as well as how the data from the market share and the patient trends suggests."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","A question for Michel, if I may -- first of all, congratulations on the new position. I know it's very early days, but I'm curious if you could maybe talk broadly about your objectives coming into Biogen, areas where you see the potential to have the most",85,"A question for Michel, if I may -- first of all, congratulations on the new position. I know it's very early days, but I'm curious if you could maybe talk broadly about your objectives coming into Biogen, areas where you see the potential to have the most impact on the commercial business under your leadership and perhaps, more specifically, how you're thinking about potentially reaccelerating growth in MS and positioning for a potential ocrelizumab entry, while still balancing the company's focus on achieving cost savings?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Brian. Brian, this is Paul. We had Michel prepared for a wholesale or inventory question. Michel?",17,"Thanks, Brian. Brian, this is Paul. We had Michel prepared for a wholesale or inventory question. Michel?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","So thanks for the question. Good morning, everybody. This is Michel Vounatsos. Week 1 at Biogen. So as you can imagine, I am more on the learning and listening mode and it's far too early for me to assess the strategy. I will be focusing a lot of time on",120,"So thanks for the question. Good morning, everybody. This is Michel Vounatsos. Week 1 at Biogen. So as you can imagine, I am more on the learning and listening mode and it's far too early for me to assess the strategy. I will be focusing a lot of time on the key geographies, obviously, and the key customers, to best understand -- and the key franchises. So I hope that in the near future, I'll be in a better position to assess the next steps. What I can tell you is that I'm extremely encouraged and honored to be part of this team, and looking forward to engaging with all of you in the near future. Thanks for your understanding."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Jim Birchenough from Wells Fargo Securities.",14,"Your next question comes from the line of Jim Birchenough from Wells Fargo Securities."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Maybe a question on the pipeline and some help in assessing the risk-adjusted value of nusinersen. And on the risk side of it, when you look at the data we saw at AAN and that we've seen over the last few years, how do you get comfortable with the compari",82,"Maybe a question on the pipeline and some help in assessing the risk-adjusted value of nusinersen. And on the risk side of it, when you look at the data we saw at AAN and that we've seen over the last few years, how do you get comfortable with the comparison with historical controls? And then on the opportunity, perhaps you could speak to how you view that opportunity in SMA between the Type 1 and then the Type 2, 3 patient?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Well the comparison with historical controls is always a little bit dangerous to do because you have to choose cohorts and you try to match them to your patients. But the standard of practice changes over time. So these patients might be getting better ov",197,"Well the comparison with historical controls is always a little bit dangerous to do because you have to choose cohorts and you try to match them to your patients. But the standard of practice changes over time. So these patients might be getting better over time just by the clinical practice improving. On the other hand, when you start to see lack of events of the type that was shown at AAN, since December of 2014, no new events, that's a pretty striking difference. And these are hard endpoints, like time to tracheostomy or ventilation and time to death. It's hard for me to see how that kind of thing could be happening due to simply improving medical care. So I think we're getting more and more encouraged, but I would note that we have these 2 well-controlled trials, 1 in infant onset SMA and 1 in childhood onset SMA. And that, to me, is the definitive data set that we're going to be looking at. And in terms of the opportunities in infant and childhood, I mean, I think they're both big opportunities, and I look forward to being able to help patients in both categories."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","I actually wanted to follow up on nusinersen. George, in your scripted comments, when you talked about doing whatever you can to minimize the time to Phase III data for the product, is there anything specific that can actually be done to shorten that time",70,"I actually wanted to follow up on nusinersen. George, in your scripted comments, when you talked about doing whatever you can to minimize the time to Phase III data for the product, is there anything specific that can actually be done to shorten that time line, given that enrollment is complete for one of the trials and close to it for the other? Is there anything else you're referring to?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Look, at this time, let me just say that we are cognizant of the need to get this drug to patients as soon as we can, if it works. So the first part of that is being confident that it works. And as Al said, we're going to need to see data from the control",172,"Look, at this time, let me just say that we are cognizant of the need to get this drug to patients as soon as we can, if it works. So the first part of that is being confident that it works. And as Al said, we're going to need to see data from the controlled trials in order to make that case to the agencies, certainly, and then for us to be absolutely certain as well. So we want to get there as quickly as we can. And once we have those data, we absolutely want to minimize the time until these kids have access to it, again, if it works. And these are the -- especially the Type 1 kids who don't have a lot of time. And so there are a lot of kids out there today who could -- desperately need something, and so that's -- we're trying to shorten that time frame. But I don't want to get into any of the specifics of how we're doing that."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Terence Flynn from Goldman Sachs.",13,"Your next question comes from the line of Terence Flynn from Goldman Sachs."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just on the LINGO MS data coming in midyear, I know you guys are looking at a range of endpoints here, including disability and cognition. I think disability is pretty easy for all of us to benchmark as there's a lot of data there. But on the cognition si",79,"Just on the LINGO MS data coming in midyear, I know you guys are looking at a range of endpoints here, including disability and cognition. I think disability is pretty easy for all of us to benchmark as there's a lot of data there. But on the cognition side, I know you're using this PASAT-3 scale. Anything you can do there just to help frame for us in terms of what would be a meaningful outcome on that measurement?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, it's -- we've had a lot of experience with PASAT. We've been using it in MS trials for about 20 years now. One of the things we know is that there's a practice effect, and so I expect to see some improvement on the score even in untreated patients ju",164,"Yes, it's -- we've had a lot of experience with PASAT. We've been using it in MS trials for about 20 years now. One of the things we know is that there's a practice effect, and so I expect to see some improvement on the score even in untreated patients just because of the practice effect. What I am hoping to see with anti-LINGO, and I don't know whether we will or not, is that there would be an even better learning effect in the anti-LINGO treated patients and that it would be great to see a dose response, that would make it even more compelling if we saw that. In terms of what is considered clinically meaningful, that hasn't been established in the world of MS yet. We have no established precedents on that. I will say that some compounds have shown some efficacy on this by virtue of preventing new MS lesions, but certainly not in this new era of reparative therapies."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ian Somaiya from BMO Capital Markets.",14,"Your next question comes from the line of Ian Somaiya from BMO Capital Markets."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","Just a question for Al. On aducanumab, I was just hoping to get your thoughts on targeting of Abeta. Specifically, I think you've implied and I think there's plenty of data out there suggesting that beta-amyloid levels or amyloid beta levels might have ac",111,"Just a question for Al. On aducanumab, I was just hoping to get your thoughts on targeting of Abeta. Specifically, I think you've implied and I think there's plenty of data out there suggesting that beta-amyloid levels or amyloid beta levels might have actually plateaued by the time a patient shows any signs of mild cognitive impairment. I'm just curious to get your thoughts sort of the appropriateness of targeting Abeta in patients where plaque sort of already reached sort of a level, and what potentially could be driving the disease in these patients in terms of their progression? And whether there's another target that would be -- make more sense?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, so it's true that when you look at plaque burden, it does tend to plateau in the -- already in the prodromal phase, and certainly by the mild stage, it's pretty flat. And so what drives the progression beyond that, we believe, is probably tau. Tau co",187,"Yes, so it's true that when you look at plaque burden, it does tend to plateau in the -- already in the prodromal phase, and certainly by the mild stage, it's pretty flat. And so what drives the progression beyond that, we believe, is probably tau. Tau comes on later. If you look at the imaging studies, tau comes on later, and there's a lot of data, preclinical data, that shows that Abeta pathology triggers tau pathology. So we're learning a lot about tau now. We know that in normal aging, there is some aggregated tau in the medial temporal lobe; but in patients with Alzheimer's disease, it spreads beyond the medial temporal lobe. And that spread is probably triggered by Abeta. And so that's the reason why we have some programs in tau. We've just -- we have some preclinical as well as early clinical programs of both antibodies as well as antisense. And so in the later stages, we might need to treat for tau, perhaps in combination with the Abeta therapies because I don't think you want to reaccumulate Abeta once you've removed it."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","And your last question comes from the line of Chris Raymond from Raymond James.",14,"And your last question comes from the line of Chris Raymond from Raymond James."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Analysts","So just a question on anti-LINGO. So at AAN, there was some interesting data on clemastine. That agent seems to have at least some sort of similarity in terms of mechanism to LINGO in terms of impacting oligodendrocyte differentiation, at least. Wondering",70,"So just a question on anti-LINGO. So at AAN, there was some interesting data on clemastine. That agent seems to have at least some sort of similarity in terms of mechanism to LINGO in terms of impacting oligodendrocyte differentiation, at least. Wondering, Al, if you had any thoughts -- is there any kind of readthrough we should be thinking about with respect to that agent and the results there?"
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Yes, so we've -- the clemastine came from this micropillar assay that was developed in San Francisco, where they have oligodendrocytes wrapping myelin essentially around tubes. And what they found was that there were a number of antimuscarinic compounds t",228,"Yes, so we've -- the clemastine came from this micropillar assay that was developed in San Francisco, where they have oligodendrocytes wrapping myelin essentially around tubes. And what they found was that there were a number of antimuscarinic compounds that work, benztropine as well as clemastine. We've actually tested clemastine in our oligodendrocyte differentiation assay here, and in our hands, it's less potent than BIIB061, our oral compound that we have in early clinical trials, and it's also less effective overall in a side-by-side comparison in our hands. Nevertheless, I did look at the data, it's -- crossover designs like the one that they did are not -- probably not the best approach for looking at disease-modifying therapies because when you switch from clemastine to placebo, I don't expect that if it is causing myelination, how would the placebo patients look? They would continue to get the benefit from the clemastine that they had received in the period prior. So nevertheless, they did show a modest effect on latency of the conductions between the retina and the brain. And we're keeping a close eye on that. I think that these are all early day experiments in reparative therapies, and I believe we have established one of the best ways of looking at this in our anti-LINGO program, both in acute optic neuritis as well as the MS program."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Executives","Okay. If there are no further questions, let me thank you all for your time this morning, and we'll sign off. Thanks.",22,"Okay. If there are no further questions, let me thank you all for your time this morning, and we'll sign off. Thanks."
29726,328802932,962052,"Biogen Inc., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2016 Financial Results and Business Update. [Operator Instructions] Thank you. I would now like to turn",59,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2016 Financial Results and Business Update. [Operator Instructions] Thank you. I would now like to turn the call over to Mr. Matt Calistri, Senior Director of Investor Relations. Please go ahead."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Dan. Thank you, everyone, and welcome to Biogen so second quarter 2016 earnings conference call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including",220,"Thanks, Dan. Thank you, everyone, and welcome to Biogen so second quarter 2016 earnings conference call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today.
Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally.
We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Michael Ehlers, EVP of Research and Development; our Chief Commercial Officer, Michel Vounatsos; and our CFO, Paul Clancy. We'll also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock. Now I'll turn the call over to George."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Matt, and good morning, everyone. Thanks for joining us. I'd like to begin with a personal statement, I'll be stepping down as CEO of a Biogen some time within the next few months. The board and I recognize that this is an excellent time",1072,"Okay. Thank you, Matt, and good morning, everyone. Thanks for joining us. I'd like to begin with a personal statement, I'll be stepping down as CEO of a Biogen some time within the next few months. The board and I recognize that this is an excellent time for transition. The company is doing well now. The management team is complete and extremely capable. The commercial and R&D activities are going well and we're on our way to adding to the pipeline through internal and external opportunities. So good time for a new CEO to take the helm and see Biogen through to what I believe is a very exciting future. 
This also is an opportune time for me to return to the West Coast, take on one more set of activities and spend more time with my family. I've been at Biogen for 6 years, I'm proud of the company and what we've been able to accomplish in that time. We've introduced 6 new products onto the market and increased our levels, earnings and stock price all by several fold. And I believe that we're well positioned to keep delivering on our potential to bring even more therapies to patients and returns to investors. 
Our R&D and commercial organizations are now world-class, joining our already industry-leading biologics manufacturing capabilities. All aspects of the company are operating at a high-level. We've brought several potential game-changing compounds into later-stage development and are in the process of adding further to that pipeline. 
The addition of Michel Vounatsos, Mike Ehlers and Paul McKenzie, the company has a full and vibrant leadership team that's capable of moving the company thoughtfully forward. I truly believe that the company has a bright future and it's with mixed emotions that I leave at this time and not see that future come fully to fruition. 
We're making the announcement now in order to provide an orderly transition for the company and to allow the board to conduct an open and effective search. I'll work with the board to find a great successor who can continue to build on what we have accomplished. We expect to consider both internal and external candidates, and I'm confident that we'll identify an outstanding new leader. I expect to remain as CEO until a successor is identified and can begin. In the interim, I'll continue to work with the board and management team to accomplish Biogen's goals for 2016. I believe that we're in a good trajectory, that we have a great new additions to the management team, and I look forward to a successful second half of the year. 
So enough about me. Let's turn to the business. Biogen had a solid second quarter, delivering strong financial performance and important advances in our pipeline. For the second quarter of 2016, Biogen generated $2.9 billion in total revenues, a 12% increase from the same period a year ago. Our GAAP earnings were $4.79 per share, a 22% increase year-over-year, and non-GAAP EPS was $5.21, a 23% increase year-over-year. 
We continued to grow our leading MS franchise and our hemophilia business and our efforts to maximize revenues while thoughtfully managing expenses helped to drive attractive earnings growth. As a result, we've raised our financial guidance for the full year. And today, we announced that our Board of Directors has authorized a program to repurchase up to $5 billion of our common stock. 
Looking back, we had quite an eventful second quarter. To begin, we welcome 3 new members of our management team, a new Head of commercial, Michel Vounatsos, joined us in April. He's completed a thorough assessment and has identified 4 key priorities for driving our MS business forward, which he'll share with you later on this call. Our new Head of R&D, Mike Ehlers, joined us at the end of May. Mike is a brilliant neuroscientist and an established R&D leader who has excelled in both academic and corporate settings. Mike has demonstrated the ability to translate science into the development of important new medicines and he's already bringing terrific leadership to the organization. And finally, with John Cox preparing to lead the new hemophilia company, we promoted Paul McKenzie to oversee our Pharmaceutical Operations and Technology Group. This 3 new leaders bring a wealth of experience and expertise, and we believe that they are poised to take Biogen to its next phase of growth. I'm proud to have them in our organization. 
Last quarter brought a number of positive developments for both our commercial products and our pipeline. We announced our intent the spinoff our hemophilia business. That business continues to perform well with combined second quarter revenues of over $200 million for ELOCTATE and ALPROLIX. ALPROLIX also was approved by the European Commission for the treatment of hemophilia B and would be commercialized in the EU by our collaboration partner, Sobi. 
We had a positive label update for TYSABRI in Europe, including an extended indication. We received regulatory approval for ZINBRYTA in both the U.S. and the EU for the treatment of relapsing MS. [indiscernible] biosimilar referencing Remicade received approval in Europe. This will be the second anti-TNF biosimilar that we'll manufacture and commercialize in the EU. And SB5, an adalimumab biosimilar candidate referencing Humira has been accepted for review by the European Medicines Agency. Aducanumab was accepted into the European Medicines Agency's PRIority MEdicines program, known as PRIME. It was 1 of only 4 applications accepted out of 18 submitted and the only Alzheimer's disease therapy in development that was accepted. On the early-stage research front, we entered into a broad collaboration and alliance with the University of Pennsylvania and 2 world-renowned gene therapy experts, Dr. James Wilson and Jean Bennett. 
This quarter, we also reported the top line results of this synergy trial for opicinumab. As you are all aware, opicinumab missed both the primary and secondary endpoints, it certainly was disappointing. However, the rigorous design and planning of synergy has yielded an abundance of data that will help us make a well-informed decision about our path forward with opicinumab and our work in remyelination, generally. These results are indicative of the significant challenge of targeting neuro repair. During the upcoming [indiscernible] conference in September, we expect to present more detailed efficacy, biomarker and safety data. 
I'll now turn the call over to Mike, and we're eager for you to get to know Mike and experience his passion for our business."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, George, and good morning, everyone. By way of introduction, I spent a number of years in academia as professor in Howard Hughs Medical Institute, investigator at Duke University where my research was focused on cell biological and circuit mecha",758,"Thank you, George, and good morning, everyone. By way of introduction, I spent a number of years in academia as professor in Howard Hughs Medical Institute, investigator at Duke University where my research was focused on cell biological and circuit mechanisms of brain function in a normal developing and deceased nervous system. My career took an exciting turn 6 years ago when I joined Pfizer. I served as the Chief Scientific Officer for the company's neuroscience and pain research unit and ultimately became group leader for biotherapeutics R&D with responsibly over rare disease, the centers for therapeutic innovation and all large biomolecules sciences. 
I'm just now finishing my second month at Biogen, so there is still a lot I'm getting up to speed on. But I can tell you from the outset that I am working to reshape and progress our pipeline while aggressively pursuing promising assets, both internally and externally. I plan to update you on progress on these fronts in the future. 
In the meantime, I will comment on the important clinical study redux this quarter and note some good progress made in advancing our clinical programs. 
Starting with opicinumab, our anti-LINGO, as George discussed. The top line results from the Phase II SYNERGY study were reported in which opicinumab unfortunately missed both of the primary and secondary endpoints. However, evidence of a clinical effect with a complex unexpected dose response was observed. The SYNERGY top line efficacy safety and biomarker results will be presented at ECTRIMS in September. 
Continuing in MS. EC approval was received for an extended indication for TYSABRI and highly active relapsing-remitting MS patients with inadequate response to prior MS therapy. TYSABRI was previously only indicated for patients who had failed to respond to beta interferon or a glatiramer acetate. This label extension follows recent EC approval for a new patient management plan, including an updated risk algorithm based on JC virus antibody index values. These changes will allow physicians to have more individualized benefit risk discussions with their patients. 
Turning to other promising late-stage assets, our collaboration partner, Ionis, continues to execute a Phase III studies of nusinersen for infants and children with spinal muscular atrophy, both of which are now fully enrolled. In Alzheimer's disease, it was recently announced that aducanumab was one of only 4 applicants accepted at the European Medicine Agency's PRIority MEdicines program or PRIME. PRIME aims to bring treatments to patients faster by enhancing the EMA's support for the development of investigational medicines for diseases without available treatment or in need of better treatment options. 
We continue to work diligently to enroll our aducanumab Phase III trials. Looking ahead, safety data from the titration arm of the Phase 1b study is anticipated by the end of this year. 
We are working toward the start of Phase III trials for amiselimod or MT-1303 in inflammatory bowel disease and did 074 formerly known as raxatrigine in trigeminal neuralgia an initiation of the Phase II trial with [indiscernible] 074 in patients with neuropathic pain, from [indiscernible] is planned for later this year. 
And further activities, natalizumab's clinical profile and treatment window supports its continued investigation as a potential novel approach for treating acute ischemic stroke and the first patient was recently dosed in a second Phase II study in stroke called action II. Encouraging data was recently generated on earlier stage assets, BIIB059 or anti [indiscernible] for systemic lupus erythematosus and BG11 or stx100 for idiopathic pulmonary fibrosis. Anti-BDCA2 data in healthy volunteers and a lupus cohort of 12 subjects is provided confidence to move into Phase II with trial initiation plan to begin over the summer. These data are anticipated to be presented later this year. 
The BG 11 study is enrolling its final cohort and it is expected that data will be presented after the trial completes. Finally, ask George mentioned, Biogen announced the broad collaboration and alliance with the University of Pennsylvania, and Dr. James Wilson and Jean Bennett to advance gene therapy and gene editing technologies. The expanse of research and translational development collaboration is multiple objectives and will primary focus on the development of therapeutic approach as the target of the eye, skeletal muscle and the central nervous system. 
Again, I am pleased to participate in my  first earnings call here at Biogen. I anticipate sharing more detail on the advancement of the Biogen pipeline in the coming months as the company works diligently to deliver new therapies to patients. With that, I will now pass the call to my good colleague, Michel Vounatsos."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Mike. I'm very pleased to be with you this morning. I shared my initial thoughts on the MS market and OMS portfolio, outline my priorities going forward and then I will we discuss this quarter's results for MS products. Since I arrived at Biogen",1131,"Thanks, Mike. I'm very pleased to be with you this morning. I shared my initial thoughts on the MS market and OMS portfolio, outline my priorities going forward and then I will we discuss this quarter's results for MS products. 
Since I arrived at Biogen 3 months ago, I have spent time in the field with our operations team, meeting with patients, the neurology community and many of the scientifical leaders in multiple sclerosis. Also, I have engaged with the strong Biogen leaders across our commercial organizations. I have listened and learned a lot. And together with the team, we have prioritized immediate opportunities across 4 key areas. 
We believe these opportunities will benefit our MS franchise today and at the same time, prepare the organization for potential future product launches. Before speaking about our therapies, I think it is important to note MS is a growing market, with approximately 850,000 treated patients worldwide out of a global prevalence estimated at 2.3 million, which includes progressive forms of MS. 
We estimate the number of treated patients worldwide is growing in the mid-single digits on an annual basis, driven by low single-digit growth in the U.S. and high single-digit growth in Europe. The relatively higher market growth rate overseas is largely due to increasing the rate of diagnosis and treatment. And as a leader in MS, we believe we are well-positioned to benefit from this trend over time. 
Using the U.S. as an example, where we have the most detailed data, we estimate that approximately 3/4 of the 300,000 treated patients are stable and presumably satisfied on the current therapy. We believe Biogen is holding a clear leadership position in this stable segment of the market. 
We believe the dynamic opportunity of patients in the U.S. is comprised of approximately 15,000 newly diagnosed patients and approximately 60,000 patients changing medication each year. We believe that Biogen also holds a leadership position in new patient stuffs within this dynamic portion of the market. 
Turning to our MS portfolio. We believe that the value of our products is well-recognized in the eyes of many of our customers, as reflected in our leading global market share of approximately 38%. We believe the breadth of our portfolio is and will continue to be a source of strength in the marketplace by allowing a physician to prescribe the right drug to the right patient at the right time. 
As the most prescribed oral therapy for MS worldwide, TECFIDERA benefits from a compelling combination of efficacy, convenience and relative safety. As a result, we estimate that TECFIDERA captures roughly 25% of newly diagnosed and switching patients. 
Our market research indicates that TYSABRI is clearly viewed as differentiated in terms of efficacy and retains an important role for patients with highly active disease, capturing roughly 30% of all patients switching for efficacy reasons. Our interferon products, AVONEX and PLEGRIDY, combined, hold leading share amongst the interferon therapies. Despite facing headwinds due to the uptake of the orals, we believe these products will continue to play an important role going forward. 
We are also preparing to launch ZINBRYTA next month in the U.S. and Germany. ZINBRYTA is the first is a new class of MS therapy. We believe it will be used by patients switching for efficacy reasons, benefiting from once-monthly at home subcutaneous administration and a differentiated mechanism of action. 
Going forward, we will concentrate our work in the commercial across 4 key priorities, namely: portfolio strategy, commercial excellence, medical leadership, trust and value. With portfolio strategy, we plan to further define our strategy for products, market segments and geographies. We will work to ensure that our targeted growth opportunities drives consistency across our resource allocation, messaging, marketing tactics and sales force execution. 
Within commercial excellence, we will work to increase our sophistication in multichannel marketing, including enhancing our digital capabilities while also strengthening our engagement with key customers at the local level. 
While clearly perceived as a leader in neurology research and clinical development, we believe we also have an opportunity to further enhance our medical leadership, these includes close collaboration with our medical field teams and partnership with scientific leaders. 
Finally, trust and value. We will work towards developing innovative, beyond the peel solution for our customers to enhance our reputation and strengthen our partnership and role as a leader in MS. I think that as the leader in MS, we have this responsibility. Today, we already have a well-defined plan outlining next steps and target dates, which we have started to implement across the organization. We are initiating this with the aim to accelerate our business to be more focused, to make conscious choices and to be diligent in resource allocation. We believe that this work will be beneficial for our company and our shareholders. For competitive reasons, I am not prepared to go more into the details of these 4 initiatives, but I look forward to updating you on our progress at future meetings. 
Turning to the results for the quarter. Total MS revenues were $2.2 billion, an increase of 9% versus Q2 of last year. We believe our global market share continue to grow. Starting with TECFIDERA, in the U.S., we saw a modest increase in demand compared to the first quarter, largely due to a normalization of the seasonality typically seen early in the year. All of our metric lead us to expect a continued stable trend for TECFIDERA going forward. 
Outside the U.S., we continue to see increased adoption in the U.K., Italy, Spain. In fact, the number of TECFIDERA patients in Europe has increased approximately 40% of the last year. PLEGRIDY is now available in roughly 20 markets in Europe, and when launched, we believe it is helping to slow the rate of decline of our interferons. 
TYSABRI continued to outpatient this quarter. We recognize the potential for increased competition from other high-efficacy therapies, but we believe TYSABRI's 10 years of post-marketing experience and well understood safety profile position it very well. In collaboration with AbbVie, we are actively repairing to launch ZINBRYTA starting next month. We are particularly encouraged by the broad indication and data reinforcing, the product safety, included in the EU label. We are also making progress in our biosimilar business this quarter. We are seeing strong initial update for BENEPALI, the first biosimilar approved in the EU referencing Enbrel, and we expect to launch FLIXABI, our biosimilar referencing Remicade, in the coming weeks. While we only expect a modest contribution from biosimilars in 2016, we do believe this is an active opportunity in the longer term. So the team delivered a very solid quarter. I look forward to taking Biogen into what I believe is an exciting future. 
With that, I turn the call over to Paul."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Michel. In the second quarter, our GAAP diluted earnings per share were $4.79, a 22% increase year-over-year, while our none-GAAP diluted earnings per share were $5.21, an increase of 23%. Total revenue for Q2 grew 12% year-over-year to approximat",1154,"Thanks, Michel. In the second quarter, our GAAP diluted earnings per share were $4.79, a 22% increase year-over-year, while our none-GAAP diluted earnings per share were $5.21, an increase of 23%. Total revenue for Q2 grew 12% year-over-year to approximately to $2.9 billion. It's important to note we had $173 million in foreign exchange hedge gains in the full year of 2015, which impact our year-over-year revenue comparisons this year. 
In Q2, versus prior year, revenues were unfavorably impacted by $45 million from hedging, combined with the $1 million benefit from foreign exchange rates, overall revenue was weakened by approximately $44 million year-over-year. I'll highlight the impact of foreign exchange in hedging on each of our major MS therapies. 
Global second quarter TECFIDERA revenue was $987 million, an increase of 12% versus the same quarter last year. This included revenues at $780 million in the U.S., and $206 million outside the U.S. In the U.S., TECFIDERA modestly benefited from an inventory rebalancing in the whole seller China versus prior quarter. Outside the U.S., foreign exchange and hedge impacts weakened TECFIDERA revenue comparison by approximately $13 million. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $728 million during the second quarter, an increase of 6% versus the same quarter last year. This included $519 million in the U.S. and $209 million in sales outside the U.S. In the U.S., AVONEX also modestly benefited from an inventory rebalancing in the wholesaler channel versus prior quarter. Outside the U.S., foreign exchange in the hedge impacts weakened interpret revenue comparison by approximately $17 million. TYSABRI world-wide revenues were $497 million this quarter, an increase of 7% versus the same quarter last year. This included $305 million in the U.S. and $192 million outside the U.S. 
Foreign exchange and the hedge impacts weakened TYSABRI revenue comparison by approximately $13 million. 
Turning to our hemophilia business, which generated $205 million this quarter. ELOCTATE revenue for the quarter was $125 million and ALPROLIX revenue in Q2 was $80 million. We can continue to work towards spinning off our hemophilia business and related assets and plan to file the form 10 later this summer and complete the distribution in early 2017. 
Turning to our anti-CD20 revenues. We recorded $349 million for Q2, on increase from prior year quarter, driven by solid demand. Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing, were $79 million. Now turning to the expense lines on the P&L. You to gap cost of goods sold were $370 million or 13% of revenue. Non-GAAP cost of goods sold were $354 million or 12% of revenue. As a percentage of cells, COGS was impacted by increased inventory write-offs versus the lowest teen in prior quarter. In addition, based on our evaluation of our small-scale manufacturing capacity needs, we bought a GAAP only charge for accelerated depreciation related to our intent to close or they've asked our small-scale manufacturing facility in Cambridge. Q2 GAAP and non-GAAP R&D expense was $473 million or 16% of revenue, which includes $20 million related to the gene therapy collaboration with the University of Pennsylvania. Overall, R&D reflects relatively low business development expense though this remains a critical a strategic priority for us as we look to bring in high quality assets. 
Q2 GAAP SG&A was $492 million or 17% of revenue. Q2 non-GAAP SG&A expense was $489 million, also 17% of revenue. We remain committed to achieving savings by reducing lower priority priorities and services for the balance of the year. Recall over the last three years, we've gone through a number of product launches and thought it was the right decision to invest behind these products. 
Starting in 2015, we pivoted, we took a number of actions to curb operating expense growth, including restructuring and further efforts to reduce costs., which is reflected in our operating leverage for the quarter. This will also allow us to reinvest in the pipeline. Other net expense was $59 million in Q2, which includes $66 million in interest expense related toward our 2015 bond offering. 
In Q2, both of our GAAP and non-GAAP tax rates were approximately 25%. Our weighted average diluted share count was approximately $219 million for Q2. This brings us to our diluted earnings per share, which were $4.79 on a GAAP basis and $5.21 on a non-GAAP basis for the second quarter. We ended the quarter with approximately $7.3 billion in cash and marketable securities with approximately 40% of these in the United States. Today, we also announced that $5 billion share repurchase program, which we anticipate will be executed over the course of the next 3 years. 
We believe this leaves ample room for flexibility for strategic deployment. So overall, we had a strong quarter, driven by revenue growth from our MS therapies, rebounding from the seasonality seen in the first quarter, continued growth from our hemophilia business and diligent cost controls. Is now brings us to our full year 2016 guidance. We now expect revenues of approximately $11.2 billion to $11.4 billion for modest improvement from prior guidance. Our outlook questions continued stable demand, patient demand for TECFIDERA in 2016 in the United States. We believe TYSABRI will also remain on a stable trajectory for the balance of the year. Our outlook questions AVONEX and PLEGRIDY patients combined will continue to gradually decline as business move toward orals. 
For ZINBRYTA, we anticipate a modest revenue contribution in the U.S. and EU as launches are expected to be again in August. In our revenues outlook is based on a stable foreign exchange rates. So on up was expense perspective, licks expect upward pressure on cost of goods sold to do the unexpected issuance by the U.S. patents office of a patent to a third-party related to recombinant interferon beta protein. This patent issued on June 28 and expiring in June 2033 is relevant to AVONEX and PLEGRIDY. We will play pay royal in the mid-single digits during the life of this patent. For the remainder of 2016, we expect the royalty payment to be approximately $50 million. We anticipate GAAP and non-GAAP R&D expense between 17% and 18% of sales and GAAP and non-GAAP SG&A expense to be between 16% and 17% of revenue. We anticipate GAAP EPS results between 1810 and 1840 and non-GAAP EPS to be between $19.70 and $20. 
Our outlook assumes a very modest reduction in our full year weighted average diluted share count. Of note, this guidance assumes contribution from our hemophilia business through the balance of the year, as we expect the spinoff to complete in early 2017. 
Additionally, this guidance does not include any impact from potential acquisitions or large late stage business development transactions as both are hard to predict. Overall, this increase in guidance reflects this, solid revenues seen this quarter, combined with the continued operating expense control. 
I'll turn the call over to George for his closing comments."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you Paul. Financially, I'm pleased with where we are so for this year. Our results year-to-date have been better than expected. We've raised guidance, and we have a new share repurchase program authorized by the board. We've made good progress",412,"Okay. Thank you Paul. Financially, I'm pleased with where we are so for this year. Our results year-to-date have been better than expected. We've raised guidance, and we have a new share repurchase program authorized by the board. We've made good progress towards the 3 focus areas I discussed after the fourth quarter, careful management of expenses, maximizing revenues and rapidly advancing the pipeline. As I look forward and think about the future growth of Biogen, I want to stress how those key focus areas will evolve. The team expects to continue managing expenses but as you know, we can save our way to growth. Maximizing revenues and rapidly advancing the pipeline will become front and center. Especially with Michel and Mike now in their respective roles. Michel Sparky priorities portfolio strategy, commercial excellence, medical leadership and trust and value will be the pillars we used to maximize revenues. And under Matt's leadership the momentum to reshape the pipeline, rationalize existing programs and aggressively pursue promising assets of both internally and externally. We believe this focus will help advance more assets for the pipeline and ideally deliver more therapies to patients. At the same time, as we're bringing focus and investment to our core areas of expertise in neurology, we'll continue to be opportunistic when we see internal and external opportunities to enhance shareholder value. As a result, we progress some of the most promising earlier stage assets that we have in our pipeline even outside of neurology. We have invested in our biosimilar joint venture to leverage our competitive strengths in manufacturing and commercialization. 
We've chosen to spinoff our growing hemophilia business because we believe it's the right decision to ensure fit and glucose. And as we've announced today, we'll buy back shares when appropriate. So we've delivered strong financial results this quarter, while making progress advancing our pipeline and our commercial business. We have a great leadership team and a passionate group of employees who come to work every day to make a positive impact on patients' lives. 
It's been an honor and a privilege to serve this organization as the CEO for the last six years and I remain committed to leading the company until my successor is identified. 
I want to take this opportunity to thank all of our employees for their hard work and dedication. And I want to thank you all for joining us this morning and, operator, we'll now open up the call for questions."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Mark Schoenebaum from Evercore ISI.",15,"[Operator Instructions] Your first question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Just one, George, I want to say the stock only quintupled under your leadership, so I was wondering if you could -- yes, I think  you should be accountable for that. So I was wondering if you could address that. Congratulations, you will be missed. Thanks",79,"Just one, George, I want to say the stock only quintupled under your leadership, so I was wondering if you could -- yes, I think  you should be accountable for that. So I was wondering if you could address that. Congratulations, you will be missed. Thanks for the honesty, transparency that you brought to Biogen over the years. And I'd like to know who your least favorite sell-side analyst is, please? Or just assure me that it's not me."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Definitely not you.",3,"Definitely not you."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Okay. Got it.",3,"Okay. Got it."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Especially after that last comment.",5,"Especially after that last comment."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Okay. Very good. And Paul, [indiscernible] management.",7,"Okay. Very good. And Paul, [indiscernible] management."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","You've moved up from the bottom, Mark.",8,"You've moved up from the bottom, Mark."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My question is this has been asked before, but I just want engage you guys in the a little bit of discussion. Why not release the efficacy data from the titration cohort of the amab trial given that -- I know it's small numbers, but the numbers aren't tha",97,"My question is this has been asked before, but I just want engage you guys in the a little bit of discussion. Why not release the efficacy data from the titration cohort of the amab trial given that -- I know it's small numbers, but the numbers aren't that much smaller than the individual dose arms we've already seen. And the follow-up is just can you update us with any specifics on enrollment. Is enrollment tracking within your expectations? And can you just remind us at this point when you expect data readouts and is there interims?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","This is Al. So yes, I mean, it makes sense that the number of patients is roughly the same. Our plan is to introduce the safety data, the tolerability data from the titration. But and efficacy is in exploratory endpoint. I'm sure at some scientific meetin",91,"This is Al. So yes, I mean, it makes sense that the number of patients is roughly the same. Our plan is to introduce the safety data, the tolerability data from the titration. But and efficacy is in exploratory endpoint. I'm sure at some scientific meeting, we'll be able to disclose that for completeness sake. And in terms of enrollment, we are not really commenting on it except to say that we're pleased and that things are on track, and we hope to update you more on that in the future."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My congrats to George as well then I don't know your accomplishments and best of luck in the future. I guess the question on the business development front. As you talk about aggressively reshaping the pipeline and pursuing promising assets. I'm curious y",93,"My congrats to George as well then I don't know your accomplishments and best of luck in the future. I guess the question on the business development front. As you talk about aggressively reshaping the pipeline and pursuing promising assets. I'm curious your latest thinking in terms stage development, size of potential deal, the types of assets therapeutically that you might focus on. How are you thinking these days about balancing maintenance of focus of neurology versus further diversifying the business and how does the CEO transition potentially affect all these goals?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Well first, let me take that last point first. I don't think the CEO transition affects these goals at all. The company is committed to bolstering the pipeline, and we're working aggressively to do that. And actually, we would look at deals at all st",202,"Yes. Well first, let me take that last point first. I don't think the CEO transition affects these goals at all. The company is committed to bolstering the pipeline, and we're working aggressively to do that. And actually, we would look at deals at all stages of development, from preclinical through Phase III, and we are currently doing that. We're in a number of discussions now, and we hope to bring some of those to conclusion. We are focused, largely, on neurology. That's where we have our core expertise, and I think we believe that you can make more sophisticated decisions about things in areas you understand really in detail. So mainly we're looking in neurology with Mike's arrival. We have a new person here who's got his own set of expertise, his own views on things. And I would say we're not, we wouldn't rule out things outside of neurology. But the bar gets higher as they get further from our center of excellence. As Mike put it yesterday, we want to have kind of laser vision, but we don't want to have tunnel vision, and we want to be open to things that are interesting and can provide shareholder value."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink Partners."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","George, we're not sure what's so special about California, but all the very best of luck with you in the next chapter, and thanks again for all of the information you've shared with us and for the success you've had at Biogen.",42,"George, we're not sure what's so special about California, but all the very best of luck with you in the next chapter, and thanks again for all of the information you've shared with us and for the success you've had at Biogen."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, Geoff. I would say if you're not sure what's special about it, you haven't been there.",18,"Thank you, Geoff. I would say if you're not sure what's special about it, you haven't been there."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","So one question, a couple of questions for Michel, actually. Michel, could you give us a sense of what your contributions from price and volume were on the MS franchise during the quarter on the U.S. side? And then what your price contribution price effec",110,"So one question, a couple of questions for Michel, actually. Michel, could you give us a sense of what your contributions from price and volume were on the MS franchise during the quarter on the U.S. side? And then what your price contribution price effect was on ex U.S. side. And then could you secondly add, as you look at the MS franchise, presumably, you will have no role in ocrelizumab commercialization, but nevertheless, your partner, could you give us your view of how you see that playing out in terms of the effect that drug might have been in the MS market and/on the outlook for Biogen's own products?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks for the question. And let me start with ocre and probably comment on the other part of the question. First, I would like to say that we are very pleased, and we upload any new innovation in MS for which we have contributed, we contribute and will c",239,"Thanks for the question. And let me start with ocre and probably comment on the other part of the question. First, I would like to say that we are very pleased, and we upload any new innovation in MS for which we have contributed, we contribute and will continue to invest in our [indiscernible]. So this is a great news for patients in need of gaps in therapy and I think this is a great news and results on PPMS is even more encouraging. So we are very happy about that. Having said that, we have a strong presence in the high efficacy segment of the market. And this is basically a market trend where we can see that, basically, provide us treat earlier and physician treating earlier more aggressively and TYSABRI's is holding a very strong position in the high efficacy segment. And ZINBRYTA will come and will complement this presence there. So I anticipate that ocre will be playing into the segment also, and we will see how it plays, but for the time being there is no risk-benefit assessment so we have to be very cautious before talking so I'll wait to see where regulator stands. But I will say that the first approach from again a humble but leadership position is to care for our assets and elevate the capability of the organization and the for capabilities that we are launching will just do that."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Geoff, this is Paul. On the price versus volume question, I think the way you framed it is probably pretty accurate is that it's a tale of 2 cities. In the United States, the lion's share from a change year-over-year basis is price, and it's pretty stable",164,"Geoff, this is Paul. On the price versus volume question, I think the way you framed it is probably pretty accurate is that it's a tale of 2 cities. In the United States, the lion's share from a change year-over-year basis is price, and it's pretty stable unit trend on TECFIDERA, pretty stable unit trends on TYSABRI and modest gradual decline on the interferon franchise. ex United States, we are not seeing any pricing on a year-over-year basis and all of the gains are attributable to volume and unit expansion. TYSABRI is holding well outside the United States as well as the interferon business, and we continue to, in a small way, penetrate some markets and get some accretive benefits of things even outside of Europe. And TECFIDERA continues to expand on a year-over-year basis and can't be gaining market share particularly as we are moving into a relatively early launch timing in southern European countries and having very good success in the U.K."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Congrats, George, to see you leave on a high note. Best of luck with the next opportunity. Maybe just a quick one for Paul on these new interferon patents that you are paying a royalty on are expected to pay a royalty on. Can you clarify a little bit whos",77,"Congrats, George, to see you leave on a high note. Best of luck with the next opportunity. Maybe just a quick one for Paul on these new interferon patents that you are paying a royalty on are expected to pay a royalty on. Can you clarify a little bit whose patent that is? And what happened to your own interferon patent that you thought was at one point going to be able to extract royalties from others?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes, great question, Eric every, thanks. It was as I noted unexpected that it is not actually related despite it is on the recombinant interferon beta protein, it's actually not the same. It has to do with JF CR. In the Q this afternoon, we'll actually ha",166,"Yes, great question, Eric every, thanks. It was as I noted unexpected that it is not actually related despite it is on the recombinant interferon beta protein, it's actually not the same. It has to do with JF CR. In the Q this afternoon, we'll actually have the patent number for you. I actually just actually don't have it handy for myself. And it's a mid-single-digit royalty. We aren't disclosing the name of the third-party, but so just a third-party at this point in time. And we expect it will be $50 million impact all in the second half effectively, and will be a bigger impact as we go into 2017 on a full year basis. The 755 patent, we continue to feel like that, despite it was back to 2009 when it was issued, but we still feel and we're still in litigation with other parties on that. But there's a chance that we're coming towards the end of that process for something more favorable."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","George, I also want to offer my congrats. You will be missed. So I had a question for Michel, maybe a bigger picture commercial question. now that you've had a chance to look at the products, the assets at Biogen and a the fresh look at the MS market, may",109,"George, I also want to offer my congrats. You will be missed. So I had a question for Michel, maybe a bigger picture commercial question. now that you've had a chance to look at the products, the assets at Biogen and a the fresh look at the MS market, maybe just give us some perspective on what you see is the bigger growth opportunities ahead on a volume basis. Is it geographic? Is it West of World opportunities? Is it new product launches? And then maybe for Paul, just wanted to check and see what you guys learned from the DTC campaign for tech and the sustainability of that?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you for the great question. In my 25 years experience around the world, I have never seen such a situation whereby we have 5 or 6 assets in the same therapy area. 20 years of those unique experience in MS, a solid portfolio today, a solid pipeline,",265,"Thank you for the great question. In my 25 years experience around the world, I have never seen such a situation whereby we have 5 or 6 assets in the same therapy area. 20 years of those unique experience in MS, a solid portfolio today, a solid pipeline, a remarkable group of talents with clinical experience and scientific experience within the company. So it's a leadership position on interferons, a leadership position on orals, a leadership position on high efficacy products. So this is a remarkable situation. And on top of that, we are launching ZINBRYTA. So the dynamic is very good. Having said that, when you peel the onion and you get to discover the opportunity and the operations, you'll find ways to do better. And this is why, together with the team, we have prioritized 4 key areas, portfolio management, 5, 6 assets in the same therapy area. It's a challenge on how to manage that well. Commercial excellence, medical leadership, value. And I believe that with those, we'll be able to make further difference. Geographically, also we can see that some parts are better managed than others. And I have already started to make some decisions. We don't wait, and you can expect that more will come. So this is what I would like to say -- and the portfolio management doesn't mean that all the products will be resourced and promoted equally. It's all about the growth opportunity that will be outlined and this is where there will be a clear I would say alignment between those resource allocation and execution."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Geoff, the beginning part of your question is, yes, just to confirm, we have sunsetted the television campaign as it relates to TECFIDERA. I think our -- I mean look, it was an innovative -- I'd applaud our organization for thinking about it and giving it",134,"Geoff, the beginning part of your question is, yes, just to confirm, we have sunsetted the television campaign as it relates to TECFIDERA. I think our -- I mean look, it was an innovative -- I'd applaud our organization for thinking about it and giving it a try. I think that our judgment at this point is that it didn't have a discernible movement on scripts and potentially came with this from anecdotal with some drawbacks as well. Michel actually confirmed his  from his perspective that quite possibly as much other levers that are still like DTC related and multichannel related that he can reallocate resources toward. So I think that's probably our learnings in a nutshell. We didn't run the test case. So we'll see what -- but I think that's our learnings."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, Paul. If I -- this is Michel. If I can add. I mean, at the outset, the main objective was to increase awareness and I think that this was achieved. But I didn't see -- I didn't see any inflection on any trends. We need to settle back to the ali",86,"Thank you, Paul. If I -- this is Michel. If I can add. I mean, at the outset, the main objective was to increase awareness and I think that this was achieved. But I didn't see -- I didn't see any inflection on any trends. We need to settle back to the alignment of the organization on four priorities for which we need to have some very strict resource allocation decisions. And I don't think that broadcast TV will be there in the foreseeable future year."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","This is Whitney [ph] on for Cory. I'll add my congrats to George as well. I guess, just to circle back on Alzheimer's. I guess, where are you with sort of combinations? And I guess, what's the desire or urgency to get some of the combos into the clinic be",63,"This is Whitney [ph] on for Cory. I'll add my congrats to George as well. I guess, just to circle back on Alzheimer's. I guess, where are you with sort of combinations? And I guess, what's the desire or urgency to get some of the combos into the clinic before you maybe have a Phase III data on any of the individual components?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","This is Al, Whitney. And we'd like the idea of combination to think one day we will be using combination therapies for Alzheimer's disease. One of the reasons why we brought in BACE inhibitor into our pipeline with our collaboration with a side their reas",211,"This is Al, Whitney. And we'd like the idea of combination to think one day we will be using combination therapies for Alzheimer's disease. One of the reasons why we brought in BACE inhibitor into our pipeline with our collaboration with a side their reason we have top programs internally and that we're in search of even other things potentially to add to the mix is based on and part on that believe that combination could be helpful, and you can think of it in 2 ways. One is to combine 2 drugs, each of which are active, to increase the efficacy overall or to reduce the dose of 2 active therapies so that you get better safety or tolerability for the same efficacy. And also there may be sequential treatments where you start early, perhaps even before symptoms with one type of medicine and then treat with something else when you have a high burden and then something else still when [indiscernible] starts to progress. When you start to think about combination therapy, though, it's often difficult to do the right studies without some evidence of efficacy of each drug as monotherapy. And then you can start to think about the right dosing regimen. And so I hope that's helpful."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My appreciation to George as well. Happy to see you joining me on the West Coast. I'm lonely out here so happy to have you back here. I question for Al. There will be LINGO data presented at ECTRIMS, can you maybe just revisit this briefly and give us som",130,"My appreciation to George as well. Happy to see you joining me on the West Coast. I'm lonely out here so happy to have you back here. I question for Al. There will be LINGO data presented at ECTRIMS, can you maybe just revisit this briefly and give us some color about what is going on here and in terms of what we saw because obviously that was a surprise, and I guess is there anything specific that we should pay attention to at ECTRIMS that you've done work on that would peak our interest back here? Or is there some issues here with the remyelination pathway and that would bring our questions into your oral? So how does this change our thinking about remyelination and what we saw here?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Michael, thanks for the question. So first, I want to say this is a really large and rich data set, really the first of its kind, not only in MS but to my knowledge, in neurology where we're in the early stages of figuring out how to repair the brain",348,"Yes, Michael, thanks for the question. So first, I want to say this is a really large and rich data set, really the first of its kind, not only in MS but to my knowledge, in neurology where we're in the early stages of figuring out how to repair the brain and how to measure measurements of outcome measures of repair. The things we are focusing on right now when we look at this rich data set are what are the right cohort of patients to treat? In this trial, we've looked at relapsing MS, patients all the way to secondary progressive. So it's a wide range of patients. What's the optimal cohort? What's the right dose? We studied 4 different doses, and we saw a complex dose response curve. What we actually saw was sort of a bell-shaped curve where we lost efficacy at the highest dose and then the middle doses, we think we see a signal of efficacy. And so we'll share some of that at ECTRIMS. What's the right concomitant medicine to use? We envision that these repair therapies will be added to immunomodulators and so we'll be looking at that. And in particular, whether ongoing inflammation in the brain impedes repair. And finally, how do we actually measure the effects of repair if it occurs particularly on clinical outcome measures. So some of these questions will be answered by doing further analyses, which we're in the middle of doing right now intensively. And we'll share whatever we find out at ECTRIMS. And some may need another study. And so what we're honing in on is what's the next step, what's the next study? And obviously, this will be a judicious investment. If we can go to Phase III, we will try. I don't know until I see that the specific design. It could be a Phase II, it could be a Phase III, it could be a Phase II/III. And at that part, we probably won't be able to share at ECTRIMS, but sometime soon, we hope to be able to share that."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","I guess thinking about George, I remember meeting you when you first became the CEO and I remember you talking about reasons for joining the company [indiscernible] Biogen. And so now I'm the company's success and feel the respect what do you think Biogen",60,"I guess thinking about George, I remember meeting you when you first became the CEO and I remember you talking about reasons for joining the company [indiscernible] Biogen. And so now I'm the company's success and feel the respect what do you think Biogen really needs from a new CEO at this point in time versus when you came in?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Well, look, the company now is a very different company from what it was a few years ago. We have a full and excellent management team. We have a pipeline that is, I think, quite exciting but needs to be to grow. So I think the company needs a good manage",192,"Well, look, the company now is a very different company from what it was a few years ago. We have a full and excellent management team. We have a pipeline that is, I think, quite exciting but needs to be to grow. So I think the company needs a good management. I think the strategy of the company is solid. And what we need is good leadership and somebody who can work with people who are here, work with Michel, maximize the commercial potential, work with Mike, maximize the potential of our pipeline, grow the pipeline and can work with the rest of the organization to ensure that we go forward in a way that is responsible, where we minimize expenses but that where we invest aggressively in those areas that really have the potential to add value. So being CEO is complicated, and I think those are the priorities I would set, of course, the search will be conducted by the board. But I don't think they would be do it too differently. I think there would be a continued focus on innovation, and I am confident we'll get someone excellent."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ronny Gal [ph] from Bernstein.",13,"Your next question comes from the line of Ronny Gal [ph] from Bernstein."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Two questions. First, biosimilar is you had a pretty good first quarter. Can you describe a little bit to us where you've launched already, where you're still expecting to launch? And now that you're a little bit of whether you fit in that market, could y",168,"Two questions. First, biosimilar is you had a pretty good first quarter. Can you describe a little bit to us where you've launched already, where you're still expecting to launch? And now that you're a little bit of whether you fit in that market, could you give us a feel for what you're thinking about kind of 3 to 5 year trajectory for this franchise and for biosimilar, anti-TNF [indiscernible] should this be 30% of the market, 50%, 70% of the market overall? And then separately, you kind of mentioned the impact of high deductible co-pays in the U.S. sales in the first quarter. Has there been still some impact of those in the second quarter that is as we look from the outset of revenue, should we see another step up in revenue being in the third quarter or is it fully incorporated in the first quarter and kind of the run rate for pricing in the second quarter is roughly what we should see going forward?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","So this is Michel. Thanks for the great question. So as you have seen, 2 great companies came together with complementary capabilities in order to launch  anti TNF to get started with and then we see the opportunity. So as far as Biogen is involved togeth",224,"So this is Michel. Thanks for the great question. So as you have seen, 2 great companies came together with complementary capabilities in order to launch  anti TNF to get started with and then we see the opportunity. So as far as Biogen is involved together with partners, we have launched the products, the 3 anti-TNFs that we have agreement on, 2 out of the 3 are approved and are underway to be launched. The preliminary results are very encouraging. As you can imagine, there is a tremendous level of variation variability between countries in terms of tendering, in terms of [indiscernible] of competition, in terms of provider decision-making. And it's difficult to take an overall I would say recipe on how to [indiscernible]. What I can say is the 3 anti-TNFs that we'll have the opportunity to launch will be addressing a current market that is higher than $9 billion in Europe. So this is significant and with Biogen quality. So we have put together a stand-alone BU that is flexible, agile and once the product and we'll learn country after country. Today, mostly in the Nordics and Scandinavia, where we have had very, very good results. But, as I said earlier, it's still early to comment much on the results that are negligible for 2016, but will be more important moving forward."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Ronny, this is Paul. Thanks for the second part of that question. It's a good catch. I think that the answer is that we absolutely so insurance dynamics mostly impact AVONEX in the first quarter, and we're pleased to see that that choppiness settled out,",64,"Ronny, this is Paul. Thanks for the second part of that question. It's a good catch. I think that the answer is that we absolutely so insurance dynamics mostly impact AVONEX in the first quarter, and we're pleased to see that that choppiness settled out, benefited the second quarter results. Don't expect it to be meaningful difference for the balance of the year now."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","And your final question comes from the line of Chris Raymond from Raymond James.",14,"And your final question comes from the line of Chris Raymond from Raymond James."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Congrats, George, from us as well. Just a question, I guess, on TECFIDERA. In the context of, I think, you highlighted in Q1 a $20 million inventory drawdown. Could you maybe quantify  I think, you highlighted generally there was an inventory effect in Q2",152,"Congrats, George, from us as well. Just a question, I guess, on TECFIDERA. In the context of, I think, you highlighted in Q1 a $20 million inventory drawdown. Could you maybe quantify  I think, you highlighted generally there was an inventory effect in Q2. Can you quantify what that was? And then also if I can on TECFIDERA continuing, I hear what you're saying on the television ads, but one of the things that have sort of struck us the most with our checks is TECFIDERA for some time has been sort of far and away the most requested disease-modifying therapy among patients. I guess, I'm wondering what additional levers can you pull to sort of increase that? Or is there some other aspect like maybe working at better efficiency programs to get that request converted into a script? Is there some other aspect besides just giving patients to request the drug?"
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes, thanks Chris. This is Paul. I'll take the first part. It's quite simply I think we're at a pretty normal inventory levels on TECFIDERA, so it's really just a sequential quarter rebalancing off of the seasonal load that we generally see in Q1.",44,"Yes, thanks Chris. This is Paul. I'll take the first part. It's quite simply I think we're at a pretty normal inventory levels on TECFIDERA, so it's really just a sequential quarter rebalancing off of the seasonal load that we generally see in Q1."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","So on the levers and the performance. 12% growth q-over-q is not bad. The share continues to grow to 15% globally is also pretty good, mostly driven by the newly launched markets in Europe. 40% patient share -- patients growth percentage is also very enco",186,"So on the levers and the performance. 12% growth q-over-q is not bad. The share continues to grow to 15% globally is also pretty good, mostly driven by the newly launched markets in Europe. 40% patient share -- patients growth percentage is also very encouraging. I have for my field visits and from talking to leaders identified one major issue, which is the discontinuation due to GI safety. Those patients, during the first phase on their product, are suffering for some of them abdominal pain, diarrhea, discomfort that is leading, in some cases, with very high level of variability, to discontinue on the product. And this impacts not only the outflow but eventually the inflow. Variability is tremendous. I was in the field lately on the Eastern Coast in the U.S., 1.5% of the patient discontinued at 6 months, in some others, it was 30%. So with Mike Ehlers, we are fully aligned in order to work together with the community, with the physicians, with the peer-to-peer in order to best assess, best educate and bring down an average which is 20% today to lower levels."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. With that, I thank you all for joining us this morning. Thanks for the questions. And I will sign off now. Thank you.",24,"Okay. With that, I thank you all for joining us this morning. Thanks for the questions. And I will sign off now. Thank you."
29726,366896620,1009229,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the call o",57,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the call over to Mr. Matt Calistri, Senior Director of Investor Relations. Please go ahead."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Dan. Thank you, everyone, and welcome to Biogen Second Quarter 2016 Earnings Conference Call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a r",218,"Thanks, Dan. Thank you, everyone, and welcome to Biogen Second Quarter 2016 Earnings Conference Call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 include the reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We've also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Michael Ehlers, EVP of Research and Development; our Chief Commercial Officer, Michel Vounatsos; and our CFO, Paul Clancy. We'll also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock. 
Now I'll turn the call over to George."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Matt, and good morning, everyone. Thanks for joining us. I'd like to begin with a personal statement. I'll be stepping down as CEO of a Biogen sometime within the next few months. The board and I recognize that this is an excellent time",1077,"Okay. Thank you, Matt, and good morning, everyone. Thanks for joining us. 
I'd like to begin with a personal statement. I'll be stepping down as CEO of a Biogen sometime within the next few months. The board and I recognize that this is an excellent time for a transition. The company is doing well now. The management team is complete and extremely capable. The commercial and R&D activities are going well, and we're on our way to adding to the pipeline through internal and external opportunities. So good time for a new CEO to take the helm and see Biogen through to what I believe is a very exciting future. This also is an opportune time for me to return to the West Coast, take on one more set of activities and spend more time with my family. 
I've been at Biogen for 6 years. I'm proud of the company and what we've been able to accomplish in that time. We've introduced 6 new products on to the market and increased our revenues, earnings and stock price all by severalfold, and I believe that we're well positioned to keep delivering on our potential to bring even more therapies to patients and returns to investors. Our R&D and commercial organizations are now world class, joining our already industry-leading biologics manufacturing capabilities. All aspects of the company are operating at a high level. We brought several potentially game-changing compounds into later-stage development and are in the process of adding further to that pipeline. The addition of Michel Vounatsos, Mike Ehlers and Paul McKenzie, the company has a full and vibrant leadership team that's capable of moving the company thoughtfully forward. I truly believe that the company has a bright future, and it's with mixed emotions that I leave at this time and not see that future come fully to fruition. 
We're making the announcement now in order to provide an orderly transition for the company and to allow the board to conduct an open and effective search. I'll work with the board to find a great successor who can continue to build on what we have accomplished. We expect to consider both internal and external candidates, and I'm confident that we'll identify an outstanding new leader. I expect to remain as CEO until a successor is identified and can begin. In the interim, I continue to work with the board and management team to accomplish Biogen's goals for 2016. I believe that we're in a good trajectory, that we have a great new additions to the management team and I look forward to a successful second half of the year. 
So enough about me. Let's turn to the business. Biogen had a solid second quarter, delivering strong financial performance and important advances in our pipeline. For the second quarter of 2016, Biogen generated $2.9 billion in total revenues, a 12% increase from the same period a year ago. Our GAAP earnings were $4.79 per share, a 22% increase year-over-year, and non-GAAP EPS was $5.21, a 23% increase year-over-year. We continue to grow our leading MS franchise and our hemophilia business, and our efforts to maximize revenues while thoughtfully managing expenses helped to drive attractive earnings growth. As a result, we've raised our financial guidance for the full year. And today, we announced that our Board of Directors has authorized a program to repurchase up to $5 billion of our common stock. 
Looking back, we had quite an eventful second quarter. To begin, we welcome 3 new members of our management team, a new Head of Commercial, Michel Vounatsos, joined us in April. He's completed a thorough assessment and has identified 4 key priorities for driving our MS business forward, which he'll share with you later in this call. Our new Head of R&D, Mike Ehlers, joined us at the end of May. Mike is a brilliant neuroscientist and an established R&D leader who has excelled in both academic and corporate settings. Mike has demonstrated the ability to translate science into the development of important new medicines, and he's already bringing terrific leadership to the organization. And finally, with John Cox preparing to lead the new hemophilia company, we promoted Paul McKenzie to oversee our Pharmaceutical Operations and Technology group. These 3 new leaders bring a wealth of experience and expertise, and we believe that they're poised to take Biogen into its next phase of growth. I'm proud to have them in our organization. 
Last quarter brought a number of positive developments for both our commercial products and our pipeline. We announced our intent to spin off our hemophilia business. That business continues to perform well with combined second quarter revenues of over $200 million for ELOCTATE and ALPROLIX. ALPROLIX also was approved by the European Commission for the treatment of hemophilia B and would be commercialized in the EU by our collaboration partner, Sobi. We had a positive label update for TYSABRI in Europe, including an extended indication. We received regulatory approval for ZINBRYTA in both the U.S. and the EU for the treatment of relapsing MS. FLIXABI  an infliximab biosimilar referencing Remicade, received approval in Europe. This will be the second anti-TNF biosimilar that we'll manufacture and commercialize in the EU. And SB5, an adalimumab biosimilar candidate referencing Humira, has been accepted for review by the European Medicines Agency. Aducanumab was accepted into the European Medicines Agency's PRIority MEdicines program, known as PRIME. It was one of only 4 applications accepted out of 18 submitted and the only Alzheimer's disease therapy in development that was accepted. On the early-stage research front, we entered into a broad collaboration and alliance with the University of Pennsylvania and 2 world-renowned gene therapy experts, Drs. James Wilson and Jean Bennett. 
This quarter, we also reported the top line results of the SYNERGY trial for opicinumab. As you are all aware, opicinumab missed both the primary and secondary endpoints. It was -- certainly was disappointing. However, the rigorous design and planning of SYNERGY has yielded an abundance of data that will help us make a well-informed decision about our path forward with opicinumab and our work in remyelination generally. These results are indicative of the significant challenge of targeting neurorepair. During the upcoming ECTRIMS conference in September, we expect to present more detailed efficacy, biomarker and safety data. 
I'll now turn the call over to Mike, and we're eager for you to get to know Mike and experience his passion for our business."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, George, and good morning, everyone. By way of introduction, I spent a number of years in academia as professor in Howard Hughes Medical Institute investigator at Duke University where my research was focused on cell biological and circuit mecha",755,"Thank you, George, and good morning, everyone. By way of introduction, I spent a number of years in academia as professor in Howard Hughes Medical Institute investigator at Duke University where my research was focused on cell biological and circuit mechanisms of brain function in a normal, developing and diseased nervous system. My career took an exciting turn 6 years ago when I joined Pfizer. I served as the Chief Scientific Officer for the company's Neuroscience and Pain Research Unit and, ultimately, became group leader for BioTherapeutics R&D with responsibility over rare disease, the centers for therapeutic innovation and all large biomolecule sciences. 
I'm just now finishing my second month at Biogen, so there is still a lot I'm getting up to speed on. But I can tell you from the outset that I am working to reshape and progress our pipeline while aggressively pursuing promising assets, both internally and externally. I plan to update you on progress on these fronts in the future. In the meantime, I will comment on the important clinical study readouts this quarter and note some good progress made in advancing our clinical programs. 
Starting with opicinumab, or anti-LINGO, as George discussed. The top line results from the Phase II SYNERGY study were reported in which opicinumab unfortunately missed both of the primary and secondary endpoints. However, evidence of a clinical effect with a complex, unexpected dose response was observed. The SYNERGY top line efficacy safety and biomarker results will be presented at ECTRIMS in September. 
Continuing in MS. EC approval was received for an extended indication for TYSABRI in highly active, relapsing-remitting MS patients with inadequate response to prior MS therapy. TYSABRI was previously only indicated for patients who had failed to respond to beta interferon or a glatiramer acetate. This label extension follows recent EC approval for a new patient management plan, including an updated risk algorithm based on JC virus antibody index values. These changes will allow physicians to have more individualized benefit risk discussions with their patients. 
Turning to other promising late-stage assets. Our collaboration partner, Ionis, continues to execute the Phase III studies of nusinersen for infants and children with spinal muscular atrophy, both of which are now fully enrolled. In Alzheimer's disease, it was recently announced that aducanumab was one of only 4 applicants accepted into the European Medicine Agency's PRIority MEdicines program, or PRIME. PRIME aims to bring treatments to patients faster by enhancing the EMA's support for the development of investigational medicines for diseases without available treatment or in need of better treatment options. We continue to work diligently to enroll our aducanumab Phase III trials. Looking ahead, safety data from the titration arm of the Phase 1b study is anticipated by the end of this year. We are working toward the start of Phase III trials for amiselimod or MT-1303 in inflammatory bowel disease and BIIB074, formerly known as raxatrigine, in trigeminal neuralgia. An initiation of the Phase II trial with BIIB074 in patients with neuropathic pain from lumbosacral radiculopathy is planned for later this year. 
In further activities, natalizumab's clinical profile and treatment window supports its continued investigation as a potential novel approach for treating acute ischemic stroke, and the first patient was recently dosed in a second Phase II study in stroke called ACTION 2. Encouraging data was recently generated on earlier-stage assets, BIIB059 or anti-BDCA2 for systemic lupus erythematosus and BG11 (sic) [ BG00011 ] or STX-100 for idiopathic pulmonary fibrosis. Anti-BDCA2 data in healthy volunteers and a lupus cohort of 12 subjects has provided confidence to move into Phase II with trial initiation plan to begin over the summer. These data are anticipated to be presented later this year. The BG11 study is enrolling its final cohort and it is expected that data will be presented after the trial completes. 
Finally, as George mentioned, Biogen announced the broad collaboration and alliance with the University of Pennsylvania and Dr. James Wilson and Jean Bennett to advance gene therapy and gene editing technologies. The expansive research and translational development collaboration has multiple objectives and will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. 
Again, I am pleased to participate in my  first earnings call here at Biogen. I anticipate sharing more detail on the advancement of the Biogen pipeline in the coming months as the company works diligently to deliver new therapies to patients. 
With that, I will now pass the call to my good colleague, Michel Vounatsos."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Mike. I'm very pleased to be with you this morning. I share my initial thoughts on the MS market and our MS portfolio, outline my priorities going forward and then I will discuss this quarter's results for MS products. Since I arrived at Biogen",1131,"Thanks, Mike. I'm very pleased to be with you this morning. I share my initial thoughts on the MS market and our MS portfolio, outline my priorities going forward and then I will discuss this quarter's results for MS products. 
Since I arrived at Biogen 3 months ago, I have spent time in the field with our operations team, meeting with patients, the neurology community and many of the scientific leaders in multiple sclerosis. Also, I have engaged with the strong Biogen leaders across our commercial organizations. I have listened and learned a lot, and together with the team, we have prioritized immediate opportunities across 4 key areas. We believe these opportunities will benefit our MS franchise today and, at the same time, prepare the organization for potential future product launches. 
Before speaking about our therapies, I think it is important to note, MS is a growing market with approximately 850,000 treated patients worldwide out of a global prevalence estimated at 2.3 million, which includes progressive forms of MS. We estimate the number of treated patients worldwide is growing in the mid-single digits on an annual basis, driven by low single-digit growth in the U.S. and high single-digit growth in Europe. The relatively higher market growth rate overseas is largely due to increasing rate of diagnosis and treatment. And as a leader in MS, we believe we are well positioned to benefit from this trend over time. 
Using the U.S. as an example, where we have the most detailed data, we estimate that approximately 3/4 of the 300,000 treated patients are stable and presumably satisfied on the current therapy. We believe Biogen is holding a clear leadership position in this stable segment of the market. We believe the dynamic opportunity of patients in the U.S. is comprised of approximately 15,000 newly diagnosed patients and approximately 60,000 patients changing medication each year. We believe that Biogen also holds a leadership position in new patient starts within this dynamic portion of the market. 
Turning to our MS portfolio. We believe that the value of our products is well recognized in the eyes of many of our customers as reflected in our leading global market share of approximately 38%. We believe the breadth of our portfolio is and will continue to be a source of strength in the marketplace by allowing physician to prescribe the right drug to the right patient at the right time.   
As the most prescribed oral therapy for MS worldwide, TECFIDERA benefits from a compelling combination of efficacy, convenience and relative safety. As a result, we estimate that TECFIDERA captures roughly 25% of newly diagnosed and switching patients. Our market research indicates that TYSABRI is clearly viewed as differentiated in terms of efficacy and retains an important role for patients with highly active disease, capturing roughly 30% of all patients switching for efficacy reasons. Our interferon products, AVONEX and PLEGRIDY, combined, hold leading share amongst the interferon therapies. Despite facing headwinds due to the uptake of the orals, we believe these products will continue to play an important role going forward. We are also preparing to launch ZINBRYTA next month in the U.S and Germany. ZINBRYTA is the first in a new class of MS therapy. We believe it will be used by patients switching for efficacy reasons, benefiting from ""once monthly at home"" subcutaneous administration and a differentiated mechanism of action. 
Going forward, we will concentrate our work in the commercial across 4 key priorities, namely portfolio strategy, commercial excellence, medical leadership, trust and value. With portfolio strategy, we plan to further define our strategy for products, market segments and geographies. We will work to ensure that our targeted growth opportunities drive consistency across our resource allocation, messaging, marketing tactics and sales force execution. Within commercial excellence, we will work to increase our sophistication in multichannel marketing, including enhancing our digital capabilities while also strengthening our engagement with key customers at the local level. While clearly perceived as a leader in neurology research and clinical development, we believe we also have an opportunity to further enhance our medical leadership. This includes close collaboration with our medical field teams and partnership with scientific leaders. Finally, trust and value. We will work towards developing innovative beyond-the-pill solution for our customers to enhance our reputation and strengthen our partnership and role as a leader in MS. I think that as the leader in MS, we have this responsibility. 
Today, we already have a well-defined plan outlining next steps and target dates, which we have started to implement across the organization. We are initiating this with the aim to accelerate our business to be more focused, to make conscious choices and to be diligent in resource allocation. We believe that this work will be beneficial for our company and our shareholders. For competitive reasons, I am not prepared to go more into the details of these 4 initiatives, but I look forward to updating you on our progress at future meetings. 
Turning to the results for the quarter. Total MS revenues were $2.2 billion this quarter, an increase of 9% versus Q2 of last year. We believe our global market share continues to grow. 
Starting with TECFIDERA. In the U.S., we saw a modest increase in demands compared to the first quarter, largely due to  normalization of the seasonality typically seen early in the year. All of our metric lead us to expect a continued, stable trend for TECFIDERA going forward. Outside the U.S., we continue to see increased adoption in the U.K., Italy, Spain. In fact, the number of TECFIDERA patients in Europe has increased approximately 40% over the last year. 
PLEGRIDY is now available in roughly 20 markets in Europe, and where launched, we believe it is helping to slow the rate of decline of our interferons. 
TYSABRI continued to add patient this quarter. We recognize the potential for increased competition from other high-efficacy therapies, but we believe TYSABRI's 10 years of post-marketing experience and well-understood safety profile position it very well. 
In collaboration with AbbVie, we are actively preparing to launch ZINBRYTA starting next month. We are particularly encouraged by the broad indication and data, reinforcing the product safety included in the EU label. 
We are also making progress in our biosimilar business this quarter. We are seeing strong initial update for BENEPALI, the first biosimilar approved in the EU referencing Enbrel, And we expect to launch FLIXABI, our biosimilar referencing Remicade, in the coming weeks. While we only expect a modest contribution from biosimilars in 2016, we do believe this is an attractive opportunity in the longer term. 
So the team delivered a very solid quarter. I look forward to taking Biogen into what I believe is an exciting future. 
With that, I turn the call over to Paul."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Michel. In the second quarter, our GAAP diluted earnings per share were $4.79, a 22% increase year-over-year, while our none-GAAP diluted earnings per share were $5.21, an increase of 23%. Total revenue for Q2 grew 12% year-over-year to approximat",1141,"Thanks, Michel. In the second quarter, our GAAP diluted earnings per share were $4.79, a 22% increase year-over-year, while our none-GAAP diluted earnings per share were $5.21, an increase of 23%. Total revenue for Q2 grew 12% year-over-year to approximately $2.9 billion. It's important to note we had $173 million in foreign exchange hedge gains in the full year of 2015, which impact our year-over-year revenue comparisons this year. In Q2, versus prior year, revenues were unfavorably impacted by $45 million from hedging. Combined with the $1 million benefit from foreign exchange rates, overall revenue was weakened by approximately $44 million year-over-year. I'll highlight the impact of foreign exchange in hedging on each of our major MS therapies. 
Global second quarter TECFIDERA revenue was $987 million, an increase of 12% versus the same quarter last year. This included revenues at $780 million in the U.S. and $206 million outside the U.S. In the U.S., TECFIDERA modestly benefited from an inventory rebalancing in the wholesaler channel versus prior quarter. Outside the U.S., foreign exchange and hedge impact weakened TECFIDERA revenue comparison by approximately $13 million. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $728 million during the second quarter, an increase of 6% versus the same quarter last year. This included $519 million in the U.S. and $209 million in sales outside the U.S. In the U.S., AVONEX also modestly benefited from an inventory rebalancing in the wholesaler channel versus prior quarter. Outside the U.S., foreign exchange and the hedge impact weakened interferon revenue comparison by approximately $17 million. 
TYSABRI worldwide revenues were $497 million this quarter, an increase of 7% versus the same quarter last year. This included $305 million in the U.S. and $192 million outside the U.S. Foreign exchange and the hedge impact weakened TYSABRI revenue comparison by approximately $13 million. 
Turning to our hemophilia business, which generated $205 million this quarter. ELOCTATE revenue for the quarter was $125 million, and ALPROLIX revenue in Q2 was $80 million. We continue to work towards spinning off our hemophilia business and related assets and plan to file the Form 10 later this summer and complete the distribution in early 2017. 
Turning to our anti-CD20 revenues. We recorded $349 million for Q2, an increase from prior quarter, driven by solid demand. Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing, were $79 million. 
Now turning to the expense lines on the P&L. Q2 GAAP cost of goods sold were $370 million or 13% of revenue. Non-GAAP cost of goods sold were $354 million or 12% of revenue. As a percentage of sales, COGS was impacted by increased inventory write-offs versus the lows seen in prior quarter. In addition, based on our evaluation of our small-scale manufacturing capacity needs, we booked a GAAP-only charge for accelerated depreciation related to our intent to close or divest our small-scale manufacturing facility in Cambridge. 
Q2 GAAP and non-GAAP R&D expense was $473 million or 16% of revenue, which includes $20 million related to the gene therapy collaboration with the University of Pennsylvania. Overall, R&D reflects relatively low business development expense, though this remains a critical strategic priority for us as we look to bring in high-quality assets. 
Q2 GAAP SG&A was $492 million or 17% of revenue. Q2 non-GAAP SG&A expense was $489 million, also 17% of revenue. We remain committed to achieving savings by reducing lower priorities and services for the balance of the year. Recall, over the last few years, we've gone through a number of product launches and thought it was the right decision to invest behind these products. Starting in 2015, we pivoted and took a number of actions to curb operating expense growth, including a restructuring in further efforts to reduce costs, which is reflected in our operating leverage for the quarter. This will also allow us to reinvest in the pipeline. Other net expense was $59 million in Q2, which includes $66 million in interest expense related to our 2015 bond offering. 
In Q2, both our GAAP and non-GAAP tax rates were approximately 25%. Our weighted average diluted share count was approximately $219 million for Q2. This brings us to our diluted earnings per share, which were $4.79 on a GAAP basis and $5.21 on a non-GAAP basis for the second quarter. We ended the quarter with approximately $7.3 billion in cash and marketable securities with approximately 40% of this in the United States. Today, we also announced a $5 billion share repurchase program, which we anticipate will be executed over the course of the next 3 years. We believe this leaves ample room for flexibility for strategic deployment. 
So overall, we had a strong quarter, driven by revenue growth from our MS therapies rebounding from the seasonality seen in the first quarter, continued growth from our hemophilia business and diligent cost controls. 
This now brings us to our full year 2016 guidance. We now expect revenues of approximately $11.2 billion to $11.4 billion, a modest improvement from prior guidance. Our outlook assumes continued stable demand, patient demand for TECFIDERA in 2016 in the United States. We believe TYSABRI will also remain on a stable trajectory for the balance of the year. Our outlook questions AVONEX and PLEGRIDY patients, combined, will continue to gradually decline as patients move toward orals. For ZINBRYTA, we anticipate a modest revenue contribution in the U.S. and EU as launches are expected to begin in August. And our revenues outlook is based on stable foreign exchange rates. 
From an expense perspective, we anticipate upward pressure on cost of goods sold due to the unexpected issuance by the U.S. Patent Office of a patent to a third party related to recombinant interferon beta protein. This patent, issued on June 28 and expiring in June 2033, is relevant to AVONEX and PLEGRIDY. We will play -- pay royalties in the mid-single digits during the life of this patent. For the remainder of 2016, we expect the royalty payment to be approximately $50 million. We anticipate GAAP and non-GAAP R&D expense between 17% and 18% of sales and GAAP and non-GAAP SG&A expense to be between 16% and 17% of revenue. We anticipate GAAP EPS results between $18.10 and $18.40 and non-GAAP EPS to be between $19.70 and $20. Our outlook assumes a very modest reduction in our full year weighted average diluted share count. 
Of note, this guidance assumes contribution from our hemophilia business through the balance of the year as we expect the spin-off to complete in early 2017. Additionally, this guidance does not include any impact from potential acquisitions or large late-stage business development transactions as both are hard to predict. Overall, this increase in guidance reflects the solid revenues seen this quarter, combined with the continued operating expense control. 
I'll turn the call over to George for his closing comments."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you Paul. Look, financially, I'm pleased with where we are so far this year. Our results year-to-date have been better than expected. We've raised guidance, and we have a new share repurchase program authorized by the board. We've made good pr",413,"Okay. Thank you Paul. Look, financially, I'm pleased with where we are so far this year. Our results year-to-date have been better than expected. We've raised guidance, and we have a new share repurchase program authorized by the board. We've made good progress towards the 3 focus areas I discussed after the first quarter: careful management of expenses, maximizing revenues and rapidly advancing the pipeline. 
As I look forward and think about the future growth of Biogen, I want to stress how those key focus areas will evolve. The team expects to continue managing expenses, but as you know, we can't save our way to growth. Maximizing revenues and rapidly advancing the pipeline will become front and center, Especially with Michel and Mike now in their respective roles. Michel's 4 key priorities of portfolio strategy, commercial excellence, medical leadership and trust and value will be the pillars we use to maximize revenues. And under Mike's leadership, we intend to reshape the pipeline, rationalize existing programs and aggressively pursue promising assets, both internally and externally. We believe this focus will help advance more assets through the pipeline and ideally deliver more therapies to patients. 
At the same time as we're bringing focus and investment to our core area of expertise in neurology, we'll continue to be opportunistic when we see internal and external opportunities to enhance shareholder value. As a result, we progressed some of the most promising earlier-stage assets that we have in our pipeline even outside of neurology. We have invested in our biosimilar joint venture to leverage our competitive strengths in manufacturing and commercialization. We've chosen to spin-off our growing hemophilia business because we believe it's the right decision to ensure fit and focus, And as we've announced today, we'll buy back shares when appropriate. 
So we've delivered strong financial results this quarter while making progress advancing our pipeline and our commercial business. We have a great leadership team and a passionate group of employees who come to work every day to make a positive impact on patients' lives. It's been an honor and a privilege to serve this organization as the CEO for the last 6 years, and I remain committed to leading the company until my successor is identified. 
I want to take this opportunity to thank all of our employees for their hard work and dedication, And I want to thank you, all, for joining us this morning. 
And operator, we'll now open up the call for questions."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Mark Schoenebaum from Evercore ISI.",15,"[Operator Instructions] Your first question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Just one. George, I want to say I just -- the stock only quintupled under your leadership, so I was wondering if you could -- yes, I think you should be held accountable for that. So I was wondering if you could address that. No, congratulations. You will",85,"Just one. George, I want to say I just -- the stock only quintupled under your leadership, so I was wondering if you could -- yes, I think you should be held accountable for that. So I was wondering if you could address that. No, congratulations. You will be missed. Thanks for the honesty, transparency that you brought to Biogen over the years. And I'd like to know who your least favorite sell-side analyst is, please? Or not -- assure me that it's not me."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","It's definitely not you.",5,"It's definitely not you."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Okay, Got it.",3,"Okay, Got it."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Especially after that last comment.",5,"Especially after that last comment."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Okay, Very good. And Paul, good [indiscernible] management of the...",10,"Okay, Very good. And Paul, good [indiscernible] management of the..."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","You moved up from the bottom, Mark.",7,"You moved up from the bottom, Mark."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My question is -- this has been asked before, but I just want to kind of engage you guys in a little bit of discussion. Why not release the efficacy data from the titration cohort of the amaB trial, given that -- I know it's small numbers, but the numbers",101,"My question is -- this has been asked before, but I just want to kind of engage you guys in a little bit of discussion. Why not release the efficacy data from the titration cohort of the amaB trial, given that -- I know it's small numbers, but the numbers aren't that much smaller than the individual dose arms we've already seen. And the follow-up is just can you update us with any specifics on enrollment? Is enrollment tracking within your expectations? And can you just remind us at this point when'd you expect data readouts and if there are interims?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Mark, this is Al. So yes, I mean, it makes sense that the number of patients is roughly the same. Our plan is to introduce the safety data, the tolerability data from the titration. But -- and efficacy is an exploratory endpoint. I'm sure, at some scienti",92,"Mark, this is Al. So yes, I mean, it makes sense that the number of patients is roughly the same. Our plan is to introduce the safety data, the tolerability data from the titration. But -- and efficacy is an exploratory endpoint. I'm sure, at some scientific meeting, we'll be able to disclose that for completeness sake. And in terms of enrollment, we're not really commenting on it except to say that we're pleased and that things are on track, and we hope to update you more on that in the future."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My congrats to George as well and all your accomplishments, and best of luck in the future. I guess the question on the business development front. As you talk about aggressively reshaping the pipeline and pursuing promising assets, I'm curious your lates",92,"My congrats to George as well and all your accomplishments, and best of luck in the future. I guess the question on the business development front. As you talk about aggressively reshaping the pipeline and pursuing promising assets, I'm curious your latest thinking in terms of stage development, size of potential deals, the types of assets therapeutically that you might focus on. How are you thinking these days about balancing maintenance of -- focus on neurology versus further diversifying the business? And how does the CEO transition potentially affect all these goals?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Well, first, let me take that last point first. I don't think the CEO transition affects these goals at all. The company is committed to bolstering the pipeline, and we're working aggressively to do that. And actually, we would look at deals at all s",206,"Yes. Well, first, let me take that last point first. I don't think the CEO transition affects these goals at all. The company is committed to bolstering the pipeline, and we're working aggressively to do that. And actually, we would look at deals at all stages of development, from preclinical through Phase III, and we're currently doing that. We're in a number of discussions now, and we hope to bring some of those to conclusion. We are focused, largely, on neurology. That's where we have our core expertise, and I think we believe that the -- you can make more sophisticated decisions about things in areas that you understand really in detail. So mainly, we're looking in neurology with Mike's arrival. We have a new person here who's got his own set of expertise, his own views on things. And I would say we're not -- we wouldn't rule out things outside of neurology, But the bar gets higher as they get further from our center of excellence. The -- as Mike put it yesterday, we want to have kind of laser vision, but we don't want to have tunnel vision. We want to be open to things that are interesting and can provide shareholder value."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink Partners."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","George, we're not sure what's so special about California, but all the very best of luck with you, your next chapter, and thanks again for all the information you've shared with us and for the success you've had at Biogen.",40,"George, we're not sure what's so special about California, but all the very best of luck with you, your next chapter, and thanks again for all the information you've shared with us and for the success you've had at Biogen."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, Geoff. I would say if you're not sure what's special about it, you haven't been there.",18,"Thank you, Geoff. I would say if you're not sure what's special about it, you haven't been there."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","So one question -- a couple of questions for Michel, actually. Michel, could you give us a sense of what your contributions from price and volume were on the MS franchise during the quarter on the U.S. side and then what your price -- contributional price",115,"So one question -- a couple of questions for Michel, actually. Michel, could you give us a sense of what your contributions from price and volume were on the MS franchise during the quarter on the U.S. side and then what your price -- contributional price effect was on the ex U.S. side? And then could you, secondly, add -- as you look at the MS franchise, presumably, you'll have no role in ocrelizumab's commercialization, but nevertheless, the -- your partner. Could you give us your view of how you see that playing out in terms of the effect that drug might have in the MS market and on the outlook for Biogen's own products?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks for the question, and let me start with ocre and probably comment on the other part of the question. First, I would like to say that we are very pleased, and we applaud any new innovation in MS for which we have contributed, we contribute and will",244,"Thanks for the question, and let me start with ocre and probably comment on the other part of the question. First, I would like to say that we are very pleased, and we applaud any new innovation in MS for which we have contributed, we contribute and will continue to invest in our pipe. So this is a great news for patients in need. There are still gaps in therapy, and I think this is a great news. And Roche's results on PPMS is even more encouraging. So we are very happy about that. Having said that, we have a strong presence in the high-efficacy segment of the market, And this is basically a market trend where we can see that basically provide us a treating earlier and physician treating earlier more aggressively. And TYSABRI held -- is holding a very strong position in the high-efficacy segment, And ZINBRYTA will come and will complement this presence there. So I anticipate that ocre will be playing into the segment also, and we will see how it plays. But for the time being, there is no risk-benefit assessment so we have to be very cautious before talking. So I'll wait to see where regulator stands. But I will say that the first approach from, again, a humble but leadership position is to take care of our assets and elevate the capability of the organization, and the 4 capabilities that we are launching will just do that."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Geoff, this is Paul. On the price versus volume question, I think the way you framed it is probably pretty accurate, is that it's a tale of 2 cities. In the United States, the lion's share from a change year-over-year basis is price. And it's pretty stabl",161,"Geoff, this is Paul. On the price versus volume question, I think the way you framed it is probably pretty accurate, is that it's a tale of 2 cities. In the United States, the lion's share from a change year-over-year basis is price. And it's pretty stable unit trends on TECFIDERA, pretty stable unit trends on TYSABRI and modest gradual decline on the interferon franchise. Ex United States, we are not seeing any pricing on a year-over-year basis, and all of the gains are attributable to volume and unit expansion. TYSABRI is holding well outside the United States as well as the interferon business, and we continue to, in a small way, penetrate some markets and get some accretive benefits of things even outside of Europe. And TECFIDERA continues to expand on a year-over-year basis and gaining market share, particularly as we are moving into relatively early launch timing in Southern European countries and having very good success in the U.K."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Congrats, George, to see you leave on a high note. Best of luck with the next opportunity. Maybe just a quick one for Paul on these new interferon patents you're paying a royalty on or expected to pay a royalty on. Can you clarify a little bit whose paten",75,"Congrats, George, to see you leave on a high note. Best of luck with the next opportunity. Maybe just a quick one for Paul on these new interferon patents you're paying a royalty on or expected to pay a royalty on. Can you clarify a little bit whose patent that is? And what happened to your own interferon patent that you thought was, at one point, going to be able to extract royalties from others?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Great question, Eric. Thanks. It was, as I noted, unexpected that it is not actually related. Despite it is on the recombinant interferon beta protein, it's actually not the same. It has to do with JFCR. In the Q this afternoon, we'll actually have t",171,"Yes. Great question, Eric. Thanks. It was, as I noted, unexpected that it is not actually related. Despite it is on the recombinant interferon beta protein, it's actually not the same. It has to do with JFCR. In the Q this afternoon, we'll actually have the patent number for you. I actually -- just actually don't have it handy for myself. And it's a mid-single-digit royalty. We aren't disclosing the name of the third party, but -- so just the third party at this point in time. And we expect it will be $50 million impact, all in the second half effectively, and will be a bigger impact as we go into 2017 on a full year basis. The '755 patent, we continue to feel like -- that -- despite it was like back to 2009 when it was issued, but we still feel and we're still in litigation with other parties on that. But there's a chance that we're coming towards the end of that process. Hope for something favorable."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","George, I also want to offer my congrats. You will be missed. So I had a question for Michel, maybe a bigger picture commercial question. Now that you've had a chance to look at the products, the assets at Biogen and a fresh look at the MS market, maybe j",108,"George, I also want to offer my congrats. You will be missed. So I had a question for Michel, maybe a bigger picture commercial question. Now that you've had a chance to look at the products, the assets at Biogen and a fresh look at the MS market, maybe just give us some perspective on what you see as the bigger growth opportunities ahead on a volume basis. Is it geographic? Is it rest of world opportunities? Is it new product launches? And then maybe for Paul. Just want to check and see what you guys learned from the DTC campaign for TEC and the sustainability of that?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you for the great question. In my 25 years experience around the world, I have never seen such a situation whereby we have 5 or 6 assets in the same therapy area. 20 years of those solid, unique, I would say, experience in MS, a solid portfolio toda",273,"Thank you for the great question. In my 25 years experience around the world, I have never seen such a situation whereby we have 5 or 6 assets in the same therapy area. 20 years of those solid, unique, I would say, experience in MS, a solid portfolio today, a solid pipeline, a remarkable group of talents of -- with clinical experience and scientific experience within the company. So it's a leadership position on interferons, a leadership position on orals, a leadership position on high-efficacy products. So this is a remarkable situation. And on top of that, we are launching ZINBRYTA. So the dynamic is very good. Having said that, when you peel the onion and you get to discover the opportunity and the operations, you'll find ways to do better. And this is why, together with the team, we have prioritized 4 key areas: portfolio management, 5, 6 assets in the same therapy area. It's a challenge on how to manage that well; commercial excellence; medical leadership; trust and value. And I believe that with those, we'll be able to make further difference. Geographically, also, we can see that some parts are better managed than others. And I have already started to make some decisions. We don't wait, and you can expect that more will come. So this is what I would like to say -- and the portfolio management doesn't mean that all the products will be resourced and promoted equally. It's all about the growth opportunity, the way that you outline, and this is where there will be a clear, I would say, alignment between those resource allocation and execution."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Geoff, the beginning part of your question is, yes, just to confirm, we have sunsetted the television campaign as it relates to TECFIDERA. I think our -- I mean, look, it was a innovative -- I'd applaud our organization for thinking about it and giving it",137,"Geoff, the beginning part of your question is, yes, just to confirm, we have sunsetted the television campaign as it relates to TECFIDERA. I think our -- I mean, look, it was a innovative -- I'd applaud our organization for thinking about it and giving it a try. I think that our judgment at this point is that it didn't have a discernible movement on scripts and potentially came with this more -- as much from anecdotal, with some drawbacks as well. Michel actually confirmed his -- from his perspective that, quite possibly, as much other levers that are still like DTC-related and multichannel-related that we can reallocate resources toward. So I think that's probably our learnings in a nutshell. We didn't run the test case. So we'll see what -- but I think that's our learnings."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, Paul. If I -- this is Michel. If I can add. I mean, at the outset, and I was not here, the main objective was increase awareness, and I think that this was achieved. But I didn't see  any inflection on any trends. We need to circle back to the",86,"Thank you, Paul. If I -- this is Michel. If I can add. I mean, at the outset, and I was not here, the main objective was increase awareness, and I think that this was achieved. But I didn't see  any inflection on any trends. We need to circle back to the alignment of the organization on 4 priorities for which we need to have some very strict resource allocation decisions, and I don't think that broadcast TV will be there in the foreseeable future year."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","This is Whitney on for Cory. I'll add my congrats to George as well. I guess just to circle back on Alzheimer's. I guess where are you with the sort of combinations? And I guess what's the desire or urgency to get some of the combos into the clinic before",62,"This is Whitney on for Cory. I'll add my congrats to George as well. I guess just to circle back on Alzheimer's. I guess where are you with the sort of combinations? And I guess what's the desire or urgency to get some of the combos into the clinic before you maybe have Phase III data on any of the individual components?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","This is Al, Whitney. And we like the idea of combination, to think one day we will be using combination therapies for Alzheimer's disease. One of the reasons why we brought in BACE inhibitor into our pipeline with our collaboration with Eisai, the reason",213,"This is Al, Whitney. And we like the idea of combination, to think one day we will be using combination therapies for Alzheimer's disease. One of the reasons why we brought in BACE inhibitor into our pipeline with our collaboration with Eisai, the reason why we have tau programs internally and that we're in search of even other things potentially to add to the mix is based on -- in part on that belief, that combination could be helpful. And you can think of it in 2 ways. One is to combine 2 drugs, each of which are active, to increase the efficacy overall or to reduce the dose of 2 active therapies so that you get better safety or tolerability for the same efficacy. And also, there may be sequential treatments where you start early, perhaps even before symptoms, with one type of medicine and then treat with something else when you have a high plaque burden and then something else still when tau starts to progress. When you start to think about combination therapy though, it's often difficult to do the right studies without some evidence of efficacy of each drug as monotherapy, and then you can start to think about the right dosing regimen. And so I hope that's helpful."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My appreciation to George as well. Happy to see you joining me on the West Coast. I'm lonely out here. So happy to have you back here. A question for Al. There will be LINGO data presented at ECTRIMS. Can you maybe just revisit this briefly and give us so",128,"My appreciation to George as well. Happy to see you joining me on the West Coast. I'm lonely out here. So happy to have you back here. A question for Al. There will be LINGO data presented at ECTRIMS. Can you maybe just revisit this briefly and give us some color about what is going on here in terms of what we saw? Because obviously, that was a surprise. And I guess is there anything specific that we should pay attention to at ECTRIMS that you've done work on that would peak our interest back here? Or is there some issue here with remyelination pathway and that would bring our questions into your oral? So how does this change our thinking about remyelination and what we saw here?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Michael, thanks for the question. So first, I want to say this is a really large and rich data set, really the first of its kind, not only in MS but, to my knowledge, in neurology where we're in the early stages of figuring out how to repair the brai",352,"Yes, Michael, thanks for the question. So first, I want to say this is a really large and rich data set, really the first of its kind, not only in MS but, to my knowledge, in neurology where we're in the early stages of figuring out how to repair the brain and how to measure measurements of outcome, measures of repair. The things we're focusing on right now when we look at this rich data set are what are the right cohort of patients to treat. In this trial, we've looked at relapsing MS patients, all the way to secondary progressive. So it's a wide range of patients. What's the right -- what's the optimal cohort? What's the right dose? We studied 4 different doses, and we saw a complex dose response curve. What we actually saw was sort of a bell-shaped curve where we lost efficacy at the highest dose, and then the middle doses, we think we see a signal of efficacy. And so we'll share some of that at ECTRIMS. What's the right concomitant medicine to use? We envision that these repair therapies will be added to immunomodulators, and so we'll be looking at that and, in particular, whether ongoing inflammation in the brain impedes repair. And finally, how do we actually measure the effects of repair if it occurs, particularly, on clinical outcome measures? So some of these questions will be answered by doing further analyses, which we're in the middle of doing right now, intensively, and we'll share whatever we find out at ECTRIMS. And some may need another study. And so what we're honing in on is what's the next step, what's the next study? And obviously, this will be a judicious investment. If we can go to Phase III, we would try. I don't know until I see the specific design. It's -- it could be a Phase II, it could be a Phase III, it could be a Phase II/III. And at that part, we probably won't be able to share at ECTRIMS, but sometime soon, we hope to be able to share that."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","I guess thinking about George, I remember meeting you when you first became the CEO, and I remember you talking about reasons for joining the company and that [indiscernible] pipeline product was so well needed. At the time, it really changed Biogen. And",82,"I guess thinking about George, I remember meeting you when you first became the CEO, and I remember you talking about reasons for joining the company and that [indiscernible] pipeline product was so well needed. At the time, it really changed Biogen. And so now the company is a different company and there's been pipeline success and there's been some failures, what do you think Biogen really needs from a new CEO at this point in time versus when you came in?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Well, look, the company now is a very different company from what it was a few years ago. We have a full and excellent management team. We have a pipeline that is, I think, quite exciting but needs to be to grow. So I think the company needs good manageme",193,"Well, look, the company now is a very different company from what it was a few years ago. We have a full and excellent management team. We have a pipeline that is, I think, quite exciting but needs to be to grow. So I think the company needs good management. I think the strategy of the company is solid, and what we need is good leadership and somebody who can work with the people who are here, work with Michel to maximize the commercial potential, work with Mike, commercialize the potential of our pipeline, grow the pipeline and can work with the rest of the organization to ensure that we go forward in a way that is responsible, where we minimize expenses but that where we invest aggressively in those areas that really have the potential to add value. So being CEO is complicated, and I think those are the -- those are priorities I would set. Of course, the search will be conducted by the board, but I don't think they would do it too differently. I think there'll be a continued focus on innovation, and I'm confident we'll get someone excellent."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ronny Gal from Bernstein.",12,"Your next question comes from the line of Ronny Gal from Bernstein."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Two questions. First, biosimilars. You had a pretty good first quarter. Can you describe a little bit to us where you've launched already, where you're still expecting to launch? And now that you're a little bit of -- wetted your feet in that market, coul",173,"Two questions. First, biosimilars. You had a pretty good first quarter. Can you describe a little bit to us where you've launched already, where you're still expecting to launch? And now that you're a little bit of -- wetted your feet in that market, could you just give us a feel for your thinking about kind of the 3- to 5-year trajectory for this franchise and for biosimilar [indiscernible] anti-TNF in Europe in general? Should this be 30% of the market, 50%, 70% of the market overall? And then separately, you kind of mentioned the impact of high deductible co-pays on the U.S. sales in the first quarter. Has there been still some impact to those in the second quarter? That is, as we look from the outside of revenue, should we see another step-up in revenue being it in the third quarter? Or has it been fully incorporated in the first quarter and kind of the run rate for pricing in the second quarter is roughly what we should see going forward?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","So this is Michel. Thanks for the great question. So as you have seen, 2 great companies came together with complementary capabilities in order to launch anti-TNFs, to get started with, and then we see what these -- the follow-up opportunities. So as far",237,"So this is Michel. Thanks for the great question. So as you have seen, 2 great companies came together with complementary capabilities in order to launch anti-TNFs, to get started with, and then we see what these -- the follow-up opportunities. So as far as Biogen is involved, together with the partners, we have launched the products, the 3 anti-TNFs that we -- for which we have the agreement on. Two out of the 3 are approved and are underway to be launched. The preliminary results are very encouraging. As you can imagine, there is a tremendous level of variation viability between countries in terms of tendering, in terms of aggressivity of competition, in terms of provider decision-making, and it's difficult to take an overall, I would say, recipe on how to best launch. What I can say is that the 3 anti-TNFs that we'll have the opportunity to launch will be addressing a current market that is higher than $9 billion in Europe. So this is significant and with Biogen quality. So we have put together a stand-alone BU that is flexible, agile in order to launch the product. And we learn country after country, today, mostly in the Nordics and Scandinavia, where we have had very, very good results. But as I said earlier, it's still early to comment much on the results that are negligible for 2016, but will be more important moving forward."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Ronny, this is Paul. Thanks for the second part of that question. It's a good catch. I think that the answer is that we absolutely saw insurance dynamics mostly impact AVONEX in the first quarter and we're pleased to see that, that choppiness settled out",66,"Ronny, this is Paul. Thanks for the second part of that question. It's a good catch. I think that the answer is that we absolutely saw insurance dynamics mostly impact AVONEX in the first quarter and we're pleased to see that, that choppiness settled out and benefited the second quarter results. Don't expect it to be meaningful or different for the balance of the year now."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","And your final question comes from the line of Chris Raymond from Raymond James.",14,"And your final question comes from the line of Chris Raymond from Raymond James."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","And congrats, George, from us as well. Just a question, I guess, on TECFIDERA. In the context of -- I think you highlighted in Q1 a $20 million inventory drawdown. Could you maybe quantify -- I think you highlighted, generally, there was an inventory effe",155,"And congrats, George, from us as well. Just a question, I guess, on TECFIDERA. In the context of -- I think you highlighted in Q1 a $20 million inventory drawdown. Could you maybe quantify -- I think you highlighted, generally, there was an inventory effect in Q2. Can you quantify what that was? And then also, if I can, on TECFIDERA continuing. I hear what you're saying on the television ads, but one of the things that have sort of struck us the most with our checks is TECFIDERA, for some time, has been sort of far and away the most requested disease-modifying therapy among patients. I guess I'm wondering what additional levers can you pull to sort of increase that. Or is there some other aspect, like maybe working at better efficiency programs to get that request converted into a script? Is there some other aspect besides just getting patients to request the drug?"
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Thanks, Chris. Paul. I'll take the first part. It's quite simply -- I think we're at pretty normal inventory levels on TECFIDERA, so it's really just a sequential quarter rebalancing off of this -- the seasonal low that we generally see in Q1.",44,"Yes. Thanks, Chris. Paul. I'll take the first part. It's quite simply -- I think we're at pretty normal inventory levels on TECFIDERA, so it's really just a sequential quarter rebalancing off of this -- the seasonal low that we generally see in Q1."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","So on the levers and the performance. 12% growth q-over-q is not bad. The share continues to grow to 15% globally is also pretty good, mostly driven by the newly launched markets in Europe. 40% patient share -- patients growth percentage is also very enco",189,"So on the levers and the performance. 12% growth q-over-q is not bad. The share continues to grow to 15% globally is also pretty good, mostly driven by the newly launched markets in Europe. 40% patient share -- patients growth percentage is also very encouraging. I have, for my field visits and from talking to leaders, identified one major issue, which is the discontinuation due to GI safety. Those patients, during the first phase on the product, are suffering, for some of them, on abdominal pain, diarrhea, discomfort that is leading, in some cases, with very high level of viability to discontinue on the product. And this impacts not only the outflow but, eventually, the inflow. Viability is tremendous. I was in the field lately and -- on the Eastern Coast in the U.S. 1.5% of the patient discontinued at 6 months. In some others, it was 30%. So with Mike Ehlers, we are fully aligned in order to work together with the community, with the physicians, with the peer-to-peer in order to best assess, best educate and bring down an average, which is 20% today, to lower levels."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. With that, I thank you all for joining us this morning. Thanks for the questions, and we'll sign off now. Thank you.",23,"Okay. With that, I thank you all for joining us this morning. Thanks for the questions, and we'll sign off now. Thank you."
29726,366896620,1009546,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the call o",57,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the call over to Mr. Matt Calistri, Senior Director of Investor Relations. Please go ahead."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Dan. Thank you, everyone, and welcome to Biogen Second Quarter 2016 Earnings Conference Call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a r",219,"Thanks, Dan. Thank you, everyone, and welcome to Biogen Second Quarter 2016 Earnings Conference Call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 includes the reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Michael Ehlers, EVP of Research and Development; our Chief Commercial Officer, Michel Vounatsos; and our CFO, Paul Clancy. We'll also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock. 
Now I'll turn the call over to George."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Matt, and good morning, everyone. Thanks for joining us. I'd like to begin with a personal statement. I'll be stepping down as CEO of a Biogen sometime within the next few months. The board and I recognize that this is an excellent time",1080,"Okay. Thank you, Matt, and good morning, everyone. Thanks for joining us. 
I'd like to begin with a personal statement. I'll be stepping down as CEO of a Biogen sometime within the next few months. The board and I recognize that this is an excellent time for a transition. The company is doing well now. The management team is complete and extremely capable. The commercial and R&D activities are going well, and we're on our way to adding to the pipeline through internal and external opportunities. So a good time for a new CEO to take the helm and see Biogen through to what I believe is a very exciting future. This also is an opportune time for me to return to the West Coast, take on one more set of activities and spend more time with my family. 
I've been at Biogen for 6 years. I'm proud of the company and what we've been able to accomplish in that time. We've introduced 6 new products on to the market and increased our revenues, earnings and stock price all by severalfold, and I believe that we're well positioned to keep delivering on our potential to bring even more therapies to patients and returns to our investors. Our R&D and commercial organizations are now world class, joining our already industry-leading biologics manufacturing capabilities. All aspects of the company are operating at a high level. We have brought several potentially game-changing compounds into later-stage development and are in the process of adding further to that pipeline. With the addition of Michel Vounatsos, Mike Ehlers and Paul McKenzie, the company has a full and vibrant leadership team that's capable of moving the company thoughtfully forward. I truly believe that the company has a bright future, and it's with mixed emotions that I leave at this time and not see that future come fully to fruition. 
We're making the announcement now in order to provide an orderly transition for the company and to allow the board to conduct an open and effective search. I'll work with the board to find a great successor who can continue to build on what we have accomplished. We expect to consider both internal and external candidates, and I'm confident that we'll identify an outstanding new leader. I expect to remain as CEO until a successor is identified and can begin. In the interim, I continue to work with the board and management team to accomplish Biogen's goals for 2016. I believe that we're on a good trajectory, that we have great new additions to the management team and I look forward to a successful second half of the year. 
So enough about me. Let's turn to the business. Biogen had a solid second quarter, delivering strong financial performance and important advances in our pipeline. For the second quarter of 2016, Biogen generated $2.9 billion in total revenues, a 12% increase from the same period a year ago. Our GAAP earnings were $4.79 per share, a 22% increase year-over-year, and non-GAAP EPS was $5.21, a 23% increase year-over-year. We continue to grow our leading MS franchise and our hemophilia business, and our efforts to maximize revenues while thoughtfully managing expenses helped to drive attractive earnings growth. As a result, we've raised our financial guidance for the full year. And today, we announced that our Board of Directors has authorized a program to repurchase up to $5 billion of our common stock. 
Looking back, we had quite an eventful second quarter. To begin, we welcome 3 new members of our management team, a new Head of Commercial, Michel Vounatsos, joined us in April. He's completed a thorough assessment and has identified 4 key priorities for driving our MS business forward, which he'll share with you later in this call. Our new Head of R&D, Mike Ehlers, joined us at the end of May. Mike is a brilliant neuroscientist and an established R&D leader who has excelled in both academic and corporate settings. Mike has demonstrated the ability to translate science into the development of important new medicines, and he's already bringing terrific leadership to the organization. And finally, with John Cox preparing to lead the new hemophilia company, we promoted Paul McKenzie to oversee our Pharmaceutical Operations and Technology group. These 3 new leaders bring a wealth of experience and expertise, and we believe that they're poised to take Biogen into its next phase of growth. I'm proud to have them in our organization. 
Last quarter brought a number of positive developments for both our commercial products and our pipeline. We announced our intent to spin off our hemophilia business. That business continues to perform well with combined second quarter revenues of over $200 million for ELOCTATE and ALPROLIX. ALPROLIX also was approved by the European Commission for the treatment of hemophilia B and will be commercialized in the EU by our collaboration partner, Sobi. We had a positive label update for TYSABRI in Europe, including an extended indication. We received regulatory approval for ZINBRYTA in both the U.S. and the EU for the treatment of relapsing MS. FLIXABI an infliximab biosimilar referencing Remicade, received approval in Europe. This will be the second anti-TNF biosimilar that we'll manufacture and commercialize in the EU. And SB5, an adalimumab biosimilar candidate referencing Humira, has been accepted for review by the European Medicines Agency. Aducanumab was accepted into the European Medicines Agency's PRIority MEdicines program, known as PRIME. It was one of only 4 applications accepted out of 18 submitted and the only Alzheimer's disease therapy in development that was accepted. On the early-stage research front, we entered into a broad collaboration and alliance with the University of Pennsylvania and 2 world-renowned gene therapy experts, Drs. James Wilson and Jean Bennett. 
This quarter, we also reported the top line results of the SYNERGY trial for opicinumab. As you are all aware, opicinumab missed both the primary and secondary endpoints. It was -- certainly was disappointing. However, the rigorous design and planning of SYNERGY has yielded an abundance of data that will help us make a well-informed decision about our path forward with opicinumab and our work in remyelination generally. These results are indicative of the significant challenge of targeting neurorepair. During the upcoming ECTRIMS conference in September, we expect to present more detailed efficacy, biomarker and safety data. 
I'll now turn the call over to Mike, and we're eager for you to get to know Mike and experience his passion for our business."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, George, and good morning, everyone. By way of introduction, I spent a number of years in academia as professor and Howard Hughes Medical Institute investigator at Duke University, where my research was focused on cell biological and circuit mec",754,"Thank you, George, and good morning, everyone. By way of introduction, I spent a number of years in academia as professor and Howard Hughes Medical Institute investigator at Duke University, where my research was focused on cell biological and circuit mechanisms of brain function in the normal, developing and diseased nervous system. My career took an exciting turn 6 years ago when I joined Pfizer. I served as the Chief Scientific Officer for the company's Neuroscience and Pain Research Unit and, ultimately, became group leader for BioTherapeutics R&D with responsibility over rare disease, the centers for therapeutic innovation and all large biomolecule sciences. 
I'm just now finishing my second month at Biogen, so there is still a lot I'm getting up to speed on. But I can tell you from the outset that I am working to reshape and progress our pipeline while aggressively pursuing promising assets, both internally and externally. I plan to update you on progress on these fronts in the future. In the meantime, I will comment on the important clinical study readouts this quarter and note some good progress made in advancing our clinical programs. 
Starting with opicinumab, or anti-LINGO, as George discussed. The top line results from the Phase II SYNERGY study were reported in which opicinumab unfortunately missed both the primary and secondary endpoints. However, evidence of a clinical effect with a complex, unexpected dose response was observed. The SYNERGY top line efficacy safety and biomarker results will be presented at ECTRIMS in September. 
Continuing in MS. EC approval was received for an extended indication for TYSABRI in highly active, relapsing-remitting MS patients with inadequate response to prior MS therapy. TYSABRI was previously only indicated for patients who had failed to respond to beta interferon or a glatiramer acetate. This label extension follows recent EC approval for a new patient management plan, including an updated risk algorithm based on JC virus antibody index values. These changes will allow physicians to have more individualized benefit risk discussions with their patients. 
Turning to other promising late-stage assets. Our collaboration partner, Ionis, continues to execute the Phase III studies of nusinersen for infants and children with spinal muscular atrophy, both of which are now fully enrolled. In Alzheimer's disease, it was recently announced that aducanumab was one of only 4 applicants accepted into the European Medicine Agency's PRIority MEdicines program, or PRIME. PRIME aims to bring treatments to patients faster by enhancing the EMA's support for the development of investigational medicines for diseases without available treatment or in need of better treatment options. We continue to work diligently to enroll our aducanumab Phase III trials. Looking ahead, safety data from the titration arm of the Phase 1b study is anticipated by the end of this year. We are working toward the start of Phase III trials for amiselimod or MT-1303 in inflammatory bowel disease and BIIB074, formerly known as raxatrigine, in trigeminal neuralgia. An initiation of the Phase II trial with BIIB074 in patients with neuropathic pain from lumbosacral radiculopathy is planned for later this year. 
In further activities, natalizumab's clinical profile and treatment window supports its continued investigation as a potential novel approach for treating acute ischemic stroke, and the first patient was recently dosed in a second Phase II study in stroke called ACTION 2. Encouraging data was recently generated on earlier-stage assets, BIIB059 or anti-BDCA2 for systemic lupus erythematosus and BG11 (sic) [ BG00011 ] or STX-100 for idiopathic pulmonary fibrosis. Anti-BDCA2 data in healthy volunteers and a lupus cohort of 12 subjects has provided confidence to move into Phase II with trial initiation planned to begin over the summer. These data are anticipated to be presented later this year. The BG11 study is enrolling its final cohort and it is expected that data will be presented after the trial completes. 
Finally, as George mentioned, Biogen announced the broad collaboration and alliance with the University of Pennsylvania and Dr. James Wilson and Jean Bennett to advance gene therapy and gene editing technologies. The expansive research and translational development collaboration has multiple objectives and will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. 
Again, I am pleased to participate in my first earnings call here at Biogen. I anticipate sharing more detail on the advancement of the Biogen pipeline in the coming months as the company works diligently to deliver new therapies to patients. 
With that, I will now pass the call to my good colleague, Michel Vounatsos."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Mike. I'm very pleased to be with you this morning. I share my initial thoughts on the MS market and our MS portfolio, outline my priorities going forward and then I will discuss this quarter's results for MS products. Since I arrived at Biogen",1132,"Thanks, Mike. I'm very pleased to be with you this morning. I share my initial thoughts on the MS market and our MS portfolio, outline my priorities going forward and then I will discuss this quarter's results for MS products. 
Since I arrived at Biogen 3 months ago, I have spent time in the field with our operations team, meeting with patients, the neurology community and many of the scientific leaders in multiple sclerosis. Also, I have engaged with the strong Biogen leaders across our commercial organizations. I have listened and learned a lot, and together with the team, we have prioritized immediate opportunities across 4 key areas. We believe these opportunities will benefit our MS franchise today and, at the same time, prepare the organization for potential future product launches. 
Before speaking about our therapies, I think it is important to note, MS is a growing market with approximately 850,000 treated patients worldwide out of a global prevalence estimated at 2.3 million, which includes progressive forms of MS. We estimate the number of treated patients worldwide is growing in the mid-single digits on an annual basis, driven by low single-digit growth in the U.S. and high single-digit growth in Europe. The relatively higher market growth rate overseas is largely due to increasing rate of diagnosis and treatment. And as a leader in MS, we believe we are well positioned to benefit from this trend over time. 
Using the U.S. as an example, where we have the most detailed data, we estimate that approximately 3/4 of the 300,000 treated patients are stable and presumably satisfied on the current therapy. We believe Biogen is holding a clear leadership position in this stable segment of the market. We believe the dynamic opportunity of patients in the U.S. is comprised of approximately 15,000 newly diagnosed patients and approximately 60,000 patients changing medication each year. We believe that Biogen also holds a leadership position in new patient starts within this dynamic portion of the market. 
Turning to our MS portfolio. We believe that the value of our products is well recognized in the eyes of many of our customers, as reflected in our leading global market share of approximately 38%. We believe the breadth of our portfolio is and will continue to be a source of strength in the marketplace by allowing physician to prescribe the right drug to the right patient at the right time.   
As the most prescribed oral therapy for MS worldwide, TECFIDERA benefits from a compelling combination of efficacy, convenience and relative safety. As a result, we estimate that TECFIDERA captures roughly 25% of newly diagnosed and switching patients. Our market research indicates that TYSABRI is clearly viewed as differentiated in terms of efficacy and retains an important role for patients with highly active disease, capturing roughly 30% of all patients switching for efficacy reasons. Our interferon products, AVONEX and PLEGRIDY, combined, hold leading share amongst the interferon therapies. Despite facing headwinds due to the uptake of the orals, we believe these products will continue to play an important role going forward. We are also preparing to launch ZINBRYTA next month in the U.S and Germany. ZINBRYTA is the first in a new class of MS therapy. We believe it will be used by patients switching for efficacy reasons, benefiting from ""once monthly at home"" subcutaneous administration and a differentiated mechanism of action. 
Going forward, we will concentrate our work in the commercial organization across 4 key priorities, namely portfolio strategy, commercial excellence, medical leadership, trust and value. With portfolio strategy, we plan to further define our strategy for products, market segments and geographies. We will work to ensure that our targeted growth opportunities drive consistency across our resource allocation, messaging, marketing tactics and sales force execution. Within commercial excellence, we will work to increase our sophistication in multichannel marketing, including enhancing our digital capabilities while also strengthening our engagement with key customers at the local level. While clearly perceived as a leader in neurology research and clinical development, we believe we also have an opportunity to further enhance our medical leadership. This includes close collaboration with our medical field teams and partnership with scientific leaders. Finally, trust and value. We will work towards developing innovative beyond-the-pill solution for our customers to enhance our reputation and strengthen our partnership and role as a leader in MS. I think that as the leader in MS, we have this responsibility. 
Today, we already have a well-defined plan outlining next steps and target dates, which we have started to implement across the organization. We are initiating this with the aim to accelerate our business to be more focused, to make conscious choices and to be diligent in resource allocation. We believe that this work will be beneficial for our company and our shareholders. For competitive reasons, I am not prepared to go more into the details of these 4 initiatives, but I look forward to updating you on our progress at future meetings. 
Turning to the results for the quarter. Total MS revenues were $2.2 billion this quarter, an increase of 9% versus Q2 of last year. We believe our global market share continues to grow. 
Starting with TECFIDERA. In the U.S., we saw a modest increase in demands compared to the first quarter, largely due to normalization of the seasonality typically seen early in the year. All of our metric lead us to expect a continued, stable trend for TECFIDERA going forward. Outside the U.S., we continue to see increased adoption in the U.K., Italy, Spain. In fact, the number of TECFIDERA patients in Europe has increased approximately 40% over the last year. 
PLEGRIDY is now available in roughly 20 markets in Europe, and where launched, we believe it is helping to slow the rate of decline of our interferons. 
TYSABRI continued to add patient this quarter. We recognize the potential for increased competition from other high-efficacy therapies, but we believe TYSABRI's 10 years of post-marketing experience and well-understood safety profile position it very well. 
In collaboration with AbbVie, we are actively preparing to launch ZINBRYTA starting next month. We are particularly encouraged by the broad indication and data, reinforcing the product safety included in the EU label. 
We are also making progress in our biosimilar business this quarter. We are seeing strong initial update for BENEPALI, the first biosimilar approved in the EU referencing Enbrel, and we expect to launch FLIXABI, our biosimilar referencing Remicade, in the coming weeks. While we only expect a modest contribution from biosimilars in 2016, we do believe this is an attractive opportunity in the longer term. 
So the team delivered a very solid quarter. I look forward to taking Biogen into what I believe is an exciting future. 
With that, I turn the call over to Paul."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Michel. In the second quarter, our GAAP diluted earnings per share were $4.79, a 22% increase year-over-year, while our none-GAAP diluted earnings per share were $5.21, an increase of 23%. Total revenue for Q2 grew 12% year-over-year to approximat",1141,"Thanks, Michel. In the second quarter, our GAAP diluted earnings per share were $4.79, a 22% increase year-over-year, while our none-GAAP diluted earnings per share were $5.21, an increase of 23%. Total revenue for Q2 grew 12% year-over-year to approximately $2.9 billion. It's important to note we had $173 million in foreign exchange hedge gains in the full year of 2015, which impact our year-over-year revenue comparisons this year. In Q2, versus prior year, revenues were unfavorably impacted by $45 million from hedging. Combined with the $1 million benefit from foreign exchange rates, overall revenue was weakened by approximately $44 million year-over-year. I'll highlight the impact of foreign exchange in hedging on each of our major MS therapies. 
Global second quarter TECFIDERA revenue was $987 million, an increase of 12% versus the same quarter last year. This included revenues of $780 million in the U.S. and $206 million outside the U.S. In the U.S., TECFIDERA modestly benefited from an inventory rebalancing in the wholesaler channel versus prior quarter. Outside the U.S., foreign exchange and hedge impact weakened TECFIDERA revenue comparison by approximately $13 million. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $728 million during the second quarter, an increase of 6% versus the same quarter last year. This included $519 million in the U.S. and $209 million in sales outside the U.S. In the U.S., AVONEX also modestly benefited from an inventory rebalancing in the wholesaler channel versus prior quarter. Outside the U.S., foreign exchange and the hedge impact weakened interferon revenue comparison by approximately $17 million. 
TYSABRI worldwide revenues were $497 million this quarter, an increase of 7% versus the same quarter last year. This included $305 million in the U.S. and $192 million outside the U.S. Foreign exchange and the hedge impact weakened TYSABRI revenue comparison by approximately $13 million. 
Turning to our hemophilia business, which generated $205 million this quarter. ELOCTATE revenue for the quarter was $125 million, and ALPROLIX revenue in Q2 was $80 million. We continue to work towards spinning off our hemophilia business and related assets and plan to file the Form 10 later this summer and complete the distribution in early 2017. 
Turning to our anti-CD20 revenues. We recorded $349 million for Q2, an increase from prior quarter, driven by solid demand. Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing, were $79 million. 
Now turning to the expense lines on the P&L. Q2 GAAP cost of goods sold were $370 million or 13% of revenue. Non-GAAP cost of goods sold were $354 million or 12% of revenue. As a percentage of sales, COGS was impacted by increased inventory write-offs versus the lows seen in prior quarter. In addition, based on our evaluation of our small-scale manufacturing capacity needs, we booked a GAAP-only charge for accelerated depreciation related to our intent to close or divest our small-scale manufacturing facility in Cambridge. 
Q2 GAAP and non-GAAP R&D expense was $473 million or 16% of revenue, which includes $20 million related to the gene therapy collaboration with the University of Pennsylvania. Overall, R&D reflects relatively low business development expense, though this remains a critical strategic priority for us as we look to bring in high-quality assets. 
Q2 GAAP SG&A was $492 million or 17% of revenue. Q2 non-GAAP SG&A expense was $489 million, also 17% of revenue. We remain committed to achieving savings by reducing lower priorities and services for the balance of the year. Recall, over the last few years, we've gone through a number of product launches and thought it was the right decision to invest behind these products. Starting in 2015, we pivoted and took a number of actions to curb operating expense growth, including a restructuring and further efforts to reduce costs, which is reflected in our operating leverage for the quarter. This will also allow us to reinvest in the pipeline. Other net expense was $59 million in Q2, which includes $66 million in interest expense related to our 2015 bond offering. 
In Q2, both our GAAP and non-GAAP tax rates were approximately 25%. Our weighted average diluted share count was approximately $219 million for Q2. This brings us to our diluted earnings per share, which were $4.79 on a GAAP basis and $5.21 on a non-GAAP basis for the second quarter. We ended the quarter with approximately $7.3 billion in cash and marketable securities with approximately 40% of this in the United States. Today, we also announced a $5 billion share repurchase program, which we anticipate will be executed over the course of the next 3 years. We believe this leaves ample room for flexibility for strategic deployment. 
So overall, we had a strong quarter, driven by revenue growth from our MS therapies rebounding from the seasonality seen in the first quarter, continued growth from our hemophilia business and diligent cost controls. 
This now brings us to our full year 2016 guidance. We now expect revenues of approximately $11.2 billion to $11.4 billion, a modest improvement from prior guidance. Our outlook assumes continued stable demand, patient demand for TECFIDERA in 2016 in the United States. We believe TYSABRI will also remain on a stable trajectory for the balance of the year. Our outlook assumes AVONEX and PLEGRIDY patients, combined, will continue to gradually decline as patients move toward orals. For ZINBRYTA, we anticipate a modest revenue contribution in the U.S. and EU as launches are expected to begin in August. And our revenues outlook is based on stable foreign exchange rates. 
From an expense perspective, we anticipate upward pressure on cost of goods sold due to the unexpected issuance by the U.S. Patent Office of a patent to a third party related to recombinant interferon beta protein. This patent, issued on June 28 and expiring in June 2033, is relevant to AVONEX and PLEGRIDY. We will play -- pay royalties in the mid-single digits during the life of this patent. For the remainder of 2016, we expect the royalty payment to be approximately $50 million. We anticipate GAAP and non-GAAP R&D expense between 17% and 18% of sales and GAAP and non-GAAP SG&A expense to be between 16% and 17% of revenue. We anticipate GAAP EPS results between $18.10 and $18.40 and non-GAAP EPS to be between $19.70 and $20. Our outlook assumes a very modest reduction in our full year weighted average diluted share count. 
Of note, this guidance assumes contribution from our hemophilia business through the balance of the year as we expect the spin-off to complete in early 2017. Additionally, this guidance does not include any impact from potential acquisitions or large late-stage business development transactions as both are hard to predict. Overall, this increase in guidance reflects the solid revenues seen this quarter, combined with the continued operating expense control. 
I'll turn the call over to George for his closing comments."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Paul. Look, financially, I'm pleased with where we are so far this year. Our results year-to-date have been better than expected. We've raised guidance, and we have a new share repurchase program authorized by the board. We have made good",415,"Okay. Thank you, Paul. Look, financially, I'm pleased with where we are so far this year. Our results year-to-date have been better than expected. We've raised guidance, and we have a new share repurchase program authorized by the board. We have made good progress towards the 3 focus areas I discussed after the first quarter: careful management of expenses, maximizing revenues and rapidly advancing the pipeline. 
As I look forward and think about the future growth of Biogen, I want to stress how those key focus areas will evolve. The team expects to continue managing expenses, but as you know, we can't save our way to growth. Maximizing revenues and rapidly advancing the pipeline will become front and center, especially with Michel and Mike now in their respective roles. Michel's 4 key priorities of portfolio strategy, commercial excellence, medical leadership and trust and value will be the pillars we use to maximize revenues. And under Mike's leadership, we intend to reshape the pipeline, rationalize existing programs and aggressively pursue promising assets, both internally and externally. We believe this focus will help advance more assets through the pipeline and ideally deliver more therapies to patients. 
At the same time as we're bringing focus and investment to our core area of expertise in neurology, we'll continue to be opportunistic when we see internal and external opportunities to enhance shareholder value. As a result, we have progressed some of the most promising earlier-stage assets that we have in our pipeline even outside of neurology. We have invested in our biosimilar joint venture to leverage our competitive strengths in manufacturing and commercialization. We've chosen to spin-off our growing hemophilia business because we believe it's the right decision to ensure fit and focus. And as we've announced today, we'll buy back shares when appropriate. 
So we've delivered strong financial results this quarter while making progress advancing our pipeline and our commercial business. We have a great leadership team and a passionate group of employees who come to work every day to make a positive impact on patients' lives. It's been an honor and a privilege to serve this organization as the CEO for the last 6 years, and I remain committed to leading the company until my successor is identified. 
I want to take this opportunity to thank all of our employees for their hard work and dedication. And I want to thank you, all, for joining us this morning. 
And operator, we'll now open up the call for questions."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Mark Schoenebaum from Evercore ISI.",15,"[Operator Instructions] Your first question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Just one. George, I want to say I just -- the stock only quintupled under your leadership, so I was wondering if you could -- yes, I think you should be held accountable for that. So I was wondering if you could address that. No, congratulations. You will",85,"Just one. George, I want to say I just -- the stock only quintupled under your leadership, so I was wondering if you could -- yes, I think you should be held accountable for that. So I was wondering if you could address that. No, congratulations. You will be missed. Thanks for the honesty, transparency that you brought to Biogen over the years. And I'd like to know who your least favorite sell-side analyst is, please? Or not -- assure me that it's not me."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","It's definitely not you.",5,"It's definitely not you."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Okay, Got it.",3,"Okay, Got it."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Especially after that last comment.",5,"Especially after that last comment."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Okay, Very good. And Paul, good [indiscernible] management of the...",10,"Okay, Very good. And Paul, good [indiscernible] management of the..."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","You moved up from the bottom, Mark.",7,"You moved up from the bottom, Mark."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My question is -- this has been asked before, but I just want to kind of engage you guys in a little bit of discussion. Why not release the efficacy data from the titration cohort of the amaB trial, given that -- I know it's small numbers, but the numbers",101,"My question is -- this has been asked before, but I just want to kind of engage you guys in a little bit of discussion. Why not release the efficacy data from the titration cohort of the amaB trial, given that -- I know it's small numbers, but the numbers aren't that much smaller than the individual dose arms we've already seen. And the follow-up is just can you update us with any specifics on enrollment? Is enrollment tracking within your expectations? And can you just remind us at this point when you'd expect data readouts and if there are interims?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Mark, this is Al. So yes, I mean, it makes sense that the number of patients is roughly the same. Our plan is to introduce the safety data, the tolerability data from the titration. But -- and efficacy is an exploratory endpoint. I'm sure, at some scienti",92,"Mark, this is Al. So yes, I mean, it makes sense that the number of patients is roughly the same. Our plan is to introduce the safety data, the tolerability data from the titration. But -- and efficacy is an exploratory endpoint. I'm sure, at some scientific meeting, we'll be able to disclose that for completeness sake. And in terms of enrollment, we're not really commenting on it except to say that we're pleased and that things are on track, and we hope to update you more on that in the future."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My congrats to George as well on all your accomplishments, and best of luck in the future. I guess a question on the business development front. As you talk about aggressively reshaping the pipeline and pursuing promising assets, I'm curious your latest t",92,"My congrats to George as well on all your accomplishments, and best of luck in the future. I guess a question on the business development front. As you talk about aggressively reshaping the pipeline and pursuing promising assets, I'm curious your latest thinking in terms of stage development, size of potential deals, the types of assets therapeutically that you might focus on. How are you thinking these days about balancing maintenance of -- focus on neurology versus further diversifying the business? And how does the CEO transition potentially affect all these goals?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Well, first, let me take that last point first. I don't think the CEO transition affects these goals at all. The company is committed to bolstering the pipeline, and we're working aggressively to do that. And actually, would look at deals at all stag",206,"Yes. Well, first, let me take that last point first. I don't think the CEO transition affects these goals at all. The company is committed to bolstering the pipeline, and we're working aggressively to do that. And actually, would look at deals at all stages of development, from preclinical through Phase III, and we are currently doing that. We're in a number of discussions now, and we hope to bring some of those to conclusion. We are focused, largely, on neurology. That's where we have our core expertise, and I think we believe that the -- you can make more sophisticated decisions about things in areas that you understand really in detail. So mainly we're looking in neurology, with Mike's arrival. We have a new person here who's got his own set of expertise, his own views on things. And I would say we're not -- we wouldn't rule out things outside of neurology, but the bar gets higher as they get further from our center of excellence. The -- as Mike put it yesterday, we want to have kind of laser vision, but we don't want to have tunnel vision. We want to be open to things that are interesting and can provide shareholder value."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink Partners."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","George, we're not sure what's so special about California, but all the very best of luck with your next chapter, and thanks again for all the information you've shared with us and for the success you've had at Biogen.",39,"George, we're not sure what's so special about California, but all the very best of luck with your next chapter, and thanks again for all the information you've shared with us and for the success you've had at Biogen."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, Geoff. I would say if you're not sure what's special about it, you haven't been there.",18,"Thank you, Geoff. I would say if you're not sure what's special about it, you haven't been there."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","So one question -- a couple of questions for Michel, actually. Michel, could you give us a sense of what your contributions from price and volume were on the MS franchise during the quarter on the U.S. side and then what your price -- contributional price",115,"So one question -- a couple of questions for Michel, actually. Michel, could you give us a sense of what your contributions from price and volume were on the MS franchise during the quarter on the U.S. side and then what your price -- contributional price effect was on the ex U.S. side? And then could you, secondly, add -- as you look at the MS franchise, presumably, you'll have no role in ocrelizumab's commercialization, but nevertheless, they're your partner. Could you give us your view of how you see that playing out in terms of the effect that, that drug might have in the MS market and on the outlook for Biogen's own products?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks for the question, and let me start with ocre and Paul will comment on the other part of the question. First, I would like to say that we are very pleased, and we applaud any new innovation in MS for which we have contributed, we contribute and will",245,"Thanks for the question, and let me start with ocre and Paul will comment on the other part of the question. First, I would like to say that we are very pleased, and we applaud any new innovation in MS for which we have contributed, we contribute and will continue to invest in our pipe. So this is a great news for patients in need. There are still gaps in therapy, and I think this is a great news. And Roche's results on PPMS is even more encouraging. So we are very happy about that. Having said that, we have a strong presence in the high-efficacy segment of the market, and this is basically a market trend where we can see that basically provide us a treating earlier and physician treating earlier more aggressively. And TYSABRI held -- is holding a very strong position in the high-efficacy segment, and ZINBRYTA will come and will complement this presence there. So I anticipate that ocre will be playing into the segment also, and we will see how it plays. But for the time being, there is no risk-benefit assessment so we have to be very cautious before talking. So I'll wait to see where regulator stands. But I will say that the first approach from, again, a humble but leadership position is to take care of our assets and elevate the capability of the organization, and the 4 capabilities that we are launching will just do that."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Geoff, this is Paul. On the price versus volume question, I think the way you framed it is probably pretty accurate, is that it's a tale of 2 cities. In the United States, the lion's share from a change year-over-year basis is price. And it's pretty stabl",161,"Geoff, this is Paul. On the price versus volume question, I think the way you framed it is probably pretty accurate, is that it's a tale of 2 cities. In the United States, the lion's share from a change year-over-year basis is price. And it's pretty stable unit trends on TECFIDERA, pretty stable unit trends on TYSABRI and modest gradual decline on the interferon franchise. Ex United States, we are not seeing any pricing on a year-over-year basis, and all of the gains are attributable to volume and unit expansion. TYSABRI is holding well outside the United States as well as the interferon business, and we continue to, in a small way, penetrate some markets and get some accretive benefits of things even outside of Europe. And TECFIDERA continues to expand on a year-over-year basis and gaining market share, particularly as we are moving into relatively early launch timing in Southern European countries and having very good success in the U.K."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Congrats, George, good to see you leave on a high note. Best of luck with the next opportunity. Maybe just a quick one for Paul on this new interferon patent you're paying a royalty on or expect to pay a royalty on. Can you clarify a little bit whose pate",76,"Congrats, George, good to see you leave on a high note. Best of luck with the next opportunity. Maybe just a quick one for Paul on this new interferon patent you're paying a royalty on or expect to pay a royalty on. Can you clarify a little bit whose patent that is? And what happened to your own interferon patent that you thought was, at one point, going to be able to extract royalties from others?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Great question, Eric. Thanks. It was, as I noted, unexpected that it is not actually related. Despite it is on the recombinant interferon beta protein, it's actually not the same. It has to do with JFCR. In the Q this afternoon, we'll actually have t",171,"Yes. Great question, Eric. Thanks. It was, as I noted, unexpected that it is not actually related. Despite it is on the recombinant interferon beta protein, it's actually not the same. It has to do with JFCR. In the Q this afternoon, we'll actually have the patent number for you. I actually -- just actually don't have it handy for myself. And it's a mid-single-digit royalty. We aren't disclosing the name of the third party, but -- so just the third party at this point in time. And we expect it will be $50 million impact, all in the second half effectively, and will be a bigger impact as we go into 2017 on a full year basis. The '755 patent, we continue to feel like -- that -- despite it was like back to 2009 when it was issued, but we still feel and we're still in litigation with other parties on that. But there's a chance that we're coming towards the end of that process. Hope for something favorable."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","George, I also want to offer my congrats. You will be missed. So I had a question for Michel, maybe a bigger picture commercial question. Now that you've had a chance to look at the products, the assets at Biogen and a fresh look at the MS market, maybe j",108,"George, I also want to offer my congrats. You will be missed. So I had a question for Michel, maybe a bigger picture commercial question. Now that you've had a chance to look at the products, the assets at Biogen and a fresh look at the MS market, maybe just give us some perspective on what you see as the bigger growth opportunities ahead on a volume basis. Is it geographic? Is it rest of world opportunities? Is it new product launches? And then maybe for Paul. Just want to check and see what you guys learned from the DTC campaign for TEC and the sustainability of that?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you for the great question. In my 25 years experience around the world, I have never seen such a situation whereby we have 5 or 6 assets in the same therapy area. 20 years of those solid, unique, I would say, experience in MS, a solid portfolio t",273,"Thank you for the great question. In my 25 years experience around the world, I have never seen such a situation whereby we have 5 or 6 assets in the same therapy area. 20 years of those solid, unique, I would say, experience in MS, a solid portfolio today, a solid pipeline, a remarkable group of talents of -- with clinical experience and scientific experience within the company. So it's a leadership position on interferons, a leadership position on orals, a leadership position on high-efficacy products. So this is a remarkable situation. And on top of that, we are launching ZINBRYTA. So the dynamic is very good. Having said that, when you peel the onion and you get to discover the opportunity and the operations, you'll find ways to do better. And this is why, together with the team, we have prioritized 4 key areas: portfolio management, 5, 6 assets in the same therapy area. It's a challenge on how to manage that well; commercial excellence; medical leadership; trust and value. And I believe that with those, we'll be able to make further difference. Geographically, also, we can see that some parts are better managed than others. And I have already started to make some decisions. We don't wait, and you can expect that more will come. So this is what I would like to say -- and the portfolio management doesn't mean that all the products will be resourced and promoted equally. It's all about the growth opportunity, the way that you outline, and this is where there will be a clear, I would say, alignment between those resource allocation and execution."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Geoff, the beginning part of your question is, yes, just to confirm, we have sunsetted the television campaign as it relates to TECFIDERA. I think our -- I mean, look, it was a innovative -- I'd applaud our organization for thinking about it and giving it",137,"Geoff, the beginning part of your question is, yes, just to confirm, we have sunsetted the television campaign as it relates to TECFIDERA. I think our -- I mean, look, it was a innovative -- I'd applaud our organization for thinking about it and giving it a try. I think that our judgment at this point is that it didn't have a discernible movement on scripts and potentially came with this more -- as much from anecdotal, with some drawbacks as well. Michel actually confirmed his -- from his perspective that, quite possibly, as much other levers that are still like DTC-related and multichannel-related that we can reallocate resources toward. So I think that's probably our learnings in a nutshell. We didn't run the test case. So we'll see what -- but I think that's our learnings."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, Paul. If I -- this is Michel. If I can add. I mean, at the outset, and I was not here, the main objective was increase awareness, and I think that this was achieved. But I didn't see any inflection on any trends. We need to circle back to the a",86,"Thank you, Paul. If I -- this is Michel. If I can add. I mean, at the outset, and I was not here, the main objective was increase awareness, and I think that this was achieved. But I didn't see any inflection on any trends. We need to circle back to the alignment of the organization on 4 priorities for which we need to have some very strict resource allocation decisions, and I don't think that broadcast TV will be there in the foreseeable future year."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","This is Whitney on for Cory. I'll add my congrats to George as well. I guess just to circle back on Alzheimer's. I guess where are you with the sort of combinations? And I guess what's the desire or urgency to get some of the combos into the clinic before",62,"This is Whitney on for Cory. I'll add my congrats to George as well. I guess just to circle back on Alzheimer's. I guess where are you with the sort of combinations? And I guess what's the desire or urgency to get some of the combos into the clinic before you maybe have Phase III data on any of the individual components?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","This is Al, Whitney. And we like the idea of combination, to think one day we will be using combination therapies for Alzheimer's disease. One of the reasons why we brought in BACE inhibitor into our pipeline with our collaboration with Eisai, the reason",213,"This is Al, Whitney. And we like the idea of combination, to think one day we will be using combination therapies for Alzheimer's disease. One of the reasons why we brought in BACE inhibitor into our pipeline with our collaboration with Eisai, the reason why we have tau programs internally and that we're in search of even other things potentially to add to the mix is based on -- in part on that belief, that combination could be helpful. And you can think of it in 2 ways. One is to combine 2 drugs, each of which are active, to increase the efficacy overall or to reduce the dose of 2 active therapies so that you get better safety or tolerability for the same efficacy. And also, there may be sequential treatments where you start early, perhaps even before symptoms, with one type of medicine and then treat with something else when you have a high plaque burden and then something else still when tau starts to progress. When you start to think about combination therapy though, it's often difficult to do the right studies without some evidence of efficacy of each drug as monotherapy, and then you can start to think about the right dosing regimen. And so I hope that's helpful."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My appreciation to George as well. Happy to see you joining me on the West Coast. I'm lonely out here. So happy to have you back here. A question for Al. There will be LINGO data presented at ECTRIMS. Can you maybe just revisit this briefly and give us so",128,"My appreciation to George as well. Happy to see you joining me on the West Coast. I'm lonely out here. So happy to have you back here. A question for Al. There will be LINGO data presented at ECTRIMS. Can you maybe just revisit this briefly and give us some color about what is going on here in terms of what we saw? Because obviously, that was a surprise. And I guess is there anything specific that we should pay attention to at ECTRIMS that you've done work on that would pique our interest back here? Or is there some issue here with remyelination pathway and that would bring our questions into your oral? So how does this change our thinking about remyelination and what we saw here?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Michael, thanks for the question. So first, I want to say this is a really large and rich data set, really the first of its kind, not only in MS but, to my knowledge, in neurology where we're in the early stages of figuring out how to repair the brai",351,"Yes, Michael, thanks for the question. So first, I want to say this is a really large and rich data set, really the first of its kind, not only in MS but, to my knowledge, in neurology where we're in the early stages of figuring out how to repair the brain and how to measure measurements of outcome, measures of repair. The things we're focusing on right now when we look at this rich data set are what are the right cohort of patients to treat. In this trial, we've looked at relapsing MS patients, all the way to secondary progressive. So it's a wide range of patients. What's the right -- what's the optimal cohort? What's the right dose? We studied 4 different doses, and we saw a complex dose response curve. What we actually saw was sort of a bell-shaped curve where we lost efficacy at the highest dose, and then the middle doses, we think we see a signal of efficacy. And so we'll share some of that at ECTRIMS. What's the right concomitant medicine to use? We envision that these repair therapies will be added to immunomodulators, and so we'll be looking at that and, in particular, whether ongoing inflammation in the brain impedes repair. And finally, how do we actually measure the effects of repair if it occurs, particularly, on clinical outcome measures? So some of these questions will be answered by doing further analyses, which we're in the middle of doing right now, intensively, and we'll share whatever we find out at ECTRIMS. And some may need another study. And so what we're honing in on is what's the next step, what's the next study? And obviously, this will be a judicious investment. If we can go to Phase III, we would try. I don't know until I see the specific design. It's -- it could be a Phase II, it could be a Phase III, it could be a Phase II/III. And that part, we probably won't be able to share at ECTRIMS, but sometime soon, we hope to be able to share that."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","I guess thinking about George, I remember meeting you when you first became the CEO, and I remember you talking about reasons for joining the company and that you were [indiscernible] pipeline product was so well needed. At the time, it really changed Bio",84,"I guess thinking about George, I remember meeting you when you first became the CEO, and I remember you talking about reasons for joining the company and that you were [indiscernible] pipeline product was so well needed. At the time, it really changed Biogen. And so now the company is a different company and there's been pipeline success and there's been some failures, what do you think Biogen really needs from a new CEO at this point in time versus when you came in?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Well, look, the company now is a very different company from what it was a few years ago. We have a full and excellent management team. We have a pipeline that is, I think, quite exciting but needs to be to grow. So I think the company needs good manageme",193,"Well, look, the company now is a very different company from what it was a few years ago. We have a full and excellent management team. We have a pipeline that is, I think, quite exciting but needs to be to grow. So I think the company needs good management. I think the strategy of the company is solid, and what we need is good leadership and somebody who can work with the people who are here, work with Michel to maximize the commercial potential, work with Mike, commercialize the potential of our pipeline, grow the pipeline and can work with the rest of the organization to ensure that we go forward in a way that is responsible, where we minimize expenses but that where we invest aggressively in those areas that really have the potential to add value. So being CEO is complicated, and I think those are the -- those are priorities I would set. Of course, the search will be conducted by the board, but I don't think they would do it too differently. I think there'll be a continued focus on innovation, and I'm confident we'll get someone excellent."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ronny Gal from Bernstein.",12,"Your next question comes from the line of Ronny Gal from Bernstein."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Two questions. First, biosimilars. You had a pretty good first quarter. Can you describe a little bit to us where you've launched already, where you're still expecting to launch? And now that you're a little bit of -- wetted your feet in that market, coul",172,"Two questions. First, biosimilars. You had a pretty good first quarter. Can you describe a little bit to us where you've launched already, where you're still expecting to launch? And now that you're a little bit of -- wetted your feet in that market, could you just give us a feel for your thinking about kind of the 3- to 5-year trajectory for this franchise and for biosimilar, for anti-TNF in Europe in general? Should this be 30% of the market, 50%, 70% of the market overall? And then separately, you kind of mentioned the impact of high deductible co-pays on the U.S. sales in the first quarter. Has there been still some impact to those in the second quarter? That is, as we look from the outside of revenue, should we see another step-up in revenue beginning in the third quarter? Or has it been fully incorporated in the first quarter and kind of the run rate for pricing in the second quarter is roughly what we should see going forward?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","So this is Michel. Thanks for the great question. So as you have seen, 2 great companies came together with complementary capabilities in order to launch anti-TNFs, to get started with, and then we see what these -- the follow-up opportunities. So as far",237,"So this is Michel. Thanks for the great question. So as you have seen, 2 great companies came together with complementary capabilities in order to launch anti-TNFs, to get started with, and then we see what these -- the follow-up opportunities. So as far as Biogen is involved, together with the partners, we have launched the products, the 3 anti-TNFs that we -- for which we have the agreement on. Two out of the 3 are approved and are underway to be launched. The preliminary results are very encouraging. As you can imagine, there is a tremendous level of variation viability between countries in terms of tendering, in terms of aggressivity of competition, in terms of provider decision-making, and it's difficult to take an overall, I would say, recipe on how to best launch. What I can say is that the 3 anti-TNFs that we'll have the opportunity to launch will be addressing a current market that is higher than $9 billion in Europe. So this is significant and with Biogen quality. So we have put together a stand-alone BU that is flexible, agile in order to launch the product. And we learn country after country, today, mostly in the Nordics and Scandinavia, where we have had very, very good results. But as I said earlier, it's still early to comment much on the results that are negligible for 2016, but will be more important moving forward."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Ronny, this is Paul. Thanks for the second part of that question. It's a good catch. I think that the answer is that we absolutely saw insurance dynamics mostly impact AVONEX in the first quarter and we're pleased to see that, that choppiness settled out",66,"Ronny, this is Paul. Thanks for the second part of that question. It's a good catch. I think that the answer is that we absolutely saw insurance dynamics mostly impact AVONEX in the first quarter and we're pleased to see that, that choppiness settled out and benefited the second quarter results. Don't expect it to be meaningful or different for the balance of the year now."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","And your final question comes from the line of Chris Raymond from Raymond James.",14,"And your final question comes from the line of Chris Raymond from Raymond James."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","And congrats, George, from us as well. Just a question, I guess, on TECFIDERA. In the context of -- I think you highlighted in Q1 a $20 million inventory drawdown. Could you maybe quantify -- I think you highlighted, generally, there was an inventory effe",155,"And congrats, George, from us as well. Just a question, I guess, on TECFIDERA. In the context of -- I think you highlighted in Q1 a $20 million inventory drawdown. Could you maybe quantify -- I think you highlighted, generally, there was an inventory effect in Q2. Can you quantify what that was? And then also, if I can, on TECFIDERA continuing. I hear what you're saying on the television ads, but one of the things that has sort of struck us the most with our checks is TECFIDERA, for some time, has been sort of far and away the most requested disease-modifying therapy among patients. I guess I'm wondering what additional levers can you pull to sort of increase that. Or is there some other aspect, like maybe working at better efficiency programs to get that request converted into a script? Is there some other aspect besides just getting patients to request the drug?"
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Thanks, Chris. It's Paul, I'll take the first part. It's quite simply -- I think we're at pretty normal inventory levels on TECFIDERA, so it's really just a sequential quarter rebalancing off of this -- the seasonal low that we generally see in Q1.",45,"Yes. Thanks, Chris. It's Paul, I'll take the first part. It's quite simply -- I think we're at pretty normal inventory levels on TECFIDERA, so it's really just a sequential quarter rebalancing off of this -- the seasonal low that we generally see in Q1."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","So on the levers and the performance. 12% growth q-over-q is not bad. The share continues to grow to 15% globally is also pretty good, mostly driven by the newly launched markets in Europe. 40% patient share -- patients growth percentage is also very enco",189,"So on the levers and the performance. 12% growth q-over-q is not bad. The share continues to grow to 15% globally is also pretty good, mostly driven by the newly launched markets in Europe. 40% patient share -- patients growth percentage is also very encouraging. I have, for my field visits and from talking to leaders, identified one major issue, which is the discontinuation due to GI safety. Those patients, during the first phase on the product, are suffering, for some of them, on abdominal pain, diarrhea, discomfort that is leading, in some cases, with very high level of viability to discontinue on the product. And this impacts not only the outflow but, eventually, the inflow. Viability is tremendous. I was in the field lately and -- on the Eastern Coast in the U.S. 1.5% of the patient discontinued at 6 months. In some others, it was 30%. So with Mike Ehlers, we are fully aligned in order to work together with the community, with the physicians, with the peer-to-peer in order to best assess, best educate and bring down an average, which is 20% today, to lower levels."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. With that, I thank you all for joining us this morning. Thanks for the questions, and we'll sign off now. Thank you.",23,"Okay. With that, I thank you all for joining us this morning. Thanks for the questions, and we'll sign off now. Thank you."
29726,366896620,1009744,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the call o",57,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the call over to Mr. Matt Calistri, Senior Director of Investor Relations. Please go ahead."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Dan. Thank you, everyone, and welcome to Biogen Second Quarter 2016 Earnings Conference Call.Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a r",219,"Thanks, Dan. Thank you, everyone, and welcome to Biogen Second Quarter 2016 Earnings Conference Call.
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 includes the reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We have also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Michael Ehlers, EVP of Research and Development; our Chief Commercial Officer, Michel Vounatsos; and our CFO, Paul Clancy. We'll also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock. 
Now I'll turn the call over to George."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Matt, and good morning, everyone. Thanks for joining us. I'd like to begin with a personal statement. I'll be stepping down as CEO of a Biogen sometime within the next few months. The board and I recognize that this is an excellent time",1080,"Okay. Thank you, Matt, and good morning, everyone. Thanks for joining us. 
I'd like to begin with a personal statement. I'll be stepping down as CEO of a Biogen sometime within the next few months. The board and I recognize that this is an excellent time for a transition. The company is doing well now. The management team is complete and extremely capable. The commercial and R&D activities are going well, and we're on our way to adding to the pipeline through internal and external opportunities. So a good time for a new CEO to take the helm and see Biogen through to what I believe is a very exciting future. This also is an opportune time for me to return to the West Coast, take on one more set of activities and spend more time with my family. 
I've been at Biogen for 6 years. I'm proud of the company and what we've been able to accomplish in that time. We've introduced 6 new products on to the market and increased our revenues, earnings and stock price all by severalfold, and I believe that we're well positioned to keep delivering on our potential to bring even more therapies to patients and returns to our investors. Our R&D and commercial organizations are now world class, joining our already industry-leading biologics manufacturing capabilities. All aspects of the company are operating at a high level. We have brought several potentially game-changing compounds into later-stage development and are in the process of adding further to that pipeline. With the addition of Michel Vounatsos, Mike Ehlers and Paul McKenzie, the company has a full and vibrant leadership team that's capable of moving the company thoughtfully forward. I truly believe that the company has a bright future, and it's with mixed emotions that I leave at this time and not see that future come fully to fruition. 
We're making the announcement now in order to provide an orderly transition for the company and to allow the board to conduct an open and effective search. I'll work with the board to find a great successor who can continue to build on what we have accomplished. We expect to consider both internal and external candidates, and I'm confident that we'll identify an outstanding new leader. I expect to remain as CEO until a successor is identified and can begin. In the interim, I continue to work with the board and management team to accomplish Biogen's goals for 2016. I believe that we're on a good trajectory, that we have great new additions to the management team and I look forward to a successful second half of the year. 
So enough about me. Let's turn to the business. Biogen had a solid second quarter, delivering strong financial performance and important advances in our pipeline. For the second quarter of 2016, Biogen generated $2.9 billion in total revenues, a 12% increase from the same period a year ago. Our GAAP earnings were $4.79 per share, a 22% increase year-over-year, and non-GAAP EPS was $5.21, a 23% increase year-over-year. We continue to grow our leading MS franchise and our hemophilia business, and our efforts to maximize revenues while thoughtfully managing expenses helped to drive attractive earnings growth. As a result, we've raised our financial guidance for the full year. And today, we announced that our Board of Directors has authorized a program to repurchase up to $5 billion of our common stock. 
Looking back, we had quite an eventful second quarter. To begin, we welcome 3 new members of our management team, a new Head of Commercial, Michel Vounatsos, joined us in April. He's completed a thorough assessment and has identified 4 key priorities for driving our MS business forward, which he'll share with you later in this call. Our new Head of R&D, Mike Ehlers, joined us at the end of May. Mike is a brilliant neuroscientist and an established R&D leader who has excelled in both academic and corporate settings. Mike has demonstrated the ability to translate science into the development of important new medicines, and he's already bringing terrific leadership to the organization. And finally, with John Cox preparing to lead the new hemophilia company, we promoted Paul McKenzie to oversee our Pharmaceutical Operations and Technology group. These 3 new leaders bring a wealth of experience and expertise, and we believe that they're poised to take Biogen into its next phase of growth. I'm proud to have them in our organization. 
Last quarter brought a number of positive developments for both our commercial products and our pipeline. We announced our intent to spin off our hemophilia business. That business continues to perform well with combined second quarter revenues of over $200 million for ELOCTATE and ALPROLIX. ALPROLIX also was approved by the European Commission for the treatment of hemophilia B and will be commercialized in the EU by our collaboration partner, Sobi. We had a positive label update for TYSABRI in Europe, including an extended indication. We received regulatory approval for ZINBRYTA in both the U.S. and the EU for the treatment of relapsing MS. FLIXABI an infliximab biosimilar referencing Remicade, received approval in Europe. This will be the second anti-TNF biosimilar that we'll manufacture and commercialize in the EU. And SB5, an adalimumab biosimilar candidate referencing Humira, has been accepted for review by the European Medicines Agency. Aducanumab was accepted into the European Medicines Agency's PRIority MEdicines program, known as PRIME. It was one of only 4 applications accepted out of 18 submitted and the only Alzheimer's disease therapy in development that was accepted. On the early-stage research front, we entered into a broad collaboration and alliance with the University of Pennsylvania and 2 world-renowned gene therapy experts, Drs. James Wilson and Jean Bennett. 
This quarter, we also reported the top line results of the SYNERGY trial for opicinumab. As you are all aware, opicinumab missed both the primary and secondary endpoints. It was -- certainly was disappointing. However, the rigorous design and planning of SYNERGY has yielded an abundance of data that will help us make a well-informed decision about our path forward with opicinumab and our work in remyelination generally. These results are indicative of the significant challenge of targeting neurorepair. During the upcoming ECTRIMS conference in September, we expect to present more detailed efficacy, biomarker and safety data. 
I'll now turn the call over to Mike, and we're eager for you to get to know Mike and experience his passion for our business."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, George, and good morning, everyone. By way of introduction, I spent a number of years in academia as professor and Howard Hughes Medical Institute investigator at Duke University, where my research was focused on cell biological and circuit mec",754,"Thank you, George, and good morning, everyone. By way of introduction, I spent a number of years in academia as professor and Howard Hughes Medical Institute investigator at Duke University, where my research was focused on cell biological and circuit mechanisms of brain function in the normal, developing and diseased nervous system. My career took an exciting turn 6 years ago when I joined Pfizer. I served as the Chief Scientific Officer for the company's Neuroscience and Pain Research Unit and, ultimately, became group leader for BioTherapeutics R&D with responsibility over rare disease, the centers for therapeutic innovation and all large biomolecule sciences. 
I'm just now finishing my second month at Biogen, so there is still a lot I'm getting up to speed on. But I can tell you from the outset that I am working to reshape and progress our pipeline while aggressively pursuing promising assets, both internally and externally. I plan to update you on progress on these fronts in the future. In the meantime, I will comment on the important clinical study readouts this quarter and note some good progress made in advancing our clinical programs. 
Starting with opicinumab, or anti-LINGO, as George discussed. The top line results from the Phase II SYNERGY study were reported in which opicinumab unfortunately missed both the primary and secondary endpoints. However, evidence of a clinical effect with a complex, unexpected dose response was observed. The SYNERGY top line efficacy safety and biomarker results will be presented at ECTRIMS in September. 
Continuing in MS. EC approval was received for an extended indication for TYSABRI in highly active, relapsing-remitting MS patients with inadequate response to prior MS therapy. TYSABRI was previously only indicated for patients who had failed to respond to beta interferon or a glatiramer acetate. This label extension follows recent EC approval for a new patient management plan, including an updated risk algorithm based on JC virus antibody index values. These changes will allow physicians to have more individualized benefit risk discussions with their patients. 
Turning to other promising late-stage assets. Our collaboration partner, Ionis, continues to execute the Phase III studies of nusinersen for infants and children with spinal muscular atrophy, both of which are now fully enrolled. In Alzheimer's disease, it was recently announced that aducanumab was one of only 4 applicants accepted into the European Medicine Agency's PRIority MEdicines program, or PRIME. PRIME aims to bring treatments to patients faster by enhancing the EMA's support for the development of investigational medicines for diseases without available treatment or in need of better treatment options. We continue to work diligently to enroll our aducanumab Phase III trials. Looking ahead, safety data from the titration arm of the Phase 1b study is anticipated by the end of this year. We are working toward the start of Phase III trials for amiselimod or MT-1303 in inflammatory bowel disease and BIIB074, formerly known as raxatrigine, in trigeminal neuralgia. An initiation of the Phase II trial with BIIB074 in patients with neuropathic pain from lumbosacral radiculopathy is planned for later this year. 
In further activities, natalizumab's clinical profile and treatment window supports its continued investigation as a potential novel approach for treating acute ischemic stroke, and the first patient was recently dosed in a second Phase II study in stroke called ACTION 2. Encouraging data was recently generated on earlier-stage assets, BIIB059 or anti-BDCA2 for systemic lupus erythematosus and BG11 (sic) [ BG00011 ] or STX-100 for idiopathic pulmonary fibrosis. Anti-BDCA2 data in healthy volunteers and a lupus cohort of 12 subjects has provided confidence to move into Phase II with trial initiation planned to begin over the summer. These data are anticipated to be presented later this year. The BG11 study is enrolling its final cohort and it is expected that data will be presented after the trial completes. 
Finally, as George mentioned, Biogen announced the broad collaboration and alliance with the University of Pennsylvania and Dr. James Wilson and Jean Bennett to advance gene therapy and gene editing technologies. The expansive research and translational development collaboration has multiple objectives and will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system. 
Again, I am pleased to participate in my first earnings call here at Biogen. I anticipate sharing more detail on the advancement of the Biogen pipeline in the coming months as the company works diligently to deliver new therapies to patients. 
With that, I will now pass the call to my good colleague, Michel Vounatsos."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Mike. I'm very pleased to be with you this morning. I share my initial thoughts on the MS market and our MS portfolio, outline my priorities going forward and then I will discuss this quarter's results for MS products. Since I arrived at Biogen",1132,"Thanks, Mike. I'm very pleased to be with you this morning. I share my initial thoughts on the MS market and our MS portfolio, outline my priorities going forward and then I will discuss this quarter's results for MS products. 
Since I arrived at Biogen 3 months ago, I have spent time in the field with our operations team, meeting with patients, the neurology community and many of the scientific leaders in multiple sclerosis. Also, I have engaged with the strong Biogen leaders across our commercial organizations. I have listened and learned a lot, and together with the team, we have prioritized immediate opportunities across 4 key areas. We believe these opportunities will benefit our MS franchise today and, at the same time, prepare the organization for potential future product launches. 
Before speaking about our therapies, I think it is important to note, MS is a growing market with approximately 850,000 treated patients worldwide out of a global prevalence estimated at 2.3 million, which includes progressive forms of MS. We estimate the number of treated patients worldwide is growing in the mid-single digits on an annual basis, driven by low single-digit growth in the U.S. and high single-digit growth in Europe. The relatively higher market growth rate overseas is largely due to increasing rate of diagnosis and treatment. And as a leader in MS, we believe we are well positioned to benefit from this trend over time. 
Using the U.S. as an example, where we have the most detailed data, we estimate that approximately 3/4 of the 300,000 treated patients are stable and presumably satisfied on the current therapy. We believe Biogen is holding a clear leadership position in this stable segment of the market. We believe the dynamic opportunity of patients in the U.S. is comprised of approximately 15,000 newly diagnosed patients and approximately 60,000 patients changing medication each year. We believe that Biogen also holds a leadership position in new patient starts within this dynamic portion of the market. 
Turning to our MS portfolio. We believe that the value of our products is well recognized in the eyes of many of our customers, as reflected in our leading global market share of approximately 38%. We believe the breadth of our portfolio is and will continue to be a source of strength in the marketplace by allowing physician to prescribe the right drug to the right patient at the right time.   
As the most prescribed oral therapy for MS worldwide, TECFIDERA benefits from a compelling combination of efficacy, convenience and relative safety. As a result, we estimate that TECFIDERA captures roughly 25% of newly diagnosed and switching patients. Our market research indicates that TYSABRI is clearly viewed as differentiated in terms of efficacy and retains an important role for patients with highly active disease, capturing roughly 30% of all patients switching for efficacy reasons. Our interferon products, AVONEX and PLEGRIDY, combined, hold leading share amongst the interferon therapies. Despite facing headwinds due to the uptake of the orals, we believe these products will continue to play an important role going forward. We are also preparing to launch ZINBRYTA next month in the U.S and Germany. ZINBRYTA is the first in a new class of MS therapy. We believe it will be used by patients switching for efficacy reasons, benefiting from ""once monthly at home"" subcutaneous administration and a differentiated mechanism of action. 
Going forward, we will concentrate our work in the commercial organization across 4 key priorities, namely portfolio strategy, commercial excellence, medical leadership, trust and value. With portfolio strategy, we plan to further define our strategy for products, market segments and geographies. We will work to ensure that our targeted growth opportunities drive consistency across our resource allocation, messaging, marketing tactics and sales force execution. Within commercial excellence, we will work to increase our sophistication in multichannel marketing, including enhancing our digital capabilities while also strengthening our engagement with key customers at the local level. While clearly perceived as a leader in neurology research and clinical development, we believe we also have an opportunity to further enhance our medical leadership. This includes close collaboration with our medical field teams and partnership with scientific leaders. Finally, trust and value. We will work towards developing innovative beyond-the-pill solution for our customers to enhance our reputation and strengthen our partnership and role as a leader in MS. I think that as the leader in MS, we have this responsibility. 
Today, we already have a well-defined plan outlining next steps and target dates, which we have started to implement across the organization. We are initiating this with the aim to accelerate our business to be more focused, to make conscious choices and to be diligent in resource allocation. We believe that this work will be beneficial for our company and our shareholders. For competitive reasons, I am not prepared to go more into the details of these 4 initiatives, but I look forward to updating you on our progress at future meetings. 
Turning to the results for the quarter. Total MS revenues were $2.2 billion this quarter, an increase of 9% versus Q2 of last year. We believe our global market share continues to grow. 
Starting with TECFIDERA. In the U.S., we saw a modest increase in demands compared to the first quarter, largely due to normalization of the seasonality typically seen early in the year. All of our metric lead us to expect a continued, stable trend for TECFIDERA going forward. Outside the U.S., we continue to see increased adoption in the U.K., Italy, Spain. In fact, the number of TECFIDERA patients in Europe has increased approximately 40% over the last year. 
PLEGRIDY is now available in roughly 20 markets in Europe, and where launched, we believe it is helping to slow the rate of decline of our interferons. 
TYSABRI continued to add patient this quarter. We recognize the potential for increased competition from other high-efficacy therapies, but we believe TYSABRI's 10 years of post-marketing experience and well-understood safety profile position it very well. 
In collaboration with AbbVie, we are actively preparing to launch ZINBRYTA starting next month. We are particularly encouraged by the broad indication and data, reinforcing the product safety included in the EU label. 
We are also making progress in our biosimilar business this quarter. We are seeing strong initial update for BENEPALI, the first biosimilar approved in the EU referencing Enbrel, and we expect to launch FLIXABI, our biosimilar referencing Remicade, in the coming weeks. While we only expect a modest contribution from biosimilars in 2016, we do believe this is an attractive opportunity in the longer term. 
So the team delivered a very solid quarter. I look forward to taking Biogen into what I believe is an exciting future. 
With that, I turn the call over to Paul."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks, Michel. In the second quarter, our GAAP diluted earnings per share were $4.79, a 22% increase year-over-year, while our none-GAAP diluted earnings per share were $5.21, an increase of 23%. Total revenue for Q2 grew 12% year-over-year to approximat",1141,"Thanks, Michel. In the second quarter, our GAAP diluted earnings per share were $4.79, a 22% increase year-over-year, while our none-GAAP diluted earnings per share were $5.21, an increase of 23%. Total revenue for Q2 grew 12% year-over-year to approximately $2.9 billion. It's important to note we had $173 million in foreign exchange hedge gains in the full year of 2015, which impact our year-over-year revenue comparisons this year. In Q2, versus prior year, revenues were unfavorably impacted by $45 million from hedging. Combined with the $1 million benefit from foreign exchange rates, overall revenue was weakened by approximately $44 million year-over-year. I'll highlight the impact of foreign exchange in hedging on each of our major MS therapies. 
Global second quarter TECFIDERA revenue was $987 million, an increase of 12% versus the same quarter last year. This included revenues of $780 million in the U.S. and $206 million outside the U.S. In the U.S., TECFIDERA modestly benefited from an inventory rebalancing in the wholesaler channel versus prior quarter. Outside the U.S., foreign exchange and hedge impact weakened TECFIDERA revenue comparison by approximately $13 million. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $728 million during the second quarter, an increase of 6% versus the same quarter last year. This included $519 million in the U.S. and $209 million in sales outside the U.S. In the U.S., AVONEX also modestly benefited from an inventory rebalancing in the wholesaler channel versus prior quarter. Outside the U.S., foreign exchange and the hedge impact weakened interferon revenue comparison by approximately $17 million. 
TYSABRI worldwide revenues were $497 million this quarter, an increase of 7% versus the same quarter last year. This included $305 million in the U.S. and $192 million outside the U.S. Foreign exchange and the hedge impact weakened TYSABRI revenue comparison by approximately $13 million. 
Turning to our hemophilia business, which generated $205 million this quarter. ELOCTATE revenue for the quarter was $125 million, and ALPROLIX revenue in Q2 was $80 million. We continue to work towards spinning off our hemophilia business and related assets and plan to file the Form 10 later this summer and complete the distribution in early 2017. 
Turning to our anti-CD20 revenues. We recorded $349 million for Q2, an increase from prior quarter, driven by solid demand. Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing, were $79 million. 
Now turning to the expense lines on the P&L. Q2 GAAP cost of goods sold were $370 million or 13% of revenue. Non-GAAP cost of goods sold were $354 million or 12% of revenue. As a percentage of sales, COGS was impacted by increased inventory write-offs versus the lows seen in prior quarter. In addition, based on our evaluation of our small-scale manufacturing capacity needs, we booked a GAAP-only charge for accelerated depreciation related to our intent to close or divest our small-scale manufacturing facility in Cambridge. 
Q2 GAAP and non-GAAP R&D expense was $473 million or 16% of revenue, which includes $20 million related to the gene therapy collaboration with the University of Pennsylvania. Overall, R&D reflects relatively low business development expense, though this remains a critical strategic priority for us as we look to bring in high-quality assets. 
Q2 GAAP SG&A was $492 million or 17% of revenue. Q2 non-GAAP SG&A expense was $489 million, also 17% of revenue. We remain committed to achieving savings by reducing lower priorities and services for the balance of the year. Recall, over the last few years, we've gone through a number of product launches and thought it was the right decision to invest behind these products. Starting in 2015, we pivoted and took a number of actions to curb operating expense growth, including a restructuring and further efforts to reduce costs, which is reflected in our operating leverage for the quarter. This will also allow us to reinvest in the pipeline. Other net expense was $59 million in Q2, which includes $66 million in interest expense related to our 2015 bond offering. 
In Q2, both our GAAP and non-GAAP tax rates were approximately 25%. Our weighted average diluted share count was approximately $219 million for Q2. This brings us to our diluted earnings per share, which were $4.79 on a GAAP basis and $5.21 on a non-GAAP basis for the second quarter. We ended the quarter with approximately $7.3 billion in cash and marketable securities with approximately 40% of this in the United States. Today, we also announced a $5 billion share repurchase program, which we anticipate will be executed over the course of the next 3 years. We believe this leaves ample room for flexibility for strategic deployment. 
So overall, we had a strong quarter, driven by revenue growth from our MS therapies rebounding from the seasonality seen in the first quarter, continued growth from our hemophilia business and diligent cost controls. 
This now brings us to our full year 2016 guidance. We now expect revenues of approximately $11.2 billion to $11.4 billion, a modest improvement from prior guidance. Our outlook assumes continued stable demand, patient demand for TECFIDERA in 2016 in the United States. We believe TYSABRI will also remain on a stable trajectory for the balance of the year. Our outlook assumes AVONEX and PLEGRIDY patients, combined, will continue to gradually decline as patients move toward orals. For ZINBRYTA, we anticipate a modest revenue contribution in the U.S. and EU as launches are expected to begin in August. And our revenues outlook is based on stable foreign exchange rates. 
From an expense perspective, we anticipate upward pressure on cost of goods sold due to the unexpected issuance by the U.S. Patent Office of a patent to a third party related to recombinant interferon beta protein. This patent, issued on June 28 and expiring in June 2033, is relevant to AVONEX and PLEGRIDY. We will play -- pay royalties in the mid-single digits during the life of this patent. For the remainder of 2016, we expect the royalty payment to be approximately $50 million. We anticipate GAAP and non-GAAP R&D expense between 17% and 18% of sales and GAAP and non-GAAP SG&A expense to be between 16% and 17% of revenue. We anticipate GAAP EPS results between $18.10 and $18.40 and non-GAAP EPS to be between $19.70 and $20. Our outlook assumes a very modest reduction in our full year weighted average diluted share count. 
Of note, this guidance assumes contribution from our hemophilia business through the balance of the year as we expect the spin-off to complete in early 2017. Additionally, this guidance does not include any impact from potential acquisitions or large late-stage business development transactions as both are hard to predict. Overall, this increase in guidance reflects the solid revenues seen this quarter, combined with the continued operating expense control. 
I'll turn the call over to George for his closing comments."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Paul. Look, financially, I'm pleased with where we are so far this year. Our results year-to-date have been better than expected. We've raised guidance, and we have a new share repurchase program authorized by the board. We have made good",415,"Okay. Thank you, Paul. Look, financially, I'm pleased with where we are so far this year. Our results year-to-date have been better than expected. We've raised guidance, and we have a new share repurchase program authorized by the board. We have made good progress towards the 3 focus areas I discussed after the first quarter: careful management of expenses, maximizing revenues and rapidly advancing the pipeline. 
As I look forward and think about the future growth of Biogen, I want to stress how those key focus areas will evolve. The team expects to continue managing expenses, but as you know, we can't save our way to growth. Maximizing revenues and rapidly advancing the pipeline will become front and center, especially with Michel and Mike now in their respective roles. Michel's 4 key priorities of portfolio strategy, commercial excellence, medical leadership and trust and value will be the pillars we use to maximize revenues. And under Mike's leadership, we intend to reshape the pipeline, rationalize existing programs and aggressively pursue promising assets, both internally and externally. We believe this focus will help advance more assets through the pipeline and ideally deliver more therapies to patients. 
At the same time as we're bringing focus and investment to our core area of expertise in neurology, we'll continue to be opportunistic when we see internal and external opportunities to enhance shareholder value. As a result, we have progressed some of the most promising earlier-stage assets that we have in our pipeline even outside of neurology. We have invested in our biosimilar joint venture to leverage our competitive strengths in manufacturing and commercialization. We've chosen to spin-off our growing hemophilia business because we believe it's the right decision to ensure fit and focus. And as we've announced today, we'll buy back shares when appropriate. 
So we've delivered strong financial results this quarter while making progress advancing our pipeline and our commercial business. We have a great leadership team and a passionate group of employees who come to work every day to make a positive impact on patients' lives. It's been an honor and a privilege to serve this organization as the CEO for the last 6 years, and I remain committed to leading the company until my successor is identified. 
I want to take this opportunity to thank all of our employees for their hard work and dedication. And I want to thank you, all, for joining us this morning. 
And operator, we'll now open up the call for questions."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Mark Schoenebaum from Evercore ISI.",15,"[Operator Instructions] Your first question comes from the line of Mark Schoenebaum from Evercore ISI."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Just one. George, I want to say I just -- the stock only quintupled under your leadership, so I was wondering if you could -- yes, I think you should be held accountable for that. So I was wondering if you could address that. No, congratulations. You will",85,"Just one. George, I want to say I just -- the stock only quintupled under your leadership, so I was wondering if you could -- yes, I think you should be held accountable for that. So I was wondering if you could address that. No, congratulations. You will be missed. Thanks for the honesty, transparency that you brought to Biogen over the years. And I'd like to know who your least favorite sell-side analyst is, please? Or not -- assure me that it's not me."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","It's definitely not you.",5,"It's definitely not you."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Okay, Got it.",3,"Okay, Got it."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Especially after that last comment.",5,"Especially after that last comment."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Okay, Very good. And Paul, good [indiscernible] management of the...",10,"Okay, Very good. And Paul, good [indiscernible] management of the..."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","You moved up from the bottom, Mark.",7,"You moved up from the bottom, Mark."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My question is -- this has been asked before, but I just want to kind of engage you guys in a little bit of discussion. Why not release the efficacy data from the titration cohort of the amaB trial, given that -- I know it's small numbers, but the numbers",101,"My question is -- this has been asked before, but I just want to kind of engage you guys in a little bit of discussion. Why not release the efficacy data from the titration cohort of the amaB trial, given that -- I know it's small numbers, but the numbers aren't that much smaller than the individual dose arms we've already seen. And the follow-up is just can you update us with any specifics on enrollment? Is enrollment tracking within your expectations? And can you just remind us at this point when you'd expect data readouts and if there are interims?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Mark, this is Al. So yes, I mean, it makes sense that the number of patients is roughly the same. Our plan is to introduce the safety data, the tolerability data from the titration. But -- and efficacy is an exploratory endpoint. I'm sure, at some scienti",92,"Mark, this is Al. So yes, I mean, it makes sense that the number of patients is roughly the same. Our plan is to introduce the safety data, the tolerability data from the titration. But -- and efficacy is an exploratory endpoint. I'm sure, at some scientific meeting, we'll be able to disclose that for completeness sake. And in terms of enrollment, we're not really commenting on it except to say that we're pleased and that things are on track, and we hope to update you more on that in the future."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams from Jefferies.",12,"Your next question comes from the line of Brian Abrahams from Jefferies."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My congrats to George as well on all your accomplishments, and best of luck in the future. I guess a question on the business development front. As you talk about aggressively reshaping the pipeline and pursuing promising assets, I'm curious your latest t",92,"My congrats to George as well on all your accomplishments, and best of luck in the future. I guess a question on the business development front. As you talk about aggressively reshaping the pipeline and pursuing promising assets, I'm curious your latest thinking in terms of stage development, size of potential deals, the types of assets therapeutically that you might focus on. How are you thinking these days about balancing maintenance of -- focus on neurology versus further diversifying the business? And how does the CEO transition potentially affect all these goals?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Well, first, let me take that last point first. I don't think the CEO transition affects these goals at all. The company is committed to bolstering the pipeline, and we're working aggressively to do that. And actually, would look at deals at all stag",206,"Yes. Well, first, let me take that last point first. I don't think the CEO transition affects these goals at all. The company is committed to bolstering the pipeline, and we're working aggressively to do that. And actually, would look at deals at all stages of development, from preclinical through Phase III, and we are currently doing that. We're in a number of discussions now, and we hope to bring some of those to conclusion. We are focused, largely, on neurology. That's where we have our core expertise, and I think we believe that the -- you can make more sophisticated decisions about things in areas that you understand really in detail. So mainly we're looking in neurology, with Mike's arrival. We have a new person here who's got his own set of expertise, his own views on things. And I would say we're not -- we wouldn't rule out things outside of neurology, but the bar gets higher as they get further from our center of excellence. The -- as Mike put it yesterday, we want to have kind of laser vision, but we don't want to have tunnel vision. We want to be open to things that are interesting and can provide shareholder value."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink Partners."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","George, we're not sure what's so special about California, but all the very best of luck with your next chapter, and thanks again for all the information you've shared with us and for the success you've had at Biogen.",39,"George, we're not sure what's so special about California, but all the very best of luck with your next chapter, and thanks again for all the information you've shared with us and for the success you've had at Biogen."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, Geoff. I would say if you're not sure what's special about it, you haven't been there.",18,"Thank you, Geoff. I would say if you're not sure what's special about it, you haven't been there."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","So one question -- a couple of questions for Michel, actually. Michel, could you give us a sense of what your contributions from price and volume were on the MS franchise during the quarter on the U.S. side and then what your price -- contributional price",115,"So one question -- a couple of questions for Michel, actually. Michel, could you give us a sense of what your contributions from price and volume were on the MS franchise during the quarter on the U.S. side and then what your price -- contributional price effect was on the ex U.S. side? And then could you, secondly, add -- as you look at the MS franchise, presumably, you'll have no role in ocrelizumab's commercialization, but nevertheless, they're your partner. Could you give us your view of how you see that playing out in terms of the effect that, that drug might have in the MS market and on the outlook for Biogen's own products?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thanks for the question, and let me start with ocre and Paul will comment on the other part of the question. First, I would like to say that we are very pleased, and we applaud any new innovation in MS for which we have contributed, we contribute and will",245,"Thanks for the question, and let me start with ocre and Paul will comment on the other part of the question. First, I would like to say that we are very pleased, and we applaud any new innovation in MS for which we have contributed, we contribute and will continue to invest in our pipe. So this is a great news for patients in need. There are still gaps in therapy, and I think this is a great news. And Roche's results on PPMS is even more encouraging. So we are very happy about that. Having said that, we have a strong presence in the high-efficacy segment of the market, and this is basically a market trend where we can see that basically provide us a treating earlier and physician treating earlier more aggressively. And TYSABRI held -- is holding a very strong position in the high-efficacy segment, and ZINBRYTA will come and will complement this presence there. So I anticipate that ocre will be playing into the segment also, and we will see how it plays. But for the time being, there is no risk-benefit assessment so we have to be very cautious before talking. So I'll wait to see where regulator stands. But I will say that the first approach from, again, a humble but leadership position is to take care of our assets and elevate the capability of the organization, and the 4 capabilities that we are launching will just do that."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Geoff, this is Paul. On the price versus volume question, I think the way you framed it is probably pretty accurate, is that it's a tale of 2 cities. In the United States, the lion's share from a change year-over-year basis is price. And it's pretty stabl",161,"Geoff, this is Paul. On the price versus volume question, I think the way you framed it is probably pretty accurate, is that it's a tale of 2 cities. In the United States, the lion's share from a change year-over-year basis is price. And it's pretty stable unit trends on TECFIDERA, pretty stable unit trends on TYSABRI and modest gradual decline on the interferon franchise. Ex United States, we are not seeing any pricing on a year-over-year basis, and all of the gains are attributable to volume and unit expansion. TYSABRI is holding well outside the United States as well as the interferon business, and we continue to, in a small way, penetrate some markets and get some accretive benefits of things even outside of Europe. And TECFIDERA continues to expand on a year-over-year basis and gaining market share, particularly as we are moving into relatively early launch timing in Southern European countries and having very good success in the U.K."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Eric Schmidt from Cowen and Company.",14,"Your next question comes from the line of Eric Schmidt from Cowen and Company."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Congrats, George, good to see you leave on a high note. Best of luck with the next opportunity. Maybe just a quick one for Paul on this new interferon patent you're paying a royalty on or expect to pay a royalty on. Can you clarify a little bit whose pate",76,"Congrats, George, good to see you leave on a high note. Best of luck with the next opportunity. Maybe just a quick one for Paul on this new interferon patent you're paying a royalty on or expect to pay a royalty on. Can you clarify a little bit whose patent that is? And what happened to your own interferon patent that you thought was, at one point, going to be able to extract royalties from others?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Great question, Eric. Thanks. It was, as I noted, unexpected that it is not actually related. Despite it is on the recombinant interferon beta protein, it's actually not the same. It has to do with JFCR. In the Q this afternoon, we'll actually have t",171,"Yes. Great question, Eric. Thanks. It was, as I noted, unexpected that it is not actually related. Despite it is on the recombinant interferon beta protein, it's actually not the same. It has to do with JFCR. In the Q this afternoon, we'll actually have the patent number for you. I actually -- just actually don't have it handy for myself. And it's a mid-single-digit royalty. We aren't disclosing the name of the third party, but -- so just the third party at this point in time. And we expect it will be $50 million impact, all in the second half effectively, and will be a bigger impact as we go into 2017 on a full year basis. The '755 patent, we continue to feel like -- that -- despite it was like back to 2009 when it was issued, but we still feel and we're still in litigation with other parties on that. But there's a chance that we're coming towards the end of that process. Hope for something favorable."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","George, I also want to offer my congrats. You will be missed. So I had a question for Michel, maybe a bigger picture commercial question. Now that you've had a chance to look at the products, the assets at Biogen and a fresh look at the MS market, maybe j",108,"George, I also want to offer my congrats. You will be missed. So I had a question for Michel, maybe a bigger picture commercial question. Now that you've had a chance to look at the products, the assets at Biogen and a fresh look at the MS market, maybe just give us some perspective on what you see as the bigger growth opportunities ahead on a volume basis. Is it geographic? Is it rest of world opportunities? Is it new product launches? And then maybe for Paul. Just want to check and see what you guys learned from the DTC campaign for TEC and the sustainability of that?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you for the great question. In my 25 years experience around the world, I have never seen such a situation whereby we have 5 or 6 assets in the same therapy area. 20 years of those solid, unique, I would say, experience in MS, a solid portfolio t",273,"Thank you for the great question. In my 25 years experience around the world, I have never seen such a situation whereby we have 5 or 6 assets in the same therapy area. 20 years of those solid, unique, I would say, experience in MS, a solid portfolio today, a solid pipeline, a remarkable group of talents of -- with clinical experience and scientific experience within the company. So it's a leadership position on interferons, a leadership position on orals, a leadership position on high-efficacy products. So this is a remarkable situation. And on top of that, we are launching ZINBRYTA. So the dynamic is very good. Having said that, when you peel the onion and you get to discover the opportunity and the operations, you'll find ways to do better. And this is why, together with the team, we have prioritized 4 key areas: portfolio management, 5, 6 assets in the same therapy area. It's a challenge on how to manage that well; commercial excellence; medical leadership; trust and value. And I believe that with those, we'll be able to make further difference. Geographically, also, we can see that some parts are better managed than others. And I have already started to make some decisions. We don't wait, and you can expect that more will come. So this is what I would like to say -- and the portfolio management doesn't mean that all the products will be resourced and promoted equally. It's all about the growth opportunity, the way that you outline, and this is where there will be a clear, I would say, alignment between those resource allocation and execution."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Geoff, the beginning part of your question is, yes, just to confirm, we have sunsetted the television campaign as it relates to TECFIDERA. I think our -- I mean, look, it was a innovative -- I'd applaud our organization for thinking about it and giving it",137,"Geoff, the beginning part of your question is, yes, just to confirm, we have sunsetted the television campaign as it relates to TECFIDERA. I think our -- I mean, look, it was a innovative -- I'd applaud our organization for thinking about it and giving it a try. I think that our judgment at this point is that it didn't have a discernible movement on scripts and potentially came with this more -- as much from anecdotal, with some drawbacks as well. Michel actually confirmed his -- from his perspective that, quite possibly, as much other levers that are still like DTC-related and multichannel-related that we can reallocate resources toward. So I think that's probably our learnings in a nutshell. We didn't run the test case. So we'll see what -- but I think that's our learnings."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Thank you, Paul. If I -- this is Michel. If I can add. I mean, at the outset, and I was not here, the main objective was increase awareness, and I think that this was achieved. But I didn't see any inflection on any trends. We need to circle back to the a",86,"Thank you, Paul. If I -- this is Michel. If I can add. I mean, at the outset, and I was not here, the main objective was increase awareness, and I think that this was achieved. But I didn't see any inflection on any trends. We need to circle back to the alignment of the organization on 4 priorities for which we need to have some very strict resource allocation decisions, and I don't think that broadcast TV will be there in the foreseeable future year."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov from JPMorgan.",12,"Your next question comes from the line of Cory Kasimov from JPMorgan."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","This is Whitney on for Cory. I'll add my congrats to George as well. I guess just to circle back on Alzheimer's. I guess where are you with the sort of combinations? And I guess what's the desire or urgency to get some of the combos into the clinic before",62,"This is Whitney on for Cory. I'll add my congrats to George as well. I guess just to circle back on Alzheimer's. I guess where are you with the sort of combinations? And I guess what's the desire or urgency to get some of the combos into the clinic before you maybe have Phase III data on any of the individual components?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","This is Al, Whitney. And we like the idea of combination, to think one day we will be using combination therapies for Alzheimer's disease. One of the reasons why we brought in BACE inhibitor into our pipeline with our collaboration with Eisai, the reason",213,"This is Al, Whitney. And we like the idea of combination, to think one day we will be using combination therapies for Alzheimer's disease. One of the reasons why we brought in BACE inhibitor into our pipeline with our collaboration with Eisai, the reason why we have tau programs internally and that we're in search of even other things potentially to add to the mix is based on -- in part on that belief, that combination could be helpful. And you can think of it in 2 ways. One is to combine 2 drugs, each of which are active, to increase the efficacy overall or to reduce the dose of 2 active therapies so that you get better safety or tolerability for the same efficacy. And also, there may be sequential treatments where you start early, perhaps even before symptoms, with one type of medicine and then treat with something else when you have a high plaque burden and then something else still when tau starts to progress. When you start to think about combination therapy though, it's often difficult to do the right studies without some evidence of efficacy of each drug as monotherapy, and then you can start to think about the right dosing regimen. And so I hope that's helpful."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee from RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee from RBC Capital Markets."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","My appreciation to George as well. Happy to see you joining me on the West Coast. I'm lonely out here. So happy to have you back here. A question for Al. There will be LINGO data presented at ECTRIMS. Can you maybe just revisit this briefly and give us so",128,"My appreciation to George as well. Happy to see you joining me on the West Coast. I'm lonely out here. So happy to have you back here. A question for Al. There will be LINGO data presented at ECTRIMS. Can you maybe just revisit this briefly and give us some color about what is going on here in terms of what we saw? Because obviously, that was a surprise. And I guess is there anything specific that we should pay attention to at ECTRIMS that you've done work on that would pique our interest back here? Or is there some issue here with remyelination pathway and that would bring our questions into your oral? So how does this change our thinking about remyelination and what we saw here?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes, Michael, thanks for the question. So first, I want to say this is a really large and rich data set, really the first of its kind, not only in MS but, to my knowledge, in neurology where we're in the early stages of figuring out how to repair the brai",351,"Yes, Michael, thanks for the question. So first, I want to say this is a really large and rich data set, really the first of its kind, not only in MS but, to my knowledge, in neurology where we're in the early stages of figuring out how to repair the brain and how to measure measurements of outcome, measures of repair. The things we're focusing on right now when we look at this rich data set are what are the right cohort of patients to treat. In this trial, we've looked at relapsing MS patients, all the way to secondary progressive. So it's a wide range of patients. What's the right -- what's the optimal cohort? What's the right dose? We studied 4 different doses, and we saw a complex dose response curve. What we actually saw was sort of a bell-shaped curve where we lost efficacy at the highest dose, and then the middle doses, we think we see a signal of efficacy. And so we'll share some of that at ECTRIMS. What's the right concomitant medicine to use? We envision that these repair therapies will be added to immunomodulators, and so we'll be looking at that and, in particular, whether ongoing inflammation in the brain impedes repair. And finally, how do we actually measure the effects of repair if it occurs, particularly, on clinical outcome measures? So some of these questions will be answered by doing further analyses, which we're in the middle of doing right now, intensively, and we'll share whatever we find out at ECTRIMS. And some may need another study. And so what we're honing in on is what's the next step, what's the next study? And obviously, this will be a judicious investment. If we can go to Phase III, we would try. I don't know until I see the specific design. It's -- it could be a Phase II, it could be a Phase III, it could be a Phase II/III. And that part, we probably won't be able to share at ECTRIMS, but sometime soon, we hope to be able to share that."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","I guess thinking about George, I remember meeting you when you first became the CEO, and I remember you talking about reasons for joining the company and that you were [indiscernible] pipeline product was so well needed. At the time, it really changed Bio",84,"I guess thinking about George, I remember meeting you when you first became the CEO, and I remember you talking about reasons for joining the company and that you were [indiscernible] pipeline product was so well needed. At the time, it really changed Biogen. And so now the company is a different company and there's been pipeline success and there's been some failures, what do you think Biogen really needs from a new CEO at this point in time versus when you came in?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Well, look, the company now is a very different company from what it was a few years ago. We have a full and excellent management team. We have a pipeline that is, I think, quite exciting but needs to be to grow. So I think the company needs good manageme",193,"Well, look, the company now is a very different company from what it was a few years ago. We have a full and excellent management team. We have a pipeline that is, I think, quite exciting but needs to be to grow. So I think the company needs good management. I think the strategy of the company is solid, and what we need is good leadership and somebody who can work with the people who are here, work with Michel to maximize the commercial potential, work with Mike, commercialize the potential of our pipeline, grow the pipeline and can work with the rest of the organization to ensure that we go forward in a way that is responsible, where we minimize expenses but that where we invest aggressively in those areas that really have the potential to add value. So being CEO is complicated, and I think those are the -- those are priorities I would set. Of course, the search will be conducted by the board, but I don't think they would do it too differently. I think there'll be a continued focus on innovation, and I'm confident we'll get someone excellent."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ronny Gal from Bernstein.",12,"Your next question comes from the line of Ronny Gal from Bernstein."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","Two questions. First, biosimilars. You had a pretty good first quarter. Can you describe a little bit to us where you've launched already, where you're still expecting to launch? And now that you're a little bit of -- wetted your feet in that market, coul",172,"Two questions. First, biosimilars. You had a pretty good first quarter. Can you describe a little bit to us where you've launched already, where you're still expecting to launch? And now that you're a little bit of -- wetted your feet in that market, could you just give us a feel for your thinking about kind of the 3- to 5-year trajectory for this franchise and for biosimilar, for anti-TNF in Europe in general? Should this be 30% of the market, 50%, 70% of the market overall? And then separately, you kind of mentioned the impact of high deductible co-pays on the U.S. sales in the first quarter. Has there been still some impact to those in the second quarter? That is, as we look from the outside of revenue, should we see another step-up in revenue beginning in the third quarter? Or has it been fully incorporated in the first quarter and kind of the run rate for pricing in the second quarter is roughly what we should see going forward?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","So this is Michel. Thanks for the great question. So as you have seen, 2 great companies came together with complementary capabilities in order to launch anti-TNFs, to get started with, and then we see what these -- the follow-up opportunities. So as far",237,"So this is Michel. Thanks for the great question. So as you have seen, 2 great companies came together with complementary capabilities in order to launch anti-TNFs, to get started with, and then we see what these -- the follow-up opportunities. So as far as Biogen is involved, together with the partners, we have launched the products, the 3 anti-TNFs that we -- for which we have the agreement on. Two out of the 3 are approved and are underway to be launched. The preliminary results are very encouraging. As you can imagine, there is a tremendous level of variation viability between countries in terms of tendering, in terms of aggressivity of competition, in terms of provider decision-making, and it's difficult to take an overall, I would say, recipe on how to best launch. What I can say is that the 3 anti-TNFs that we'll have the opportunity to launch will be addressing a current market that is higher than $9 billion in Europe. So this is significant and with Biogen quality. So we have put together a stand-alone BU that is flexible, agile in order to launch the product. And we learn country after country, today, mostly in the Nordics and Scandinavia, where we have had very, very good results. But as I said earlier, it's still early to comment much on the results that are negligible for 2016, but will be more important moving forward."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Ronny, this is Paul. Thanks for the second part of that question. It's a good catch. I think that the answer is that we absolutely saw insurance dynamics mostly impact AVONEX in the first quarter and we're pleased to see that, that choppiness settled out",66,"Ronny, this is Paul. Thanks for the second part of that question. It's a good catch. I think that the answer is that we absolutely saw insurance dynamics mostly impact AVONEX in the first quarter and we're pleased to see that, that choppiness settled out and benefited the second quarter results. Don't expect it to be meaningful or different for the balance of the year now."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","And your final question comes from the line of Chris Raymond from Raymond James.",14,"And your final question comes from the line of Chris Raymond from Raymond James."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Analysts","And congrats, George, from us as well. Just a question, I guess, on TECFIDERA. In the context of -- I think you highlighted in Q1 a $20 million inventory drawdown. Could you maybe quantify -- I think you highlighted, generally, there was an inventory effe",155,"And congrats, George, from us as well. Just a question, I guess, on TECFIDERA. In the context of -- I think you highlighted in Q1 a $20 million inventory drawdown. Could you maybe quantify -- I think you highlighted, generally, there was an inventory effect in Q2. Can you quantify what that was? And then also, if I can, on TECFIDERA continuing. I hear what you're saying on the television ads, but one of the things that has sort of struck us the most with our checks is TECFIDERA, for some time, has been sort of far and away the most requested disease-modifying therapy among patients. I guess I'm wondering what additional levers can you pull to sort of increase that. Or is there some other aspect, like maybe working at better efficiency programs to get that request converted into a script? Is there some other aspect besides just getting patients to request the drug?"
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Yes. Thanks, Chris. It's Paul, I'll take the first part. It's quite simply -- I think we're at pretty normal inventory levels on TECFIDERA, so it's really just a sequential quarter rebalancing off of this -- the seasonal low that we generally see in Q1.",45,"Yes. Thanks, Chris. It's Paul, I'll take the first part. It's quite simply -- I think we're at pretty normal inventory levels on TECFIDERA, so it's really just a sequential quarter rebalancing off of this -- the seasonal low that we generally see in Q1."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","So on the levers and the performance. 12% growth q-over-q is not bad. The share continues to grow to 15% globally is also pretty good, mostly driven by the newly launched markets in Europe. 40% patient share -- patients growth percentage is also very enco",189,"So on the levers and the performance. 12% growth q-over-q is not bad. The share continues to grow to 15% globally is also pretty good, mostly driven by the newly launched markets in Europe. 40% patient share -- patients growth percentage is also very encouraging. I have, for my field visits and from talking to leaders, identified one major issue, which is the discontinuation due to GI safety. Those patients, during the first phase on the product, are suffering, for some of them, on abdominal pain, diarrhea, discomfort that is leading, in some cases, with very high level of viability to discontinue on the product. And this impacts not only the outflow but, eventually, the inflow. Viability is tremendous. I was in the field lately and -- on the Eastern Coast in the U.S. 1.5% of the patient discontinued at 6 months. In some others, it was 30%. So with Mike Ehlers, we are fully aligned in order to work together with the community, with the physicians, with the peer-to-peer in order to best assess, best educate and bring down an average, which is 20% today, to lower levels."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Executives","Okay. With that, I thank you all for joining us this morning. Thanks for the questions, and we'll sign off now. Thank you.",23,"Okay. With that, I thank you all for joining us this morning. Thanks for the questions, and we'll sign off now. Thank you."
29726,366896620,1010156,"Biogen Inc., Q2 2016 Earnings Call, Jul 21, 2016",2016-07-21,"Earnings Calls","Biogen Inc.","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the confere",58,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the conference over to Matthew Calistri, Senior Director of Investor Relations. You may begin your conference."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, Dan, and welcome, everyone, to Biogen's Third Quarter 2016 Earnings Conference Call. Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconc",222,"Thank you, Dan, and welcome, everyone, to Biogen's Third Quarter 2016 Earnings Conference Call. 
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We've also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Michael Ehlers, EVP of Research and Development; our Chief Commercial Officer, Michel Vounatsos; and our CFO, Paul Clancy. We'll also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock.
Now I'll turn the call over to George."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Thanks, Matt, and good morning, everyone. Thanks for joining us today. Happy to say, Biogen delivered another solid quarter, complete with strong financial performance and significant advancements in the pipeline. For the third quarter of 2016, Biog",530,"Okay. Thanks, Matt, and good morning, everyone. Thanks for joining us today. Happy to say, Biogen delivered another solid quarter, complete with strong financial performance and significant advancements in the pipeline. For the third quarter of 2016, Biogen generated a record $3 billion in revenues, 6% increase in the same period a year ago. Our GAAP earnings were $4.71 per share, a 13% increase versus Q3 last year, and non-GAAP earnings were $5.19 per share, a 16% increase. 
I'll come back to the financials in a minute, but first, I'd like to highlight some of the important third quarter pipeline progress. One of the most exciting milestones this quarter was the positive interim analysis of nusinersen in the ENDEAR study. Recognizing the tremendous need in the SMA community, we move quickly to establish the expanded access program and completed the NDA filing with the FDA in less than 2 months, the fastest time of filing time in Biogen's 38-year history. We continue to be grateful to the patients, families, investigators and employees who work tirelessly to bring this program program to this point. We've also filed with the EMA where nusinersen has received Accelerated  Assessment status. If approved, nusinersen would be the first treatment for patients with spinal muscular atrophy, a leading genetic cause of death in infants. 
We were honored when one of our key pipeline programs was featured on the cover of Nature, specifically, the results of our preclinical research in Phase Ib study of aducanumab. This redistinction [ph] was a first for Biogen research and one that I think further highlights the important work that we're doing in the area of Alzheimer's disease. We also announced that aducanumab was granted Fast Track designation by the FDA. 
Our commercial business continue to deliver solid results this quarter. We furthered our leadership in MS with the launch of ZINBRYTA in collaboration with AbbVie, and we continue to grow the number of patients benefiting from our full portfolio of MS products. 
Our third quarter hemophilia revenues grew to $217 million, and we made further progress with the spinoff of our hemophilia business into a separate, independent, publicly traded company, known as Bioverativ, with the initial filing of the Form 10 in August. We continue to expect to complete that transaction in early 2017. 
In Europe, we doubled our biosimilars revenues over the prior quarter as BENEPALI continues to launch in markets across the continent and pick up share at a rate previously unseen for a biosimilar anti-TNF, and we launched FLIXABI, our biosimilar of infliximab. We continue to believe that our work in biosimilars is an important growth opportunity for Biogen. 
So we've seen great progress in both our pipeline and our commercial portfolio during the quarter. As you'll hear shortly from Mike and Michel, our entire executive leadership team is focused on driving commercial performance, prioritizing our assets, advancing our clinical programs and reshaping our pipeline, and our 70,000 employees globally remain committed to delivering therapies that we believe can make a positive difference in the lives of patients. 
I'll now turn the call over to Mike so that he can give you a thorough update on our pipeline."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, George, and good morning, everyone. Let me provide some highlights from this quarter, starting with multiple sclerosis. Last month, at ECTRIMS, we presented clinical findings from our broad portfolio MS therapies as well as top line results for",1486,"Thank you, George, and good morning, everyone. Let me provide some highlights from this quarter, starting with multiple sclerosis. Last month, at ECTRIMS, we presented clinical findings from our broad portfolio MS therapies as well as top line results for opicinumab, or anti-LINGO, a potential neuroreparative therapy for people with relapsing forms of multiple sclerosis. 
We presented real-world data and clinical evidence showing that TECFIDERA consistently demonstrates strong efficacy by reducing MS disease activity in patients who have had up to 9 years of treatment. These data also affirm TECFIDERA's well-characterized safety profile. Importantly, we believe these findings provide additional support for the early use of TECFIDERA to improve patient outcomes. 
Data were also presented for ZINBRYTA, our newly launched once-monthly, self-administered subcutaneous treatment option for relapsing forms of MS. A new post-hoc analysis from the pivotal DECIDE study show that a significantly greater number of people treated with ZINBRYTA showed no evidence of disease activity compared to those taking intramuscular interferon. Additional new interim data from the long-term extension study EXTEND show that treatment with ZINBRYTA had long-term benefits in the proportion of patients who remained relapse-free as well as those who did not experience 24-week confirmed disability progression. 
For opicinumab, we presented top line results from the Phase II SYNERGY study in MS, in which opicinumab missed the primary endpoint. However, we believe the robust design of the study has allowed us to identify an appropriate patient population and dose to move forward with development. Within the 10 mg per kg dosing arm of the study, we identified a treatment effect in patients who's MRI scans had specific features suggesting evidence that reduce myelination and intact axons at study entry. This subset represented approximately 1/4 of all patients in the SYNERGY study. Based on these data, we had hypothesized that patients with similar features may have the potential to benefit from treatment with opicinumab. We're in the final stages of designing the next study and look forward to providing an update in the coming months. 
Turning to another late-stage asset. We made significant progress advancing nusinersen this quarter. As George highlighted, in August, Biogen and Ionis announced that we met the prespecified primary endpoint upon interim analysis of ENDEAR. In the analysis, patients with infantile onset SMA or SMA consistent with Type 1 who were treated with nusinersen demonstrated a highly statistically significant and clinically meaningful improvement in the achievement of motor milestones, as measured by the Hammersmith Infant Neurological Examination. The responder analysis looked to the achievement of tangible milestones, like kicking, head control, rolling, sitting, crawling, standing and walking, and we believe the results provide a real demonstration of the value nusinersen could bring for patients and their families. Data from the other end points analyzed were also consistently in favor of the treated infants. 
The ENDEAR study remains ongoing and will be stopped once enrolled patients complete their next office visit when [ph] it is anticipated to happen for all patients before the end of the year. Once this occurs, we'll be able to provide more detailed efficacy data, including an analysis on survival. 
During the quarter, we also successfully completed the rolling submission of a new drug application to the FDA for nusinersen. The U.S. filing was submitted less than 2 months after the positive interim analysis of the ENDEAR trial, a significant accomplishment for the company and recognition of the urgent need in this community. We have applied for Priority Review, which, if granted, will shorten the review period for nusinersen following the agency's acceptance of the filing. 
Earlier this month, we also filed the Marketing Authorization Application to the European Medicines Agency. The EMA's Committee for Medicinal Products for Human Use has granted nusinersen Accelerated Assessment status, which can also reduce the standard review time, and we look forward to working with both agencies over the coming months to bring this treatment to patients as quickly as possible. 
For nusinersen, our regulatory submissions are comprised of results from from the prespecified interim analysis of ENDEAR as well as all other clinical and preclinical data currently available, including open-label data in both Types 2 and 3 SMA patients. We're seeking a broad label for the treatment of SMA and are current filing applications in the U.S. and the EU. 
Our other randomized, placebo-controlled Phase III study, CHERISH, in children with later-onset SMA consistent with Type 2 was fully enrolled in March this year and remains on track for completion in the first half of 2017. 
Earlier this month, we presented additional data for nusinersen at the 2016 World Muscle Society Congress in Granada, Spain. The presentations included safety results from the interim analysis of the Phase III ENDEAR study, which demonstrated a favorable safety profile. 
Analysis of the ongoing Phase II open-label study NURTURE demonstrated a positive effect in genetically diagnosed and presymptomatic SMA infants. In the NURTURE interim analysis, all 13 infants have demonstrated increases in mean [ph] Hammersmith Infant Neurological Exam scores over time, and no infants have discontinued, withdrawn from the study or reached the primary endpoint of death or respiratory intervention in patients who had been enrolled for a minimum of 64 days and up to 13 months. 
A recent analysis of data from the CS2 and CS12 open-label studies in patients with later-onset SMA, which included both Type 2 and Type 3 patients, was also presented at World Muscle. The data showed that children with SMA treated with nusinersen exhibited improvements on several measures of motor function for up to nearly 3 years. These results are in contrast to the stable or slow decline in scores typically observed in patients with later-onset SMA over time. We continue to be encouraged by the consistently positive results for nusinersen, which we believe support its benefit in SMA. 
Now turning to Alzheimer's disease. During the quarter, a number of exciting developments occurred for our lead candidate, aducanumab. As George mentioned, results from preclinical research in the Phase 1b study of aducanumab were published in Nature, a significant achievement for the program and recognition of Biogen's high-caliber science. Aducanumab was granted Fast Track designation by the FDA, an important step in bringing this potential therapy to patients as quickly as possible. 
And in a recently completed interim analysis from the Phase 1b study, which included the titration cohort, arms 8 and 9 and the portion of the long-term extension study, efficacy and safety were consistent with results previously reported and support the design of the ongoing Phase III ENGAGE and EMERGE studies. The data from both the titration  cohort and the portion of the long-term extension study of PRIME have been accepted to the 9th Clinical Trials on Alzheimer's Disease meeting in San Diego, and we look forward to sharing additional safety and efficacy data with you in December. 
We're also making important progress across our pipeline, and we continue to shape our R&D engine for the future. Last year, we announced an agreement to license amiselimod, an oral sphingosine 1-phosphate receptor modulator, for Mitsubishi Tanabe. Since announcing the license agreement, we assessed the compound for a number of autoimmune indications with a particular interest in inflammatory bowel disease. As we prioritize our strategic objectives and the IBD landscape continues to evolve, [ph] we've decided to discontinue our current development plan for amiselimod. 
As we mentioned last quarter, we generated encouraging Phase I data on BIIB059, or anti-BDCA2, for lupus. The anti-BDCA2 Phase I study included both healthy volunteers and a cohort of 12 lupus subjects. We anticipate presenting these data at ACR next month, including results from the lupus cohort. A Phase II study evaluating the efficacy and safety of BIIB059 is underway with the first subject dose this month. 
We're also working to advance BIIB074, a novel investigational state-dependent subtype selective sodium channel blocker for neuropathic pain. We have initiated and open to enrollment a Phase I -- Phase IIb trial for lumbosacral radiculopathy, also known as sciatica. We're also close to completing enrollment in a small exploratory Phase IIa study in erythromelalgia, and we are working toward initiating a Phase III study in trigeminal neuralgia in 2017. 
BG11, or STX-100, for idiopathic pulmonary fibrosis is enrolling its final cohort in a Phase IIa study, and we expect to present the data after the trial completes in the second half of next year. BG11 blocks alpha(v)beta(6) integrin, which is selectively up-regulated in epithelial cells in fibrotic conditions, such as IPF, and is known to be a key mediator of TGF-beta activations. We believe early safety and biomarker results from this study evaluating BG11 in IPF patients are encouraging. 
In summary, we continue to make strong progress across our pipeline, and we are working aggressively to optimize and reshape our R&D activities, focusing resources to rapidly advance assets that present the greatest opportunity and address unmet need. 
With that, I will now pass the call to Michel."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, Mike. This is a solid quarter for MS business. Our portfolio of MS therapies delivered revenues of $2.3 billion, an increase of 3% versus Q3 last year and 2% versus Q2. Excluding the impact of foreign exchange, MS revenues increased 5% versus Q",1302,"Thank you, Mike. This is a solid quarter for MS business. Our portfolio of MS therapies delivered revenues of $2.3 billion, an increase of 3% versus Q3 last year and 2% versus Q2. Excluding the impact of foreign exchange, MS revenues increased 5% versus Q3 last year and 2.5% versus Q2. Biogen maintained its global leading market share of 38% and remains the leader for both newly diagnosed and switch patients, representing the dynamic portion of the MS market. 
As I communicated during our last call, the commercial organization is now focusing on 4 key opportunities: portfolio strategy, commercial excellence, medical leadership, trust and value. Since the beginning of Q3, we are now in execution mode, especially for MS in the U.S. 
With portfolio strategy, we have progressed and now identified our prioritized growth opportunities for now and 2017. It is all about making hard choices, driving consistency in resource allocation and following through with tactical plans and execution. 
With commercial excellence, in the U.S., we have piloted and defined a specific engagement model with key MS centers. The rollout is expected to be completed by year-end. Additionally, we are currently enhancing our sophistication in multichannel marketing with a strong focus on digital execution capabilities. We need to meet our customers where they are, defined by the customer journey, to provide a seamless and differentiated Biogen engagement experience, whether through direct, digital or other media. These are important steps, not only to improve performance in the short term, but also towards the creation of a new go-to-market model that is more effective and at a lower cost. 
In terms of medical leadership, during the third quarter, our R&D colleagues have identified several key opportunities as to how to improve MS care today. We believe we have the opportunity to bring to use regular and quantitative measurement of disease progression, including cognition and imaging. In addition, we just launched our MS Path initiative that will be -- we believe will create a standardized, high-quality data repository from a very diverse real-world patient population in the U.S. and EU. We believe this will open new and differentiated engagement opportunities with major MS clinical centers in the U.S. and in Europe. 
And finally, trust and value. We are developing beyond the beyond the [ph] solutions that we believe will meet customers' day-to-day needs in living with or treating MS. We are working on establishing the leading ecosystem for patients and providers to improve patient outcomes. We believe that Biogen is the only company that has the position and commitment to MS to be able to provide this level of support in a trustworthy and valuable way. 
Across these 4 priority areas, we have a well-defined plans and, as I said, since early Q3, we are now in execution mode. Delivering on those well means enhancing the fundamental capability of the commercial operation at Biogen. These priorities are intended to not only drive performance for our in-line products, but also to prepare the organization for current and future product launches. 
Turning to MS performance. In the U.S., overall MS market has experienced a 2% decline in commercial patients versus Q3 last year. While in Europe, the market continues to grow with a 7% increase in patients versus Q3 last year. For TECFIDERA, global market share has increased by approximately 1 point to 15% versus Q3 last year. 
In the U.S., we have a stable TECFIDERA performance. TECFIDERA continues to capture roughly half of all patients starting on an oral with the current oral share of 51% and overall patient share remains relatively stable at 20% since the beginning of the year. This is a clear leadership position for all 3 metrics. 
In Europe, they are approximately 65,000 patients on TECFIDERA, an increase of approximately 30% versus Q3 last year and approximately 4% versus Q2. TECFIDERA is now the most prescribed MS therapy in Germany, France, the U.K. and Italy, with more recently launched market continuing to drive patient growth. We do aspire to restore growth to the more mature markets, and we are very pleased to see early indicators that TECFIDERA again share this quarter in France, following 2 quarters of flat performance. 
Over the past year, TYSABRI has seen steady incremental share gains globally, as it continues to add patients, driven by increased share in the U.S, as well as in the emerging markets. As we continue to see shift toward increased use of high efficacy therapies, we believe TYSABRI is benefiting from growing first-line use in the U.S. 
In Europe, we are also encouraged by the recent update extending the indication for TYSABRI and allowing physician to better optimize risk management based on JC virus antibody index values. Following the EU label approval, we have also received similar label update in Japan, Canada and Switzerland. 
Our interferon therapies continue to play an important role amongst the injectable portion of the market. We believe PLEGRIDY is helping to slow the decline of our interferons, though it does not completely compensate for the loss of AVONEX patients. 
In collaboration with AbbVie, we launched ZINBRYTA in August in the U.S. and Germany, and we recently just recently obtained approval in Australia. We believe the launch of ZINBRYTA comps at the right time as we see our trend towards the increased use of high efficacy products we both grants therapies and the future entrance. 
While early in the launch, we are encouraged by the level of physician and patient interest in the strong product profile. In the U.S. for example, over half of our target physician have completed enrollment on our REMS Program, enabling them to begin prescribing. 
These are early data that we see indications that we are capturing many switching patients who otherwise may not have chosen a Biogen product. So it appears that our positioning and execution is working. 
Looking forward, we expect to receive reimbursement for ZINBRYTA in all the major European markets within the next 12 to 18 months. So overall, we had a solid performance this quarter across our MS business, despite a recent slowdown in the overall MS commercial market in the U.S. We are also very excited by the continued progress of our biosimilar business. BENEPALI is now available in 13 countries. And in most markets, we are seeing a conversion rate superior to the first infliximab biosimilar launch in Europe, with up to 60 to 80% conversion in markets, such as Norway or Denmark. 
With [ph] we believe we are able to compete beyond price. We are seeing a strong presence for the autoinjector versus that of the originator, with our research indicating that 86% of the nurse prefer our device. 
We recently also launched our infliximab biosimilar, FLIXABI, which is now available in Germany, the U.K. and the Netherlands, with 3 additional countries anticipated in Q4. We believe our ability to potentially be the first company to offer all 3 major anti-TNF in Europe could put us in a position of strength in the market. We believe biosimilars are an important growth opportunity for Biogen as we work to optimize our engagement with stakeholders across the health care system. 
In summary, we had a very productive quarter across our MS business in terms of performance. We are encouraged with our new product launches, and we see clear progress as we work hard to elevate our commercial execution capabilities to new levels and as we improve our go-to-market model. 
Also, we are particularly excited about the potential to soon launch nusinersen for SMA, with approximately 20,000 patients across the U.S., Europe and Japan and no available treatments today, we believe nusinersen represents a significant operative for both Biogen and more importantly, for the patients who today have no treatment option. 
With that, I'll turn the call over to Paul."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thanks, [ph]. In the third quarter, our GAAP diluted earnings per share were $4.71, a 13% increase versus Q3 last year. For our non-GAAP diluted earnings per share were $5.19, an increase of 16%. Total revenue for Q3 grew 6% versus Q3 last year to appro",793,"Thanks, [ph]. In the third quarter, our GAAP diluted earnings per share were $4.71, a 13% increase versus Q3 last year. For our non-GAAP diluted earnings per share were $5.19, an increase of 16%. 
Total revenue for Q3 grew 6% versus Q3 last year to approximately $3 billion. Global third quarter TECFIDERA revenues were $1,034 million, an increase of 10% versus Q3 last year. This included revenues of $845 million in the U.S., an increase of 12% versus Q3 last year and $189 million outside the U.S., an increase of 3% versus Q3 last year. 
In the U.S., we believe TECFIDERA benefited by approximately $40 million to $50 million versus Q2 due to inventory build in the channel. Outside the U.S., Q3 TECFIDERA decreased by $17 million versus Q2, largely driven by parallel trade dynamics. Versus Q3 last year, foreign exchange and hedge impact weakened TECFIDERA revenues by approximately $17 million. 
Interferon revenues included both AVONEX and [ph] were $708 million during the third quarter, a decrease of 10% versus Q3 last year. This included $506 million in the U.S. and $203 million in sales outside the U.S. 
In the U.S., we believe there was a drawdown of AVONEX inventory in the wholesale channel, resulting approximately $10 million versus Q2. Outside the U.S., foreign exchange and hedge impact weakened interferon revenue by approximately $20 million versus Q3 last year. 
TYSABRI worldwide revenues were $515 million this quarter, an increase of 7% to versus Q3 last year. This included $301 million in the U.S. and $214 million outside the U.S. Outside the U.S., TYSABRI revenue benefited by $20 million due to a favorable adjustment to our discounts and allowances. 
Foreign exchange and the hedge impact weakened TYSABRI revenue by approximately $16 million versus Q3 last year. Our hemophilia products continue to perform well this quarter. ELOCTATE revenues for the quarter were $132 million, an increase of 46% versus Q3 last year. This includes $110 million in the U.S. and $22 million outside the U.S. 
ALPROLIX revenues in Q3 were $85 million, an increase of 30% versus Q3 last year, including $67 million in the U.S. and $19 million outside the U.S. 
Our biosimilar business generated $31 million in revenues this quarter, driven primarily by BENEPALI. 
Turning to our anti-CD20 revenues, which include our profit share from RITUXAN and [ph] in the United States, as well as our profit share and royalties on sales of rituximab outside the U.S. 
We recorded $318 million for Q3, a decrease from Q2, driven by a reduction in inventory from the second quarter. Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing were $99 million in the third quarter. The increase versus Q2 was related to contract manufacturing for strategic partner, slightly offset by $13 million loss in our AbbVie collaboration profit share. 
Now turning to the expense lines on the P&L. Q3 GAAP cost of goods sold was $417 million or 14% of revenue. Non-GAAP COGS was $396 million or 13% of revenue. The increase versus Q2 was primarily attributable to a mid-single-digit royalty on U.S. sales of both AVONEX and PLEGRIDY. 
Q3 GAAP and non-GAAP R&D expense was $529 million or 18% of revenue. Both GAAP and non-GAAP R&D expense included a $75 million payment to Ionis related to the exercise of our opt-in right to develop and commercialize nusinersen globally. 
I'd like to note that our collaboration partner, E side, has stated their goal to start of Phase III trial for E2609. A $50 million milestone payment is expected to be triggered once the first patient is dosed in the E2609 Phase III trial, and there's a potential chance they could dose the first patient by the end of this year. The $50 million milestone was not considered in our midyear 2016 R&D guidance. 
Q3 GAAP SG&A expense was $463 million. Q3 non-GAAP SG&A expense was $461 million or 16% of revenue. Other net expense was $58 million in Q3, which includes $66 million in interest expense, primarily related to our 2015 bond offering. 
In Q3, both our GAAP and non-GAAP tax rates were approximately 25%. Our weighted average diluted share count was approximately 219 million for Q3. Which brings us to our diluted earnings per share which were $4.71 on a GAAP basis and $5.19 on a non-GAAP basis. 
We ended the quarter with $7.4 billion in cash and marketable securities, with approximately 40% of this in the United States. During the quarter, we repurchased 1.1 million shares of the company's common stock for a total value of $349 million. So as often, we had a number of puts and takes in the quarter, nevertheless, a very solid financial quarter. 
I'll turn the call over to George for his closing comments."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay, thank you, Pablo. I'm very pleased with what we've accomplished this quarter. We delivered solid commercial performance, strong financial results and important advances in the pipeline. I'm particularly excited about the direction we're heading as w",331,"Okay, thank you, Pablo. I'm very pleased with what we've accomplished this quarter. We delivered solid commercial performance, strong financial results and important advances in the pipeline. I'm particularly excited about the direction we're heading as we finish 2016 and look forward to 2017 and beyond. 
As I've said, I believe we are at the beginning of a transformative a record in the near the generation, which could result in a new era for Biogen as well. We're already starting to see the types of discoveries that can be expected, the science advances and the innovative child designs that you previously unseen in results and insights. We believe they are leading the effort aducanumab point to additional opportunities to invest in novel sciences, to address Alzheimer's disease and other neurodegenerative diseases. The insights we've gained from SYNERGY trial are teaching us more about remyelination and very enthusiastic about moving on to smoke forward. And the encouraging results reusing from nusinersen pointed a possibility that there can be internally new mechanisms and modalities for treating the many daunting diseases of the central nervous system. 
I'm proud to have led Biogen for more than 6 years now and it's gratifying to me to be in the position to turn a high-performing organization over to a successor. Our board search for a new CEO is progressing. We don't have a formal update on timing yet but as you'd expect, the opportunity to lead Biogen is generating plenty of interest. And in the meantime, I working closely with our management team as we strive to realize our goals for 2016 and kick off a busy and productive 2017. 
We're fortunate to have a great leadership team and a passionate group of employees who come to work everyday to make a positive impact on patients' lives and I think all of them for their hard work and dedication. Thanks to all of you for joining us this morning. And we'll open up the call for questions."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] [Operator Instructions] Your first question comes from the line of Eric Schmidt from Cowen and Company.",18,"[Operator Instructions] [Operator Instructions] Your first question comes from the line of Eric Schmidt from Cowen and Company."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I was hoping you could talk a little bit more about the parallel trade issue associated TECFIDERA, it that something new? Will certainly can do about it? Is it going to get worse in the future?",36,"I was hoping you could talk a little bit more about the parallel trade issue associated TECFIDERA, it that something new? Will certainly can do about it? Is it going to get worse in the future?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thanks, Eric. This is Paul. I'll try to take a crack at it. We did point last quarter. So in fairness, it -- looking at the numbers this quarter, we kind of noticed looking backwards. It effectively happens when a low-priced country gets extra purchasing",143,"Thanks, Eric. This is Paul. I'll try to take a crack at it. We did point last quarter. So in fairness, it -- looking at the numbers this quarter, we kind of noticed looking backwards. It effectively happens when a low-priced country gets extra purchasing patents and it ends up with a more higher-priced companies across all of our products, we look hard at this, and we try to to the extent we can management -- manage it. I don't expect it. We haven't across the whole time in multiple sclerosis for 10 or 15 years seen this to be a big issue. But we'll continue to try to manage it. I don't expect it to be a manyfold issue as we go forward over the next bunch of quarters. It could bounce around every now and then though. Thanks for the question."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just on the remyelination side for Mike or Al. So what are the puts and takes of finding a population for anti-LINGO versus expanding the program for BIIB061? Just curious if you can find lessons from SYNERGY to optimize 061 development or you have to pri",50,"Just on the remyelination side for Mike or Al. So what are the puts and takes of finding a population for anti-LINGO versus expanding the program for BIIB061? Just curious if you can find lessons from SYNERGY to optimize 061 development or you have to prioritize one over the other?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes, Geoff, this is Mike. That's a good question. So my comment on the SYNERGY results is we've been using that data to really look at the potential for unidentified population. We think we found that. We think we're probably gone up in from our developme",96,"Yes, Geoff, this is Mike. That's a good question. So my comment on the SYNERGY results is we've been using that data to really look at the potential for unidentified population. We think we found that. We think we're probably gone up in from our development of BIIB061. We're thinking about that very closely. There's reason to believe that we have -- that the same population may be something we could investigate similarly with BIIB061 with capital in from the development that's been out part of the plan how we will develop [ph] up as well."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Maybe I could add to that, this is Al. The sub population we have identified has really had good biological possibility in other words, these are patients with evidence of a that Texans that have evidence of a demyelination make sense to us to the drugs b",64,"Maybe I could add to that, this is Al. The sub population we have identified has really had good biological possibility in other words, these are patients with evidence of a that Texans that have evidence of a demyelination make sense to us to the drugs both of these drugs can work better in this population and that's why we're encouraged by these results."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges from Leerink runners.",13,"Your next question comes from the line of Geoffrey Porges from Leerink runners."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just want to throw a few questions in, in nusinersen. First, what would be the earliest that you would be in a position to actually launch the product come if the FDA acted within the speed that they've acted on some other recent applications? For high un",151,"Just want to throw a few questions in, in nusinersen. First, what would be the earliest that you would be in a position to actually launch the product come if the FDA acted within the speed that they've acted on some other recent applications? For high unmet need indications. Secondly, could you give us a sentence of the number of patients continuing from the trials on open-label basis and also the number of patients in the expand program and when would you expect those to be converted to commercial patients? And then lastly, you mentioned the 20,000 patients with SMA in North America, Europe and Japan. But what proportion of those do you consider to be really addressable with the label that you're filing for? Is that population [indiscernible] or is that an onset or is that just all the different forms of SMA? Sorry for the most part question there."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay, Jeffrey, this is Mike. I'm going to start contacting the multipart question here hopefully will remember each of the parts.",21,"Okay, Jeffrey, this is Mike. I'm going to start contacting the multipart question here hopefully will remember each of the parts."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","members of the management team to address it. So first of all, on the filing, I do want to emphasize, we have submitted the file, we have applied for Priority Review. We haven't heard that under the determination of that. That will obviously dictate when",391,"members of the management team to address it. So first of all, on the filing, I do want to emphasize, we have submitted the file, we have applied for Priority Review. We haven't heard that under the determination of that. That will obviously dictate when we will get approval for that in the U.S. Similarly, accelerated assessment application we have in Europe, again, that would potentially reduce the review time but are expected that finally, to be validated in the coming weeks present or sometime in dependence on regulator except as in this dirty review accelerated assessment. With that, I'm going to let talk about the launch based on that, but let me address a couple of the other things that you mentioned. Our extended access program is active. We've got patients who are receiving drug. This is obviously country-by-country specific in how they're administering it and it's an ongoing work in progress. That program will really be relevant during this period and while were filing before we've got the approval. We anticipate that, that it's going to be out small number of patients that we can get in the relevant countries based on the greater the established on our expanded access program. On the incidence and prevalence in the label, what we would say is this is 20,000 patients prevalence today in the U.S., Europe and Japan. SMA, as a whole, has an incidental of about 13,000 patients here across those roughly. The data that we've submitted through from the interim analysis of ENDEAR, these are type 1 patients. We've included data across all of our [ph] as well as preclinical data. We are going to seek a broad lable for the treatment of SMA. That's obviously will be something under review. And based on that, that will determine the overall size of the patient population. I'll also let Michel sort of comment and I'll turn it over to him. My final comment to that is we expect be successful, and lunch, the final evidence numbers will increase over time to the extent that we have an impact on the survival on these populations. So the label, there's a lot of open questions. We'll have to wait and see and that is going to determine what the ultimate upside is. So Michel, maybe I'll do it over to you on."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes, thank you, Mike. So basically the label is a question mark. The time lien is also a question mark. I have the opportunity to regulate the U.S. operation in terms of launch readiness and I can tell you that I'm very pleased to lead a team that is gett",133,"Yes, thank you, Mike. So basically the label is a question mark. The time lien is also a question mark. I have the opportunity to regulate the U.S. operation in terms of launch readiness and I can tell you that I'm very pleased to lead a team that is getting together, high qualified, highly committed team in order to best serve the unmet medical need together with hopefully a good product with a good label and approved on time. So the is there and basically, the label will get, which proportion of the current prevalence we can address at launch. So for that, we have to wait a little bit. 20,000 patients in terms of prevalence in the we have qualified but not many more beyond and we are also looking to that."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your next question comes from the line of Ronny Gal from Bernstein.",14,"[Operator Instructions] Your next question comes from the line of Ronny Gal from Bernstein."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So just first quick clarification, on the intermingle, is this another Phase II or are you actually starting a pivotal program with that? And then my question is really on market access for multiple sclerosis in 2017. Now that those contacts have written,",74,"So just first quick clarification, on the intermingle, is this another Phase II or are you actually starting a pivotal program with that? And then my question is really on market access for multiple sclerosis in 2017. Now that those contacts have written, can you give us kind of directional view at your axis versus 2016 and the pricing that you're able to -- the pricing environment for your products and during that year?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","This is Mike and I will probably let Al comment as well in the anti-LINGO. We're very much in the design phase of this. Looking at the potential offer a trial, we're looking at timing, we're looking at cost, we're looking at feasibility. We don't have an",78,"This is Mike and I will probably let Al comment as well in the anti-LINGO. We're very much in the design phase of this. Looking at the potential offer a trial, we're looking at timing, we're looking at cost, we're looking at feasibility. We don't have an answer today but we think in the coming weeks, we'll have a determination about whether we conduct Phase IIb trial or whether we look to go straight into Phase III."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","I didn't have any further comment.",7,"I didn't have any further comment."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So concerning the formulary access in the U.S., we do not comment on the way 2017 will look like nor on the gross to net. What I can tell you is that the organization is committed to continue to generate profitable growth and for that we go out to their c",107,"So concerning the formulary access in the U.S., we do not comment on the way 2017 will look like nor on the gross to net. What I can tell you is that the organization is committed to continue to generate profitable growth and for that we go out to their cost picture, hopefully, how we supply and how we procure our business. And as I explained earlier, we are working with our go-to-market model. We don't believe the region frequency model that prevailed in the past is sustainable, and we are basically step by step building a new go-to-market model. So we are working on that."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ryan Abrams with Jefferies.",12,"Your next question comes from the line of Ryan Abrams with Jefferies."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I guess the question is for Michael, I was wondering if you could clarify what you guys has meant by on the aducanumab titration data, what you've meant by efficacy results that are consistent with results previously reported? Are you referring to imaging",98,"I guess the question is for Michael, I was wondering if you could clarify what you guys has meant by on the aducanumab titration data, what you've meant by efficacy results that are consistent with results previously reported? Are you referring to imaging or cognition? And then on the safety side, when you talk about safety looking consistent with what's previously been reported and supporting the design of the Phase III, does that suggest that the ARIA is consistent with what you're seeing or does it support the idea of titration potentially reducing the risk of ARIA population?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes, Brian, thank you for that. And by the way, these are all things which we will have a lot more to talk about at [indiscernible] in San Diego in December. So let me comment on that. So when we say consistent with, we're referring to both imaging and fu",135,"Yes, Brian, thank you for that. And by the way, these are all things which we will have a lot more to talk about at [indiscernible] in San Diego in December. So let me comment on that. So when we say consistent with, we're referring to both imaging and functional endpoints and cognition. As you know, we've looked at before uses some of the boxes you see some of the boxes and MMSE, as well as amyloid that. On the titration side and safety side, again, we'll have a lot more details on this but what I'd say is what we're seeing is consistent with what we had hypothesized around for the safety basis of aducanumab. In another words, it's within the range of what we've seen and reported before with the Phase 1b study."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee with RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee with RBC Capital Markets."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","A follow up on the Alzheimer's prior question. I just want to understand the context of the efficacy comments in particular, given that I think there's still some questions around placebo arm and I think you're still using partly the placebo from before.",97,"A follow up on the Alzheimer's prior question. I just want to understand the context of the efficacy comments in particular, given that I think there's still some questions around placebo arm and I think you're still using partly the placebo from before. So I just want to understand sort of caveats, and I guess how confident you are versus that arm? And just a quick follow-up is you did mentioned a line about MT-3 [ph] so just wanted to understand what happened there? And is that commercial cognition thing or what happened in that decision?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Hi, Michael, this is Al Sandrock. The additional cohorts included some additional placebo patients. So we will show the data from the additional placebo patients, as well as the placebo patients from prior cohorts and that will be shown at CTAD. And the e",73,"Hi, Michael, this is Al Sandrock. The additional cohorts included some additional placebo patients. So we will show the data from the additional placebo patients, as well as the placebo patients from prior cohorts and that will be shown at CTAD. And the efficacy is on PET imaging, as well as on the clinical cognitive assessments that we looked at previously, MMSE and CDR hundred boxes. That will be all shown at CTAD."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So Michael, this is Mike. I'll sort of comment on the amiselimod. This was really -- as we look at the landscape was evolving, both in terms of a regulatory competitive landscape, changing features there and the corresponding fit with our strategic priori",82,"So Michael, this is Mike. I'll sort of comment on the amiselimod. This was really -- as we look at the landscape was evolving, both in terms of a regulatory competitive landscape, changing features there and the corresponding fit with our strategic priorities about where we can best allocate resources based on our own expertise and competency, we just determined that this was -- that it wasn't as good as a fit as other things, which we could allocate our resources toward."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch.",16,"Your next question comes from the line of Ying Huang from Bank of America Merrill Lynch."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just quickly, we're just anxious waiting for the top line and from [ph] Phase III in December. Can you frame us what could the read through be for the safety program for aducanumab? And then secondly, what's your view on the recent data from [ph] and what",56,"Just quickly, we're just anxious waiting for the top line and from [ph] Phase III in December. Can you frame us what could the read through be for the safety program for aducanumab? And then secondly, what's your view on the recent data from [ph] and what that could mean for nusinersen in the commercial opportunity?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay, thanks for the question. I'll take a stab and then see if anyone want to open up. So first of all, I don't think we'll speculate on that. The potential results of [ph] trial based on that. I mean, there are scenarios that one can envision that we ar",302,"Okay, thanks for the question. I'll take a stab and then see if anyone want to open up. So first of all, I don't think we'll speculate on that. The potential results of [ph] trial based on that. I mean, there are scenarios that one can envision that we are certainly taking into consideration. We look very much look forward to seeing their data. A couple of things I would point out on this is, is although both a beta antibodies, these are as will the fundamental the quiet mechanisms of fashions, whereas with if there were positive results out of the also today's trial this will to the Inc. and the Lord hypothesis of Alzheimer's disease, and I think will go for the potential results of aducanumab. However, because these are fundamentally different mechanisms we're going at is it's fare more difficult to interpret negative result if so it's a matter we would be able to see it. We believe it will be much more difficult to make a conclusion about a negative result on solanezumab, vis--vis, the potential results of aducanumab. On [ph], people would comment is, is look, we welcome innovative therapies for SMA. We think it's a very serious very important this is the area where highly committed to this disease area and to the patients and families. We think that gene therapy as an overall approach is a viable 1 in spinal muscular atrophy and, in fact, we're quite excited about our own internal program that we have and our collaboration with in that regard as well. So we look forward to seeing how the combination of nusinersen potentially being launched and the next-generation therapeutics that we are certainly working on will play out over time. We see great prospect for the treatment of spinal muscular atrophy."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","And the only thing I would add on the Alzheimer's is the population is a little different. In [ph] they're studying the mild patients, which make sense because that's where they so some evidence of efficacy and expedition too. Whereas, in the case of aduc",68,"And the only thing I would add on the Alzheimer's is the population is a little different. In [ph] they're studying the mild patients, which make sense because that's where they so some evidence of efficacy and expedition too. Whereas, in the case of aducanumab, we are studying abnormal in the early mild patients. And I agree with everything Mike said about the differences in the antibody."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matthew Harrison with Morgan Stanley.",13,"Your next question comes from the line of Matthew Harrison with Morgan Stanley."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I just want to go back to SMA for a second, again. Just trying to better understand your comments around a broad label and I guess what data supports a label outside of SMA 1 patient and what's the rational that you might be able to achieve the label outs",62,"I just want to go back to SMA for a second, again. Just trying to better understand your comments around a broad label and I guess what data supports a label outside of SMA 1 patient and what's the rational that you might be able to achieve the label outside of SMA and 1 patient is ahead of the randomized study data?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay, Matthew, thanks for the question. I mean, I guess, I would first start by saying, we really are that going to comment on the data prospects for our label. But what I will say is that we have ongoing studies in type 2 patients, where we're looking at",150,"Okay, Matthew, thanks for the question. I mean, I guess, I would first start by saying, we really are that going to comment on the data prospects for our label. But what I will say is that we have ongoing studies in type 2 patients, where we're looking at the potential efficacy of nusinersen. As you know, also we have an ongoing trial, as I've mentioned, in presymptomatic genetically diagnosed infants. And so all of that data -- this data that we look to include in our filing application. And from that, the extent of the label that we achieved that will be based on the agency's review of the totality of the data and evidence. We will present evidence based on those populations and our effort to seek a broad label what the database will be able to present at the appropriate time. Many of these have not completed."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of John Scotti read Evercore ISI.",13,"Your next question comes from the line of John Scotti read Evercore ISI."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So on the CEO search, could you just elaborate a bit more, I'm not sure measurement exactly but I know that this is a big topic for investors right now. on timing, is it unreasonable to hear something about the year end? And exactly what is the profile of",147,"So on the CEO search, could you just elaborate a bit more, I'm not sure measurement exactly but I know that this is a big topic for investors right now. on timing, is it unreasonable to hear something about the year end? And exactly what is the profile of the person you're looking for? Is it somewhat from industry, out of industry, et cetera? And then on the MS market, Michel, I had a quick question. So you said that in the U.S., the volumes are declining year-over-year, and do you see this trend continuing? And if so, is it fair to say that any growth from tech, which stable patient sure, and I guess also perhaps the entire MS market as a whole would come from price going forward? Or do you see volumes inflecting at some point and if so, what would be the catalyst?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","This is George. Maybe I comment on the CEO search first. Look, I'm not going to comment on the specific timing. I can tell you that I think, we all believe that the sooner we can get through this and have a new CEO come, the better it is for all of us. So",114,"This is George. Maybe I comment on the CEO search first. Look, I'm not going to comment on the specific timing. I can tell you that I think, we all believe that the sooner we can get through this and have a new CEO come, the better it is for all of us. So it's a very active search. The board is interviewing a number of candidates. There are, as you would expect, a very high-quality of candidates coming in and being interviewed from a variety of backgrounds, actually. And we'll give you an update on that as soon as we can, but I don't want to comment anymore on the specific timing today."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So concerning the U.S. markets, thanks for the question. What we have seen during the past quarters was basically a slowdown towards a low single digit market growth in the U.S. What we have seen during the past months or weeks was a shift in the mix betw",432,"So concerning the U.S. markets, thanks for the question. What we have seen during the past quarters was basically a slowdown towards a low single digit market growth in the U.S. What we have seen during the past months or weeks was a shift in the mix between commercial and free that is impacting basically the commercial units performance. So I don't know if it's an overall market trend but this is what we have seen internally. What I can tell you is that TECFIDERA remains the #1 priority for the organization. We have a plan, as alluded last time, we are working based on the portfolio work that we are doing on [ph] GI, discontinuation that remains at an average of approximately 22%. And we have the good opportunity to make some inroad there because basically, this quote was from 5% to 35%. So there are [ph] centers, and messengers where they are able to manage with the right engagement and heard a different type of engagements that are being practiced in the different centers. There is no evidence yet. One can speculate that we can see a temporary association between the increase of the and the GI [ph] symptomology, but this was not confirmed by clinical trials because of many different confounding factors. So we work on peg GI. We see early sense if it's heading towards the right direction also in Europe, but it's too early to claim any big success here. We are working on the capture rates and one balance the other that's why we have a stable patient base. And the space of the market isn't in the lower than what we have estimated in our assumptions, but it's not an excuse for not increasing share. So we do not give up, we invest, we are committed. I can tell you the team in the U.S. is all up and running. They have diluted a new engagement model with critical MS centers. I'm very pleased to see the perception improvement. And now we have to continue execute the full rollout of this new plan will be towards the end of the year. By latest, by early January. So we are committed. We don't give up on the large Metro market, where the share of tech is relatively stable versus the latest launch markets where we make -- continue to make fast inroads like in Italy, Spain or the U.K. And the good news that we could turn to positive and we continue for Germany and we continue for the U.S. We are committed. Thank you."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas from Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas from Citigroup."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So just a follow-up on market trends in MS. So help us understand why do you think -- is there anything going on with the MS market is why is it shrinking in the U.S.? Are you seeing any people who are trying the orals and then hopping off and not getting",96,"So just a follow-up on market trends in MS. So help us understand why do you think -- is there anything going on with the MS market is why is it shrinking in the U.S.? Are you seeing any people who are trying the orals and then hopping off and not getting back into the MS treatment bucket? And then on PLEGRIDY, sort of the market having certain small percentage in the market. It's interesting that do you think you can grow that and what are you specifically to be to grow the market share?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So thanks for the question. It's very difficult to speculate on the future trend of the market. So we have capital points negative for the quarter versus prior year. This was not a situation during the prior quarters. So time will speak. We'll see overtim",96,"So thanks for the question. It's very difficult to speculate on the future trend of the market. So we have capital points negative for the quarter versus prior year. This was not a situation during the prior quarters. So time will speak. We'll see overtime, but I don't believe that this will be sustained. And again, I spoke about some trends in the market this between commercial units being commercialized and other channels. So we are committed to gain market share in a slower pace of the market in all our mature markets, including the U.S."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Greece Raymond with Raymond James.",13,"Your next question comes from the line of Greece Raymond with Raymond James."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just back on to SMA and nusinersen. You guys have talked about your expanded access program and sort of moving that forward and sounds like there's desire to get more patients on. We sort of run across some social media chatter from parents that seem to b",103,"Just back on to SMA and nusinersen. You guys have talked about your expanded access program and sort of moving that forward and sounds like there's desire to get more patients on. We sort of run across some social media chatter from parents that seem to be sort of complaining about at least some PIs that were looking to restrict access to this program. I wondered if you could -- it would seems to be a little bit of at odds with what you guys have talked about. Can you maybe comment on that and maybe help explain what exactly is going on?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Maybe I'll sort of start. We're not going to comment on specific investigators or specific sites around this. I would say that our expanded access program was really designed to and cases and at sites in countries where we were able to with this severe di",176,"Maybe I'll sort of start. We're not going to comment on specific investigators or specific sites around this. I would say that our expanded access program was really designed to and cases and at sites in countries where we were able to with this severe disease. Before we're able to successfully launch hopefully if get a favorable review to maximize the access that we could based on criteria that were established -- medically established at relevant sites. A lot of that is determined at the site in the country level. They determine that. And we are doing our best to ensure access in the way that makes sense. But it does not jeopardize our filing and the potential approval of this for broad access. Our hope, by the way, is that this period will be short. And that we'll be able to utilize the Priority Review and the accelerated review of the assessment at the EMA, to bring this to patients as quickly as possible. So the EAP program can be as short as possible."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov with JPMorgan.",12,"Your next question comes from the line of Cory Kasimov with JPMorgan."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Wanted to ask you about your broader [ph] intentions. Obviously, you have the set back with MT1303. But as we look forward, can you talk about your strategy here and how much are able to act on it, if at all, while you have a CEO search ongoing? I guess,",94,"Wanted to ask you about your broader [ph] intentions. Obviously, you have the set back with MT1303. But as we look forward, can you talk about your strategy here and how much are able to act on it, if at all, while you have a CEO search ongoing? I guess, is this part of the business that we should assume is on hold for the time being until you get someone in who can kind of take stock of the overall organization? Or are you still proceeding with diligence of other companies as usual?"
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","No, you should not assume this is on hold. We believe this is an important part of what we had to accomplish. We are continuing with diligence on several companies as we speak and that will continue. And we will continue to work aggressively to finalize s",94,"No, you should not assume this is on hold. We believe this is an important part of what we had to accomplish. We are continuing with diligence on several companies as we speak and that will continue. And we will continue to work aggressively to finalize some of these issues. I think the areas in which we are interested are clear. We have a very good R&D team now who can make the technical assessments. We have great ability now to make the accurate commercial assessments and so we are -- we'll speed ahead."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay, that should conclude the call for today. Thank you very much.",12,"Okay, that should conclude the call for today. Thank you very much."
29726,384066926,1061268,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Thank you to everyone for attending. This concludes today's conference call. You may now disconnect.",15,"Thank you to everyone for attending. This concludes today's conference call. You may now disconnect."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the confere",58,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the conference over to Matthew Calistri, Senior Director of Investor Relations. You may begin your conference."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, Dan, and welcome, everyone, to Biogen's Third Quarter 2016 Earnings Conference Call. Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconc",222,"Thank you, Dan, and welcome, everyone, to Biogen's Third Quarter 2016 Earnings Conference Call. 
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We've also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Michael Ehlers, EVP of Research and Development; our Chief Commercial Officer, Michel Vounatsos; and our CFO, Paul Clancy. We'll also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock.
Now I'll turn the call over to George."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Thanks, Matt, and good morning, everyone. Thanks for joining us today. Happy to say, Biogen delivered another solid quarter, complete with strong financial performance and significant advancements in the pipeline. For the third quarter of 2016, Biog",529,"Okay. Thanks, Matt, and good morning, everyone. Thanks for joining us today. Happy to say, Biogen delivered another solid quarter, complete with strong financial performance and significant advancements in the pipeline. For the third quarter of 2016, Biogen generated a record $3 billion in revenues, 6% increase in the same period a year ago. Our GAAP earnings were $4.71 per share, a 13% increase versus Q3 last year, and non-GAAP earnings were $5.19 per share, a 16% increase. 
I'll come back to the financials in a minute, but first, I'd like to highlight some of the important third quarter pipeline progress. One of the most exciting milestones this quarter was the positive interim analysis of nusinersen in the ENDEAR study. Recognizing the tremendous need in the SMA community, we move quickly to establish the expanded access program and completed the NDA filing with the FDA in less than 2 months, the fastest time of filing time in Biogen's 38-year history. We continue to be grateful to the patients, families, investigators and employees who work tirelessly to bring this program to this point. We've also filed with the EMA where nusinersen has received Accelerated  Assessment status. If approved, nusinersen would be the first treatment for patients with spinal muscular atrophy, a leading genetic cause of death in infants. 
We were honored when one of our key pipeline programs was featured on the cover of Nature, specifically, the results of our preclinical research in Phase Ib study of aducanumab. This rare distinction was a first for Biogen research and one that I think further highlights the important work that we're doing in the area of Alzheimer's disease. We also announced that aducanumab was granted Fast Track designation by the FDA. 
Our commercial business continue to deliver solid results this quarter. We furthered our leadership in MS with the launch of ZINBRYTA in collaboration with AbbVie, and we continue to grow the number of patients benefiting from our full portfolio of MS products. 
Our third quarter hemophilia revenues grew to $217 million, and we made further progress with the spinoff of our hemophilia business into a separate, independent, publicly traded company, known as Bioverativ, with the initial filing of the Form 10 in August. We continue to expect to complete that transaction in early 2017. 
In Europe, we doubled our biosimilars revenues over the prior quarter as BENEPALI continues to launch in markets across the continent and pick up share at a rate previously unseen for a biosimilar anti-TNF, and we launched FLIXABI, our biosimilar of infliximab. We continue to believe that our work in biosimilars is an important growth opportunity for Biogen. 
So we've seen great progress in both our pipeline and our commercial portfolio during the quarter. As you'll hear shortly from Mike and Michel, our entire executive leadership team is focused on driving commercial performance, prioritizing our assets, advancing our clinical programs and reshaping our pipeline, and our 70,000 employees globally remain committed to delivering therapies that we believe can make a positive difference in the lives of patients. 
I'll now turn the call over to Mike so that he can give you a thorough update on our pipeline."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, George, and good morning, everyone. Let me provide some highlights from this quarter, starting with multiple sclerosis. Last month, at ECTRIMS, we presented clinical findings from our broad portfolio MS therapies as well as top line results for",1483,"Thank you, George, and good morning, everyone. Let me provide some highlights from this quarter, starting with multiple sclerosis. Last month, at ECTRIMS, we presented clinical findings from our broad portfolio MS therapies as well as top line results for opicinumab, or anti-LINGO, a potential neuroreparative therapy for people with relapsing forms of multiple sclerosis. 
We presented real-world data and clinical evidence showing that TECFIDERA consistently demonstrates strong efficacy by reducing MS disease activity in patients who have had up to 9 years of treatment. These data also affirm TECFIDERA's well-characterized safety profile. Importantly, we believe these findings provide additional support for the early use of TECFIDERA to improve patient outcomes. 
Data were also presented for ZINBRYTA, our newly launched once-monthly, self-administered subcutaneous treatment option for relapsing forms of MS. A new post-hoc analysis from the pivotal DECIDE study show that a significantly greater number of people treated with ZINBRYTA showed no evidence of disease activity compared to those taking intramuscular interferon. Additional new interim data from the long-term extension study EXTEND show that treatment with ZINBRYTA had long-term benefits in the proportion of patients who remained relapse-free as well as those who did not experience 24-week confirmed disability progression. 
For opicinumab, we presented top line results from the Phase II SYNERGY study in MS, in which opicinumab missed the primary endpoint. However, we believe the robust design of the study has allowed us to identify an appropriate patient population and dose to move forward with development. Within the 10 mg per kg dosing arm of the study, we identified a treatment effect in patients who's MRI scans had specific features suggesting evidence that reduce myelination and intact axons at study entry. This subset represented approximately 1/4 of all patients in the SYNERGY study. Based on these data, we had hypothesized that patients with similar features may have the potential to benefit from treatment with opicinumab. We're in the final stages of designing the next study and look forward to providing an update in the coming months. 
Turning to another late-stage asset. We made significant progress advancing nusinersen this quarter. As George highlighted, in August, Biogen and Ionis announced that we met the prespecified primary endpoint upon interim analysis of ENDEAR. In the analysis, patients with infantile onset SMA or SMA consistent with Type 1 who were treated with nusinersen demonstrated a highly statistically significant and clinically meaningful improvement in the achievement of motor milestones, as measured by the Hammersmith Infant Neurological Examination. The responder analysis looked to the achievement of tangible milestones, like kicking, head control, rolling, sitting, crawling, standing and walking, and we believe the results provide a real demonstration of the value nusinersen could bring for patients and their families. Data from the other end points analyzed were also consistently in favor of the treated infants. 
The ENDEAR study remains ongoing and will be stopped once enrolled patients complete their next office visit, but it is anticipated to happen for all patients before the end of the year. Once this occurs, we'll be able to provide more detailed efficacy data, including an analysis on survival. 
During the quarter, we also successfully completed the rolling submission of a new drug application to the FDA for nusinersen. The U.S. filing was submitted less than 2 months after the positive interim analysis of the ENDEAR trial, a significant accomplishment for the company and recognition of the urgent need in this community. We have applied for Priority Review, which, if granted, will shorten the review period for nusinersen following the agency's acceptance of the filing. 
Earlier this month, we also filed the Marketing Authorization Application to the European Medicines Agency. The EMA's Committee for Medicinal Products for Human Use has granted nusinersen Accelerated Assessment status, which can also reduce the standard review time, and we look forward to working with both agencies over the coming months to bring this treatment to patients as quickly as possible. 
For nusinersen, our regulatory submissions are comprised of results from from the prespecified interim analysis of ENDEAR as well as all other clinical and preclinical data currently available, including open-label data in both Types 2 and 3 SMA patients. We're seeking a broad label for the treatment of SMA and are current filing applications in the U.S. and the EU. 
Our other randomized, placebo-controlled Phase III study, CHERISH, in children with later-onset SMA consistent with Type 2 was fully enrolled in March this year and remains on track for completion in the first half of 2017. 
Earlier this month, we presented additional data for nusinersen at the 2016 World Muscle Society Congress in Granada, Spain. The presentations included safety results from the interim analysis of the Phase III ENDEAR study, which demonstrated a favorable safety profile. 
Analysis of the ongoing Phase II open-label study NURTURE demonstrated a positive effect in genetically diagnosed and presymptomatic SMA infants. In the NURTURE interim analysis, all 13 infants have demonstrated increases in mean Hammersmith Infant Neurological Exam scores over time, and no infants have discontinued, withdrawn from the study or reached the primary endpoint of death or respiratory intervention in patients who had been enrolled for a minimum of 64 days and up to 13 months. 
A recent analysis of data from the CS2 and CS12 open-label studies in patients with later-onset SMA, which included both Type 2 and Type 3 patients, was also presented at World Muscle. The data showed that children with SMA treated with nusinersen exhibited improvements on several measures of motor function for up to nearly 3 years. These results are in contrast to the stable or slow decline in scores typically observed in patients with later-onset SMA over time. We continue to be encouraged by the consistently positive results for nusinersen, which we believe support its benefit in SMA. 
Now turning to Alzheimer's disease. During the quarter, a number of exciting developments occurred for our lead candidate, aducanumab. As George mentioned, results from preclinical research in the Phase Ib study of aducanumab were published in Nature, a significant achievement for the program and recognition of Biogen's high-caliber science. Aducanumab was granted Fast Track designation by the FDA, an important step in bringing this potential therapy to patients as quickly as possible. 
And in a recently completed interim analysis from the Phase Ib study, which included the titration cohort, arms 8 and 9 and the portion of the long-term extension study, efficacy and safety were consistent with results previously reported and support the design of the ongoing Phase III ENGAGE and EMERGE studies. The data from both the titration  cohort and the portion of the long-term extension study of PRIME have been accepted to the 9th Clinical Trials on Alzheimer's Disease meeting in San Diego, and we look forward to sharing additional safety and efficacy data with you in December. 
We're also making important progress across our pipeline, and we continue to shape our R&D engine for the future. Last year, we announced an agreement to license amiselimod, an oral sphingosine 1-phosphate receptor modulator, for Mitsubishi Tanabe. Since announcing the license agreement, we assessed the compound for a number of autoimmune indications with a particular interest in inflammatory bowel disease. As we prioritize our strategic objectives and the IBD landscape continues to evolve, we've decided to discontinue our current development plan for amiselimod. 
As we mentioned last quarter, we generated encouraging Phase I data on BIIB059, or anti-BDCA2, for lupus. The anti-BDCA2 Phase I study included both healthy volunteers and a cohort of 12 lupus subjects. We anticipate presenting these data at ACR next month, including results from the lupus cohort. A Phase II study evaluating the efficacy and safety of BIIB059 is underway with the first subject dose this month. 
We're also working to advance BIIB074, a novel investigational state-dependent subtype selective sodium channel blocker for neuropathic pain. We have initiated and open to enrollment a Phase I -- Phase IIb trial for lumbosacral radiculopathy, also known as sciatica. We're also close to completing enrollment in a small exploratory Phase IIa study in erythromelalgia, and we are working toward initiating a Phase III study in trigeminal neuralgia in 2017. 
BG11, or STX-100, for idiopathic pulmonary fibrosis is enrolling its final cohort in a Phase IIa study, and we expect to present the data after the trial completes in the second half of next year. BG11 blocks alpha(v)beta(6) integrin, which is selectively up-regulated in epithelial cells in fibrotic conditions, such as IPF, and is known to be a key mediator of TGF-beta activations. We believe early safety and biomarker results from this study evaluating BG11 in IPF patients are encouraging. 
In summary, we continue to make strong progress across our pipeline, and we are working aggressively to optimize and reshape our R&D activities, focusing resources to rapidly advance assets that present the greatest opportunity and address unmet need. 
With that, I will now pass the call to Michel."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, Mike. This is a solid quarter for MS business. Our portfolio of MS therapies delivered revenues of $2.3 billion, an increase of 3% versus Q3 last year and 2% versus Q2. Excluding the impact of foreign exchange, MS revenues increased 5% versus Q",1294,"Thank you, Mike. This is a solid quarter for MS business. Our portfolio of MS therapies delivered revenues of $2.3 billion, an increase of 3% versus Q3 last year and 2% versus Q2. Excluding the impact of foreign exchange, MS revenues increased 5% versus Q3 last year and 2.5% versus Q2. Biogen maintained its global leading market share of 38% and remains the leader for both newly diagnosed and switch patients, representing the dynamic portion of the MS market. 
As I communicated during our last call, the commercial organization is now focusing on 4 key opportunities: portfolio strategy, commercial excellence, medical leadership, trust and value. Since the beginning of Q3, we are now in execution mode, especially for MS in the U.S. 
With portfolio strategy, we have progressed and now identified our prioritized growth opportunities for now and 2017. It is all about making hard choices, driving consistency in resource allocation and following through with tactical plans and execution. 
With commercial excellence, in the U.S., we have piloted and defined a specific engagement model with key MS centers. The rollout is expected to be completed by year-end. Additionally, we are currently enhancing our sophistication in multichannel marketing with a strong focus on digital execution capabilities. We need to meet our customers where they are, defined by the customer journey, to provide a seamless and differentiated Biogen engagement experience, whether through direct, digital or other media. These are important steps, not only to improve performance in the short term, but also towards the creation of a new go-to-market model that is more effective and at a lower cost. 
In terms of medical leadership, during the third quarter, our R&D colleagues have identified several key opportunities as to how to improve MS care today. We believe we have the opportunity to bring to use regular and quantitative measurement of disease progression, including cognition and imaging. In addition, we just launched our MS Path initiative that will be -- we believe will create a standardized, high-quality data repository from a very diverse real-world patient population in the U.S. and EU. We believe this will open new and differentiated engagement opportunities with major MS clinical centers in the U.S. and in Europe. 
And finally, trust and value. We are developing beyond-the-pill solutions that we believe will meet customers' day-to-day needs in living with or treating MS. We are working on establishing the leading ecosystem for patients and providers to improve patient outcomes. We believe that Biogen is the only company that has the position and commitment to MS to be able to provide this level of support in a trustworthy and valuable way. 
Across these 4 priority areas, we have well-defined plans, and as I said, since early Q3, we are now in execution mode. Delivering on those well means enhancing the fundamental capability of the commercial operation at Biogen. These priorities are intended to not only drive performance for our in-line products, but also to prepare the organization for current and future product launches. 
Turning to MS performance. In the U.S., overall MS market has experienced a 2% decline in commercial patients versus Q3 last year, while in Europe, the market continues to grow with a 7% increase in patients versus Q3 last year. For TECFIDERA, global market share has increased by approximately one point to 15% versus Q3 last year. 
In the U.S., we have a stable TECFIDERA performance. TECFIDERA continues to capture roughly half of all patients starting on an oral with the current oral share of 51%, and overall patient share remains relatively stable at 20% since the beginning of the year. This is a clear leadership position for all 3 metrics. 
In Europe, there are approximately 65,000 patients on TECFIDERA, an increase of approximately 30% versus Q3 last year and approximately 4% versus Q2. TECFIDERA is now the most prescribed MS therapy in Germany, France, the U.K. and Italy with more recently launched market continuing to drive patient growth. We do aspire to restore growth to the more mature markets, and we are very pleased to see early indicators that TECFIDERA gained share this quarter in France, following 2 quarters of flat performance. 
Over the past year, TYSABRI has seen steady incremental share gains globally as it continues to add patients, driven by increased share in the U.S. as well as in the emerging markets. As we continue to see a shift towards increased use of high efficacy therapies, we believe TYSABRI is benefiting from growing first-line use in the U.S. 
In Europe, we are also encouraged by the recent update, extending the indication for TYSABRI and allowing physician to better optimize risk management based on JC virus antibody index values. Following the EU label approval, we have also received similar label update in Japan, Canada and Switzerland. 
Our interferon therapies continue to play an important role amongst the injectable portion of the market. We believe PLEGRIDY is helping to slow the decline of our interferons, though it does not completely compensate for the loss of AVONEX patients. 
In collaboration with AbbVie, we launched ZINBRYTA in August in the U.S. and Germany, and we just recently obtained approval in Australia. We believe the launch of ZINBRYTA comes at the right time as we see a trend towards increased use of high-efficacy products with both current therapies and future entrants.
While early in the launch, we are encouraged by the level of physician and patient interest in the strong product profile. In the U.S., for example, over half of our target physician have completed enrollment on our REMS Program, enabling them to begin prescribing. These are early data that we see indications that we are capturing many switching patients who otherwise may not have chosen a Biogen product. So it appears that our positioning execution is working. Looking forward, we expect to receive reimbursement for ZINBRYTA in all the major European markets within the next 12 to 18 months. 
So overall, we had a solid performance this quarter across our MS business despite a recent slowdown in the overall MS commercial market in the U.S. 
We are also very excited about the continued progress of our biosimilar business. BENEPALI is now available in 13 countries, and in most markets, we are seeing a conversion rate superior to the first infliximab biosimilar launch in Europe with up to 60 to 80% conversion in markets such as Norway or Denmark. With BENEPALI, we believe we are able to compete beyond price. We are seeing a strong presence for the BENEPALI auto-injector versus that of the originator, with our research indicating that 86% of the nurse prefer our device. 
We recently also launched our infliximab biosimilar, FLIXABI, which is now available in Germany, the U.K. and the Netherlands with 3 additional countries anticipated in Q4. We believe our ability to potentially be the first company to offer all 3 major anti-TNFs in Europe could put us in a position of strength in the market. We believe biosimilars are an important growth opportunity for Biogen as we work to optimize our engagement with stakeholders across the health care system. 
In summary, we had a very productive quarter across our MS business in terms of performance. We are encouraged with our new product launches, and we see clear progress as we work hard to elevate our commercial execution capabilities to new levels and as we improve our go-to-market model. 
Also, we are particularly excited about the potential to soon launch nusinersen for SMA. With approximately 20,000 patients across the U.S., Europe and Japan and no available treatments today, we believe nusinersen represent a significant opportunity for both Biogen and, more importantly, for the patients who, today, have no treatment option. 
With that, I'll turn the call over to Paul."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thanks, Michel. In the third quarter, our GAAP diluted earnings per share were $4.71, a 13% increase versus Q3 last year, while our non-GAAP diluted earnings per share were $5.19, an increase of 16%. Total revenue for Q3 grew 6% versus Q3 last year to app",792,"Thanks, Michel. In the third quarter, our GAAP diluted earnings per share were $4.71, a 13% increase versus Q3 last year, while our non-GAAP diluted earnings per share were $5.19, an increase of 16%. Total revenue for Q3 grew 6% versus Q3 last year to approximately $3 billion. 
Global third quarter TECFIDERA revenues were $1,034,000,000, an increase of 10% versus Q3 last year. This included revenues of $845 million in the U.S., an increase of 12% versus Q3 last year, and $189 million outside the U.S., an increase of 3% versus Q3 last year. In the U.S., we believe TECFIDERA benefited by approximately $40 million to $50 million versus Q2 due to inventory build in the channel. Outside the U.S., Q3 TECFIDERA decreased by $17 million versus Q2, largely driven by parallel trade dynamics. Versus Q3 last year, foreign exchange and hedge impact weakened TECFIDERA revenues by approximately $17 million. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $708 million during the third quarter, a decrease of 10% versus Q3 last year. This included $506 million in the U.S. and $203 million in sales outside the U.S. In the U.S., we believe there was a drawdown of AVONEX inventory in the wholesale channel, resulting approximately $10 million versus Q2. Outside the U.S., foreign exchange and hedge impact weakened interferon revenue by approximately $20 million versus Q3 last year. 
TYSABRI worldwide revenues were $515 million this quarter, an increase of 7% versus Q3 last year. This included $301 million in the U.S. and $214 million outside the U.S. Outside the U.S., TYSABRI revenue benefited by $20 million due to a favorable adjustment to our discounts and allowances. Foreign exchange and the hedge impact weakened TYSABRI revenue by approximately $16 million versus Q3 last year. 
Our hemophilia products continue to perform well this quarter. ELOCTATE revenues for the quarter were $132 million, an increase of 46% versus Q3 last year. This includes $110 million in the U.S. and $22 million outside the U.S. ALPROLIX revenues in Q3 were $85 million, an increase of 30% versus Q3 last year, including $67 million in the U.S. and $19 million outside the U.S.  
Our biosimilar business generated $31 million in revenues this quarter, driven primarily by BENEPALI. 
Turning to our anti-CD20 revenues, which include our profit share from RITUXAN and GAZYVA in the United States as well as our profit share in royalties on sales of rituximab outside the U.S. We recorded $318 million for Q3, a decrease from Q2 driven by a reduction in inventory from the second quarter. 
Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing, were $99 million in the third quarter. The increase versus Q2 was related to contract manufacturing for a strategic partner, slightly offset by a $13 million loss in our AbbVie collaboration profit share. 
 
Now turning to the expense lines on the P&L. Q3 GAAP cost of goods sold was $417 million or 14% of revenue. Non-GAAP COGS was $396 million or 13% of revenue. The increase versus Q2 was primarily attributable to a mid-single-digit royalty on U.S. sales of both AVONEX and PLEGRIDY. 
Q3 GAAP and non-GAAP R&D expense was $529 million or 18% of revenue. Both GAAP and non-GAAP R&D expense included a $75 million payment to Ionis related to the exercise of our opt-in right to develop and commercialize nusinersen globally. I'd like to note that our collaboration partner, Eisai, has stated their goal to start a Phase III trial for E2609. A $50 million milestone payment is expected to be triggered once the first patient is dosed in the E2609 Phase III trial, and there's a potential chance they could dose the first patient by the end of this year. The $50 million milestone was not considered in our midyear 2016 R&D guidance. 
Q3 GAAP SG&A expense was $463 million. Q3 non-GAAP SG&A expense was $461 million or 16% of revenue. Other net expense was $58 million in Q3, which includes $66 million in interest expense, primarily related to our 2015 bond offering. In Q3, both our GAAP and non-GAAP tax rates were approximately 25%. 
Our weighted average diluted share count was approximately 219 million for Q3, which brings us to our diluted earnings per share which were $4.71 on a GAAP basis and $5.19 on a non-GAAP basis. We ended the quarter with $7.4 billion in cash and marketable securities with approximately 40% of this in the United States. During the quarter, we repurchased 1.1 million shares of the company's common stock for a total value of $349 million. So as often, we had a number of puts and takes in the quarter, nevertheless, a very solid financial quarter. 
I'll turn the call over to George for his closing comments."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Paul. I'm very pleased with what we have accomplished this quarter. We delivered solid commercial performance, strong financial results and important advances in the pipeline. I'm particularly excited about the direction we're heading as",327,"Okay. Thank you, Paul. I'm very pleased with what we have accomplished this quarter. We delivered solid commercial performance, strong financial results and important advances in the pipeline. I'm particularly excited about the direction we're heading as we finish 2016 and look forward to 2017 and beyond. 
As I've said, I believe we are at the beginning of a transformative era in neurodegeneration, which could result in a new era for Biogen as well. We're already starting to see the types of discoveries that can be expected, the science advances and the innovative trial designs yield previously unseen in results and insights. We believe the early data for aducanumab point to additional opportunities to invest in novel science to address Alzheimer's disease and other neurodegenerative diseases. The insights we've gained from the SYNERGY trial are teaching us more about remyelination, and we're enthusiastic about moving opicinumab forward. And the encouraging results we're seeing from nusinersen pointed a possibility that there can be entirely new mechanisms and modalities for treating the many daunting diseases of the central nervous system. 
I'm proud to have led Biogen for more than 6 years now, and it's gratifying to me to be in the position to turn a high-performing organization over to a successor. Our board search for a new CEO is progressing. We don't have a formal update on timing yet, but as you'd expect, the opportunity to lead Biogen is generating plenty of interest. And in the meantime, I'm working closely with our management team as we strive to realize our goals for 2016 and kick off a busy and productive 2017. We're fortunate to have a great leadership team and a passionate group of employees who come to work everyday to make a positive impact on patients' lives, and I thank all of them for their hard work and dedication.
 Thanks to all of you for joining us this morning, and we'll now open up the call for questions."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Eric Schmidt from Cowen and Company.",16,"[Operator Instructions] Your first question comes from the line of Eric Schmidt from Cowen and Company."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I was hoping you could talk a little bit more about the parallel trade issue associated with TECFIDERA. Is that something new? Is there anything you can do about it? Is it going to get worse in the future?",39,"I was hoping you could talk a little bit more about the parallel trade issue associated with TECFIDERA. Is that something new? Is there anything you can do about it? Is it going to get worse in the future?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thanks, Eric. This is Paul. I'll try to take a crack at it. We didn't point it out last quarter. So in fairness, it's -- looking at the numbers this quarter, we kind of noticed it in looking backwards. It effectively happens when a low-priced country gets",146,"Thanks, Eric. This is Paul. I'll try to take a crack at it. We didn't point it out last quarter. So in fairness, it's -- looking at the numbers this quarter, we kind of noticed it in looking backwards. It effectively happens when a low-priced country gets extra purchasing patents and it ends up in a more higher-priced company. Across all of our products, we look hard at this, and we try, to to the extent we can, management manage it. I don't expect it. We haven't, across the whole time in multiple sclerosis for 10 or 15 years, seen this to be a big issue, but we'll continue to try to manage it. I don't expect it to be a meaningful issue as we go forward over the next bunch of quarters. It could bounce around every now and then though. Thanks for the question."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just on the remyelination side for Mike or Al. So what are the puts and takes of finding a population for anti-LINGO versus expanding the program for BIIB061? I'm just curious if you can find -- use the lessons from SYNERGY to optimize 061 development or",56,"Just on the remyelination side for Mike or Al. So what are the puts and takes of finding a population for anti-LINGO versus expanding the program for BIIB061? I'm just curious if you can find -- use the lessons from SYNERGY to optimize 061 development or if you have to prioritize that one over the other?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Geoff, this is Mike. That's a good question. So what I comment on the SYNERGY results is we've been using that data to really look at the potential for unidentified population. We think we found that. We think this is really going to inform our devel",97,"Yes. Geoff, this is Mike. That's a good question. So what I comment on the SYNERGY results is we've been using that data to really look at the potential for unidentified population. We think we found that. We think this is really going to inform our development of BIIB061. We're thinking about that very closely. There's reason to believe that we -- that the same population may be something we could investigate similarly with BIIB061. We think it'll inform the development. That's going to be part of the plans for how we would develop opicinumab as well."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Maybe I could add to that. This is Al. The subpopulation that we identified has really good biological possibility. In other words, these are patients who have evidence of intact axons. They have evidence of demyelination. This make sense to us that the d",63,"Maybe I could add to that. This is Al. The subpopulation that we identified has really good biological possibility. In other words, these are patients who have evidence of intact axons. They have evidence of demyelination. This make sense to us that the drugs -- both of these drugs would work better in this population, and that's why we're encouraged by these results."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges with Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges with Leerink Partners."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just want to throw a few questions in on nusinersen. First, what would be the earliest that you would be in a position to actually launch the product if the FDA acted with the speed that they've acted on some other recent applications for high unmet need",150,"Just want to throw a few questions in on nusinersen. First, what would be the earliest that you would be in a position to actually launch the product if the FDA acted with the speed that they've acted on some other recent applications for high unmet need indications? Secondly, could you give us a sense of the number of patients continuing from the trials on an open-label basis and also the number of patients in the expanded access program and when you would expect those to be converted to be commercial patients? And then lastly, you mentioned the 20,000 patients with SMA in North America, Europe and Japan. But what proportion of those do you consider to be really addressable with the label that you're filing for? Is that the population under 10 or infant-onset? Or is that just all the different forms of SMA? Sorry for the multipart question."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Geoffrey, this is Mike. I'll sort of -- I'm going to start, and then we're going to tag team that, the multipart question here. Hopefully, we'll remember each of the parts.",32,"Okay. Geoffrey, this is Mike. I'll sort of -- I'm going to start, and then we're going to tag team that, the multipart question here. Hopefully, we'll remember each of the parts."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","We need all members of the management team to address it.",11,"We need all members of the management team to address it."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Chime in. So first of all, on the filing, I do want to emphasize that we've submitted the file, we've applied for Priority Review. We haven't heard back on the determination of that. That will obviously dictate when we will get approval for that in the U.",391,"Chime in. So first of all, on the filing, I do want to emphasize that we've submitted the file, we've applied for Priority Review. We haven't heard back on the determination of that. That will obviously dictate when we will get approval for that in the U.S. Similarly, the Accelerated Assessment application we have in Europe, again, that would potentially reduce the review time but we're expecting that, finally, to be validated in the coming weeks. So there's some timing dependence on regulator acceptance of this Priority Review and Accelerated Assessment. Then with that, I'm going to let Michel talk about the launch based on that, but let me address a couple of the other things you mentioned. Our extended access program is active. We've got patients who are receiving drug. This is obviously country-by-country specific in how they're administering it, and it's an ongoing work in progress. That program will really be relevant during this period in -- while were filed but before we've got approval. We anticipate that, that -- it's going to be a small number of patients that we can get in the relevant countries based on the criteria when we established our expanded access program. On the incidence and prevalence in the label, what we would say is this is 20,000 patients prevalence today in the U.S., Europe and Japan. SMA, as a whole, has an incidents, about -- of about 13,000 patients here across those roughly. The data that we've submitted from the interim analysis of ENDEAR, these were Type 1 patients. We've included data across all of our studies as well as preclinical data. We are going to seek a broad label for the treatment of SMA. That's obviously will be something under review. And based on that, that will determine the overall size of the patient population, which I'll also let Michel sort of comment when I turn over to him. My final comment on that would be that we expect that if successful and launched, that this prevalence numbers will increase over time to the extent that we have an impact on survival on these populations. So the label, there's a lot of open questions. We'll have to wait and see, and that is going to determine what the ultimate upside is. So Michel, maybe I'll turn over to you on the..."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Thank you, Mike. So basically, the label is a question mark. The time line is also a question mark. I had the opportunity to regulate the U.S. operation in terms of launch readiness, and I can tell you that I'm very pleased with the team that is gett",138,"Yes. Thank you, Mike. So basically, the label is a question mark. The time line is also a question mark. I had the opportunity to regulate the U.S. operation in terms of launch readiness, and I can tell you that I'm very pleased with the team that is getting together, high qualified, highly committed team, in order to best serve the unmet medical need, together with, hopefully, a good product that with a good label and approved on time. So the launch readiness is there, and basically, the label will determine which proportion of the current prevalence we can address at launch. So for that, we have to wait a little bit. 20,000 patients in terms of prevalence in the geography that we have qualified, but there are many more beyond, and we are also looking to that."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your next question comes from the line of Ron Gal with Bernstein.",14,"[Operator Instructions] Your next question comes from the line of Ron Gal with Bernstein."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So just first quick clarification. On the anti-LINGO, is this another Phase II? Or are you actually starting a pivotal program with that? And then my question is really on market access for multiple sclerosis in 2017. Now that those contacts have been wri",78,"So just first quick clarification. On the anti-LINGO, is this another Phase II? Or are you actually starting a pivotal program with that? And then my question is really on market access for multiple sclerosis in 2017. Now that those contacts have been written, can you give us kind of like directional view at your formulary access versus 2016 and the pricing that you're able to -- the pricing environment for your products in -- during that year?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Ron, thanks for the question. This is Mike, and I will probably let Al comment as well on opicinumab anti-LINGO. We're very much in the design phase of this, looking at the potential of a trial. We're looking at timing. We're looking at cost. We're",84,"Okay. Ron, thanks for the question. This is Mike, and I will probably let Al comment as well on opicinumab anti-LINGO. We're very much in the design phase of this, looking at the potential of a trial. We're looking at timing. We're looking at cost. We're looking at feasibility. We don't have an answer today, but we think in the coming weeks, we'll have a determination about whether we conduct a Phase IIb trial or whether we look to go straight into Phase III."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","I don't have any further comment.",7,"I don't have any further comment."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So concerning the formulary access in the U.S., we do not comment on the way 2017 will look like nor on the gross to net. What I can tell you is that the organization is committed to continue to generate profitable growth, and for that, we go after the co",106,"So concerning the formulary access in the U.S., we do not comment on the way 2017 will look like nor on the gross to net. What I can tell you is that the organization is committed to continue to generate profitable growth, and for that, we go after the cost structure, hopefully, how we supply and how we procure our business. And as I explained earlier, we are working on our go-to-market model. We don't believe the [indiscernible] frequency model that prevailed in the past is sustainable, and we are basically, step by step, building a new go-to-market model. So we are working on that."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams with Jefferies.",12,"Your next question comes from the line of Brian Abrahams with Jefferies."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I guess the question is for Mike. I was hoping you could clarify what you guys have meant by -- on the aducanumab titration data, what you've meant by efficacy results that are consistent with results previously reported? Are you referring to imaging or c",100,"I guess the question is for Mike. I was hoping you could clarify what you guys have meant by -- on the aducanumab titration data, what you've meant by efficacy results that are consistent with results previously reported? Are you referring to imaging or cognition? And then on the safety side, when you talk about safety looking consistent with what's previously been reported and supporting the design of the Phase III, does that suggest that the ARIA is consistent with what you're seeing? Or does it support the idea of titration potentially reducing the risk of ARIA in certain populations?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Brian, thank you for that. And by the way, these are all things which we will have a lot more to talk about at CTAD in San Diego in December. But -- so let me comment on that. So when I -- when we say consistent with, we're referring to both imaging",141,"Yes. Brian, thank you for that. And by the way, these are all things which we will have a lot more to talk about at CTAD in San Diego in December. But -- so let me comment on that. So when I -- when we say consistent with, we're referring to both imaging and functional endpoints in cognition. And as you know, we've looked at before is the CDI sum of boxes -- CDR sum of boxes and MMSE as well as amyloid PET. On the titration side and safety side, again, we'll have a lot more details on this. But what I'd say is what we're seeing is consistent with what we had hypothesized around for the safety basis of aducanumab. In other words, it's within the range of what we've seen and reported before with the Phase Ib study."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee with RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee with RBC Capital Markets."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","A follow-up on the Alzheimer's prior question. I just wanted to understand the context of the efficacy comments in particular, given that neither [ph] still some questions around the placebo arm and I think that you're still using partly the pool of place",98,"A follow-up on the Alzheimer's prior question. I just wanted to understand the context of the efficacy comments in particular, given that neither [ph] still some questions around the placebo arm and I think that you're still using partly the pool of placebo from before. So I just want to understand sort of caveats and I guess how confident you are versus that arm. And then just a quick follow-up is you did mentioned a line about MT-1303, so just wanted to understand what happened there. Is that commercial competition thing? Or what happened in that decision?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Michael, this is Al Sandrock. The additional cohorts included some additional placebo patients. So we will show the data from the additional placebo patients as well as the placebo patients from prior cohorts, and that'll be shown at CTAD. And the efficac",71,"Michael, this is Al Sandrock. The additional cohorts included some additional placebo patients. So we will show the data from the additional placebo patients as well as the placebo patients from prior cohorts, and that'll be shown at CTAD. And the efficacy is on PET imaging as well as on the clinical cognitive assessments that we looked at previously, MMSE and CDR sum of boxes. That'll all be shown at CTAD."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So Michael, this is Mike. I'll sort of comment on the amiselimod. This was really -- as we look at how the landscape was evolving, both in terms of a regulatory competitive landscape, changing features there and the corresponding fit with our strategic pr",83,"So Michael, this is Mike. I'll sort of comment on the amiselimod. This was really -- as we look at how the landscape was evolving, both in terms of a regulatory competitive landscape, changing features there and the corresponding fit with our strategic priorities about where we can best allocate resources based on our own expertise and competency, we just determined that this was -- that it wasn't as good of a fit as other things, which we could allocate our resources towards."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang with Bank of America Merrill Lynch.",16,"Your next question comes from the line of Ying Huang with Bank of America Merrill Lynch."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just quickly, we're all anxious awaiting for the top line from solanezumab Phase III in December. Can you frame us on what could the read-through be for the Phase III program for aducanumab? And then secondly, what's your view on the recent data from AveX",60,"Just quickly, we're all anxious awaiting for the top line from solanezumab Phase III in December. Can you frame us on what could the read-through be for the Phase III program for aducanumab? And then secondly, what's your view on the recent data from AveXis gene therapy in SMA and what that could mean for nusinersen in the commercial opportunity?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Well, thanks for the question. I'll take a stab at this and see if any wants to open up. First of all, I mean, we're not -- I don't think we'll speculate on the potential results of Eli solanezumab trial based on that. I mean, their scenario is that",315,"Okay. Well, thanks for the question. I'll take a stab at this and see if any wants to open up. First of all, I mean, we're not -- I don't think we'll speculate on the potential results of Eli solanezumab trial based on that. I mean, their scenario is that one can envision, that we are certainly taking into consideration. We look -- we very much look forward to seeing their data. A couple of things I would point out on this is, is although both A beta antibodies, these are actually fundamentally quite different mechanisms of action. So whereas we think if there were positive results out of the solanezumab trial, this would give great credence to the amyloid hypothesis of Alzheimer's disease and, I think, bode well for the potential results of aducanumab. However, because these are fundamentally different mechanisms they're going at is that it is far more difficult to interpret a negative result if solanezumab were to find it as we would be able to see it. We believe it will be much more difficult to make a conclusion about a negative result on solanezumab vis--vis the potential results of aducanumab. On AveXis, I think what we would comment is, look, we welcome innovative therapies for SMA. We think it's a very serious, very important this disease area. We're highly committed to this disease area and to the patients and families. We think that gene therapy, as an overall approach, is a viable one in spinal muscular atrophy, and in fact, we're quite excited about our own internal program that we have and our collaboration with UPenn in that regard as well. So we look forward to seeing how the combination of nusinersen potentially being launched and the next-generation therapeutics that we're certainly working on will play out over time. We see great prospect for the treatment of spinal muscular atrophy."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","And the only thing I would add on the Alzheimer's is the population is a little different. In solanezumab, they're studying the mild patients, which make sense because that's where they saw some evidence of efficacy and expedition too. Whereas in the case",68,"And the only thing I would add on the Alzheimer's is the population is a little different. In solanezumab, they're studying the mild patients, which make sense because that's where they saw some evidence of efficacy and expedition too. Whereas in the case of aducanumab, we're studying prodromal in the early mild patients. And then I agree with everything Mike said about the differences in the antibodies."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matthew Harrison with Morgan Stanley.",13,"Your next question comes from the line of Matthew Harrison with Morgan Stanley."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I just want to go back to SMA for a second, again, just trying to better understand your comments around a broad label. And I guess what data supports a label outside of SMA 1 patients? And what's the rationale that you might be able to achieve a label ou",60,"I just want to go back to SMA for a second, again, just trying to better understand your comments around a broad label. And I guess what data supports a label outside of SMA 1 patients? And what's the rationale that you might be able to achieve a label outside of SMA 1 patients ahead of the randomized study data?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Matthew, thanks for the question. I mean, I guess I would first start by saying, we really are not going to comment on the data prospects for our label. But what I will say is that we have ongoing studies in Type 2 patients, where we're looking at t",156,"Okay. Matthew, thanks for the question. I mean, I guess I would first start by saying, we really are not going to comment on the data prospects for our label. But what I will say is that we have ongoing studies in Type 2 patients, where we're looking at the potential efficacy of nusinersen. As you know also, we have an ongoing trial, as I had mentioned, in presymptomatic genetically diagnosed infants. And so all of that data -- this data that we look to include in our filing application and, from that, the extent of the label that we achieved, that will be based on the agency's review of the totality of the data and the evidence. We will present evidence based on those populations in our effort to seek a broad label. What that data is we'll be able to -- we'll present at the appropriate time. Many of these studies have not completed."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of John Scotti with Evercore ISI.",13,"Your next question comes from the line of John Scotti with Evercore ISI."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So on the CEO search, could you just elaborate a bit more? I'm not sure what exactly, but I know this is a big topic for investors right now. On timing, is it unreasonable to hear something by year-end? And then exactly, what is the profile of the person",146,"So on the CEO search, could you just elaborate a bit more? I'm not sure what exactly, but I know this is a big topic for investors right now. On timing, is it unreasonable to hear something by year-end? And then exactly, what is the profile of the person you're looking for? Is it someone from industry, out of industry, et cetera? And then on the MS market, Michel, I had a quick question. So you said that in the U.S., the volumes are declining year-over-year. And do you see this trend continuing? And if so, is it fair to say that any growth from TEC, which -- stable patient share and I guess also, perhaps, the entire MS market as a whole, would come from price going forward? Or do you see volumes inflecting at some point? And if so, what would be the catalyst?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. This is George. Maybe I'll comment on the CEO search first. Look, I'm not going to comment on the specific timing. I can tell you that I think we all believe that the sooner we can get through this and have a new CEO come, the better it is for all o",116,"Okay. This is George. Maybe I'll comment on the CEO search first. Look, I'm not going to comment on the specific timing. I can tell you that I think we all believe that the sooner we can get through this and have a new CEO come, the better it is for all of us. So it's a very active search. The board is interviewing a number of candidates. There are, as you would expect, a very high quality of candidates coming in and being interviewed from a variety of backgrounds, actually. And we'll give you an update on that as soon as we can, but I don't want to comment anymore on the specific timing today."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So concerning the U.S. markets, thanks for the question, what we have seen during the past quarters was basically a slowdown towards a low single-digit market growth in the U.S. What we have seen during the past months or weeks was a shift in the mix betw",432,"So concerning the U.S. markets, thanks for the question, what we have seen during the past quarters was basically a slowdown towards a low single-digit market growth in the U.S. What we have seen during the past months or weeks was a shift in the mix between commercial and free that is impacting basically the commercial units' performance. So I don't know if it's an overall market trend but this is what we have seen internally. What I can tell you is that TECFIDERA remains the #1 priority for the organization. We have a plan, as alluded last time, we are working based on the portfolio work that we are doing on Peg GI discontinuation that remains at an average of approximately 22%. We have the good opportunity to make some inroad there because, basically, the scope goes from 5% to 35%. So there are some centers, some MS centers where they're able to manage with the right engagement and hear the different type of engagements that are being practiced in the different centers, there is no evidence yet. One can speculate that we can see a temporal association between the increase of eosinophil and the GI symptomology, but this was not confirmed by clinical trials because of many different confounding factors. So we work on Peg GI. We see early signs if it's heading towards the right direction also in Europe, but it's too early to claim any big success here. We are working on the capture rates, and one balance the other. That's why we have a stable patient base. And the pace of the market is certainly lower than what we have estimated in our assumptions, but it's not an excuse for not increasing share. So we do not give up. We invest. We are committed. I can tell you the team in the U.S. is all up and running. They have piloted a new engagement model with critical MS centers. I'm very pleased to see the perception improvement. And now we have to continue to execute, and the full rollout of this new plan will be towards the end of the year or, by latest, early January. So we are committed. We don't give up on the large mature market, where the share of TEC is relatively stable, versus the latest launch markets where we make -- continue to make fast inroads, like in Italy, Spain or the U.K. And the good news is that we could turn to positive France. And we'll continue for Germany, and we'll continue for the U.S. We are committed. Thank you."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas with Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas with Citigroup."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So just to follow up on market trends in MS. So help us understand why do you think -- is there anything going on with the MS market? Why is it shrinking in the U.S.? Are you seeing any people who are trying the orals and then hopping off and not getting",96,"So just to follow up on market trends in MS. So help us understand why do you think -- is there anything going on with the MS market? Why is it shrinking in the U.S.? Are you seeing any people who are trying the orals and then hopping off and not getting back into the MS treatment bucket? And then on PLEGRIDY sort of the market, having a certain small percentage of the market, it's interesting. But do you think you can grow that? And what are you specifically doing to grow the PLEGRIDY market share?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So thanks for the question. It's very difficult to speculate on the future trend of the market. So we have -- see a couple of points negative for the quarter versus prior year. This was not the situation during the prior quarters. So time will speak. We'l",100,"So thanks for the question. It's very difficult to speculate on the future trend of the market. So we have -- see a couple of points negative for the quarter versus prior year. This was not the situation during the prior quarters. So time will speak. We'll see over time, but I don't believe that this will be sustained. And again, I spoke about some trends in the marketplace between commercial units being commercialized and other channels. So we are committed to gain market share in a slower pace of the market in all our mature markets, including the U.S."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Chris Raymond with Raymond James.",13,"Your next question comes from the line of Chris Raymond with Raymond James."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just back on to SMA and nusinersen. You guys have talked about your expanded access program and sort of moving that forward, and sounds like there's desire to get more patients on. We sort of run -- ran across some social media chatter from parents that s",104,"Just back on to SMA and nusinersen. You guys have talked about your expanded access program and sort of moving that forward, and sounds like there's desire to get more patients on. We sort of run -- ran across some social media chatter from parents that seem to be sort of complaining about, at least, some PIs that were looking to restrict access to this program. I wonder if you could -- that would seems to be a little bit at odds with what you guys have talked about. Can you maybe comment on that and maybe help explain what exactly is going on?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Chris, maybe I'll sort of start. I mean, the essence is we're not going to comment on specific investigators or specific sites around this. I would say that our expanded access program was really designed to in cases and at sites in countries where we wer",185,"Chris, maybe I'll sort of start. I mean, the essence is we're not going to comment on specific investigators or specific sites around this. I would say that our expanded access program was really designed to in cases and at sites in countries where we were able to with this severe disease before we're able to successfully launch, hopefully, if we get a favorable review, to maximize the access that we could based on criteria that were medically established at relevant sites. A lot of that is determined at the site in the country level. They determine that. And we are doing our best to ensure access in the way that makes sense but that does not jeopardize our filing and the potential approval of this for broad access. Our hope, by the way, is that this period will be short, and that we'll be able to utilize the Priority Review and the Accelerated review -- the assessment at the EMA to bring this to patients as quickly as possible so that the CAP (sic) [ EAP ] program can be as short as possible."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov with JPMorgan.",12,"Your next question comes from the line of Cory Kasimov with JPMorgan."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Wanted to ask you about your broader biz dev intentions. And obviously, you had the setback with MT-1303. But as we look forward, can you talk about your strategy here and how much you're able to act on it, if at all, while you have a CEO search ongoing?",95,"Wanted to ask you about your broader biz dev intentions. And obviously, you had the setback with MT-1303. But as we look forward, can you talk about your strategy here and how much you're able to act on it, if at all, while you have a CEO search ongoing? I guess is this part of the business that we should assume is on hold for the time being until you get someone in who can kind of take stock of the overall organization? Or are you still proceeding with diligence of other companies as usual?"
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","No, you should not assume this is on hold. We all believe this is an important part of what we have to accomplish. We are continuing with diligence on several companies as we speak, and that will continue. And we will continue to work aggressively to fina",94,"No, you should not assume this is on hold. We all believe this is an important part of what we have to accomplish. We are continuing with diligence on several companies as we speak, and that will continue. And we will continue to work aggressively to finalize some of these issues. I think the areas in which we are interested are clear. We have a very good R&D team now who can make the technical assessments. We have great ability now to make the accurate commercial assessments, and so we are full speed ahead."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","All right. Dan, that should conclude the call for today. Thank you very much.",14,"All right. Dan, that should conclude the call for today. Thank you very much."
29726,384066926,1061610,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Thank you to everyone for attending. This concludes today's conference call. You may now disconnect.",15,"Thank you to everyone for attending. This concludes today's conference call. You may now disconnect."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the confere",58,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the conference over to Matthew Calistri, Senior Director of Investor Relations. You may begin your conference."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, Dan, and welcome, everyone, to Biogen's Third Quarter 2016 Earnings Conference Call. Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconc",222,"Thank you, Dan, and welcome, everyone, to Biogen's Third Quarter 2016 Earnings Conference Call. 
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We've also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Michael Ehlers, EVP of Research and Development; our Chief Commercial Officer, Michel Vounatsos; and our CFO, Paul Clancy. We'll also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock.
Now I'll turn the call over to George."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Thanks, Matt, and good morning, everyone. Thanks for joining us today. Happy to say, Biogen delivered another solid quarter, complete with strong financial performance and significant advancements in the pipeline. For the third quarter of 2016, Biog",529,"Okay. Thanks, Matt, and good morning, everyone. Thanks for joining us today. Happy to say, Biogen delivered another solid quarter, complete with strong financial performance and significant advancements in the pipeline. For the third quarter of 2016, Biogen generated a record $3 billion in revenues, 6% increase from the same period a year ago. Our GAAP earnings were $4.71 per share, a 13% increase versus Q3 last year, and non-GAAP earnings were $5.19 per share, a 16% increase. 
I'll come back to the financials in a minute, but first, I'd like to highlight some of the important third quarter pipeline progress. One of the most exciting milestones this quarter was the positive interim analysis of nusinersen in the ENDEAR study. Recognizing the tremendous need in the SMA community, we moved quickly to establish the expanded access program and completed the NDA filing with the FDA in less than 2 months, the fastest time of filing time in Biogen's 38-year history. We continue to be grateful to the patients, families, investigators and employees who work tirelessly to bring this program to this point. We've also filed with the EMA where nusinersen has received Accelerated  Assessment status. If approved, nusinersen would be the first treatment for patients with spinal muscular atrophy, a leading genetic cause of death in infants. 
We were honored when one of our key pipeline programs was featured on the cover of Nature, specifically, the results of our preclinical research in Phase Ib study of aducanumab. This rare distinction was a first for Biogen research and one that I think further highlights the important work that we're doing in the area of Alzheimer's disease. We also announced that aducanumab was granted Fast Track designation by the FDA. 
Our commercial business continue to deliver solid results this quarter. We furthered our leadership in MS with the launch of ZINBRYTA in collaboration with AbbVie, and we continue to grow the number of patients benefiting from our full portfolio of MS products. 
Our third quarter hemophilia revenues grew to $217 million, and we made further progress with the spinoff of our hemophilia business into a separate, independent, publicly traded company, known as Bioverativ, with the initial filing of the Form 10 in August. We continue to expect to complete that transaction in early 2017. 
In Europe, we doubled our biosimilars revenues over the prior quarter as BENEPALI continues to launch in markets across the continent and pick up share at a rate previously unseen for a biosimilar anti-TNF, and we launched FLIXABI, our biosimilar of infliximab. We continue to believe that our work in biosimilars is an important growth opportunity for Biogen. 
So we've seen great progress in both our pipeline and our commercial portfolio during the quarter. As you'll hear shortly from Mike and Michel, our entire executive leadership team is focused on driving commercial performance, prioritizing our assets, advancing our clinical programs and reshaping our pipeline, and our 7,000 employees globally remain committed to delivering therapies that we believe can make a positive difference in the lives of patients. 
I'll now turn the call over to Mike so that he can give you a thorough update on our pipeline."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, George, and good morning, everyone. Let me provide some highlights from this quarter, starting with multiple sclerosis. Last month, at ECTRIMS, we presented clinical findings from our broad portfolio of MS therapies as well as top line results",1483,"Thank you, George, and good morning, everyone. Let me provide some highlights from this quarter, starting with multiple sclerosis. Last month, at ECTRIMS, we presented clinical findings from our broad portfolio of MS therapies as well as top line results for opicinumab, or anti-LINGO, a potential neuroreparative therapy for people with relapsing forms of multiple sclerosis. 
We presented real-world data and clinical evidence showing that TECFIDERA consistently demonstrates strong efficacy by reducing MS disease activity in patients who have had up to 9 years of treatment. These data also affirm TECFIDERA's well-characterized safety profile. Importantly, we believe these findings provide additional support for the early use of TECFIDERA to improve patient outcomes. 
Data were also presented for ZINBRYTA, our newly launched once-monthly, self-administered subcutaneous treatment option for relapsing forms of MS. A new post-hoc analysis from the pivotal DECIDE study showed that a significantly greater number of people treated with ZINBRYTA showed no evidence of disease activity compared to those taking intramuscular interferon. Additional new interim data from the long-term extension study EXTEND show that treatment with ZINBRYTA had long-term benefits in the proportion of patients who remained relapse-free as well as those who did not experience 24-week confirmed disability progression. 
For opicinumab, we presented top line results from the Phase II SYNERGY study in MS, in which opicinumab missed the primary endpoint. However, we believe the robust design of the study has allowed us to identify an appropriate patient population and dose to move forward with development. Within the 10 mg per kg dosing arm of the study, we identified a treatment effect in patients who's MRI scans had specific features suggesting evidence that reduced myelination and intact axons at study entry. This subset represented approximately 1/4 of all patients in the SYNERGY study. Based on these data, we hypothesized that patients with similar features may have the potential to benefit from treatment with opicinumab. We're in the final stages of designing the next study and look forward to providing an update in the coming months. 
Turning to another late-stage asset. We made significant progress advancing nusinersen this quarter. As George highlighted, in August, Biogen and Ionis announced that we met the prespecified primary endpoint upon interim analysis of ENDEAR. In the analysis, patients with infantile onset SMA or SMA consistent with Type 1 who were treated with nusinersen demonstrated a highly statistically significant and clinically meaningful improvement in the achievement of motor milestones, as measured by the Hammersmith Infant Neurological Examination. The responder analysis looked to the achievement of tangible milestones, like kicking, head control, rolling, sitting, crawling, standing and walking, and we believe the results provide a real demonstration of the value nusinersen could bring for patients and their families. Data from the other end points analyzed were also consistently in favor of the treated infants. 
The ENDEAR study remains ongoing and will be stopped once enrolled patients complete their next office visit, but it is anticipated to happen for all patients before the end of the year. Once this occurs, we'll be able to provide more detailed efficacy data, including an analysis on survival. 
During the quarter, we also successfully completed the rolling submission of a new drug application to the FDA for nusinersen. The U.S. filing was submitted less than 2 months after the positive interim analysis of the ENDEAR trial, a significant accomplishment for the company and recognition of the urgent need in this community. We have applied for Priority Review, which, if granted, will shorten the review period for nusinersen following the agency's acceptance of the filing. 
Earlier this month, we also filed the Marketing Authorization Application to the European Medicines Agency. The EMA's Committee for Medicinal Products for Human Use has granted nusinersen Accelerated Assessment status, which can also reduce the standard review time, and we look forward to working with both agencies over the coming months to bring this treatment to patients as quickly as possible. 
For nusinersen, our regulatory submissions are comprised of results from from the prespecified interim analysis of ENDEAR as well as all other clinical and preclinical data currently available, including open-label data in both Types 2 and 3 SMA patients. We're seeking a broad label for the treatment of SMA and our current filing applications in the U.S. and the EU. 
Our other randomized, placebo-controlled Phase III study, CHERISH, in children with later-onset SMA consistent with Type 2 was fully enrolled in March this year and remains on track for completion in the first half of 2017. 
Earlier this month, we presented additional data for nusinersen at the 2016 World Muscle Society Congress in Granada, Spain. The presentations included safety results from the interim analysis of the Phase III ENDEAR study, which demonstrated a favorable safety profile. 
Analysis of the ongoing Phase II open-label study NURTURE demonstrated a positive effect in genetically diagnosed and presymptomatic SMA infants. In the NURTURE interim analysis, all 13 infants have demonstrated increases in mean Hammersmith Infant Neurological Exam scores over time, and no infants have discontinued, withdrawn from the study or reached the primary endpoint of death or respiratory intervention in patients who had been enrolled for a minimum of 64 days and up to 13 months. 
A recent analysis of data from the CS2 and CS12 open-label studies in patients with later-onset SMA, which included both Type 2 and Type 3 patients, was also presented at World Muscle. The data showed that children with SMA treated with nusinersen exhibited improvements on several measures of motor function for up to nearly 3 years. These results are in contrast to the stable or slow decline in scores typically observed in patients with later-onset SMA over time. We continue to be encouraged by the consistently positive results for nusinersen, which we believe support its benefit in SMA. 
Now turning to Alzheimer's disease. During the quarter, a number of exciting developments occurred for our lead candidate, aducanumab. As George mentioned, results from preclinical research in the Phase Ib study of aducanumab were published in Nature, a significant achievement for the program and recognition of Biogen's high-caliber science. Aducanumab was granted Fast Track designation by the FDA, an important step in bringing this potential therapy to patients as quickly as possible. 
And in a recently completed interim analysis from the Phase Ib study, which included the titration cohort, arms 8 and 9 and the portion of the long-term extension study, efficacy and safety were consistent with results previously reported and support the design of the ongoing Phase III ENGAGE and EMERGE studies. The data from both the titration  cohort and the portion of the long-term extension study of PRIME have been accepted to the 9th Clinical Trials on Alzheimer's Disease meeting in San Diego, and we look forward to sharing additional safety and efficacy data with you in December. 
We're also making important progress across our pipeline, and we continue to shape our R&D engine for the future. Last year, we announced an agreement to license amiselimod, an oral sphingosine 1-phosphate receptor modulator, for Mitsubishi Tanabe. Since announcing the license agreement, we assessed the compound for a number of autoimmune indications with a particular interest in inflammatory bowel disease. As we prioritize our strategic objectives and the IBD landscape continues to evolve, we've decided to discontinue our current development plan for amiselimod. 
As we mentioned last quarter, we generated encouraging Phase I data on BIIB059, or anti-BDCA2, for lupus. The anti-BDCA2 Phase I study included both healthy volunteers and a cohort of 12 lupus subjects. We anticipate presenting these data at ACR next month, including results from the lupus cohort. A Phase II study evaluating the efficacy and safety of BIIB059 is underway with the first subject dose this month. 
We're also working to advance BIIB074, a novel investigational state-dependent subtype selective sodium channel blocker for neuropathic pain. We have initiated and opened to enrollment a Phase I -- Phase IIb trial for lumbosacral radiculopathy, also known as sciatica. We're also close to completing enrollment in a small exploratory Phase IIa study in erythromelalgia, and we are working toward initiating a Phase III study in trigeminal neuralgia in 2017. 
BG11, or STX-100, for idiopathic pulmonary fibrosis is enrolling its final cohort in a Phase IIa study, and we expect to present the data after the trial completes in the second half of next year. BG11 blocks alpha(v)beta(6) integrin, which is selectively up-regulated in epithelial cells in fibrotic conditions, such as IPF, and is known to be a key mediator of TGF-beta activations. We believe early safety and biomarker results from this study evaluating BG11 in IPF patients are encouraging. 
In summary, we continue to make strong progress across our pipeline, and we are working aggressively to optimize and reshape our R&D activities, focusing resources to rapidly advance assets that present the greatest opportunity and address unmet need. 
With that, I will now pass the call to Michel."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, Mike. This is a solid quarter for MS business. Our portfolio of MS therapies delivered revenues of $2.3 billion, an increase of 3% versus Q3 last year and 2% versus Q2. Excluding the impact of foreign exchange, MS revenues increased 5% versus Q",1295,"Thank you, Mike. This is a solid quarter for MS business. Our portfolio of MS therapies delivered revenues of $2.3 billion, an increase of 3% versus Q3 last year and 2% versus Q2. Excluding the impact of foreign exchange, MS revenues increased 5% versus Q3 last year and 2.5% versus Q2. Biogen maintained its global leading market share of 38% and remains the leader for both newly diagnosed and switch patients, representing the dynamic portion of the MS market. 
As I communicated during our last call, the commercial organization is now focusing on 4 key opportunities: portfolio strategy, commercial excellence, medical leadership, trust and value. Since the beginning of Q3, we are now in execution mode, especially for MS in the U.S. 
With portfolio strategy, we have progressed and now identified our prioritized growth opportunities for now and 2017. It is all about making hard choices, driving consistency in resource allocation and following through with tactical plans and execution. 
With commercial excellence, in the U.S., we have piloted and defined a specific engagement model with key MS centers. The rollout is expected to be completed by year-end. Additionally, we are currently enhancing our sophistication in multichannel marketing with a strong focus on digital execution capabilities. We need to meet our customers where they are, defined by the customer journey, to provide a seamless and differentiated Biogen engagement experience, whether through direct, digital or other media. These are important steps, not only to improve performance in the short term, but also towards the creation of a new go-to-market model that is more effective and at a lower cost. 
In terms of medical leadership, during the third quarter, our R&D colleagues have identified several key opportunities as to how to improve MS care today. We believe we have the opportunity to bring to use regular and quantitative measurement of disease progression, including cognition and imaging. In addition, we just launched our MS Path initiative that will be -- we believe will create a standardized, high-quality data repository from a very diverse real-world patient population in the U.S. and EU. We believe this will open new and differentiated engagement opportunities with major MS clinical centers in the U.S. and in Europe. 
And finally, trust and value. We are developing beyond-the-pill solutions that we believe will meet customers' day-to-day needs in living with or treating MS. We are working on establishing the leading ecosystem for patients and providers to improve patient outcomes. We believe that Biogen is the only company that has the position and commitment to MS to be able to provide this level of support in a trustworthy and valuable way. 
Across these 4 priority areas, we have well-defined plans, and as I said, since early Q3, we are now in execution mode. Delivering on those well means enhancing the fundamental capability of the commercial operation at Biogen. These priorities are intended to not only drive performance for our in-line products, but also to prepare the organization for current and future product launches. 
Turning to MS performance. In the U.S., overall MS market has experienced a 2% decline in commercial patients versus Q3 last year, while in Europe, the market continues to grow with a 7% increase in patients versus Q3 last year. For TECFIDERA, global market share has increased by approximately one point to 15% versus Q3 last year. 
In the U.S., we have a stable TECFIDERA performance. TECFIDERA continues to capture roughly half of all patients starting on an oral with the current oral share of 51%, and overall patient share remains relatively stable at 20% since the beginning of the year. This is a clear leadership position for all 3 metrics. 
In Europe, there are approximately 65,000 patients on TECFIDERA, an increase of approximately 30% versus Q3 last year and approximately 4% versus Q2. TECFIDERA is now the most prescribed MS therapy in Germany, France, the U.K. and Italy with more recently launched market continuing to drive patient growth. We do aspire to restore growth to the more mature markets, and we are very pleased to see early indicators that TECFIDERA gained share this quarter in France, following 2 quarters of flat performance. 
Over the past year, TYSABRI has seen steady incremental share gains globally as it continues to add patients, driven by increased share in the U.S. as well as in the emerging markets. As we continue to see a shift towards increased use of high efficacy therapies, we believe TYSABRI is benefiting from growing first-line use in the U.S. 
In Europe, we are also encouraged by the recent update, extending the indication for TYSABRI and allowing physician to better optimize risk management based on JC virus antibody index values. Following the EU label approval, we have also received similar label update in Japan, Canada and Switzerland. 
Our interferon therapies continue to play an important role amongst the injectable portion of the market. We believe PLEGRIDY is helping to slow the decline of our interferons, though it does not completely compensate for the loss of AVONEX patients. 
In collaboration with AbbVie, we launched ZINBRYTA in August in the U.S. and Germany, and we just recently obtained approval in Australia. We believe the launch of ZINBRYTA comes at the right time as we see a trend towards increased use of high-efficacy products with both current therapies and future entrants.
While early in the launch, we are encouraged by the level of physician and patient interest in the strong product profile. In the U.S., for example, over half of our target physician have completed enrollment on our REMS Program, enabling them to begin prescribing. These are early data that we see indications that we are capturing many switching patients who otherwise may not have chosen a Biogen product. So it appears that our positioning and execution is working. Looking forward, we expect to receive reimbursement for ZINBRYTA in all the major European markets within the next 12 to 18 months. 
So overall, we had a solid performance this quarter across our MS business despite a recent slowdown in the overall MS commercial market in the U.S. 
We are also very excited about the continued progress of our biosimilar business. BENEPALI is now available in 13 countries, and in most markets, we are seeing a conversion rate superior to the first infliximab biosimilar launch in Europe with up to 60% to 80% conversion in markets such as Norway or Denmark. With BENEPALI, we believe we are able to compete beyond price. We are seeing a strong preference for the BENEPALI auto-injector versus that of the originator, with our research indicating that 86% of the nurse prefer our device. 
We recently also launched our infliximab biosimilar, FLIXABI, which is now available in Germany, the U.K. and the Netherlands with 3 additional countries anticipated in Q4. We believe our ability to potentially be the first company to offer all 3 major anti-TNFs in Europe could put us in a position of strength in the market. We believe biosimilars are an important growth opportunity for Biogen as we work to optimize our engagement with stakeholders across the health care system. 
In summary, we had a very productive quarter across our MS business in terms of performance. We are encouraged with our new product launches, and we see clear progress as we work hard to elevate our commercial execution capabilities to new levels and as we improve our go-to-market model. 
Also, we are particularly excited about the potential to soon launch nusinersen for SMA. With approximately 20,000 patients across the U.S., Europe and Japan and no available treatments today, we believe nusinersen represents a significant opportunity for both Biogen and, more importantly, for the patients who, today, have no treatment option. 
With that, I'll turn the call over to Paul."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thanks, Michel. In the third quarter, our GAAP diluted earnings per share were $4.71, a 13% increase versus Q3 last year, while our non-GAAP diluted earnings per share were $5.19, an increase of 16%. Total revenue for Q3 grew 6% versus Q3 last year to app",793,"Thanks, Michel. In the third quarter, our GAAP diluted earnings per share were $4.71, a 13% increase versus Q3 last year, while our non-GAAP diluted earnings per share were $5.19, an increase of 16%. Total revenue for Q3 grew 6% versus Q3 last year to approximately $3 billion. 
Global third quarter TECFIDERA revenues were $1,034,000,000, an increase of 10% versus Q3 of last year. This included revenues of $845 million in the U.S., an increase of 12% versus Q3 last year, and $189 million outside the U.S., an increase of 3% versus Q3 last year. In the U.S., we believe TECFIDERA benefited by approximately $40 million to $50 million versus Q2 due to inventory build in the channel. Outside the U.S., Q3 TECFIDERA decreased by $17 million versus Q2, largely driven by parallel trade dynamics. Versus Q3 last year, foreign exchange and hedge impact weakened TECFIDERA revenues by approximately $17 million. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $708 million during the third quarter, a decrease of 10% versus Q3 last year. This included $506 million in the U.S. and $203 million in sales outside the U.S. In the U.S., we believe there was a drawdown of AVONEX inventory in the wholesale channel, resulting approximately $10 million versus Q2. Outside the U.S., foreign exchange and hedge impact weakened interferon revenue by approximately $20 million versus Q3 last year. 
TYSABRI worldwide revenues were $515 million this quarter, an increase of 7% versus Q3 last year. This included $301 million in the U.S. and $214 million outside the U.S. Outside the U.S., TYSABRI revenue benefited by $20 million due to a favorable adjustment to our discounts and allowances. Foreign exchange and the hedge impact weakened TYSABRI revenue by approximately $16 million versus Q3 last year. 
Our hemophilia products continued to perform well this quarter. ELOCTATE revenues for the quarter were $132 million, an increase of 46% versus Q3 last year. This includes $110 million in the U.S. and $22 million outside the U.S. ALPROLIX revenues in Q3 were $85 million, an increase of 30% versus Q3 last year, including $67 million in the U.S. and $19 million outside the U.S.  
Our biosimilar business generated $31 million in revenues this quarter, driven primarily by BENEPALI. 
Turning to our anti-CD20 revenues, which include our profit share for RITUXAN and GAZYVA in the United States as well as our profit share in royalties on sales of rituximab outside the U.S. We recorded $318 million for Q3, a decrease from Q2 driven by a reduction in inventory from the second quarter. 
Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing, were $99 million in the third quarter. The increase versus Q2 was related to contract manufacturing for a strategic partner, slightly offset by a $13 million loss in our AbbVie collaboration profit share. 
 
Now turning to the expense lines on the P&L. Q3 GAAP cost of goods sold was $417 million or 14% of revenue. Non-GAAP COGS was $396 million or 13% of revenue. The increase versus Q2 was primarily attributable to a mid-single-digit royalty on U.S. sales of both AVONEX and PLEGRIDY. 
Q3 GAAP and non-GAAP R&D expense was $529 million or 18% of revenue. Both GAAP and non-GAAP R&D expense included a $75 million payment to Ionis related to the exercise of our opt-in right to develop and commercialize nusinersen globally. I'd like to note that our collaboration partner, Eisai, has stated their goal to start a Phase III trial for E2609. A $50 million milestone payment is expected to be triggered once the first patient is dosed in the E2609 Phase III trial, and there's a potential chance they could dose the first patient by the end of this year. The $50 million milestone was not considered in our midyear 2016 R&D guidance. 
Q3 GAAP SG&A expense was $463 million. Q3 non-GAAP SG&A expense was $461 million or 16% of revenue. Other net expense was $58 million in Q3, which includes $66 million in interest expense, primarily related to our 2015 bond offering. In Q3, both our GAAP and non-GAAP tax rates were approximately 25%. 
Our weighted average diluted share count was approximately 219 million for Q3, which brings us to our diluted earnings per share which were $4.71 on a GAAP basis and $5.19 on a non-GAAP basis. We ended the quarter with $7.4 billion in cash and marketable securities with approximately 40% of this in the United States. During the quarter, we repurchased 1.1 million shares of the company's common stock for a total value of $349 million. So as often, we had a number of puts and takes in the quarter, nevertheless, a very solid financial quarter. 
I'll turn the call over to George for his closing comments."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Paul. I'm very pleased with what we have accomplished this quarter. We delivered solid commercial performance, strong financial results and important advances in the pipeline. I'm particularly excited about the direction we're heading as",328,"Okay. Thank you, Paul. I'm very pleased with what we have accomplished this quarter. We delivered solid commercial performance, strong financial results and important advances in the pipeline. I'm particularly excited about the direction we're heading as we finish 2016 and look forward to 2017 and beyond. 
As I've said, I believe we are at the beginning of a transformative era in neurodegeneration, which could result in a new era for Biogen as well. We're already starting to see the types of discoveries that can be expected, the science advances and the innovative trial designs yield previously unseen in results and insights. We believe the early data for aducanumab point to additional opportunities to invest in novel science to address Alzheimer's disease and other neurodegenerative diseases. The insights we've gained from the SYNERGY trial are teaching us more about remyelination, and we're enthusiastic about moving opicinumab forward. And the encouraging results we're seeing from nusinersen pointed a possibility that there can be entirely new mechanisms and modalities for treating the many daunting diseases of the central nervous system. 
I'm proud to have led Biogen for more than 6 years now, and it's gratifying to me to be in the position to turn a high-performing organization over to a successor. Our board search for a new CEO is progressing. We don't have a formal update on timing yet, but as you'd expect, the opportunity to lead Biogen is generating plenty of interest. And in the meantime, I'm working closely with our management team as we strive to realize our goals for 2016 and kick off a busy and productive 2017. We're fortunate to have a great leadership team and a passionate group of employees who come to work every day to make a positive impact on patients' lives, and I thank all of them for their hard work and dedication.
 Thanks to all of you for joining us this morning, and we'll now open up the call for questions."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Eric Schmidt from Cowen and Company.",16,"[Operator Instructions] Your first question comes from the line of Eric Schmidt from Cowen and Company."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I was hoping you could talk a little bit more about the parallel trade issue associated with TECFIDERA. Is that something new? Is there anything you can do about it? Is it going to get worse in the future?",39,"I was hoping you could talk a little bit more about the parallel trade issue associated with TECFIDERA. Is that something new? Is there anything you can do about it? Is it going to get worse in the future?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thanks, Eric. This is Paul. I'll try to take a crack at it. We didn't point it out last quarter. So in fairness, it's -- looking at the numbers this quarter, we kind of noticed it in looking backwards. It effectively happens when a low-priced country gets",146,"Thanks, Eric. This is Paul. I'll try to take a crack at it. We didn't point it out last quarter. So in fairness, it's -- looking at the numbers this quarter, we kind of noticed it in looking backwards. It effectively happens when a low-priced country gets extra purchasing patents and it ends up in a more higher-priced company. Across all of our products, we look hard at this, and we try, to to the extent we can, management manage it. I don't expect it. We haven't, across the whole time in multiple sclerosis for 10 or 15 years, seen this to be a big issue, but we'll continue to try to manage it. I don't expect it to be a meaningful issue as we go forward over the next bunch of quarters. It could bounce around every now and then though. Thanks for the question."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just on the remyelination side for Mike or Al. So what are the puts and takes of finding a population for anti-LINGO versus expanding the program for BIIB061? I'm just curious if you can find -- use the lessons from SYNERGY to optimize 061 development or",56,"Just on the remyelination side for Mike or Al. So what are the puts and takes of finding a population for anti-LINGO versus expanding the program for BIIB061? I'm just curious if you can find -- use the lessons from SYNERGY to optimize 061 development or if you have to prioritize that one over the other?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Geoff, this is Mike. That's a good question. So my comment on the SYNERGY results is we've been using that data to really look at the potential for an identified population, we think we found that. We think this is really going to inform our developm",97,"Yes. Geoff, this is Mike. That's a good question. So my comment on the SYNERGY results is we've been using that data to really look at the potential for an identified population, we think we found that. We think this is really going to inform our development of BIIB061. We're thinking about that very closely. There's reason to believe that we -- that the same population may be something we could investigate similarly with BIIB061. We think it'll inform the development. That's going to be part of the plans for how we would develop opicinumab as well."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Maybe I could add to that. This is Al. The subpopulation that we identified has really good biological possibility. In other words, these are patients who have evidence of intact axons. They have evidence of demyelination. This make sense to us that the d",63,"Maybe I could add to that. This is Al. The subpopulation that we identified has really good biological possibility. In other words, these are patients who have evidence of intact axons. They have evidence of demyelination. This make sense to us that the drugs -- both of these drugs would work better in this population, and that's why we're encouraged by these results."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges with Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges with Leerink Partners."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just want to throw a few questions in on nusinersen. First, what would be the earliest that you would be in a position to actually launch the product if the FDA acted with the speed that they've acted on some other recent applications for high unmet need",151,"Just want to throw a few questions in on nusinersen. First, what would be the earliest that you would be in a position to actually launch the product if the FDA acted with the speed that they've acted on some other recent applications for high unmet need indications? Secondly, could you give us a sense of the number of patients continuing from the trials on an open-label basis and also the number of patients in the expanded access program and when you would expect those to be converted to -- become commercial patients? And then lastly, you mentioned the 20,000 patients with SMA in North America, Europe and Japan. But what proportion of those do you consider to be really addressable with the label that you're filing for? Is that the population under 10 or infant-onset? Or is that just all the different forms of SMA? Sorry for the multipart question."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Geoffrey, this is Mike. I'll sort of -- I'm going to start, and then we're going to tag team that, the multipart question here. Hopefully, we'll remember each of the parts.",32,"Okay. Geoffrey, this is Mike. I'll sort of -- I'm going to start, and then we're going to tag team that, the multipart question here. Hopefully, we'll remember each of the parts."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","We need all members of the management team to address it.",11,"We need all members of the management team to address it."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Chime in. So first of all, on the filing, I do want to emphasize that we've submitted the file, we've applied for Priority Review. We haven't heard back on the determination of that. That will obviously dictate when we will get approval for that in the U.",395,"Chime in. So first of all, on the filing, I do want to emphasize that we've submitted the file, we've applied for Priority Review. We haven't heard back on the determination of that. That will obviously dictate when we will get approval for that in the U.S. Similarly, the Accelerated Assessment application we have in Europe, again, that would potentially reduce the review time but we're expecting that, finally, to be validated in the coming weeks. So there's some timing dependence on regulator acceptance of this Priority Review and Accelerated Assessment. Then with that, I'm going to let Michel talk about the launch based on that, but let me address a couple of the other things you mentioned. Our extended access program is active. We've got patients who are receiving drug. This is obviously country-by-country specific in how they're administering it, and it's an ongoing work in progress. That program will really be relevant during this period in -- while we're filed but before we've got approval. We anticipate that, that -- it's going to be a small number of patients that we can get in the relevant countries based on the criteria that we established in our expanded access program. On the incidence and prevalence in the label, what we would say is this is 20,000 patients prevalence today in the U.S., Europe and Japan. SMA, as a whole, has an incidence, about -- of about 13,000 patients a year across those, roughly. The data that we've submitted were from the interim analysis of ENDEAR, these were Type 1 patients. We've included data across all of our studies as well as preclinical data. We are going to seek a broad label for the treatment of SMA. That's obviously will be something under review. And based on that, that will determine the overall size of the patient population, which I'll also let Michel sort of comment on when I turn over to him. My final comment on that would be that we expect that if successful and launched, that these prevalence numbers will increase over time to the extent that we have an impact on survival in these populations. So the label, there's a lot of open questions. We'll have to wait and see, and that is going to determine what the ultimate upside is. So Michel, maybe I'll turn over to you on the..."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Thank you, Mike. So basically, the label is a question mark. The time line is also a question mark. I had the opportunity to review lately the U.S. operation in terms of launch readiness, and I can tell you that I'm very pleased with the team that is",139,"Yes. Thank you, Mike. So basically, the label is a question mark. The time line is also a question mark. I had the opportunity to review lately the U.S. operation in terms of launch readiness, and I can tell you that I'm very pleased with the team that is getting together, high qualified, highly committed team, in order to best serve the unmet medical need, together with, hopefully, a good product that with a good label and approved on time. So the launch readiness is there, and basically, the label will determine which proportion of the current prevalence we can address at launch. So for that, we have to wait a little bit. 20,000 patients in terms of prevalence in the geography that we have qualified, but there are many more beyond, and we are also looking to that."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your next question comes from the line of Ron Gal with Bernstein.",14,"[Operator Instructions] Your next question comes from the line of Ron Gal with Bernstein."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So just first quick clarification. On the anti-LINGO, is this another Phase II? Or are you actually starting a pivotal program with that? And then my question is really on market access for multiple sclerosis in 2017. Now that those contacts have been wri",78,"So just first quick clarification. On the anti-LINGO, is this another Phase II? Or are you actually starting a pivotal program with that? And then my question is really on market access for multiple sclerosis in 2017. Now that those contacts have been written, can you give us kind of like directional view at your formulary access versus 2016 and the pricing that you're able to -- the pricing environment for your products in -- during that year?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Ron, thanks for the question. This is Mike, and I will probably let Al comment as well on opicinumab anti-LINGO. We're very much in the design phase of this, looking at the potential of a trial. We're looking at timing. We're looking at cost. We're",84,"Okay. Ron, thanks for the question. This is Mike, and I will probably let Al comment as well on opicinumab anti-LINGO. We're very much in the design phase of this, looking at the potential of a trial. We're looking at timing. We're looking at cost. We're looking at feasibility. We don't have an answer today, but we think in the coming weeks, we'll have a determination about whether we conduct a Phase IIb trial or whether we look to go straight into Phase III."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","I don't have any further comment.",7,"I don't have any further comment."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So concerning the formulary access in the U.S., we do not comment on the way 2017 will look like nor on the gross to net. What I can tell you is that the organization is committed to continue to generate profitable growth, and for that, we go after the co",106,"So concerning the formulary access in the U.S., we do not comment on the way 2017 will look like nor on the gross to net. What I can tell you is that the organization is committed to continue to generate profitable growth, and for that, we go after the cost structure, forcefully, how we supply and how we procure our business. And as I explained earlier, we are working on our go-to-market model. We don't believe the region frequency model that prevailed in the past is sustainable, and we are basically, step by step, building a new go-to-market model. So we are working on that."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams with Jefferies.",12,"Your next question comes from the line of Brian Abrahams with Jefferies."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I guess the question is for Mike. I was hoping you could clarify what you guys have meant by -- on the aducanumab titration data, what you've meant by efficacy results that are consistent with results previously reported? Are you referring to imaging or c",100,"I guess the question is for Mike. I was hoping you could clarify what you guys have meant by -- on the aducanumab titration data, what you've meant by efficacy results that are consistent with results previously reported? Are you referring to imaging or cognition? And then on the safety side, when you talk about safety looking consistent with what's previously been reported and supporting the design of the Phase III, does that suggest that the ARIA is consistent with what you're seeing? Or does it support the idea of titration potentially reducing the risk of ARIA in certain populations?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Brian, thank you for that. And by the way, these are all things which we will have a lot more to talk about at CTAD in San Diego in December. But -- so let me comment on that. So when I -- when we say consistent with, we're referring to both imaging",141,"Yes. Brian, thank you for that. And by the way, these are all things which we will have a lot more to talk about at CTAD in San Diego in December. But -- so let me comment on that. So when I -- when we say consistent with, we're referring to both imaging and functional endpoints in cognition. And as you know, we've looked at before is the CDI sum of boxes -- CDR sum of boxes and MMSE as well as amyloid PET. On the titration side and safety side, again, we'll have a lot more details on this. But what I'd say is what we're seeing is consistent with what we had hypothesized around for the safety basis of aducanumab. In other words, it's within the range of what we've seen and reported before with the Phase Ib study."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee with RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee with RBC Capital Markets."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","A follow-up on the Alzheimer's prior question. I just wanted to understand the context of the efficacy comments in particular, given that I think there are still some questions around the placebo arm and I think that you're still using partly the pool of",102,"A follow-up on the Alzheimer's prior question. I just wanted to understand the context of the efficacy comments in particular, given that I think there are still some questions around the placebo arm and I think that you're still using partly the pool of placebo from before. So I just want to understand sort of the caveats and I guess how confident you are versus that arm. And then just a quick follow-up is you did mention a line about MT-1303, so just wanted to understand what happened there. Is that a commercial competition thing? Or what happened in that decision?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Michael, this is Al Sandrock. The additional cohorts included some additional placebo patients. So we will show the data from the additional placebo patients as well as the placebo patients from prior cohorts, and that'll be shown at CTAD. And the efficac",71,"Michael, this is Al Sandrock. The additional cohorts included some additional placebo patients. So we will show the data from the additional placebo patients as well as the placebo patients from prior cohorts, and that'll be shown at CTAD. And the efficacy is on PET imaging as well as on the clinical cognitive assessments that we looked at previously, MMSE and CDR sum of boxes. That'll all be shown at CTAD."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So Michael, this is Mike. I'll sort of comment on the amiselimod. This was really -- as we look at how the landscape was evolving, both in terms of a regulatory competitive landscape, changing features there and the corresponding fit with our strategic pr",83,"So Michael, this is Mike. I'll sort of comment on the amiselimod. This was really -- as we look at how the landscape was evolving, both in terms of a regulatory competitive landscape, changing features there and the corresponding fit with our strategic priorities about where we can best allocate resources based on our own expertise and competency, we just determined that this was -- that it wasn't as good of a fit as other things, which we could allocate our resources towards."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang with Bank of America Merrill Lynch.",16,"Your next question comes from the line of Ying Huang with Bank of America Merrill Lynch."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just quickly, we're all anxiously awaiting for the top line from solanezumab Phase III in December. Can you frame us on what could the read-through be for the Phase III program for aducanumab? And then secondly, what's your view on the recent data from Av",60,"Just quickly, we're all anxiously awaiting for the top line from solanezumab Phase III in December. Can you frame us on what could the read-through be for the Phase III program for aducanumab? And then secondly, what's your view on the recent data from AveXis gene therapy in SMA and what that could mean for nusinersen in the commercial opportunity?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Well, thanks for the question. I'll take a stab at this and see if any wants to open up. First of all, I mean, we're not -- I don't think we'll speculate on the potential results of Eli solanezumab trial based on that. I mean, they're scenarios that",313,"Okay. Well, thanks for the question. I'll take a stab at this and see if any wants to open up. First of all, I mean, we're not -- I don't think we'll speculate on the potential results of Eli solanezumab trial based on that. I mean, they're scenarios that one can envision, that we are certainly taking into consideration. We look -- we very much look forward to seeing their data. A couple of things I would point out on this is, is although both A beta antibodies, these are actually fundamentally quite different mechanisms of action. So whereas we think if there were positive results out of the solanezumab trial, this would give great credence to the amyloid hypothesis of Alzheimer's disease and, I think, bode well for the potential results of aducanumab. However, because these are fundamentally different mechanisms they're going at is that it is far more difficult to interpret a negative result if solanezumab were to find it as we would be able to see it. We believe it will be much more difficult to make a conclusion about a negative result on solanezumab vis--vis the potential results of aducanumab. On AveXis, I think what we would comment is, look, we welcome innovative therapies for SMA. We think it's a very serious, very important disease area. We're highly committed to this disease area and to the patients and families. We think that gene therapy, as an overall approach, is a viable one in spinal muscular atrophy, and in fact, we're quite excited about our own internal program that we have and our collaboration with UPenn in that regard as well. So we look forward to seeing how the combination of nusinersen potentially being launched and the next-generation therapeutics that we're certainly working on will play out over time. We see great prospect for the treatment of spinal muscular atrophy."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","And the only thing I would add on the Alzheimer's is the population is a little different. In solanezumab, they're studying the mild patients, which make sense because that's where they saw some evidence of efficacy in Expedition II. Whereas in the case o",68,"And the only thing I would add on the Alzheimer's is the population is a little different. In solanezumab, they're studying the mild patients, which make sense because that's where they saw some evidence of efficacy in Expedition II. Whereas in the case of aducanumab, we're studying prodromal in the early mild patients. And then I agree with everything Mike said about the differences in the antibodies."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matthew Harrison with Morgan Stanley.",13,"Your next question comes from the line of Matthew Harrison with Morgan Stanley."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I just want to go back to SMA for a second, again, just trying to better understand your comments around a broad label. And I guess what data supports a label outside of SMA 1 patients? And what's the rationale that you might be able to achieve a label ou",60,"I just want to go back to SMA for a second, again, just trying to better understand your comments around a broad label. And I guess what data supports a label outside of SMA 1 patients? And what's the rationale that you might be able to achieve a label outside of SMA 1 patients ahead of the randomized study data?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Matthew, thanks for the question. I mean, I guess I would first start by saying, we really are not going to comment on the data prospects for our label. But what I will say is that we have ongoing studies in Type 2 patients, where we're looking at t",156,"Okay. Matthew, thanks for the question. I mean, I guess I would first start by saying, we really are not going to comment on the data prospects for our label. But what I will say is that we have ongoing studies in Type 2 patients, where we're looking at the potential efficacy of nusinersen. As you know also, we have an ongoing trial, as I had mentioned, in presymptomatic genetically diagnosed infants. And so all of that data -- this data that we look to include in our filing application and, from that, the extent of the label that we achieve, that will be based on the agency's review of the totality of the data and the evidence. We will present evidence based on those populations in our effort to seek a broad label. What that data is we'll be able to -- we'll present at the appropriate time. Many of these studies have not completed."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of John Scotti with Evercore ISI.",13,"Your next question comes from the line of John Scotti with Evercore ISI."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So on the CEO search, could you just elaborate a bit more? I'm not sure what exactly, but I know this is a big topic for investors right now. On timing, is it unreasonable to hear something by year-end? And then exactly, what is the profile of the person",146,"So on the CEO search, could you just elaborate a bit more? I'm not sure what exactly, but I know this is a big topic for investors right now. On timing, is it unreasonable to hear something by year-end? And then exactly, what is the profile of the person you're looking for? Is it someone from industry, out of industry, et cetera? And then on the MS market, Michel, I had a quick question. So you said that in the U.S., the volumes are declining year-over-year. And do you see this trend continuing? And if so, is it fair to say that any growth from TEC, which -- stable patient share and I guess also, perhaps, the entire MS market as a whole, would come from price going forward? Or do you see volumes inflecting at some point? And if so, what would be the catalyst?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. This is George. Maybe I'll comment on the CEO search first. Look, I'm not going to comment on the specific timing. I can tell you that I think we all believe that the sooner we can get through this and have a new CEO come, the better it is for all o",114,"Okay. This is George. Maybe I'll comment on the CEO search first. Look, I'm not going to comment on the specific timing. I can tell you that I think we all believe that the sooner we can get through this and have a new CEO come, the better it is for all of us. So it's a very active search. The board is interviewing a number of candidates. There are, as you would expect, very high quality candidates coming in and being interviewed from a variety of backgrounds, actually. And we'll give you an update on that as soon as we can, but I don't want to comment anymore on the specific timing today."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So concerning the U.S. markets, thanks for the question, what we have seen during the past quarters was basically a slowdown towards a low single-digit market growth in the U.S. What we have seen during the past months or weeks was a shift in the mix betw",432,"So concerning the U.S. markets, thanks for the question, what we have seen during the past quarters was basically a slowdown towards a low single-digit market growth in the U.S. What we have seen during the past months or weeks was a shift in the mix between commercial and free that is impacting basically the commercial units' performance. So I don't know if it's an overall market trend but this is what we have seen internally. What I can tell you is that TECFIDERA remains the #1 priority for the organization. We have a plan, as alluded last time, we are working based on the portfolio work that we are doing on Peg GI discontinuation that remains at an average of approximately 22%. We have the good opportunity to make some inroad there because, basically, the scope goes from 5% to 35%. So there are some centers, some MS centers where they're able to manage with the right engagement and here the different type of engagements that are being practiced in the different centers, there is no evidence yet. One can speculate that we can see a temporal association between the increase of eosinophil and the GI symptomology, but this was not confirmed by clinical trials because of many different confounding factors. So we work on Peg GI. We see early signs if it's heading towards the right direction also in Europe, but it's too early to claim any big success here. We are working on the capture rates, and one balance the other. That's why we have a stable patient base. And the pace of the market is certainly lower than what we have estimated in our assumptions, but it's not an excuse for not increasing share. So we do not give up. We invest. We are committed. I can tell you the team in the U.S. is all up and running. They have piloted a new engagement model with critical MS centers. I'm very pleased to see the perception improvement. And now we have to continue to execute, and the full rollout of this new plan will be towards the end of the year or, by latest, early January. So we are committed. We don't give up on the large mature market, where the share of TEC is relatively stable, versus the latest launch markets where we make -- continue to make fast inroads, like in Italy, Spain or the U.K. And the good news is that we could turn to positive France. And we'll continue for Germany, and we'll continue for the U.S. We are committed. Thank you."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas with Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas with Citigroup."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So just to follow up on market trends in MS. So help us understand why do you think -- is there anything going on with the MS market? Why is it shrinking in the U.S.? Are you seeing any people who are trying the orals and then hopping off and not getting",96,"So just to follow up on market trends in MS. So help us understand why do you think -- is there anything going on with the MS market? Why is it shrinking in the U.S.? Are you seeing any people who are trying the orals and then hopping off and not getting back into the MS treatment bucket? And then on PLEGRIDY sort of the market, having a certain small percentage of the market, it's interesting. But do you think you can grow that? And what are you specifically doing to grow the PLEGRIDY market share?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So thanks for the question. It's very difficult to speculate on the future trend of the market. So we have -- see a couple of points negative for the quarter versus prior year. This was not the situation during the prior quarters. So time will speak. We'l",100,"So thanks for the question. It's very difficult to speculate on the future trend of the market. So we have -- see a couple of points negative for the quarter versus prior year. This was not the situation during the prior quarters. So time will speak. We'll see over time, but I don't believe that this will be sustained. And again, I spoke about some trends in the marketplace between commercial units being commercialized and other channels. So we are committed to gain market share in a slower pace of the market in all our mature markets, including the U.S."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Chris Raymond with Raymond James.",13,"Your next question comes from the line of Chris Raymond with Raymond James."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just back on to SMA and nusinersen. You guys have talked about your expanded access program and sort of moving that forward, and sounds like there's a desire to get more patients on. We sort of run -- ran across some social media chatter from parents that",105,"Just back on to SMA and nusinersen. You guys have talked about your expanded access program and sort of moving that forward, and sounds like there's a desire to get more patients on. We sort of run -- ran across some social media chatter from parents that seem to be sort of complaining about, at least, some PIs that were looking to restrict access to this program. I wonder if you could -- that would seems to be a little bit at odds with what you guys have talked about. Can you maybe comment on that and maybe help explain what exactly is going on?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Chris, maybe I'll sort of start. I mean, the essence is we're not going to comment on specific investigators or specific sites around this. I would say that our expanded access program was really designed to -- in cases and at sites in countries where we",187,"Chris, maybe I'll sort of start. I mean, the essence is we're not going to comment on specific investigators or specific sites around this. I would say that our expanded access program was really designed to -- in cases and at sites in countries where we were able to, with this severe disease, before we're able to successfully launch, hopefully, if we get a favorable review -- to maximize the access that we could based on criteria that were medically established at relevant sites. A lot of that is determined at the site in the country level. They determine that. And we are doing our best to ensure access in the way that makes sense but that does not jeopardize our filing and the potential approval of this for broad access. Our hope, by the way, is that this period will be short, and that we'll be able to utilize the Priority Review and the Accelerated review -- the assessment at the EMA to bring this to patients as quickly as possible so that the CAP (sic) [ EAP ] program can be as short as possible."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov with JPMorgan.",12,"Your next question comes from the line of Cory Kasimov with JPMorgan."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Wanted to ask you about your broader biz dev intentions. And obviously, you had the setback with MT-1303. But as we look forward, can you talk about your strategy here and how much you're able to act on it, if at all, while you have a CEO search ongoing?",95,"Wanted to ask you about your broader biz dev intentions. And obviously, you had the setback with MT-1303. But as we look forward, can you talk about your strategy here and how much you're able to act on it, if at all, while you have a CEO search ongoing? I guess is this part of the business that we should assume is on hold for the time being until you get someone in who can kind of take stock of the overall organization? Or are you still proceeding with diligence of other companies as usual?"
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","No, you should not assume this is on hold. We all believe this is an important part of what we have to accomplish. We are continuing with diligence on several companies as we speak, and that will continue. And we will continue to work aggressively to fina",94,"No, you should not assume this is on hold. We all believe this is an important part of what we have to accomplish. We are continuing with diligence on several companies as we speak, and that will continue. And we will continue to work aggressively to finalize some of these issues. I think the areas in which we are interested are clear. We have a very good R&D team now who can make the technical assessments. We have great ability now to make the accurate commercial assessments, and so we are full speed ahead."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","All right. Dan, that should conclude the call for today. Thank you very much.",14,"All right. Dan, that should conclude the call for today. Thank you very much."
29726,384066926,1061857,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Thank you to everyone for attending. This concludes today's conference call. You may now disconnect.",15,"Thank you to everyone for attending. This concludes today's conference call. You may now disconnect."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the confere",58,"Good morning. My name is Dan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Third Quarter 2016 Financial Results and Business Update. [Operator Instructions] I would now like to turn the conference over to Matthew Calistri, Senior Director of Investor Relations. You may begin your conference."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, Dan, and welcome, everyone, to Biogen's Third Quarter 2016 Earnings Conference Call. Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconc",222,"Thank you, Dan, and welcome, everyone, to Biogen's Third Quarter 2016 Earnings Conference Call. 
Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the press release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. Our GAAP financials are provided in Tables 1 and 2. Table 3 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We've also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
On today's call, I'm joined by our Chief Executive Officer, Dr. George Scangos; Dr. Michael Ehlers, EVP of Research and Development; our Chief Commercial Officer, Michel Vounatsos; and our CFO, Paul Clancy. We'll also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock.
Now I'll turn the call over to George."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Thanks, Matt, and good morning, everyone. Thanks for joining us today. Happy to say, Biogen delivered another solid quarter, complete with strong financial performance and significant advancements in the pipeline. For the third quarter of 2016, Biog",529,"Okay. Thanks, Matt, and good morning, everyone. Thanks for joining us today. Happy to say, Biogen delivered another solid quarter, complete with strong financial performance and significant advancements in the pipeline. For the third quarter of 2016, Biogen generated a record $3 billion in revenues, 6% increase from the same period a year ago. Our GAAP earnings were $4.71 per share, a 13% increase versus Q3 last year, and non-GAAP earnings were $5.19 per share, a 16% increase. 
I'll come back to the financials in a minute, but first, I'd like to highlight some of the important third quarter pipeline progress. One of the most exciting milestones this quarter was the positive interim analysis of nusinersen in the ENDEAR study. Recognizing the tremendous need in the SMA community, we moved quickly to establish the expanded access program and completed the NDA filing with the FDA in less than 2 months, the fastest time of filing time in Biogen's 38-year history. We continue to be grateful to the patients, families, investigators and employees who work tirelessly to bring this program to this point. We've also filed with the EMA where nusinersen has received Accelerated  Assessment status. If approved, nusinersen would be the first treatment for patients with spinal muscular atrophy, a leading genetic cause of death in infants. 
We were honored when one of our key pipeline programs was featured on the cover of Nature, specifically, the results of our preclinical research in Phase Ib study of aducanumab. This rare distinction was a first for Biogen research and one that I think further highlights the important work that we're doing in the area of Alzheimer's disease. We also announced that aducanumab was granted Fast Track designation by the FDA. 
Our commercial business continue to deliver solid results this quarter. We furthered our leadership in MS with the launch of ZINBRYTA in collaboration with AbbVie, and we continue to grow the number of patients benefiting from our full portfolio of MS products. 
Our third quarter hemophilia revenues grew to $217 million, and we made further progress with the spinoff of our hemophilia business into a separate, independent, publicly traded company, known as Bioverativ, with the initial filing of the Form 10 in August. We continue to expect to complete that transaction in early 2017. 
In Europe, we doubled our biosimilars revenues over the prior quarter as BENEPALI continues to launch in markets across the continent and pick up share at a rate previously unseen for a biosimilar anti-TNF, and we launched FLIXABI, our biosimilar of infliximab. We continue to believe that our work in biosimilars is an important growth opportunity for Biogen. 
So we've seen great progress in both our pipeline and our commercial portfolio during the quarter. As you'll hear shortly from Mike and Michel, our entire executive leadership team is focused on driving commercial performance, prioritizing our assets, advancing our clinical programs and reshaping our pipeline, and our 7,000 employees globally remain committed to delivering therapies that we believe can make a positive difference in the lives of patients. 
I'll now turn the call over to Mike so that he can give you a thorough update on our pipeline."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, George, and good morning, everyone. Let me provide some highlights from this quarter, starting with multiple sclerosis. Last month, at ECTRIMS, we presented clinical findings from our broad portfolio of MS therapies as well as top line results",1482,"Thank you, George, and good morning, everyone. Let me provide some highlights from this quarter, starting with multiple sclerosis. Last month, at ECTRIMS, we presented clinical findings from our broad portfolio of MS therapies as well as top line results for opicinumab, or anti-LINGO, a potential neuroreparative therapy for people with relapsing forms of multiple sclerosis. 
We presented real-world data and clinical evidence showing that TECFIDERA consistently demonstrates strong efficacy by reducing MS disease activity in patients who have had up to 9 years of treatment. These data also affirm TECFIDERA's well-characterized safety profile. Importantly, we believe these findings provide additional support for the early use of TECFIDERA to improve patient outcomes. 
Data were also presented for ZINBRYTA, our newly launched once-monthly, self-administered subcutaneous treatment option for relapsing forms of MS. A new post-hoc analysis from the pivotal DECIDE study showed that a significantly greater number of people treated with ZINBRYTA showed no evidence of disease activity compared to those taking intramuscular interferon. Additional new interim data from the long-term extension study EXTEND show that treatment with ZINBRYTA had long-term benefits in the proportion of patients who remained relapse-free as well as those who did not experience 24-week confirmed disability progression. 
For opicinumab, we presented top line results from the Phase II SYNERGY study in MS, in which opicinumab missed the primary endpoint. However, we believe the robust design of the study has allowed us to identify an appropriate patient population and dose to move forward with development. Within the 10 mg per kg dosing arm of the study, we identified a treatment effect in patients whose MRI scans had specific features suggesting evidence that reduced myelination and intact axons at study entry. This subset represented approximately 1/4 of all patients in the SYNERGY study. Based on these data, we hypothesized that patients with similar features may have the potential to benefit from treatment with opicinumab. We're in the final stages of designing the next study and look forward to providing an update in the coming months. 
Turning to another late-stage asset. We made significant progress advancing nusinersen this quarter. As George highlighted, in August, Biogen and Ionis announced that we met the prespecified primary endpoint upon interim analysis of ENDEAR. In the analysis, patients with infantile onset SMA or SMA consistent with Type 1 who were treated with nusinersen demonstrated a highly statistically significant and clinically meaningful improvement in the achievement of motor milestones, as measured by the Hammersmith Infant Neurological Examination. The responder analysis looked to the achievement of tangible milestones, like kicking, head control, rolling, sitting, crawling, standing and walking, and we believe the results provide a real demonstration of the value nusinersen could bring for patients and their families. Data from the other end points analyzed were also consistently in favor of the treated infants. 
The ENDEAR study remains ongoing and will be stopped once enrolled patients complete their next office visit, but it is anticipated to happen for all patients before the end of the year. Once this occurs, we'll be able to provide more detailed efficacy data, including an analysis on survival. 
During the quarter, we also successfully completed the rolling submission of a new drug application to the FDA for nusinersen. The U.S. filing was submitted less than 2 months after the positive interim analysis of the ENDEAR trial, a significant accomplishment for the company and recognition of the urgent need in this community. We have applied for Priority Review, which, if granted, will shorten the review period for nusinersen following the agency's acceptance of the filing. 
Earlier this month, we also filed the Marketing Authorization Application to the European Medicines Agency. The EMA's Committee for Medicinal Products for Human Use has granted nusinersen Accelerated Assessment status, which can also reduce the standard review time, and we look forward to working with both agencies over the coming months to bring this treatment to patients as quickly as possible. 
For nusinersen, our regulatory submissions are comprised of results from the prespecified interim analysis of ENDEAR as well as all other clinical and preclinical data currently available, including open-label data in both Types 2 and 3 SMA patients. We're seeking a broad label for the treatment of SMA and our current filing applications in the U.S. and the EU. 
Our other randomized, placebo-controlled Phase III study, CHERISH, in children with later-onset SMA consistent with Type 2 was fully enrolled in March this year and remains on track for completion in the first half of 2017. 
Earlier this month, we presented additional data for nusinersen at the 2016 World Muscle Society Congress in Granada, Spain. The presentations included safety results from the interim analysis of the Phase III ENDEAR study, which demonstrated a favorable safety profile. 
Analysis of the ongoing Phase II open-label study NURTURE demonstrated a positive effect in genetically diagnosed and presymptomatic SMA infants. In the NURTURE interim analysis, all 13 infants have demonstrated increases in mean Hammersmith Infant Neurological Exam scores over time, and no infants have discontinued, withdrawn from the study or reached the primary endpoint of death or respiratory intervention in patients who had been enrolled for a minimum of 64 days and up to 13 months. 
A recent analysis of data from the CS2 and CS12 open-label studies in patients with later-onset SMA, which included both Type 2 and Type 3 patients, was also presented at World Muscle. The data showed that children with SMA treated with nusinersen exhibited improvements on several measures of motor function for up to nearly 3 years. These results are in contrast to the stable or slow decline in scores typically observed in patients with later-onset SMA over time. We continue to be encouraged by the consistently positive results for nusinersen, which we believe support its benefit in SMA. 
Now turning to Alzheimer's disease. During the quarter, a number of exciting developments occurred for our lead candidate, aducanumab. As George mentioned, results from preclinical research in the Phase Ib study of aducanumab were published in Nature, a significant achievement for the program and recognition of Biogen's high-caliber science. Aducanumab was granted Fast Track designation by the FDA, an important step in bringing this potential therapy to patients as quickly as possible. 
And in a recently completed interim analysis from the Phase Ib study, which included the titration cohort, arms 8 and 9 and the portion of the long-term extension study, efficacy and safety were consistent with results previously reported and support the design of the ongoing Phase III ENGAGE and EMERGE studies. The data from both the titration  cohort and the portion of the long-term extension study of PRIME have been accepted to the 9th Clinical Trials on Alzheimer's Disease meeting in San Diego, and we look forward to sharing additional safety and efficacy data with you in December. 
We're also making important progress across our pipeline, and we continue to shape our R&D engine for the future. Last year, we announced an agreement to license amiselimod, an oral sphingosine 1-phosphate receptor modulator, for Mitsubishi Tanabe. Since announcing the license agreement, we assessed the compound for a number of autoimmune indications with a particular interest in inflammatory bowel disease. As we prioritize our strategic objectives and the IBD landscape continues to evolve, we've decided to discontinue our current development plan for amiselimod. 
As we mentioned last quarter, we generated encouraging Phase I data on BIIB059, or anti-BDCA2, for lupus. The anti-BDCA2 Phase I study included both healthy volunteers and a cohort of 12 lupus subjects. We anticipate presenting these data at ACR next month, including results from the lupus cohort. A Phase II study evaluating the efficacy and safety of BIIB059 is underway with the first subject dose this month. 
We're also working to advance BIIB074, a novel investigational state-dependent subtype selective sodium channel blocker for neuropathic pain. We have initiated and opened to enrollment a Phase I -- Phase IIb trial for lumbosacral radiculopathy, also known as sciatica. We're also close to completing enrollment in a small exploratory Phase IIa study in erythromelalgia, and we are working toward initiating a Phase III study in trigeminal neuralgia in 2017. 
BG11, or STX-100, for idiopathic pulmonary fibrosis is enrolling its final cohort in a Phase IIa study, and we expect to present the data after the trial completes in the second half of next year. BG11 blocks alpha(v)beta(6) integrin, which is selectively up-regulated in epithelial cells in fibrotic conditions, such as IPF, and is known to be a key mediator of TGF-beta activations. We believe early safety and biomarker results from this study evaluating BG11 in IPF patients are encouraging. 
In summary, we continue to make strong progress across our pipeline, and we are working aggressively to optimize and reshape our R&D activities, focusing resources to rapidly advance assets that present the greatest opportunity and address unmet need. 
With that, I will now pass the call to Michel."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thank you, Mike. This is a solid quarter for MS business. Our portfolio of MS therapies delivered revenues of $2.3 billion, an increase of 3% versus Q3 last year and 2% versus Q2. Excluding the impact of foreign exchange, MS revenues increased 5% versus Q",1295,"Thank you, Mike. This is a solid quarter for MS business. Our portfolio of MS therapies delivered revenues of $2.3 billion, an increase of 3% versus Q3 last year and 2% versus Q2. Excluding the impact of foreign exchange, MS revenues increased 5% versus Q3 last year and 2.5% versus Q2. Biogen maintained its global leading market share of 38% and remains the leader for both newly diagnosed and switch patients, representing the dynamic portion of the MS market. 
As I communicated during our last call, the commercial organization is now focusing on 4 key opportunities: portfolio strategy, commercial excellence, medical leadership, trust and value. Since the beginning of Q3, we are now in execution mode, especially for MS in the U.S. 
With portfolio strategy, we have progressed and now identified our prioritized growth opportunities for now and 2017. It is all about making hard choices, driving consistency in resource allocation and following through with tactical plans and execution. 
With commercial excellence, in the U.S., we have piloted and defined a specific engagement model with key MS centers. The rollout is expected to be completed by year-end. Additionally, we are currently enhancing our sophistication in multichannel marketing with a strong focus on digital execution capabilities. We need to meet our customers where they are, defined by the customer journey, to provide a seamless and differentiated Biogen engagement experience, whether through direct, digital or other media. These are important steps, not only to improve performance in the short term, but also towards the creation of a new go-to-market model that is more effective and at a lower cost. 
In terms of medical leadership, during the third quarter, our R&D colleagues have identified several key opportunities as to how to improve MS care today. We believe we have the opportunity to bring to use regular and quantitative measurement of disease progression, including cognition and imaging. In addition, we just launched our MS Path initiative that will be -- we believe will create a standardized, high-quality data repository from a very diverse real-world patient population in the U.S. and EU. We believe this will open new and differentiated engagement opportunities with major MS clinical centers in the U.S. and in Europe. 
And finally, trust and value. We are developing beyond-the-pill solutions that we believe will meet customers' day-to-day needs in living with or treating MS. We are working on establishing the leading ecosystem for patients and providers to improve patient outcomes. We believe that Biogen is the only company that has the position and commitment to MS to be able to provide this level of support in a trustworthy and valuable way. 
Across these 4 priority areas, we have well-defined plans, and as I said, since early Q3, we are now in execution mode. Delivering on those well means enhancing the fundamental capability of the commercial operation at Biogen. These priorities are intended to not only drive performance for our in-line products, but also to prepare the organization for current and future product launches. 
Turning to MS performance. In the U.S., overall MS market has experienced a 2% decline in commercial patients versus Q3 last year, while in Europe, the market continues to grow with a 7% increase in patients versus Q3 last year. For TECFIDERA, global market share has increased by approximately one point to 15% versus Q3 last year. 
In the U.S., we have a stable TECFIDERA performance. TECFIDERA continues to capture roughly half of all patients starting on an oral with the current oral share of 51%, and overall patient share remains relatively stable at 20% since the beginning of the year. This is a clear leadership position for all 3 metrics. 
In Europe, there are approximately 65,000 patients on TECFIDERA, an increase of approximately 30% versus Q3 last year and approximately 4% versus Q2. TECFIDERA is now the most prescribed MS therapy in Germany, France, the U.K. and Italy with more recently launched market continuing to drive patient growth. We do aspire to restore growth to the more mature markets, and we are very pleased to see early indicators that TECFIDERA gained share this quarter in France, following 2 quarters of flat performance. 
Over the past year, TYSABRI has seen steady incremental share gains globally as it continues to add patients, driven by increased share in the U.S. as well as in the emerging markets. As we continue to see a shift towards increased use of high efficacy therapies, we believe TYSABRI is benefiting from growing first-line use in the U.S. 
In Europe, we are also encouraged by the recent update, extending the indication for TYSABRI and allowing physician to better optimize risk management based on JC virus antibody index values. Following the EU label approval, we have also received similar label update in Japan, Canada and Switzerland. 
Our interferon therapies continue to play an important role amongst the injectable portion of the market. We believe PLEGRIDY is helping to slow the decline of our interferons, though it does not completely compensate for the loss of AVONEX patients. 
In collaboration with AbbVie, we launched ZINBRYTA in August in the U.S. and Germany, and we just recently obtained approval in Australia. We believe the launch of ZINBRYTA comes at the right time as we see a trend towards increased use of high-efficacy products with both current therapies and future entrants.
While early in the launch, we are encouraged by the level of physician and patient interest in the strong product profile. In the U.S., for example, over half of our target physician have completed enrollment on our REMS Program, enabling them to begin prescribing. These are early data that we see indications that we are capturing many switching patients who otherwise may not have chosen a Biogen product. So it appears that our positioning and execution is working. Looking forward, we expect to receive reimbursement for ZINBRYTA in all the major European markets within the next 12 to 18 months. 
So overall, we had a solid performance this quarter across our MS business despite a recent slowdown in the overall MS commercial market in the U.S. 
We are also very excited about the continued progress of our biosimilar business. BENEPALI is now available in 13 countries, and in most markets, we are seeing a conversion rate superior to the first infliximab biosimilar launch in Europe with up to 60% to 80% conversion in markets such as Norway or Denmark. With BENEPALI, we believe we are able to compete beyond price. We are seeing a strong preference for the BENEPALI auto-injector versus that of the originator, with our research indicating that 86% of the nurse prefer our device. 
We recently also launched our infliximab biosimilar, FLIXABI, which is now available in Germany, the U.K. and the Netherlands with 3 additional countries anticipated in Q4. We believe our ability to potentially be the first company to offer all 3 major anti-TNFs in Europe could put us in a position of strength in the market. We believe biosimilars are an important growth opportunity for Biogen as we work to optimize our engagement with stakeholders across the health care system. 
In summary, we had a very productive quarter across our MS business in terms of performance. We are encouraged with our new product launches, and we see clear progress as we work hard to elevate our commercial execution capabilities to new levels and as we improve our go-to-market model. 
Also, we are particularly excited about the potential to soon launch nusinersen for SMA. With approximately 20,000 patients across the U.S., Europe and Japan and no available treatments today, we believe nusinersen represents a significant opportunity for both Biogen and, more importantly, for the patients who, today, have no treatment option. 
With that, I'll turn the call over to Paul."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thanks, Michel. In the third quarter, our GAAP diluted earnings per share were $4.71, a 13% increase versus Q3 last year, while our non-GAAP diluted earnings per share were $5.19, an increase of 16%. Total revenue for Q3 grew 6% versus Q3 last year to app",793,"Thanks, Michel. In the third quarter, our GAAP diluted earnings per share were $4.71, a 13% increase versus Q3 last year, while our non-GAAP diluted earnings per share were $5.19, an increase of 16%. Total revenue for Q3 grew 6% versus Q3 last year to approximately $3 billion. 
Global third quarter TECFIDERA revenues were $1,034,000,000, an increase of 10% versus Q3 of last year. This included revenues of $845 million in the U.S., an increase of 12% versus Q3 last year, and $189 million outside the U.S., an increase of 3% versus Q3 last year. In the U.S., we believe TECFIDERA benefited by approximately $40 million to $50 million versus Q2 due to inventory build in the channel. Outside the U.S., Q3 TECFIDERA decreased by $17 million versus Q2, largely driven by parallel trade dynamics. Versus Q3 last year, foreign exchange and hedge impact weakened TECFIDERA revenues by approximately $17 million. 
Interferon revenues, including both AVONEX and PLEGRIDY, were $708 million during the third quarter, a decrease of 10% versus Q3 last year. This included $506 million in the U.S. and $203 million in sales outside the U.S. In the U.S., we believe there was a drawdown of AVONEX inventory in the wholesale channel, resulting approximately $10 million versus Q2. Outside the U.S., foreign exchange and hedge impact weakened interferon revenue by approximately $20 million versus Q3 last year. 
TYSABRI worldwide revenues were $515 million this quarter, an increase of 7% versus Q3 last year. This included $301 million in the U.S. and $214 million outside the U.S. Outside the U.S., TYSABRI revenue benefited by $20 million due to a favorable adjustment to our discounts and allowances. Foreign exchange and the hedge impact weakened TYSABRI revenue by approximately $16 million versus Q3 last year. 
Our hemophilia products continued to perform well this quarter. ELOCTATE revenues for the quarter were $132 million, an increase of 46% versus Q3 last year. This includes $110 million in the U.S. and $22 million outside the U.S. ALPROLIX revenues in Q3 were $85 million, an increase of 30% versus Q3 last year, including $67 million in the U.S. and $19 million outside the U.S.  
Our biosimilar business generated $31 million in revenues this quarter, driven primarily by BENEPALI. 
Turning to our anti-CD20 revenues, which include our profit share for RITUXAN and GAZYVA in the United States as well as our profit share in royalties on sales of rituximab outside the U.S. We recorded $318 million for Q3, a decrease from Q2 driven by a reduction in inventory from the second quarter. 
Total other revenues, which include revenues from collaboration relationships, royalties and contract manufacturing, were $99 million in the third quarter. The increase versus Q2 was related to contract manufacturing for a strategic partner, slightly offset by a $13 million loss in our AbbVie collaboration profit share. 
 
Now turning to the expense lines on the P&L. Q3 GAAP cost of goods sold was $417 million or 14% of revenue. Non-GAAP COGS was $396 million or 13% of revenue. The increase versus Q2 was primarily attributable to a mid-single-digit royalty on U.S. sales of both AVONEX and PLEGRIDY. 
Q3 GAAP and non-GAAP R&D expense was $529 million or 18% of revenue. Both GAAP and non-GAAP R&D expense included a $75 million payment to Ionis related to the exercise of our opt-in right to develop and commercialize nusinersen globally. I'd like to note that our collaboration partner, Eisai, has stated their goal to start a Phase III trial for E2609. A $50 million milestone payment is expected to be triggered once the first patient is dosed in the E2609 Phase III trial, and there's a potential chance they could dose the first patient by the end of this year. The $50 million milestone was not considered in our midyear 2016 R&D guidance. 
Q3 GAAP SG&A expense was $463 million. Q3 non-GAAP SG&A expense was $461 million or 16% of revenue. Other net expense was $58 million in Q3, which includes $66 million in interest expense, primarily related to our 2015 bond offering. In Q3, both our GAAP and non-GAAP tax rates were approximately 25%. 
Our weighted average diluted share count was approximately 219 million for Q3, which brings us to our diluted earnings per share which were $4.71 on a GAAP basis and $5.19 on a non-GAAP basis. We ended the quarter with $7.4 billion in cash and marketable securities with approximately 40% of this in the United States. During the quarter, we repurchased 1.1 million shares of the company's common stock for a total value of $349 million. So as often, we had a number of puts and takes in the quarter, nevertheless, a very solid financial quarter. 
I'll turn the call over to George for his closing comments."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Thank you, Paul. I'm very pleased with what we have accomplished this quarter. We delivered solid commercial performance, strong financial results and important advances in the pipeline. I'm particularly excited about the direction we're heading as",328,"Okay. Thank you, Paul. I'm very pleased with what we have accomplished this quarter. We delivered solid commercial performance, strong financial results and important advances in the pipeline. I'm particularly excited about the direction we're heading as we finish 2016 and look forward to 2017 and beyond. 
As I've said, I believe we are at the beginning of a transformative era in neurodegeneration, which could result in a new era for Biogen as well. We're already starting to see the types of discoveries that can be expected, the science advances and the innovative trial designs yield previously unseen in results and insights. We believe the early data for aducanumab point to additional opportunities to invest in novel science to address Alzheimer's disease and other neurodegenerative diseases. The insights we've gained from the SYNERGY trial are teaching us more about remyelination, and we're enthusiastic about moving opicinumab forward. And the encouraging results we're seeing from nusinersen pointed a possibility that there can be entirely new mechanisms and modalities for treating the many daunting diseases of the central nervous system. 
I'm proud to have led Biogen for more than 6 years now, and it's gratifying to me to be in the position to turn a high-performing organization over to a successor. Our board search for a new CEO is progressing. We don't have a formal update on timing yet, but as you'd expect, the opportunity to lead Biogen is generating plenty of interest. And in the meantime, I'm working closely with our management team as we strive to realize our goals for 2016 and kick off a busy and productive 2017. We're fortunate to have a great leadership team and a passionate group of employees who come to work every day to make a positive impact on patients' lives, and I thank all of them for their hard work and dedication.
 Thanks to all of you for joining us this morning, and we'll now open up the call for questions."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your first question comes from the line of Eric Schmidt from Cowen and Company.",16,"[Operator Instructions] Your first question comes from the line of Eric Schmidt from Cowen and Company."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I was hoping you could talk a little bit more about the parallel trade issue associated with TECFIDERA. Is that something new? Is there anything you can do about it? Is it going to get worse in the future?",39,"I was hoping you could talk a little bit more about the parallel trade issue associated with TECFIDERA. Is that something new? Is there anything you can do about it? Is it going to get worse in the future?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Thanks, Eric. This is Paul. I'll try to take a crack at it. We didn't point it out last quarter. So in fairness, it's -- looking at the numbers this quarter, we kind of noticed it in looking backwards. It effectively happens when a low-priced country gets",145,"Thanks, Eric. This is Paul. I'll try to take a crack at it. We didn't point it out last quarter. So in fairness, it's -- looking at the numbers this quarter, we kind of noticed it in looking backwards. It effectively happens when a low-priced country gets extra purchasing patents and it ends up in a more higher-priced company. Across all of our products, we look hard at this, and we try, to the extent we can, management manage it. I don't expect it. We haven't, across the whole time in multiple sclerosis for 10 or 15 years, seen this to be a big issue, but we'll continue to try to manage it. I don't expect it to be a meaningful issue as we go forward over the next bunch of quarters. It could bounce around every now and then though. Thanks for the question."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoff Meacham from Barclays.",12,"Your next question comes from the line of Geoff Meacham from Barclays."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just on the remyelination side for Mike or Al. So what are the puts and takes of finding a population for anti-LINGO versus expanding the program for BIIB061? I'm just curious if you can find -- use the lessons from SYNERGY to optimize 061 development or",56,"Just on the remyelination side for Mike or Al. So what are the puts and takes of finding a population for anti-LINGO versus expanding the program for BIIB061? I'm just curious if you can find -- use the lessons from SYNERGY to optimize 061 development or if you have to prioritize that one over the other?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Geoff, this is Mike. That's a good question. So my comment on the SYNERGY results is we've been using that data to really look at the potential for an identified population, we think we found that. We think this is really going to inform our developm",97,"Yes. Geoff, this is Mike. That's a good question. So my comment on the SYNERGY results is we've been using that data to really look at the potential for an identified population, we think we found that. We think this is really going to inform our development of BIIB061. We're thinking about that very closely. There's reason to believe that we -- that the same population may be something we could investigate similarly with BIIB061. We think it'll inform the development. That's going to be part of the plans for how we would develop opicinumab as well."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Maybe I could add to that. This is Al. The subpopulation that we identified has really good biological possibility. In other words, these are patients who have evidence of intact axons. They have evidence of demyelination. This make sense to us that the d",63,"Maybe I could add to that. This is Al. The subpopulation that we identified has really good biological possibility. In other words, these are patients who have evidence of intact axons. They have evidence of demyelination. This make sense to us that the drugs -- both of these drugs would work better in this population, and that's why we're encouraged by these results."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Geoffrey Porges with Leerink Partners.",13,"Your next question comes from the line of Geoffrey Porges with Leerink Partners."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just want to throw a few questions in on nusinersen. First, what would be the earliest that you would be in a position to actually launch the product if the FDA acted with the speed that they've acted on some other recent applications for high unmet need",151,"Just want to throw a few questions in on nusinersen. First, what would be the earliest that you would be in a position to actually launch the product if the FDA acted with the speed that they've acted on some other recent applications for high unmet need indications? Secondly, could you give us a sense of the number of patients continuing from the trials on an open-label basis and also the number of patients in the expanded access program and when you would expect those to be converted to -- become commercial patients? And then lastly, you mentioned the 20,000 patients with SMA in North America, Europe and Japan. But what proportion of those do you consider to be really addressable with the label that you're filing for? Is that the population under 10 or infant-onset? Or is that just all the different forms of SMA? Sorry for the multipart question."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Geoffrey, this is Mike. I'll sort of -- I'm going to start, and then we're going to tag team that, the multipart question here. Hopefully, we'll remember each of the parts.",32,"Okay. Geoffrey, this is Mike. I'll sort of -- I'm going to start, and then we're going to tag team that, the multipart question here. Hopefully, we'll remember each of the parts."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","We need all members of the management team to address it.",11,"We need all members of the management team to address it."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Chime in. So first of all, on the filing, I do want to emphasize that we've submitted the file, we've applied for Priority Review. We haven't heard back on the determination of that. That will obviously dictate when we will get approval for that in the U.",395,"Chime in. So first of all, on the filing, I do want to emphasize that we've submitted the file, we've applied for Priority Review. We haven't heard back on the determination of that. That will obviously dictate when we will get approval for that in the U.S. Similarly, the Accelerated Assessment application we have in Europe, again, that would potentially reduce the review time but we're expecting that, finally, to be validated in the coming weeks. So there's some timing dependence on regulator acceptance of this Priority Review and Accelerated Assessment. Then with that, I'm going to let Michel talk about the launch based on that, but let me address a couple of the other things you mentioned. Our extended access program is active. We've got patients who are receiving drug. This is obviously country-by-country specific in how they're administering it, and it's an ongoing work in progress. That program will really be relevant during this period in -- while we're filed but before we've got approval. We anticipate that, that -- it's going to be a small number of patients that we can get in the relevant countries based on the criteria that we established in our expanded access program. On the incidence and prevalence in the label, what we would say is this is 20,000 patients prevalence today in the U.S., Europe and Japan. SMA, as a whole, has an incidence, about -- of about 13,000 patients a year across those, roughly. The data that we've submitted were from the interim analysis of ENDEAR, these were Type 1 patients. We've included data across all of our studies as well as preclinical data. We are going to seek a broad label for the treatment of SMA. That's obviously will be something under review. And based on that, that will determine the overall size of the patient population, which I'll also let Michel sort of comment on when I turn over to him. My final comment on that would be that we expect that if successful and launched, that these prevalence numbers will increase over time to the extent that we have an impact on survival in these populations. So the label, there's a lot of open questions. We'll have to wait and see, and that is going to determine what the ultimate upside is. So Michel, maybe I'll turn over to you on the..."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Thank you, Mike. So basically, the label is a question mark. The time line is also a question mark. I had the opportunity to review lately the U.S. operation in terms of launch readiness, and I can tell you that I'm very pleased with the team that is",139,"Yes. Thank you, Mike. So basically, the label is a question mark. The time line is also a question mark. I had the opportunity to review lately the U.S. operation in terms of launch readiness, and I can tell you that I'm very pleased with the team that is getting together, high qualified, highly committed team, in order to best serve the unmet medical need, together with, hopefully, a good product that with a good label and approved on time. So the launch readiness is there, and basically, the label will determine which proportion of the current prevalence we can address at launch. So for that, we have to wait a little bit. 20,000 patients in terms of prevalence in the geography that we have qualified, but there are many more beyond, and we are also looking to that."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","[Operator Instructions] Your next question comes from the line of Ron Gal with Bernstein.",14,"[Operator Instructions] Your next question comes from the line of Ron Gal with Bernstein."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So just first quick clarification. On the anti-LINGO, is this another Phase II? Or are you actually starting a pivotal program with that? And then my question is really on market access for multiple sclerosis in 2017. Now that those contacts have been wri",78,"So just first quick clarification. On the anti-LINGO, is this another Phase II? Or are you actually starting a pivotal program with that? And then my question is really on market access for multiple sclerosis in 2017. Now that those contacts have been written, can you give us kind of like directional view at your formulary access versus 2016 and the pricing that you're able to -- the pricing environment for your products in -- during that year?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Ron, thanks for the question. This is Mike, and I will probably let Al comment as well on opicinumab anti-LINGO. We're very much in the design phase of this, looking at the potential of a trial. We're looking at timing. We're looking at cost. We're",84,"Okay. Ron, thanks for the question. This is Mike, and I will probably let Al comment as well on opicinumab anti-LINGO. We're very much in the design phase of this, looking at the potential of a trial. We're looking at timing. We're looking at cost. We're looking at feasibility. We don't have an answer today, but we think in the coming weeks, we'll have a determination about whether we conduct a Phase IIb trial or whether we look to go straight into Phase III."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","I don't have any further comment.",7,"I don't have any further comment."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So concerning the formulary access in the U.S., we do not comment on the way 2017 will look like nor on the gross to net. What I can tell you is that the organization is committed to continue to generate profitable growth, and for that, we go after the co",106,"So concerning the formulary access in the U.S., we do not comment on the way 2017 will look like nor on the gross to net. What I can tell you is that the organization is committed to continue to generate profitable growth, and for that, we go after the cost structure, forcefully, how we supply and how we procure our business. And as I explained earlier, we are working on our go-to-market model. We don't believe the region frequency model that prevailed in the past is sustainable, and we are basically, step by step, building a new go-to-market model. So we are working on that."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Brian Abrahams with Jefferies.",12,"Your next question comes from the line of Brian Abrahams with Jefferies."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I guess the question is for Mike. I was hoping you could clarify what you guys have meant by -- on the aducanumab titration data, what you've meant by efficacy results that are consistent with results previously reported? Are you referring to imaging or c",100,"I guess the question is for Mike. I was hoping you could clarify what you guys have meant by -- on the aducanumab titration data, what you've meant by efficacy results that are consistent with results previously reported? Are you referring to imaging or cognition? And then on the safety side, when you talk about safety looking consistent with what's previously been reported and supporting the design of the Phase III, does that suggest that the ARIA is consistent with what you're seeing? Or does it support the idea of titration potentially reducing the risk of ARIA in certain populations?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Yes. Brian, thank you for that. And by the way, these are all things which we will have a lot more to talk about at CTAD in San Diego in December. But -- so let me comment on that. So when I -- when we say consistent with, we're referring to both imaging",141,"Yes. Brian, thank you for that. And by the way, these are all things which we will have a lot more to talk about at CTAD in San Diego in December. But -- so let me comment on that. So when I -- when we say consistent with, we're referring to both imaging and functional endpoints in cognition. And as you know, we've looked at before is the CDI sum of boxes -- CDR sum of boxes and MMSE as well as amyloid PET. On the titration side and safety side, again, we'll have a lot more details on this. But what I'd say is what we're seeing is consistent with what we had hypothesized around for the safety basis of aducanumab. In other words, it's within the range of what we've seen and reported before with the Phase Ib study."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Michael Yee with RBC Capital Markets.",14,"Your next question comes from the line of Michael Yee with RBC Capital Markets."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","A follow-up on the Alzheimer's prior question. I just wanted to understand the context of the efficacy comments in particular, given that I think there are still some questions around the placebo arm and I think that you're still using partly the pool of",102,"A follow-up on the Alzheimer's prior question. I just wanted to understand the context of the efficacy comments in particular, given that I think there are still some questions around the placebo arm and I think that you're still using partly the pool of placebo from before. So I just want to understand sort of the caveats and I guess how confident you are versus that arm. And then just a quick follow-up is you did mention a line about MT-1303, so just wanted to understand what happened there. Is that a commercial competition thing? Or what happened in that decision?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Michael, this is Al Sandrock. The additional cohorts included some additional placebo patients. So we will show the data from the additional placebo patients as well as the placebo patients from prior cohorts, and that'll be shown at CTAD. And the efficac",71,"Michael, this is Al Sandrock. The additional cohorts included some additional placebo patients. So we will show the data from the additional placebo patients as well as the placebo patients from prior cohorts, and that'll be shown at CTAD. And the efficacy is on PET imaging as well as on the clinical cognitive assessments that we looked at previously, MMSE and CDR sum of boxes. That'll all be shown at CTAD."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So Michael, this is Mike. I'll sort of comment on the amiselimod. This was really -- as we look at how the landscape was evolving, both in terms of a regulatory competitive landscape, changing features there and the corresponding fit with our strategic pr",83,"So Michael, this is Mike. I'll sort of comment on the amiselimod. This was really -- as we look at how the landscape was evolving, both in terms of a regulatory competitive landscape, changing features there and the corresponding fit with our strategic priorities about where we can best allocate resources based on our own expertise and competency, we just determined that this was -- that it wasn't as good of a fit as other things, which we could allocate our resources towards."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Ying Huang with Bank of America Merrill Lynch.",16,"Your next question comes from the line of Ying Huang with Bank of America Merrill Lynch."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just quickly, we're all anxiously awaiting for the top line from solanezumab Phase III in December. Can you frame us on what could the read-through be for the Phase III program for aducanumab? And then secondly, what's your view on the recent data from Av",60,"Just quickly, we're all anxiously awaiting for the top line from solanezumab Phase III in December. Can you frame us on what could the read-through be for the Phase III program for aducanumab? And then secondly, what's your view on the recent data from AveXis gene therapy in SMA and what that could mean for nusinersen in the commercial opportunity?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Well, thanks for the question. I'll take a stab at this and see if any wants to open up. First of all, I mean, we're not -- I don't think we'll speculate on the potential results of Eli solanezumab trial based on that. I mean, they're scenarios that",313,"Okay. Well, thanks for the question. I'll take a stab at this and see if any wants to open up. First of all, I mean, we're not -- I don't think we'll speculate on the potential results of Eli solanezumab trial based on that. I mean, they're scenarios that one can envision, that we are certainly taking into consideration. We look -- we very much look forward to seeing their data. A couple of things I would point out on this is, is although both A beta antibodies, these are actually fundamentally quite different mechanisms of action. So whereas we think if there were positive results out of the solanezumab trial, this would give great credence to the amyloid hypothesis of Alzheimer's disease and, I think, bode well for the potential results of aducanumab. However, because these are fundamentally different mechanisms they're going at is that it is far more difficult to interpret a negative result if solanezumab were to find it as we would be able to see it. We believe it will be much more difficult to make a conclusion about a negative result on solanezumab vis--vis the potential results of aducanumab. On AveXis, I think what we would comment is, look, we welcome innovative therapies for SMA. We think it's a very serious, very important disease area. We're highly committed to this disease area and to the patients and families. We think that gene therapy, as an overall approach, is a viable one in spinal muscular atrophy, and in fact, we're quite excited about our own internal program that we have and our collaboration with UPenn in that regard as well. So we look forward to seeing how the combination of nusinersen potentially being launched and the next-generation therapeutics that we're certainly working on will play out over time. We see great prospect for the treatment of spinal muscular atrophy."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","And the only thing I would add on the Alzheimer's is the population is a little different. In solanezumab, they're studying the mild patients, which make sense because that's where they saw some evidence of efficacy in Expedition II. Whereas in the case o",68,"And the only thing I would add on the Alzheimer's is the population is a little different. In solanezumab, they're studying the mild patients, which make sense because that's where they saw some evidence of efficacy in Expedition II. Whereas in the case of aducanumab, we're studying prodromal in the early mild patients. And then I agree with everything Mike said about the differences in the antibodies."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Matthew Harrison with Morgan Stanley.",13,"Your next question comes from the line of Matthew Harrison with Morgan Stanley."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","I just want to go back to SMA for a second, again, just trying to better understand your comments around a broad label. And I guess what data supports a label outside of SMA 1 patients? And what's the rationale that you might be able to achieve a label ou",60,"I just want to go back to SMA for a second, again, just trying to better understand your comments around a broad label. And I guess what data supports a label outside of SMA 1 patients? And what's the rationale that you might be able to achieve a label outside of SMA 1 patients ahead of the randomized study data?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. Matthew, thanks for the question. I mean, I guess I would first start by saying, we really are not going to comment on the data prospects for our label. But what I will say is that we have ongoing studies in Type 2 patients, where we're looking at t",156,"Okay. Matthew, thanks for the question. I mean, I guess I would first start by saying, we really are not going to comment on the data prospects for our label. But what I will say is that we have ongoing studies in Type 2 patients, where we're looking at the potential efficacy of nusinersen. As you know also, we have an ongoing trial, as I had mentioned, in presymptomatic genetically diagnosed infants. And so all of that data -- this data that we look to include in our filing application and, from that, the extent of the label that we achieve, that will be based on the agency's review of the totality of the data and the evidence. We will present evidence based on those populations in our effort to seek a broad label. What that data is we'll be able to -- we'll present at the appropriate time. Many of these studies have not completed."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of John Scotti with Evercore ISI.",13,"Your next question comes from the line of John Scotti with Evercore ISI."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So on the CEO search, could you just elaborate a bit more? I'm not sure what exactly, but I know this is a big topic for investors right now. On timing, is it unreasonable to hear something by year-end? And then exactly, what is the profile of the person",146,"So on the CEO search, could you just elaborate a bit more? I'm not sure what exactly, but I know this is a big topic for investors right now. On timing, is it unreasonable to hear something by year-end? And then exactly, what is the profile of the person you're looking for? Is it someone from industry, out of industry, et cetera? And then on the MS market, Michel, I had a quick question. So you said that in the U.S., the volumes are declining year-over-year. And do you see this trend continuing? And if so, is it fair to say that any growth from TEC, which -- stable patient share and I guess also, perhaps, the entire MS market as a whole, would come from price going forward? Or do you see volumes inflecting at some point? And if so, what would be the catalyst?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Okay. This is George. Maybe I'll comment on the CEO search first. Look, I'm not going to comment on the specific timing. I can tell you that I think we all believe that the sooner we can get through this and have a new CEO come, the better it is for all o",114,"Okay. This is George. Maybe I'll comment on the CEO search first. Look, I'm not going to comment on the specific timing. I can tell you that I think we all believe that the sooner we can get through this and have a new CEO come, the better it is for all of us. So it's a very active search. The board is interviewing a number of candidates. There are, as you would expect, very high quality candidates coming in and being interviewed from a variety of backgrounds, actually. And we'll give you an update on that as soon as we can, but I don't want to comment anymore on the specific timing today."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So concerning the U.S. markets, thanks for the question, what we have seen during the past quarters was basically a slowdown towards a low single-digit market growth in the U.S. What we have seen during the past months or weeks was a shift in the mix betw",432,"So concerning the U.S. markets, thanks for the question, what we have seen during the past quarters was basically a slowdown towards a low single-digit market growth in the U.S. What we have seen during the past months or weeks was a shift in the mix between commercial and free that is impacting basically the commercial units' performance. So I don't know if it's an overall market trend but this is what we have seen internally. What I can tell you is that TECFIDERA remains the #1 priority for the organization. We have a plan, as alluded last time, we are working based on the portfolio work that we are doing on Peg GI discontinuation that remains at an average of approximately 22%. We have the good opportunity to make some inroad there because, basically, the scope goes from 5% to 35%. So there are some centers, some MS centers where they're able to manage with the right engagement and here the different type of engagements that are being practiced in the different centers, there is no evidence yet. One can speculate that we can see a temporal association between the increase of eosinophil and the GI symptomology, but this was not confirmed by clinical trials because of many different confounding factors. So we work on Peg GI. We see early signs if it's heading towards the right direction also in Europe, but it's too early to claim any big success here. We are working on the capture rates, and one balance the other. That's why we have a stable patient base. And the pace of the market is certainly lower than what we have estimated in our assumptions, but it's not an excuse for not increasing share. So we do not give up. We invest. We are committed. I can tell you the team in the U.S. is all up and running. They have piloted a new engagement model with critical MS centers. I'm very pleased to see the perception improvement. And now we have to continue to execute, and the full rollout of this new plan will be towards the end of the year or, by latest, early January. So we are committed. We don't give up on the large mature market, where the share of TEC is relatively stable, versus the latest launch markets where we make -- continue to make fast inroads, like in Italy, Spain or the U.K. And the good news is that we could turn to positive France. And we'll continue for Germany, and we'll continue for the U.S. We are committed. Thank you."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Robyn Karnauskas with Citigroup.",12,"Your next question comes from the line of Robyn Karnauskas with Citigroup."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","So just to follow up on market trends in MS. So help us understand why do you think -- is there anything going on with the MS market? Why is it shrinking in the U.S.? Are you seeing any people who are trying the orals and then hopping off and not getting",96,"So just to follow up on market trends in MS. So help us understand why do you think -- is there anything going on with the MS market? Why is it shrinking in the U.S.? Are you seeing any people who are trying the orals and then hopping off and not getting back into the MS treatment bucket? And then on PLEGRIDY sort of the market, having a certain small percentage of the market, it's interesting. But do you think you can grow that? And what are you specifically doing to grow the PLEGRIDY market share?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","So thanks for the question. It's very difficult to speculate on the future trend of the market. So we have -- see a couple of points negative for the quarter versus prior year. This was not the situation during the prior quarters. So time will speak. We'l",100,"So thanks for the question. It's very difficult to speculate on the future trend of the market. So we have -- see a couple of points negative for the quarter versus prior year. This was not the situation during the prior quarters. So time will speak. We'll see over time, but I don't believe that this will be sustained. And again, I spoke about some trends in the marketplace between commercial units being commercialized and other channels. So we are committed to gain market share in a slower pace of the market in all our mature markets, including the U.S."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Chris Raymond with Raymond James.",13,"Your next question comes from the line of Chris Raymond with Raymond James."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Just back on to SMA and nusinersen. You guys have talked about your expanded access program and sort of moving that forward, and sounds like there's a desire to get more patients on. We sort of run -- ran across some social media chatter from parents that",105,"Just back on to SMA and nusinersen. You guys have talked about your expanded access program and sort of moving that forward, and sounds like there's a desire to get more patients on. We sort of run -- ran across some social media chatter from parents that seem to be sort of complaining about, at least, some PIs that were looking to restrict access to this program. I wonder if you could -- that would seems to be a little bit at odds with what you guys have talked about. Can you maybe comment on that and maybe help explain what exactly is going on?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","Chris, maybe I'll sort of start. I mean, the essence is we're not going to comment on specific investigators or specific sites around this. I would say that our expanded access program was really designed to -- in cases and at sites in countries where we",187,"Chris, maybe I'll sort of start. I mean, the essence is we're not going to comment on specific investigators or specific sites around this. I would say that our expanded access program was really designed to -- in cases and at sites in countries where we were able to, with this severe disease, before we're able to successfully launch, hopefully, if we get a favorable review -- to maximize the access that we could based on criteria that were medically established at relevant sites. A lot of that is determined at the site in the country level. They determine that. And we are doing our best to ensure access in the way that makes sense but that does not jeopardize our filing and the potential approval of this for broad access. Our hope, by the way, is that this period will be short, and that we'll be able to utilize the Priority Review and the Accelerated review -- the assessment at the EMA to bring this to patients as quickly as possible so that the CAP (sic) [ EAP ] program can be as short as possible."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Your next question comes from the line of Cory Kasimov with JPMorgan.",12,"Your next question comes from the line of Cory Kasimov with JPMorgan."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Analysts","Wanted to ask you about your broader biz dev intentions. And obviously, you had the setback with MT-1303. But as we look forward, can you talk about your strategy here and how much you're able to act on it, if at all, while you have a CEO search ongoing?",95,"Wanted to ask you about your broader biz dev intentions. And obviously, you had the setback with MT-1303. But as we look forward, can you talk about your strategy here and how much you're able to act on it, if at all, while you have a CEO search ongoing? I guess is this part of the business that we should assume is on hold for the time being until you get someone in who can kind of take stock of the overall organization? Or are you still proceeding with diligence of other companies as usual?"
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","No, you should not assume this is on hold. We all believe this is an important part of what we have to accomplish. We are continuing with diligence on several companies as we speak, and that will continue. And we will continue to work aggressively to fina",94,"No, you should not assume this is on hold. We all believe this is an important part of what we have to accomplish. We are continuing with diligence on several companies as we speak, and that will continue. And we will continue to work aggressively to finalize some of these issues. I think the areas in which we are interested are clear. We have a very good R&D team now who can make the technical assessments. We have great ability now to make the accurate commercial assessments, and so we are full speed ahead."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Executives","All right. Dan, that should conclude the call for today. Thank you very much.",14,"All right. Dan, that should conclude the call for today. Thank you very much."
29726,384066926,1062440,"Biogen Inc., Q3 2016 Earnings Call, Oct 26, 2016",2016-10-26,"Earnings Calls","Biogen Inc.","Operator","Thank you to everyone for attending. This concludes today's conference call. You may now disconnect.",15,"Thank you to everyone for attending. This concludes today's conference call. You may now disconnect."
